
<html lang="en"     class="pb-page"  data-request-id="09640186-999d-4d3a-8679-b907184be63e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.9b00826;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-5"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors" /></meta><meta name="dc.Creator" content="David S.  Huang" /></meta><meta name="dc.Creator" content="Emmanuelle V.  LeBlanc" /></meta><meta name="dc.Creator" content="Tanvi  Shekhar-Guturja" /></meta><meta name="dc.Creator" content="Nicole  Robbins" /></meta><meta name="dc.Creator" content="Damian J.  Krysan" /></meta><meta name="dc.Creator" content="Juan  Pizarro" /></meta><meta name="dc.Creator" content="Luke  Whitesell" /></meta><meta name="dc.Creator" content="Leah E.  Cowen" /></meta><meta name="dc.Creator" content="Lauren E.  Brown" /></meta><meta name="dc.Description" content="The molecular chaperone Hsp90, essential in all eukaryotes, plays a multifaceted role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species. The chaperone i..." /></meta><meta name="Description" content="The molecular chaperone Hsp90, essential in all eukaryotes, plays a multifaceted role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species. The chaperone i..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 12, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00826" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00826" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00826" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00826" /></link>
        
    
    

<title>Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00826" /></meta><meta property="og:title" content="Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0019.jpeg" /></meta><meta property="og:description" content="The molecular chaperone Hsp90, essential in all eukaryotes, plays a multifaceted role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species. The chaperone is also critically important, however, to the pathogen’s human host, preventing the use of known clinical Hsp90 inhibitors in antifungal applications due to concomitant host toxicity issues. With the goal of developing Hsp90 inhibitors with acceptable therapeutic indices for the treatment of invasive fungal infections, we initiated a program to design and synthesize potent inhibitors with selective activity against fungal Hsp90 isoforms over their human counterparts. Building on our previously reported derivatization of resorcylate natural products to produce fungal-selective compounds, we have developed a series of synthetic aminopyrazole-substituted resorcylate amides with broad, potent, and fungal-selective Hsp90 inhibitory activity. Herein we describe the synthesis of this series, as well as biochemical structure–activity relationships driving selectivity for the Hsp90 isoforms expressed by Cryptococcus neoformans and Candida albicans, two pathogenic fungi of major clinical importance." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00826"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00826">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00826&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00826&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00826&amp;href=/doi/10.1021/acs.jmedchem.9b00826" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2139-2180</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00779" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00851" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">David S. Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David S. Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+S.++Huang">David S. Huang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0256-5307" title="Orcid link">http://orcid.org/0000-0003-0256-5307</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emmanuelle V. LeBlanc</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emmanuelle V. LeBlanc</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emmanuelle+V.++LeBlanc">Emmanuelle V. LeBlanc</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tanvi Shekhar-Guturja</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tanvi Shekhar-Guturja</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tanvi++Shekhar-Guturja">Tanvi Shekhar-Guturja</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicole Robbins</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicole Robbins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicole++Robbins">Nicole Robbins</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Damian J. Krysan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Damian J. Krysan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Pediatrics and Microbiology/Immunology, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Damian+J.++Krysan">Damian J. Krysan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6330-3365" title="Orcid link">http://orcid.org/0000-0001-6330-3365</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Juan Pizarro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Juan Pizarro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Tropical Medicine, School of Public Health and Tropical Medicine and Vector-Borne Infectious Disease Research Center, Tulane University, New Orleans, Louisiana 70112, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Juan++Pizarro">Juan Pizarro</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0643-518X" title="Orcid link">http://orcid.org/0000-0003-0643-518X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luke Whitesell</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luke Whitesell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>L.W.: email, <a href="/cdn-cgi/l/email-protection#6509100e004b120d0c1100160009092510110a170a0b110a4b0604"><span class="__cf_email__" data-cfemail="5438213f317a233c3d2031273138381421203b263b3a203b7a3735">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luke++Whitesell">Luke Whitesell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Leah E. Cowen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leah E. Cowen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>L.E.C.: email, <a href="/cdn-cgi/l/email-protection#c0aca5a1a8eea3afb7a5ae80b5b4afb2afaeb4afeea3a1"><span class="__cf_email__" data-cfemail="bfd3daded791dcd0c8dad1ffcacbd0cdd0d1cbd091dcde">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leah+E.++Cowen">Leah E. Cowen</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Lauren E. Brown</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lauren E. Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</div></div><span class="conrtib-corresp"><strong>*</strong>L.E.B.: email, <a href="/cdn-cgi/l/email-protection#5b3929342c35373e1b392e753e3f2e"><span class="__cf_email__" data-cfemail="c1a3b3aeb6afada481a3b4efa4a5b4">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lauren+E.++Brown">Lauren E. Brown</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9489-484X" title="Orcid link">http://orcid.org/0000-0001-9489-484X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00826&amp;href=/doi/10.1021%2Facs.jmedchem.9b00826" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2139–2180</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 12, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 May 2019</li><li><span class="item_label"><b>Published</b> online</span>12 September 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00826" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00826</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2139%26pageCount%3D42%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDavid%2BS.%2BHuang%252C%2BEmmanuelle%2BV.%2BLeBlanc%252C%2BTanvi%2BShekhar-Guturja%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D5%26contentID%3Dacs.jmedchem.9b00826%26title%3DDesign%2Band%2BSynthesis%2Bof%2BFungal-Selective%2BResorcylate%2BAminopyrazole%2BHsp90%2BInhibitors%26numPages%3D42%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2180%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00826"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2428</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">18</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00826" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;S. Huang&quot;},{&quot;first_name&quot;:&quot;Emmanuelle&quot;,&quot;last_name&quot;:&quot;V. LeBlanc&quot;},{&quot;first_name&quot;:&quot;Tanvi&quot;,&quot;last_name&quot;:&quot;Shekhar-Guturja&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;Robbins&quot;},{&quot;first_name&quot;:&quot;Damian&quot;,&quot;last_name&quot;:&quot;J. Krysan&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;Pizarro&quot;},{&quot;first_name&quot;:&quot;Luke&quot;,&quot;last_name&quot;:&quot;Whitesell&quot;},{&quot;first_name&quot;:&quot;Leah&quot;,&quot;last_name&quot;:&quot;E. Cowen&quot;},{&quot;first_name&quot;:&quot;Lauren&quot;,&quot;last_name&quot;:&quot;E. Brown&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;2139-2180&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00826&quot;},&quot;abstract&quot;:&quot;The molecular chaperone Hsp90, essential in all eukaryotes, plays a multifaceted role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species. The chaperone is also critically important, however, to the pathogen’s human host, preventing the use of known clinical Hsp90 inhibitors in antifungal applications due to concomitant host toxicity issues. With the goal of developing Hsp90 inhibitors with acceptable therapeutic indices for the treatment of invasive fungal infections, we initiated a program to design and synthesize potent inhibitors with selective activity against fungal Hsp90 isoforms over their human counterparts. Building on our previously reported derivatization of resorcylate natural products to produce fungal-selective compounds, we have developed a series of synthetic aminopyrazole-substituted resorcylate amides with broad, potent, and fungal-selective Hsp90 inhibitory activity. Herein we describe the synthesis of this series, as well as biochemical structure&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00826&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00826" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00826&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00826" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00826&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00826" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00826&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00826&amp;href=/doi/10.1021/acs.jmedchem.9b00826" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00826" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00826" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00826%26sid%3Dliteratum%253Aachs%26pmid%3D31513387%26genre%3Darticle%26aulast%3DHuang%26date%3D2020%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BFungal-Selective%2BResorcylate%2BAminopyrazole%2BHsp90%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D5%26spage%3D2139%26epage%3D2180%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/jmcmar.2020.63.issue-5/20200312/jmcmar.2020.63.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The molecular chaperone Hsp90, essential in all eukaryotes, plays a multifaceted role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species. The chaperone is also critically important, however, to the pathogen’s human host, preventing the use of known clinical Hsp90 inhibitors in antifungal applications due to concomitant host toxicity issues. With the goal of developing Hsp90 inhibitors with acceptable therapeutic indices for the treatment of invasive fungal infections, we initiated a program to design and synthesize potent inhibitors with selective activity against fungal Hsp90 isoforms over their human counterparts. Building on our previously reported derivatization of resorcylate natural products to produce fungal-selective compounds, we have developed a series of synthetic aminopyrazole-substituted resorcylate amides with broad, potent, and fungal-selective Hsp90 inhibitory activity. Herein we describe the synthesis of this series, as well as biochemical structure–activity relationships driving selectivity for the Hsp90 isoforms expressed by <i>Cryptococcus neoformans</i> and <i>Candida albicans</i>, two pathogenic fungi of major clinical importance.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/5"><issue-title>Women in Medicinal Chemistry</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The morbidity and mortality caused by fungal infections cripple human health across the globe. Over a billion people are affected by superficial infections, such as ringworm and athlete’s foot. Adding to these numbers is the burden of oral and other mucosal infections. Of most concern is the increasing number of invasive systemic infections, which leads to over one million deaths each year.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> People with compromised immune function, such as patients receiving cancer chemotherapies, organ transplant recipients, and those infected with HIV, are most vulnerable to invasive fungal infections. The pathogens responsible for >90% of invasive mycoses are <i>Candida albicans</i>, <i>Aspergillus fumigatus</i>, and <i>Cryptococcus neoformans</i>. Once diagnosed, treatment options are limited to only three major classes of antifungal drugs, notoriously hampered by problems with host toxicity, the emergence of resistance, or limited spectrum of activity.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In fact, the only new class of antifungals to reach the clinic in decades has no efficacy against <i>C. neoformans</i> and related species.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Selective targeting of fungal stress responses provides a promising therapeutic strategy to mitigate resistance and more effectively combat invasive mycoses. The essential molecular chaperone Hsp90 has been extensively validated as a regulator of virulence and antifungal drug resistance in <i>Candida</i> and <i>Aspergillus</i> species.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> For instance, in <i>C. albicans</i>, genetic depletion or pharmacological inhibition of Hsp90 increases the efficacy of current antifungal drugs, reduces acquired antifungal resistance in clinical isolates, and improves clearance in a mouse model of disseminated candidiasis.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Recent studies have demonstrated the critical importance of Hsp90 for <i>C. neoformans</i> thermotolerance and shown that Hsp90 inhibition alters capsule assembly and sensitivity to antifungals, influencing virulence of the pathogen.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> While targeting Hsp90 offers a promising but relatively unexplored strategy for antifungal drug development, the chaperone has been intensively explored as a target in oncology. A structurally diverse array of drugs targeting the ATP-binding pocket of human Hsp90 continue to be evaluated for anticancer activity in patients. In contrast, allosteric approaches to targeting the function of Hsp90 at sites other than its N-terminal ATPase have only been explored in preclinical studies,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> the exception being a putative C-terminal inhibitor (RTA901) which has recently completed phase I testing in humans (NCT0266693).</div><div class="NLM_p">Unfortunately, dose-limiting toxicities coupled with relatively limited therapeutic efficacy have so far precluded FDA approval of any N-terminal Hsp90 inhibitor either alone or in combination with other therapeutic agents. In the course of these anticancer drug development and testing campaigns, no effort has been devoted to the pursuit of fungal selectivity and an Hsp90 inhibitor with the properties required for use as an antifungal has yet to be reported.</div><div class="NLM_p">Fungal selectivity is a crucial feature for an Hsp90 inhibitor to be developed as an antifungal given that Hsp90 is essential in all eukaryotes. Its function supports protein quality control mechanisms, productive folding, and the stability of conformationally labile proteins, many involved in key signaling cascades.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The chaperoning by Hsp90 of its so-called client proteins is ATP-dependent and coordinated by a suite of cochaperones and accessory factors that impart client selectivity and help regulate progression through the chaperoning cycle. Although Hsp90 is highly conserved across phylogenetic kingdoms, species-specific variations are observed at the level of conformational flexibility, intrinsic ATPase activity, chaperoning dynamics, and the involvement of specific cochaperone/accessory proteins.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Therefore, despite a very high degree of conservation at the primary sequence level, these important functional differences provide hope that species-selectivity can be achieved, either at the classical N-terminal ATP-binding pocket or alternatively via allosteric inhibitors acting at other sites.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">While efforts to achieve species-selectivity are just beginning, the pursuit of human paralog-specific Hsp90 inhibitors has already achieved considerable success. These efforts have been focused on achieving selectivity at the N-terminal nucleotide-binding domain (NBD) across the four family members expressed in humans: Hsp90α, Hsp90β, Trap1, and Grp94.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> For example, Blagg and co-workers have described successful efforts to modify the resorcylate scaffold to confer selectivity toward specific human paralogs, including selective Grp94 inhibitors with applications in oncology and glaucoma<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19">(15−19)</a> and more recently, the first Hsp90β-selective inhibitor with applications in cancer.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In addition, isoform-selective purine mimetics, such as Hsp90α/β-specific inhibitor TAS-116<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and modified analogs of BIIB021 selectively targeting Trap1,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> have been described. Modified benzamides resembling SNX-2112 have also been diverted to both Hsp90α/β-specific<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and Trap1-specific<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> activities for neurological applications.</div><div class="NLM_p">We recently disclosed the discovery of the first fungal-selective Hsp90 inhibitors,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> with activity against the <i>C. albicans</i> Hsp90 isoform, based on semisynthetic oxime-derivatization of the resorcylate macrocycle natural products radicicol (<b>1</b>) and monocillin I (<b>2</b>). For therapeutic applications, fungal-selectivity is critical as current inhibitors targeting host Hsp90 have deleterious effects that preclude their use in the context of systemic infection. Our most promising lead from this series, monocillin-derived oxime CMLD013075 (<b>3</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A), has >25-fold binding selectivity for the <i>C. albicans</i> Hsp90 NBD compared to the human ortholog, limits fungal proliferation in whole cell assays, and is less toxic to human cells compared to the nonselective compound radicicol. Importantly, the cocrystal structure of <i>C. albicans</i> Hsp90 NBD with CMLD013075 displayed unique structural rearrangements, including remodeling of the ATP-binding site, N-terminus, and lid region of the fungal chaperone. Aided by structural insights, key residues were identified as critical for the fungal selectivity of this derivative. Encouraged by these findings and using <b>3</b> as a point of departure, we now report the structure–activity relationship (SAR)-guided efforts to develop fully synthetic, nonmacrocyclic resorcylate inhibitor chemotypes, focusing on selectivity toward both <i>C. neoformans</i> and <i>C. albicans</i> Hsp90.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of aminopyrazole resorcylate-type inhibitor chemotype <b>8</b> based on precedented fungal-selective natural-product-derived inhibitors (A) and truncated resorcylates under clinical evaluation in oncology (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Replacement of the macrolactone of radicicol with acyclic isosteres including amides (onalespib (<b>4</b>)<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24−27)</a>), oxazoles (luminespib (<b>5</b>),<a onclick="showRef(event, 'ref28 ref29 ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31 ref32 ref33">(28−33)</a>), triazolones (ganetespib (<b>6</b>)<a onclick="showRef(event, 'ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42">(34−42)</a>), and ketones (KW-2478 (<b>7</b>)<a onclick="showRef(event, 'ref43 ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45 ref46">(43−46)</a>) has been a widely successful strategy for the development of multiple classes of synthetic Hsp90 inhibitors currently in clinical evaluation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). Using our macrocyclic oxime CMLD013075 as a lead template, our initial efforts focused on the replacement of the selectivity-imparting oxime with a suitable heterocyclic isostere, with the parallel goals of removing the isomerizable oxime (which we postulated could obfuscate selectivity analysis) and reducing rotational degrees of freedom to enhance binding affinity. After evaluating various heterocyclic options for similarity and synthetic tractability, we selected the aminopyrazole of general type <b>8</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C) for initial development. We hypothesized that a pendant aminopyrazole could project substituents (R<sup>1</sup>/R<sup>2</sup>/R<sup>3</sup>) in orientations similar to that of the CMLD013075 oxime, to impart fungal selectivity in the binding of Hsp90. In addition to the attractiveness of the pyrazole from the standpoint of developability,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> we also postulated that structure–activity relationships at three points of diversity (R<sup>1</sup>/R<sup>2</sup>/R<sup>3</sup>) could be easily elaborated through the coupling of aryl bromide <b>9</b> with a combination of commercial and synthetic aminopyrazoles (<b>10</b>).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis of Resorcylate Aminopyrazole Analogs</h3><div class="NLM_p">Our initial synthesis of aminopyrazole resorcylates began with 1-bromo-3,5-dimethoxybenzene <b>11</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Formylation, demethylation, MOM protection, and Pinnick oxidation afforded carboxylic acid <b>12</b>, which was then subjected to HATU-mediated amidation with isoindoline to produce amide <b>13</b>. We initially selected the isoindoline amide as it is conserved across multiple classes of acyclic resorcylate heat shock protein inhibitors,<a onclick="showRef(event, 'ref48 ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51 ref52 ref53">(48−53)</a> providing a simple, precedented model scaffold on which our selectivity-inducing strategy could be evaluated. We next installed the aminopyrazole using Pd-mediated coupling; after a brief exploration of coupling conditions<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> we ultimately settled on Pd<sub>2</sub>(dba)<sub>3</sub>/Xantphos/NaOPh in dioxane under microwave irradiation<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> as the optimal conditions across a wide scope of substrates. Following amination, acid-mediated MOM deprotection produced the desired aminopyrazole-substituted resorcylates.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. First-Generation Synthetic Route to Aminopyrazole/Isoindoline Resorcylate Amides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) POCl<sub>3</sub>, DMF, 100 °C; (b) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt; (c) MOMCl, DIPEA, DMF; (d) NaOCl<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, 2-methyl-2-butene, THF/<sup><i>t</i></sup>BuOH/H<sub>2</sub>O; (e) isoindoline·HCl, HATU, Et<sub>3</sub>N, THF/CH<sub>2</sub>Cl<sub>2</sub>; (f) <sup><i>t</i></sup>BuXphos Pd G1 (10 mol %), <sup><i>t</i></sup>BuXPhos (10 mol %), NaO<sup><i>t</i></sup>Bu, <sup><i>t</i></sup>BuOH, or Pd<sub>2</sub>(dba)<sub>3</sub> (4 mol %), Xantphos (8 mol %), NaOPh, dioxane, 60–120 °C, or Pd<sub>2</sub>(dba)<sub>3</sub> (10 mol %), Xantphos (10 mol %), NaOPh, dioxane, 170 °C, microwave; (g) HCl, methanol, 50 °C.</p></p></figure><div class="NLM_p">We also applied this first-generation synthetic sequence to explore replacement of the isoindoline amide for several early compounds (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). During the course of analog synthesis, however, we found that reversing the order of coupling/amidation resulted in a more efficient procedure with improved yields and product purities; the resultant second-generation route is depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Following esterification of carboxylic acid <b>12</b>, the resulting ester <b>17</b> was subjected to Pd-mediated coupling with <b>10</b> to afford intermediate <b>18</b>. Following ester hydrolysis, carboxylic acid <b>19</b> was subsequently amidated, which was initially performed using the HATU-mediated conditions and later optimized to employ polymer-supported carbonyldiimidazole (PS-CDI) as a coupling reagent for improved parallel processing. Finally global MOM-deprotection provided the desired products for testing. All tested compounds were purified by mass-targeted HPLC.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Early Exploration of Amide SAR Using First-Generation Synthetic Route<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) HNR<sup>4</sup>R<sup>5</sup>, HATU, Et<sub>3</sub>N, THF/CH<sub>2</sub>Cl<sub>2</sub>; (b) <b>10a</b>, Pd<sub>2</sub>(dba)<sub>3</sub> (4 mol %), Xantphos (10 mol %), NaOPh, dioxane, 170 °C, microwave; (c) HCl, methanol, 50 °C.</p></p></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Second-Generation Synthetic Route to Aminopyrazole Resorcylate Amides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C; (b) <b>10</b>, Pd<sub>2</sub>(dba)<sub>3</sub> (4 mol %), Xantphos (10 mol %), NaOPh; (c) KOH, EtOH, 95 °C; (d) HNR<sup>4</sup>R<sup>5</sup>, HATU, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>/THF, rt or HNR<sup>4</sup>R<sup>5</sup>, PS-CDI, HOBt·<i>x</i>H<sub>2</sub>O, Et<sub>3</sub>N, THF/CH<sub>2</sub>Cl<sub>2</sub>; (e) HCl, methanol, 50 °C.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Measurement of Fungal Hsp90 Binding Affinity and Selectivity</h3><div class="NLM_p last">All analogs were assessed for Hsp90 binding affinity using a fluorescence polarization (FP)-based equilibrium competition assay in fungal and human whole cell lysates. Notably, this approach allows for the assessment of compound binding while the target protein is in native complexes with cochaperones and, in the case of human cell lysate, in a biologically relevant mix of Hsp90 paralogs. Using lysates, we were able to measure the relative potency and selectivity for fungal Hsp90 versus the entire ensemble of human Hsp90 isoforms in microplate format using small amounts of test materials. To confirm target engagement with an alternative biochemical approach, the most selective analogs were also assessed by protein thermal shift assays using purified recombinant Hsp90 nucleotide binding domains (NBD) of the relevant fungal species. Thermal shift assays were performed under saturating ligand conditions, i.e., equimolar concentrations (10 μM) of protein and ligand. As a result, they provided qualitative evidence of target binding but not a quantitative measurement of ligand affinity. For quantitation, a ligand dissociation constant (<i>K</i><sub>i</sub>) for key compounds was also determined using purified NBDs in FP assays and KD measurements were made by surface plasmon resonance (SPR) using a Biacore instrument. Finally, all analogs were assessed for whole cell antifungal activity against the pathogens <i>C. albicans</i> and <i>C. neoformans</i>. Quantitative dose–response assays were performed for all compounds found to inhibit growth at a concentration ≤50 μM.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Structure–Activity Relationships for Resorcylate Aminopyrazoles</h3><div class="NLM_p">We first examined <i>N</i>-(<i>para</i>)-methoxybenzyl substituted aminopyrazoles, designed to mimic our parent <i>Candida</i>-selective inhibitor CMLD013075. We began by making systematic alterations to the resorcylate amide, with R<sup>2</sup> substitution limited to methyl and phenyl. Our initial amide diversification utilized several pyrrolidine/isoindoline-based heterocycles, which are prevalent among resorcylate amide Hsp90 inhibitors reported by Astex and Pfizer (<b>20</b>, <b>21</b>, <b>26</b>–<b>29</b>, <b>32</b>–<b>36</b>, <b>38</b>),<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> as well as new isoindoline isosteres (pyrido- and pyrazolopyrrolidines <b>22</b>–<b>25</b>). We also pursued a small series of acyclic mono- and disubstituted amides, both new (<b>30</b>, <b>31</b>) and precedented (<b>37</b>, <b>39</b>).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> From this initial set, we were pleased to find a number of compounds had <200 nM EC<sub>50</sub> values against one or both fungal species (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Consistent with published inhibitors in this space, larger, substituted isoindoline-type moieties (<b>32</b>–<b>36</b>) generally exhibited excellent potency but with no apparent selectivity for the fungal Hsp90 isoforms. In contrast, we found that the pairing of smaller heterobicylic amides with a phenyl group at the R<sup>2</sup> position (compounds <b>21</b>, <b>23</b>, <b>25</b>, <b>27</b>, and <b>29</b>) afforded modestly fungal-selective compounds; as a general trend, their R<sup>2</sup> = CH<sub>3</sub> analogs (<b>20</b>, <b>22</b>, <b>24</b>, <b>26</b>, and <b>28</b>) were more potent but nonselective. Activity was mainly relegated to the heterobicyclic amides; our limited set of acyclic and monocyclic amides (<b>30</b>, <b>31</b>, <b>37</b>–<b>39</b>) were for the most part less active and also nonselective, with the interesting exception of low potency cryptococcal-selective compound <b>30</b>. On the basis of these results and given our early hypothesis that the installation of functionality at the aminopyrazole would be the key driver in imparting selectivity, we opted to progress forward with the lower-molecular weight isoindoline, pyridopyrrolidine, and pyrazolopyrrolidine amides, selected to represent both precedented and novel resorcylate amide substitutions with varying basicities.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure–Activity Relationships for <i>N</i>-(4-Methoxybenzyl)-Substituted Aminopyrazoles, Exploring Variation of the Resorcylate Amide with Methyl- and Phenyl-Substitution at R<sup>2</sup> <a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">Fold-selectivity >5 for any compound is highlighted in red. EC<sub>50</sub> values were determined by FP-based equilibrium competition assay performed in 384-well format using whole cell lysates prepared from <i>C. neoformans</i> (a) and <i>C. albicans</i> (c) and serial compound dilutions. All determinations were performed in duplicate. To calculate fold-selectivity (b), the EC<sub>50</sub> value determined in human HepG2 cell lysate was divided by the EC<sub>50</sub> value determined in fungal cell lysate. The resulting ratio was then normalized to values determined in the same assay for the nonselective inhibitor geldanamycin using lysate of each cell type. Results for key selective compounds were confirmed by repeat assay (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">Supplemental Table 1</a>).</p></div></div><div></div></div><div class="NLM_p">Our next series of analogs explored additional R<sup>2</sup>/R<sup>3</sup> substitutions on the aminopyrazole, again keeping the R<sup>1</sup><i>para-</i>methoxybenzyl group intact (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). For the R<sup>2</sup> unsubstituted pyrazoles (<b>40</b>–<b>44</b>), we found that substitution at R<sup>3</sup> was tolerated but with decreasing potency as steric bulk increased. Several of these compounds also exhibited modest undesired selectivity toward the human isoform. On the basis of these results, we opted not to pursue this substitution pattern further. In contrast, and similar to our initial cohort, we identified wider tolerance for substitution at the R<sup>2</sup> position with several acyclic (<b>45</b>–<b>48</b>) and cyclic (<b>50</b>–<b>53</b>) aliphatic groups, as well as furan (<b>54</b>–<b>55</b>) substitution. A drop in potency was limited to the bulkier R<sup>2</sup> = <sup><i>t</i></sup>Bu analog <b>49</b>. Disappointingly, however, none of the inhibitors exhibited the modest fungal selectivity that had been observed in their R<sup>2</sup> = Ph substituted counterparts <b>21</b>, <b>23</b>, and <b>25</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of SAR at R<sup>2</sup>/R<sup>3</sup> for R<sup>1</sup> = <i>p</i>-Methoxybenzyl Substituted Aminopyrazoles<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">EC<sub>50</sub> and selectivity values were determined as described for <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div></div><div></div></div><div class="NLM_p">We next assessed replacement of the <i>p</i>-methoxybenzyl group at R<sup>1</sup>. Initially, this group had been chosen based on analogy to our <i>Candida</i>-selective inhibitor CMLD013075. Our X-ray crystallographic analysis<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJP">6CJP</a>) indicates that the aryl ring participates in a key binding interaction following a major structural rearrangement of the <i>Candida</i> Hsp90 lid region, serving as a donor in an N–H···π interaction with <i>C. albicans</i> Asn40. However, given the limited scope of radicicol- and monocillin-derived analogs that we previously explored, coupled with a current lack of structural information about the cryptococcal isoform, it is not clear that this group represents an “ideal” binding moiety for either fungal species. As an initial probe, we focused on varying solely the R<sup>1</sup> group across the isoindoline, tetrahydropyrrolopyridine, and tetrahydropyrrolopyrazole amides, leaving the R<sup>2</sup> and R<sup>3</sup> sites unsubstituted. The results for this series are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. We once again identified a wide array (aliphatic, aromatic, heteroaromatic) of aminopyrazole substitutions that afforded in most cases sub-125 nM potencies for both fungal species (<b>56</b>, <b>59</b>, <b>62</b>–<b>77</b>, and <b>80</b>–<b>86</b>) but all broadly nonselective with the exception of isoindoline <b>83</b>. This compound was exemplary as the first compound in our aminopyrazole series to exhibit sub-100 nM EC<sub>50</sub> with greater than 10-fold selectivity. Interestingly, however, in isolated cases the tetrahydropyrrolopyridine and tetrahydropyrrolopyrazole amides diverged from their isoindoline counterparts with a slight decrease in potency (compounds <b>78</b>, <b>79</b>), which was in some cases coupled with a slight increase in cryptococcal selectivity (<b>57</b>, <b>58</b> and <b>60</b>, <b>61</b>). These compounds, bearing aliphatic N-substitutions of varying size, showed 2- to 5-fold selectivity toward <i>C. neoformans</i>, with no apparent selectivity toward <i>C. albicans</i>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Exploring Alternative R<sup>1</sup> Substituents on R<sup>2</sup>/R<sup>3</sup>-Unsubstituted Aminopyrazoles<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">Fold selectivity >5 for any compound is highlighted in red. EC<sub>50</sub> and selectivity values were determined as described for <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div></div><div></div></div><div class="NLM_p">We next progressed to examining the combined modifications of the R<sup>1</sup> N-substitution with additional groups at R<sup>2</sup> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Again mindful of keeping physicochemical properties such as molecular weight and lipophilicity within an acceptable “druglike” range, we imposed a limitation for this series that each pyrazole should contain a maximum of one aryl ring at either R<sup>1</sup> or R<sup>2</sup> but not at both.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> This series produced a number of analogs with more modest submicromolar potency and cryptococcal selectivity greater than 4-fold (<b>91</b>–<b>95</b>). Of these, compounds <b>94</b> and <b>95</b> also exhibited modest selectivity for <i>C. albicans</i> Hsp90 over human Hsp90 paralogs, which was consistent with their early near neighbor analogs <b>21</b>, <b>23</b>, and <b>25</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Examining Varied Pairings of R<sup>1</sup>/R<sup>2</sup> Substitutions on the Aminopyrazole Ring<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0015.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0016.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup><sup>a</sup></sup><p class="last">Fold selectivity >5 for any compound is highlighted in red. EC<sub>50</sub> and selectivity values were determined as described for <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div></div><div></div></div><div class="NLM_p">Among our initial fungal-selective leads from this effort, compounds <b>91</b>–<b>93</b> stood out as having high cryptococcal selectivity without a concomitant loss in cryptococcal potency as seen in earlier analogs. To follow up, we designed a final array of analogs N-methylated at R<sup>1</sup>, probing more diverse aliphatic and aryl substituents at R<sup>2</sup> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Variation of R<sup>2</sup> Substituent for N-Methylated Aminopyrazoles Yields <i>C. neoformans</i>- and <i>C. albicans</i>-Selective Hsp90 Inhibitors with Diverging Isoform Selectivities<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0017.gif" alt="" id="fx9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0018.gif" alt="" id="fx10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup><sup>a</sup></sup><p class="last">Fold selectivities >5 are highlighted in red. EC<sub>50</sub> and selectivity values were determined as described for <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div></div><div></div></div><div class="NLM_p">Gratifyingly, this series produced highly selective inhibitors for both the <i>C. neoformans</i> and <i>C. albicans</i> isoforms of Hsp90. While our exploration of aliphatic substitution was limited, high cryptococcal potency (EC<sub>50</sub> < 160 nM) and in some cases modestly <i>Cryptococcus</i>-selective compounds (3- to 6.5-fold) were observed with isopropyl (<b>100</b>–<b>102</b>) and cyclohexyl (<b>103</b>–<b>105</b>) substitution at R<sup>2</sup>. The most highly selective compounds, however, were observed among the R<sup>2</sup> arylated analogs, with diverging species-selectivity based on the nature and position of the aryl ring substituent. The <i>ortho</i>-methylated analogs <b>106</b>–<b>108</b> displayed slightly enhanced cryptococcal selectivity and similar cryptococcal potency (<150 nM) as compared to their unsubstituted congeners <b>91</b>–<b>93</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), with no apparent selectivity and significantly lower potencies (≥400 nM) in lysate of <i>C. albicans</i>. Movement of the methyl substituent from <i>ortho</i>- to <i>meta-</i> (compounds <b>109</b>–<b>111</b>) afforded similarly <i>Cryptococcus</i>-selective compounds, albeit with lower potencies. Interestingly, the <i>meta</i>-methoxy substituted <b>112</b>–<b>114</b> exhibited a significant improvement in cryptococcal selectivity (27- to 33-fold) despite only modest cryptococcal potency (EC<sub>50</sub> values all >250 nM). Trifluoromethylation at the same <i>meta-</i>position (compounds <b>115</b>–<b>117</b>), resulted in a dramatic reduction in both cryptococcal selectivity and activity.</div><div class="NLM_p">Moving from testing in <i>C. neoformans</i> lysate to <i>C. albicans</i> lysate, the aforementioned <i>meta</i>-substituted compounds <b>109</b>–<b>117</b> also exhibited modest selectivity, with the best <i>Candida</i>-selectivity observed <i>m</i>-trifluoromethylated analogs <b>116</b> and <b>117</b> (4.4- and 4.6-fold, respectively). The <i>meta</i>-substituted series also exhibited consistently poor <i>C. albicans</i> potencies, with EC<sub>50</sub> values ranging from ∼300 nM to 5 μM. In contrast, improved <i>C. albicans</i> selectivities and potencies were observed among the analogs that were <i>para</i>-substituted on the R<sup>2</sup> phenyl ring. <i>para</i>-Methylated (<b>119</b>, <b>120</b>) and <i>para</i>-methoxy substituted (<b>121</b>–<b>123</b>) aminopyrazoles exhibited moderate selectivities and, in most cases, equivalently low potencies against both fungal species, with EC<sub>50</sub> values generally ranging from 0.5 to 2 μM. Incorporation of larger lipophilic substituents at the <i>para</i>-position such as trifluoromethyl (<b>124</b>–<b>126</b>) and <i>tert</i>-butyl (<b>127</b>–<b>129</b>) further depressed cryptococcal potency, with EC<sub>50</sub> values ranging from 2 to >10 μM and no apparent selectivity. In contrast these compounds (<b>124</b>–<b>129</b>) maintained improved potencies and similar selectivities against <i>Candida</i> Hsp90 to their <i>para</i>-methyl and <i>para</i>-methoxy counterparts <b>124</b>–<b>127</b>. This series also highlights what we have observed to be an occasional sensitivity to the nature of the amide/aminopyrazole pairing; for example in direct contrast to the cryptococcal potency trends observed with unsubstituted analogs <b>56</b>–<b>58</b>, pairing of the pyrido- and pyrazolopyrrolidine with the bulkier 3-CF<sub>3</sub>-Ph (<b>116</b>, <b>117</b>), 4-CF<sub>3</sub>-Ph (<b>125</b>, <b>126</b>), and 4-<sup><i>t</i></sup>Bu-Ph (<b>128</b>, <b>129</b>) substituents at R<sup>2</sup> improved <i>C. albican</i>s potency and selectivity relative to their isoindoline counterparts <b>115</b>, <b>124</b>, and <b>127</b>. This trend did not hold, however, for all analogs. Perhaps most intriguingly, the <i>para</i>-trifluoromethoxy substituted compounds <b>130</b>–<b>132</b>, which were completely nonselective and only modestly potent toward cryptococcal Hsp90, exhibited dramatic improvements in potency toward <i>C. albicans</i>, with EC<sub>50</sub> values ranging from 16 to 134 nM and 15- to 18-fold <i>Candida</i> selectivity. These divergent structure–selectivity trends, wherein <i>ortho</i>/<i>meta</i>-methyl and <i>meta</i>-methoxy compounds exhibited high <i>Cryptococcus</i> selectivity and poor <i>Candida</i> selectivity, whereas <i>para</i>-trifluoromethoxy substitution rendered high <i>Candida</i> selectivity and poor <i>Cryptococcus</i> activity, are summarized in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Summary of iterative progression to fungal selective inhibitors <b>106</b>–<b>132</b> with divergent patterns of species selectivity dependent on position of substitution on the aminopyrazole phenyl ring (red).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Relationship of Fungal to Human Selectivity</h3><div class="NLM_p">To better understand the phylogenetic origins of the divergent selectivity between fungi, we performed protein::protein BLAST sequence alignments across the different species studied. This analysis indicated that <i>C. neoformans</i> and <i>C. albicans</i> share 69% sequence identity across the entire Hsp90 protein and 71% identity across their NBD (residues 1–240). As a comparison, human Hsp90α and Hsp90β share 69% and 67% identity with <i>C. albicans</i> Hsp90 across their NBD, respectively. Thus, the two fungal species diverge in primary sequence as greatly from one another as they do from human Hsp90. In light of such sequence divergence, perhaps it is not surprising that while we set out to discriminate against human Hsp90, the potency and selectivity of our synthetic inhibitors also diverged between the two fungal species studied. A graphic summary of inhibitor potency/selectivity relationships found by screening compounds in <i>C. neoformans</i> lysate (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) and <i>C. albicans</i> lysate (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) highlights the progress made toward our goal of achieving fungal selectivity, while the divergence between compound selectivity in regards to <i>C. neoformans</i> vs <i>C. albicans</i> is best demonstrated by plotting the selectivity of compounds for one fungus vs human against selectivity for the other (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). To more accurately define their potency and selectivity, the activity of 27 compounds with a screening EC<sub>50</sub> < 1 μM in lysate of either fungal species was confirmed by repeat testing in two additional experiments, with results provided in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">Supplemental Table 1</a>.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Scatter plots depict fungal potency (<i>x</i>-axis) vs fungal selectivity (<i>y</i>-axis) relationships for all aminopyrazoles when screened using human cell lysate and lysate of either <i>C. neoformans</i> (A) or <i>C. albicans</i> (B). All potencies are reported as the inverse log<sub>10</sub> of compound EC<sub>50</sub> (pEC<sub>50</sub> as measured by FP assay). The scatter plot in panel C compares compound selectivity patterns between the two fungi. Key fungal-selective compounds for each species (<b>112</b>–<b>114</b> and <b>130</b>–<b>132</b>) are highlighted in color to underscore their divergence in potency and selectivity. Each point represents the mean of duplicate determinations in a single experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Validation of Whole Cell Lysate FP Results</h3><div class="NLM_p">To confirm the FP results obtained in lysate for our most potent and selective compounds, we prepared recombinant <i>Candida</i>, <i>Cryptococcus</i>, and human Hsp90 NBDs by expression and purification in <i>E. coli</i>. Using recombinant proteins, we were able to define assay-independent nanomolar inhibitory constants (<i>K</i><sub>i</sub>) for these compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">Figure S1</a>). We also confirmed binding of the compounds to their relevant NBD by thermal shift denaturation assays (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">Figure S1</a>). Thermal shift assays were performed under saturating ligand conditions, i.e., equimolar concentrations (10 μM) of protein and ligand. As a result, they can provide only qualitative evidence of target binding but not a quantitative measurement of ligand affinity. This feature of the thermal shift method is well demonstrated in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">Supplemental Table 2</a>, which presents <i>K</i><sub>i</sub> and thermal shift data for both high and low potency compounds. Here, compounds with <i>K</i><sub>i</sub> values of less than 50 nM for a particular NBD increase its Δ<i>T</i><sub>m</sub> to a similar extent irrespective of absolute potency. In contrast, lower affinity compounds (<i>K</i><sub>i</sub> > 100 nM) fail to increase the <i>T</i><sub>m</sub> of the respective NBD.</div><div class="NLM_p last">As an orthogonal, highly quantitative approach to FP, we measured the binding affinities of our six lead compounds for <i>C. albicans</i>, <i>C. neoformans</i>, and human Hsp90 NBDs by surface plasmon resonance (SPR, <a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">Supplemental Table 3</a>). The affinity values determined for compounds varied by less than an order of magnitude between the two different experimental techniques. The same pattern of fungal selectivity for compounds demonstrated by FP assay in whole cell lysates was also seen by SPR. The magnitude of selectivity determined by SPR assays compared to FP assays in lysate, however, was reduced. Such a difference might be expected given the absence in SPR assays of native cochaperone-containing complexes and, in the case of human cell lysate, a biologically relevant mix of Hsp90 paralogs.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Whole Cell Antifungal Activity</h3><div class="NLM_p">Having achieved promising potency and species-selectivity for several compounds at the level of fungal target engagement, we next examined the ability of these compounds to inhibit fungal growth. We found that minimal inhibitory concentrations (MICs) for most of the potent and selective analogs highlighted in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> were much higher than their EC<sub>50</sub> values in lysate, generally >50 μM. The disparity between whole cell antifungal activity and the EC<sub>50</sub> values we determined in FP assays is undoubtedly due to poor permeability/accumulation of the compounds in fungal cells. This common problem in the development of antifungals occurs because the fungal cell wall and membrane as well as the diverse drug efflux pumps expressed by fungi render it a challenge to achieve intracellular concentrations of experimental compounds sufficient to inhibit the function of their targets.</div><div class="NLM_p">Of the fungal Hsp90-selective compounds tested, only the 14-fold <i>C. neoformans</i>-selective analog <b>106</b> inhibited growth of the organism below 10 μM (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). While triazole antifungals in current clinical use against <i>Cryptococcus</i> do have MICs in excess of this range, they also possess far greater selectivity than we have achieved so far and are much less toxic to human cells. As single agents, the MICs of all our <i>Candida</i>-selective compounds were >50 μM. To provide a more sensitive read-out, however, we took advantage of the well-established ability of Hsp90 inhibitors to potentiate the activity of conventional antifungals against drug-resistant isolates of <i>C. albicans</i>.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Testing compounds <b>130</b> and <b>131</b> in combination with the widely used antifungal fluconazole, we found an MIC of 12.5 μM for the 15-fold <i>Candida</i>-selective analog <b>130</b> against a moderately fluconazole-resistant clinical isolate of <i>C. albicans</i>. This compound also converted the fungistatic activity of fluconazole to fungicidal against the same isolate, an effect consistent with Hsp90 inhibitory activity (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Biological activity of fungal-selective inhibitors: (A) growth inhibition by fungal-selective aminopyrazoles of <i>C. neoformans</i> reference strain H99 cultured in RPMI 1640 medium at 37 °C; (B) growth inhibition by fungal-selective aminopyrazoles of a <i>C. albicans</i> clinical isolate (CaCi2) with or without a background concentration of 8 μg/mL fluconazole. The effect of 48 h exposure to inhibitors over a 2-fold dilution series of concentrations is displayed in heat-map format. Color scale bar: no growth inhibition (green) to complete inhibition (black). Each colored box represents the mean of technical duplicates. The experiment was repeated as an independent biological replicate to confirm results. Following exposure to compounds, aliquots of the cultures in each well were spotted onto compound-free YPD agar and plates were incubated at 30 °C for an additional 24 h before imaging to assess fungicidal activity (panel B, right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Thus, although their potency and selectivity require further improvement, the whole cell activity of these resorcylate aminopyrazoles remains consistent with an Hsp90-targeted mode of action. Encouraged by this finding and to aid future efforts in developing the scaffold, we performed an initial evaluation of its stability to P450-mediated metabolism in liver microsomes, a major pharmacological liability of our previous fungal-selective macrocyclic oxime CMLD013075.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Although all the compounds tested suffered from relatively rapid metabolism (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">Supplemental Table 4</a>), important insights were gained into the basis of their instability. Comparing the half-lives of cryptococcal-selective compounds <b>112</b>–<b>114</b> reveals an apparent stabilizing effect of the pyrazolopyrrolidine amide, which is consistent with the previously reported metabolic instability of isoindolines due to oxidation at the 5/6 position.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The isoindoline was chosen for this study despite its known downstream pharmacological liabilities, as it represented a low molecular-weight starting point allowing for the methodical assessment of the relative potency and selectivity of different aminopyrazole substitutions. Assessment of additional analogs <b>105</b>, <b>111</b>, <b>129</b>, <b>131</b>, and <b>132</b> indicate that additional metabolic liabilities are also likely present at the aminopyrazole, with the <i>para</i>-trifluoromethoxy substitution clearly inhibiting metabolism. Still, the relatively short half-life of compound <b>132</b> (31 min) underscores the need for further optimization of metabolic stability, in addition to fungal penetration, as we advance in future work to compounds with suitable properties for testing in vivo. Metabolic stability optimization for resorcylate Hsp90 inhibitors via modification of the amide is well-precedented;<a onclick="showRef(event, 'ref24 ref50'); return false;" href="javascript:void(0);" class="ref ref24 ref50">(24,50)</a> similar strategies, paired with targeted alterations of the aminopyrazole aryl substituent, are currently under study in our laboratory and will be reported in due course.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Microsomal stability (mouse liver microsomes) of a panel of fungal-selective inhibitors. Assays were performed by Charles River Laboratories (Worcester, MA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The factors governing the ability of small molecules to cross cell wall and membrane barriers, avoid active efflux, and accumulate within fungi are not well-defined. To gain initial insights for our resorcylate aminopyrazoles, we expanded the scope of compounds tested in cellulo to include all biochemically active compounds (FP EC<sub>50</sub> < 10 μM) irrespective of their selectivity in cell-free lysates. An additional 83 compounds with diverse physicochemical and structural properties were tested to identify several (<b>21</b>, <b>27</b>, <b>29</b>, <b>49</b>, and <b>89</b>) with single agent bioactivity against <i>C. neoformans</i> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Aminopyrazoles with Whole Cell Anticryptococcal Activity<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="center" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">entry</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">MIC (μM)</th><th class="colsep0 rowsep0" align="center" char=".">FP EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">FP selectivity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="center" char=".">6.25</td><td class="colsep0 rowsep0" align="char" char=".">877</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="center" char=".">12.5</td><td class="colsep0 rowsep0" align="char" char=".">787</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="center" char=".">6.25</td><td class="colsep0 rowsep0" align="char" char=".">705</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="center" char=".">12.5</td><td class="colsep0 rowsep0" align="char" char=".">1026</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left"><b>89</b></td><td class="colsep0 rowsep0" align="center" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">560</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Minimum inhibitory concentration (MIC) value for compounds against <i>C. neoformans</i> (strain H99) was determined in dose–response format, in technical duplicate. Experiments were conducted in RPMI medium at 37 °C for 48 h. Relative viable cell number was measured by standard dye reduction (resazurin) assay.</p></div></div></div><div class="NLM_p last">The pattern of results suggests that enhancement of lipophilicity through the introduction of halogens or bulky aliphatic moieties can improve whole cell activity. To independently verify that the whole cell activity of these compounds was consistent with an ability to engage Hsp90, we complemented primary FP-based testing of <b>21</b>, <b>27</b>, <b>29</b>, <b>49</b>, <b>89</b>, and <b>106</b> with thermal shift assays using <i>C. neoformans</i> NBD (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">Supplemental Table 5</a>). Whole cell testing of all biochemically active but nonselective compounds also revealed three inhibitors (<b>21</b>, <b>41</b>, and <b>89</b>) with fungicidal activity in combination with fluconazole against the same clinical isolate of <i>C. albicans</i> used in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">Figure S2</a>). Analogous to our approach with <i>Cryptococcus</i>-active compounds, target engagement for <i>Candida</i>-active compounds was confirmed by thermal shift assay using <i>C. albicans</i> Hsp90 NBD (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">Supplemental Table 5</a>).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Through the iterative design and optimization of a novel aminopyrazole-substituted resorcylate amide chemotype, we have identified advanced analogs with markedly improved potency and selectivity for binding to fungal Hsp90 isoforms as compared to their human counterparts. Interestingly, as fungal selectivity increased, a marked divergence in structure–activity relationship between <i>C. albicans</i> and <i>C. neoformans</i> became evident. Beyond potent and selective target engagement, the need to increase intracellular accumulation and activity against whole organisms remains to be addressed in future work if useful antifungals are to be developed. By investigating the bioactivity of the entire series of analogs, we have identified key physicochemical properties (e.g., structural modification and lipophilicity enhancement through the introduction of halogens or bulky aliphatic moieties) that appear to contribute to improved whole cell activity and metabolic stability. Targeted exploration of these identified modifications in the context of our fungal-selective aminopyrazole substitutions, and medicinal chemistry work to further optimize potency and selectivity of the top fungal-selective leads are ongoing in our efforts to cripple human fungal pathogens by selectively targeting Hsp90.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10885" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10885" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Yeast Strains and Culture Conditions</h3><div class="NLM_p last">Strains used in this study were <i>C. albicans</i> CaCi2 (clinical isolate 2),<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> SC5314,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and <i>C. neoformans</i> H99.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Archives of all fungal strains were maintained at −80 °C in 25% glycerol. Active cultures were maintained on solid (2% agar) yeast extract peptone (YPD, 1% yeast extract, 2% bactopeptone, 2% glucose) at 4 °C for no more than 1 month. For growth experiments, strains were cultured in YPD medium or in RPMI medium 1640 (Gibco SKU no. 318000-089, 3.5% MOPS, 2% glucose, pH 7.0), as indicated in figure legends.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Antifungal Sensitivity Testing</h3><div class="NLM_p last">Minimum inhibitory concentrations (MICs) were determined in flat bottom, 96-well plate format using a modified broth microdilution protocol as previously described,<a onclick="showRef(event, 'ref6 ref61'); return false;" href="javascript:void(0);" class="ref ref6 ref61">(6,61)</a> except relative viable cell number was monitored by standard dye reduction assay after a 3 h incubation with resazurin at 37 °C. Radicicol and all synthetic analogs were formulated in dimethyl sulfoxide (DMSO, Sigma-Aldrich Co.); fluconazole was dissolved in sterile ddH<sub>2</sub>O. Each compound was tested in duplicate in at least two independent experiments. Minimum inhibitory concentration (MIC) data were quantitatively displayed in heat-map format using the program Java TreeView 1.1.3 (<a href="http://jtreeview.sourceforge.net" class="extLink">http://jtreeview.sourceforge.net</a>). To test for fungicidal activity, cultures from MIC plates were spotted on YPD agar plates using a spotter (Frogger, V&P Scientific, Inc.). Plates were photographed after 24 h of incubation at 30 °C.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> FP Assays</h3><div class="NLM_p">Whole cell lysates were prepared for FP assays as described previously.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Total protein concentration of human and yeast lysates was determined by Bradford assay.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Titrations of Cy3-labeled geldanamycin (Cy3-GdA) probe and lysate were evaluated to define conditions that resulted in 75% maximal probe polarization with no competitor present.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Serial dilutions of test Hsp90 inhibitors were then assayed under these same conditions to monitor loss of fluorescence polarization as an indicator of probe displacement from Hsp90. All determinations were performed in duplicate wells using 384-well black flat-bottom microtiter plates (Greiner Bio-One; 655076). Titrations of test compound in 25 μL of binding buffer (supplemented with 0.1 mg/mL bovine γ globulin) were mixed with an equal volume of freshly prepared whole-cell lysate spiked with Cy3-GdA (0.1 nM). Plates were incubated at room temperature for 4.5 h to achieve equilibrium binding for the geldanamycin-based probe. Signal in millipolarization (mP) units was measured at an excitation wavelength of 535 nm and emission wavelength of 595 nm in a SpectraMax i3 microplate reader (Molecular Devices) using Softmax Pro software (version 5.4.1). Nonlinear four-parameter curve fitting of raw displacement data was performed in GraphPad Prism 5.0 to determine EC<sub>50</sub> values as a measure of relative Hsp90-binding affinity. Results were normalized to the value determined for GdA in lysate of each cell type. This experiment was repeated for a set of 27 key compounds for SAR in at least three independent experiments.</div><div class="NLM_p last">FP assays were also performed with purified <i>C. albicans</i> and <i>C. neoformans</i> Hsp90 NBD for the determination of inhibitory constants (<i>K</i><sub>i</sub>) for relevant fungal-selective compounds. Titrations of the Cy3-GdA probe and purified proteins were evaluated to define assay conditions and to determine the dissociation constant <i>K</i><sub>d</sub> of the probe for each NBD. Serial dilutions of test Hsp90 inhibitors were then assayed in triplicate wells under these conditions. Nonlinear four-parameter curve fitting of raw displacement data was performed in GraphPad Prism 5.0 to determine IC<sub>50</sub> values. Finally, inhibitory constants (<i>K</i><sub>i</sub>) were calculated as described previously.<a onclick="showRef(event, 'ref11 ref62'); return false;" href="javascript:void(0);" class="ref ref11 ref62">(11,62)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Protein Thermal Shift Assays</h3><div class="NLM_p last">Thermal melting curves were determined using a Protein Thermal Shift Kit (ThermoFisher no. 4462263), employing a CFX384 real-time PCR system (Bio-Rad, C1000 Touch Thermal Cycler). Reactions were performed in a final volume of 10 μL and contained purified <i>C. albicans</i> or <i>C. neoformans</i> Hsp90 NBD diluted to 250 μg/mL in buffer HBS-P (GE Healthcare Life Sciences, 0.01 M HEPES, pH 7.4, 0.15 M NaCl, 0.005% v/v surfactant P20) with 10 μM synthetic analog or DMSO control, and 1× Sypro Orange dye solution. Samples were prepared in triplicate in 384-well white plates (Bio-Rad; HSP3805). The instrument was set to melt curve, step 1 (25 °C, 2 min) and step 2 (ramp to 98.6 °C, increasing 0.2 °C per 5 s cycle). The inflection point of each curve is defined as the protein melting temperature (<i>T</i><sub>m</sub>). Temperature shift, Δ<i>T</i><sub>m</sub>, was recorded as the difference between the <i>T</i><sub>m</sub> of the fungal Hsp90 NBD with compound minus <i>T</i><sub>m</sub> of the protein without compound.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> NBD Expression and Purification</h3><div class="NLM_p last">Recombinant Hsp90 NBDs were expressed and purified as previously described.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Stock protein solutions in 50% glycerol were stored at −20 °C until dilution into relevant buffers and use for FP and thermal shift assays.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> SPR Assays</h3><div class="NLM_p last">For SPR experiments, Hsp90 NBD expression constructs were modified to encode a C-terminal AviTag for site-specific on-column biotinylation with a BirA biotin-ligase kit (Avidity LLC; BirA-500). SPR experiments were performed on a Biacore T200 instrument at 25 °C. Biotinylated Hsp90 NBD was diluted to 40 μg/mL and immobilized on a streptavidin chip (Sensor Chip SA, GE Healthcare) at a density of 2000–2500 response units (RU) on the biosensor surface. Binding experiments were done in HBS-P (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 0.005% v/v surfactant P20, GE Healthcare) with 5% DMSO at a flow rate of 40 μL/min. Test compounds were injected in two dilutions series, with low concentrations ranging from 6 to 96 nM and high concentrations ranging from 60 to 960 nM, with a 60 s association time and 600 s dissociation time, with the exception of compound <b>130</b> for which the injection time was extended to 300 s after observing a very slow on-rate with this molecule. Resulting sensorgrams were analyzed with a fit to a 1:1 binding model, using BIA evaluation software.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Microsome Stability Testing</h3><div class="NLM_p last">The potential susceptibility of compounds to hepatic metabolism was assessed by Charles River Laboratories (Worcester, MA) using standard in-house protocols. Compounds were incubated at 1 μM concentration in mixed-gender CD-1 mouse liver microsomes (0.5 mg/mL) in the presence of 2 μM NADPH. Percent compound remaining was measured by LC/MS/MS at six time points (0, 15, 30, 60, 90, and 120 min) in duplicate. 7-Ethoxycoumarin was utilized as a positive control. In addition, NADPH-free control samples were assessed at two time points (0 and 15 min) in duplicate to exclude non-CYP450-mediated decomposition. First-order half-lives are calculated from the equation <i>T</i><sub>1/2</sub> = −0.693/<i>x</i>, where <i>x</i> is the slope found in the linear fit for the plot of ln(% remaining) versus incubation time. Calculated mouse intrinsic hepatic clearance (CL<sub>int</sub>) in mL min<sup>–1</sup> kg<sup>–1</sup> is extrapolated<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> based on 45 mg microsomes/g liver and 87.5 g liver/kg body weight.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Statistical Methods</h3><div class="NLM_p last">For FP experiments in support of SAR studies, GraphPad Prism 5.0 was used to perform curve fitting and calculate the concentrations of compounds resulting in 50% reduction in maximal polarization signal (EC<sub>50</sub>). All curve fits demonstrated a correlation coefficient (<i>R</i><sup>2</sup>) > 0.95 The number of independent experiments performed and the number of technical replicates in each experiment are provided in the legends of figures and tables characterizing the biochemical and biological activities of compounds. In calculating the error of selectivity determinations, the fractional error of measurements in each species was summed to yield a composite error for the derived ratio.</div></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Chemistry Methods. General Methods</h3><div class="NLM_p last">All melting points are uncorrected. <sup>1</sup>H NMR spectra were recorded at 400 or 500 MHz at ambient temperature. <sup>13</sup>C NMR spectra were recorded at 101 or 126 MHz at ambient temperature. Chemical shifts are reported in parts per million. Data for <sup>1</sup>H NMR are reported as follows: chemical shift, multiplicity (app = apparent, br = broad, s = singlet, d = doublet, t = triplet, q = quartet, sxt = sextet, hept = heptet, m = multiplet, ovrlp = overlap), coupling constants, and integration. All <sup>13</sup>C NMR spectra were recorded with complete proton decoupling. Analytical thin layer chromatography was performed using 0.25 mm silica gel 60-F plates. Flash column chromatography was performed using 200–400 mesh silica gel (Sorbent Technologies, Inc.). Automated flash chromatography was performed using prepacked columns (SI-HC, puriFlash or Premium Universal, Yamazen) on either an Interchim puriFlash450 or Yamazen Smart Flash EPCLC W-Prep2XY system. All mass-guided preparative HPLC was performed using an acetonitrile/water gradient (mobile phase modified with 0.01% formic acid) on a Waters FractionLynx system equipped with a 600 HPLC pump, a micromass ZQ quadrapole, Waters 996 diode array, and Sedere Sedex 75 ELS detectors, using an XBridge Prep C18 5 μM OBD 19 mm diameter column of either 100 mm or 250 mm length. Isolated yields refer to chromatographically and spectroscopically pure compounds, unless otherwise stated. All reactions were carried out in oven-dried glassware under an argon atmosphere unless otherwise noted. Analytical LC–MS experiments were performed using a Waters Acquity UPLC (ultraperformance liquid chromatography) with a binary solvent manager, SQ mass spectrometer, Waters 2996 PDA (photodiode array) detector, and evaporative light scattering detector (ELSD). All microwave experiments were performed on a CEM Discover microwave reactor, using a sealed 10 or 35 mL vessel with temperatures monitored by an external sensor. All compounds tested in biological assays were determined to be >95% pure by UPLC–MS-ELSD analysis.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure A: Synthesis of α-Formyl Nitriles</h3><div class="NLM_p last">All α-formyl nitriles used as synthetic precursors for aminopyrazoles <b>10</b> were synthesized via a procedure adapted from ref <a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a>. To a suspension of potassium <i>tert</i>-butoxide in THF (2.2 equiv, 1.4 M solution in THF) at room temperature was added a mixture of the requisite nitrile (1 equiv) and ethyl formate (1.05 equiv) in THF (6.3 M relative to nitrile) dropwise. After stirring overnight at room temperature, the reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and water. The resulting mixture was adjusted to pH = 4 using concentrated HCl (aq). The layers were separated, and aqueous layer was extracted twice with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with brine and dried with anhydrous MgSO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography to give the intermediate α-formyl nitrile.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure B: Synthesis of α,β-Unsaturated Nitriles</h3><div class="NLM_p last">All α,β-unsaturated nitriles used as synthetic precursors for aminopyrazoles <b>10</b> were generated from commercially available aldehydes according to the following procedure: To a solution of potassium <i>tert</i>-butoxide (2 M in THF, 1.04 equiv) at 0 °C was added diethyl cyanomethylphosphonate (1.1 equiv) dropwise. After stirring at 0 °C for 1 h, the requisite aldehyde (1 equiv) was added dropwise and the reaction was allowed to warm to room temperature overnight. The reaction mixture was poured into saturated NH<sub>4</sub>Cl (aq) and diluted with ethyl acetate. The layers were separated, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts from each suspension were removed via gravity filtration and condensed in vacuo. The crude mixture was purified via automated flash chromatography to give the intermediate α,β-unsaturated nitrile.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedures C: Syntheses of Aminopyrazoles <b>10</b></h3><div class="NLM_p"><b>C1:</b> The procedure was adapted from ref <a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a>. A suspension of 3-aminocrotonitrile (1.08 equiv) and the requisite hydrazine hydrochloride (1 equiv) in 1 M HCl (aq) (0.72 M concentration of hydrazine) was refluxed for 3 h. The resulting mixture was diluted with water and extracted twice with ethyl acetate. The aqueous layer was basicified with solid NaHCO<sub>3</sub> until solid remained. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers from each extraction sequence were separately washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts from each suspension were removed via gravity filtration, and the mother liquors were combined and condensed in vacuo. The crude residues were purified via automated flash chromatography.</div><div class="NLM_p"><b>C2:</b> A mixture of the requisite α-formyl nitrile and 4-(methoxybenzyl)hydrazine hydrochloride (1 equiv) was refluxed overnight in ethanol (0.36 M relative to α-formyl nitrile). The solution was cooled to room temperature and condensed in vacuo. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and the organic layer was washed twice with saturated NaHCO<sub>3</sub> (aq) and brine. The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography.</div><div class="NLM_p"><b>C3:</b> The procedure was adapted from ref <a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a>. To a solution of hydrazine monohydrate (1.03 equiv) in THF (5 M relative to hydrazine) at room temperature was added the requisite α,β-unsaturated nitrile (1.02 equiv), and the mixture was heated to 40 °C for 2 h. After cooling to room temperature, the requisite aldehyde (1 equiv) was added dropwise. The mixture was heated to 40 °C for an additional 2 h. After cooling to room temperature, volatile materials were condensed in vacuo. The resulting residue was dissolved in <sup><i>i</i></sup>PrOH (4.5 M relative to benzaldehyde). Sodium <i>tert</i>-butoxide (1.03 equiv) was added to the reaction mixture, and the resulting suspension was heated to 100 °C for 2.5 h and then stirred overnight at room temperature. The reaction mixture was diluted with water and extracted twice with diethyl ether. The combined organic layers were washed twice with 1 M HCl. The combined 1 M HCl washes were basicified to pH = 14 with 50% NaOH (aq) and extracted with diethyl ether. The second set of ether extractions were combined and washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts from each suspension were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography.</div><div class="NLM_p"><b>C4:</b> A solution of requisite oxonitrile (1 equiv) and (4-methoxybenzyl)hydrazine hydrochloride (2 equiv) in EtOH (0.3 M relative to oxonitrile) was heated to reflux overnight. After cooling to room temperature, volatile materials were condensed in vacuo. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub> (aq). The layers were separated, and the aqueous layer was extracted twice with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography.</div><div class="NLM_p last"><b>C5:</b> A solution of requisite oxonitrile (1 equiv) and methylhydrazine (1 equiv) in methanol (2 M) was irradiated at 120 °C for 40 min in a microwave reactor. After cooling to room temperature, volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Procedures D. Pd-Mediated Coupling of Aryl Bromides to Aminopyrazoles <b>10</b></h3><div class="NLM_p"><b>D1:</b> Inside a nitrogen glovebox were combined aryl bromide (1 equiv), amine <b>10</b> (1.1 equiv), tris(dibenzylideneacetone)dipalladium (0.04 equiv), Xantphos (0.08 equiv), and sodium phenoxide (1.5 equiv). Dioxane (0.13 M) was added to the mixture, and the reaction vessel was capped and removed from the glovebox. After the reaction was heated in an oil bath at 120 °C for 2 h, the reaction was cooled to room temperature and diluted with ethyl acetate. The resulting mixture was washed three times with saturated Na<sub>2</sub>CO<sub>3</sub> (aq), brine, then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography.</div><div class="NLM_p last"><b>D2:</b> Inside a nitrogen glovebox were combined aryl bromide (1 equiv), amine <b>10</b> (1.1 equiv), tris(dibenzylideneacetone)dipalladium (0.04 equiv), Xantphos (0.08 equiv), and sodium phenoxide (1.5 equiv) in a 10 mL microwave reaction vessel. Dioxane (0.13 M) was added to the mixture, and the reaction vessel was capped and removed from the glovebox. After the reaction was irradiated at 170 °C for 2 h in a microwave reactor, the reaction was cooled to room temperature and diluted with ethyl acetate. The resulting mixture was washed three times with saturated Na<sub>2</sub>CO<sub>3</sub> (aq), brine, then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts from each suspension were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> General Procedure E. Hydrolysis Conditions To Generate Crude Acids <b>19</b></h3><div class="NLM_p last">To a solution of ester (1 equiv) in EtOH/water (1:1 ratio, 0.06 M) was added potassium hydroxide (9.2 equiv), and then the mixture was heated to 95 °C for 1 h. After cooling to room temperature, volatile materials were condensed in vacuo. The residue was suspended in saturated NH<sub>4</sub>Cl (aq) and CH<sub>2</sub>Cl<sub>2</sub>. The layers were separated, and the aqueous layer was extracted three times with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed twice with water, brine and then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude acid <b>19</b> was used without further purification.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> General Procedure F: Global MOM-Deprotection</h3><div class="NLM_p last">To a solution of amide (1 equiv) in methanol (13.7 mM) was added HCl (2 M, 6.5 equiv). The resulting solution was stirred at 50 °C overnight. After cooling to room temperature, volatile materials were condensed in vacuo. The residue was purified on mass-guided preparative HPLC.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Procedure G: Amidation of Acids <b>19</b></h3><div class="NLM_p last">To a suspension of crude carboxylic acid <b>19</b> (1 equiv) and amine (1.5 equiv) in CH<sub>2</sub>Cl<sub>2</sub>/THF (1:1 mixture, 0.08–0.09 M) was added triethylamine followed by HATU (1.2 equiv). The suspension was stirred overnight at room temperature and then diluted with CH<sub>2</sub>Cl<sub>2</sub>. The reaction mixture was washed with saturated NaHCO<sub>3</sub> (aq), brine and then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> General Procedures H: Tandem PS-CDI-Mediated Amidation and MOM Deprotection of Crude Acids <b>19</b></h3><div class="NLM_p"><b>H1:</b> To a solution of crude carboxylic acid <b>19</b> (1 equiv) and isoindoline hydrochloride (1.5 equiv) in THF/CH<sub>2</sub>Cl<sub>2</sub> (1:1 ratio, 77 mM) was added trimethylamine (4 equiv) followed by HOBt hydrate (1.2 equiv) and PS-carbodiimide (1.18 mmol/g loading, 1.2 equiv). The suspension was shaken overnight at room temperature. The resin was removed via filtration, and the resulting filtrate was washed twice with saturated NaHCO<sub>3</sub> (aq) and once with brine. The organic layer was dried with anhydrous sodium sulfate. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The resulting residue was dissolved in methanol (20 mM), and HCl (aq) (2 M, 6.5 equiv) was added to the mixture. The resulting solution was stirred at 50 °C overnight. After cooling to room temperature, volatile materials were condensed in vacuo. The residue was purified on mass-guided preparative HPLC.</div><div class="NLM_p"><b>H2:</b> The procedure was identical to general procedure H1 except using 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine instead of isoindoline hydrochloride.</div><div class="NLM_p last"><b>H3:</b> The procedure was identical to general procedure H1 except using 1,4,5,6-tetrahydropyrrolo[3,4-<i>c</i>]pyrazole instead of isoindoline hydrochloride.</div></div><div id="sec5_9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 1-(4-Methoxybenzyl)-3-methyl-1<i>H-</i>pyrazol-5-amine (<b>10a</b>)</h3><div class="NLM_p last">Synthesized using general procedure C1 with (4-methoxybenzyl)hydrazine hydrochloride (250 mg, 1.33 mmol) and purified using automated flash chromatography (5% to 25% ethyl acetate in hexanes) to afford 189 mg of <b>10a</b> as a white/orange solid (66% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.12 (d, <i>J</i> = 8.2 Hz, 2H), 6.86 (d, <i>J</i> = 8.4 Hz, 2H), 5.37 (s, 1H), 5.08 (s, 2H), 3.80–3.74 (m, 3H), 3.30 (s, 2H), 2.19 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.0, 147.4, 145.2, 129.0, 128.1, 114.2, 91.3, 55.2, 50.8, 13.9. LC/MS (<i>m</i>/<i>z</i>): 218.126 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.04 min.</div></div><div id="sec5_9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 1-(4-Methoxybenzyl)-3-phenyl-1<i>H-</i>pyrazol-5-amine (<b>10b</b>)</h3><div class="NLM_p last">A solution of benzoylacetonitrile (350 mg, 2.41 mmol) and (4-methoxybenzyl)hydrazine hydrochloride (910 mg, 4.82 mmol) in ethanol (8 mL) was heated to reflux overnight. After cooling to room temperature, the solution was condensed in vacuo. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub> (aq). The layers were separated, and the aqueous layer was extracted twice with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration and the volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography (1% to 5% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>) to afford 498 mg of <b>10b</b> (74% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77 (dd, <i>J</i> = 8.2, 1.4 Hz, 2H), 7.38 (dd, <i>J</i> = 8.4, 6.9 Hz, 2H), 7.29 (d, <i>J</i> = 7.4 Hz, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 2H), 6.90–6.80 (m, 2H), 5.90 (s, 1H), 5.24 (s, 2H), 3.78 (s, 3H), 3.44 (s, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 149.3, 144.5, 134.5, 128.5, 127.2, 125.5, 88.9, 56.2, 32.3, 25.8, 25.3. LC/MS (<i>m</i>/<i>z</i>): 281.203 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.64 min.</div></div><div id="sec5_9_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 1-(4-Methoxybenzyl)-4-methyl-1<i>H-</i>pyrazol-5-amine (<b>10c</b>)</h3><div class="NLM_p last">2-Methyl-3-oxopropanenitrile was synthesized using general procedure A from propionitrile (0.82 mL, 11.4 mmol) in 6.7% yield after automated flash chromatography (20% to 60% ethyl acetate in hexanes). 2-Methyl-3-oxopropanenitrile (64 mg, 0.73 mmol) was subjected to general procedure C2 to afford 68 mg of <b>10c</b> as an off-white solid (41% yield) after purification via automated flash chromatography (15% to 85% ethyl acetate in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.18 (s, 1H), 7.16–7.07 (m, 2H), 6.85 (d, <i>J</i> = 8.6 Hz, 2H), 5.14 (s, 2H), 3.78 (s, 3H), 3.11 (s, 1H), 1.90 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.1, 141.3, 138.7, 128.9, 128.3, 114.2, 100.5, 55.3, 51.4, 7.9. LC/MS (<i>m</i>/<i>z</i>): 218.17 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.11 min.</div></div><div id="sec5_9_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-Isopropyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-amine (<b>10d</b>)</h3><div class="NLM_p last">2-Formyl-3-methylbutanenitrile was synthesized using general procedure A from isovaleronitrile (1.20 mL, 11.4 mmol) in 24% yield after automated flash chromatography (10% to 30% acetone in hexanes and 5% to 20% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). 2-Formyl-3-methylbutanenitrile (291 mg, 2.62 mmol) was subjected to general procedure C2 to afford 260 mg of <b>10d</b> as a white/yellow solid (40% yield) after purification via automated flash chromatography (15% to 55% ethyl acetate in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.22 (s, 1H), 7.12 (d, <i>J</i> = 8.5 Hz, 2H), 6.86 (d, <i>J</i> = 8.6 Hz, 2H), 5.14 (s, 2H), 3.78 (s, 3H), 3.13 (s, 2H), 2.62 (p, <i>J</i> = 6.9 Hz, 1H), 1.19 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.1, 140.1, 135.8, 129.0, 128.3, 114.2, 112.4, 55.2, 51.2, 23.7, 23.3. Mp: 74–76 °C. LC/MS (<i>m</i>/<i>z</i>): 245.916 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.30 min.</div></div><div id="sec5_9_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 1-(4-Methoxybenzyl)-4-phenyl-1<i>H-</i>pyrazol-5-amine (<b>10e</b>)</h3><div class="NLM_p last">Synthesized using general procedure C2 from 3-oxo-2-phenylpropanenitrile (250 mg, 1.72 mmol) to afford 223 mg of <b>10e</b> (46% yield) as an off-white solid after purification via automated flash chromatography (4% to 12% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.53 (s, 1H), 7.46–7.33 (m, 4H), 7.25–7.11 (m, 3H), 6.88 (d, <i>J</i> = 8.5 Hz, 2H), 5.21 (s, 2H), 3.79 (s, 3H), 3.61 (s, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.3, 141.2, 137.3, 133.6, 129.0, 128.4, 128.3, 126.3, 125.6, 114.4, 106.9, 55.3, 51.6. Mp: 154–156 °C. LC/MS (<i>m</i>/<i>z</i>): 281.159 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.68 min.</div></div><div id="sec5_9_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 4-Benzyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-amine (<b>10f</b>)</h3><div class="NLM_p last">2-Benzyl-3-oxopropanenitrile was synthesized using general procedure A from 3-phenylpropionitrile (1.50 mL, 11.4 mmol) in 17% yield after automated flash chromatography (10% to 30% acetone in hexanes and 5% to 20% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). 2-Benzyl-3-oxopropanenitrile (300 mg, 1.88 mmol) was subjected to general procedure C2 to afford 152 mg of <b>10f</b> (27% yield) as a white/brown solid after purification via automated flash chromatography (20% to 60% ethyl acetate in hexanes and 4% to 15% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35–7.15 (m, 5H), 7.11 (d, <i>J</i> = 8.3 Hz, 2H), 6.85 (d, <i>J</i> = 8.5 Hz, 2H), 5.14 (s, 2H), 3.78 (s, 3H), 3.70 (s, 2H), 3.03 (s, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.2, 141.7, 140.3, 138.7, 128.8, 128.6, 128.3, 126.2, 114.3, 103.9, 55.3, 51.4, 29.7. LC/MS (<i>m</i>/<i>z</i>): 295.186 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.54 min.</div></div><div id="sec5_9_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 3-Ethyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-amine (<b>10g</b>)</h3><div class="NLM_p last">Synthesized using general procedure C3 from pent-2-enenitrile (239 mg, 2.95 mmol) and <i>p</i>-anisaldehyde (0.353 mL, 2.90 mmol) to afford 131 mg of <b>10g</b> (19% yield) after purification via automated flash chromatography (10% to 30% acetone in hexanes and 5% to 20% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.12 (d, <i>J</i> = 8.6 Hz, 2H), 6.85 (d, <i>J</i> = 8.7 Hz, 2H), 5.40 (s, 1H), 5.11 (s, 2H), 3.78 (s, 3H), 3.36 (s, 2H), 2.57 (q, <i>J</i> = 7.6 Hz, 2H), 1.22 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.1, 153.6, 144.9, 128.9, 128.1, 114.2, 89.9, 55.3, 50.9, 21.8, 14.0. LC/MS (<i>m</i>/<i>z</i>): 231.933 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.14 min.</div></div><div id="sec5_9_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 3-Isopropyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-amine (<b>10h</b>)</h3><div class="NLM_p last">Synthesized using general procedure C4 from 4-methyl-3-oxopentanenitrile (100 mg, 0.900 mmol) to afford 278 mg of <b>10h</b> (>100% yield) as a yellow oil after purification via automated flash chromatography (7% to 20% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). Chromatographed product was impure and was carried forward to the next step without further purification.</div></div><div id="sec5_9_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 3-(<i>tert</i>-Butyl)-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-amine (<b>10i</b>)</h3><div class="NLM_p last">Synthesized using general procedure C4 from 4,4-dimethyl-3-oxopentanenitrile (200 mg, 1.60 mmol) and (4-methoxybenzyl)hydrazine hydrochloride (301 mg, 1.60 mmol) to afford 342 mg of <b>10i</b> (83% yield) as an orange solid after purification via automated flash chromatography (10% to 35% ethyl acetate in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.13–7.00 (m, 2H), 6.85 (d, <i>J</i> = 8.5 Hz, 2H), 5.44 (s, 1H), 5.12 (s, 2H), 3.78 (s, 3H), 3.25 (s, 2H), 1.29 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 160.6, 159.0, 144.5, 129.2, 127.9, 114.2, 88.3, 55.2, 50.9, 32.1, 30.5. Mp: 72–74 °C. LC/MS (<i>m</i>/<i>z</i>): 261.222 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.30 min.</div></div><div id="sec5_9_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 3-Cyclopropyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-amine (<b>10j</b>)</h3><div class="NLM_p last">Synthesized using general procedure C4 from 3-cyclopropyl-3-oxopropanenitrile (100 mg, 0.916 mmol) to afford 176 mg of <b>10j</b> (79% yield) as an off-white solid after purification via automated flash chromatography (7% to 20% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.12 (d, <i>J</i> = 8.5 Hz, 2H), 6.85 (d, <i>J</i> = 8.7 Hz, 2H), 5.20 (s, 1H), 5.10 (s, 2H), 3.78 (s, 3H), 3.35 (s, 2H), 1.93–1.81 (m, 1H), 0.96–0.82 (m, 2H), 0.75–0.59 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.0, 154.0, 145.0, 128.9, 128.1, 114.2, 87.4, 55.2, 50.9, 9.5, 7.7. Mp: 113–114 °C. LC/MS (<i>m</i>/<i>z</i>): 245.21 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.19 min.</div></div><div id="sec5_9_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 3-Cyclopentyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-amine (<b>10k</b>)</h3><div class="NLM_p last">3-Cyclopentylacrylonitrile was synthesized using general procedure A from cyclopentanecarboxaldehyde (0.50 mL, 4.7 mmol) to afford 390 mg (68% yield) of a 1:1.4 mixture of <i>E</i>:<i>Z</i> isomers as a colorless oil after purification via automated flash chromatography (1% to 5% ethyl acetate in hexanes). 3-Cyclopentylacrylonitrile (387 mg, 3.19 mmol) was subjected to general procedure C3 with <i>p</i>-anisaldehyde (0.381 mL, 3.14 mmol) to afford 68.7 mg of <b>10k</b> (8.2% yield) after purification via automated flash chromatography (3% to 15% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.10 (d, <i>J</i> = 8.5 Hz, 2H), 6.85 (d, <i>J</i> = 8.7 Hz, 2H), 5.39 (s, 1H), 5.09 (s, 2H), 3.77 (s, 3H), 3.31 (s, 2H), 3.06–2.89 (m, 1H), 2.09–1.94 (m, 2H), 1.83–1.53 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 156.4, 144.9, 129.1, 128.2, 114.3, 88.9, 55.3, 51.0, 39.6, 33.5, 25.5. LC/MS (<i>m</i>/<i>z</i>): 272.426 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.08 min.</div></div><div id="sec5_9_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3-(Furan-3-yl)-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-amine (<b>10l</b>)</h3><div class="NLM_p last">To a solution of potassium <i>tert</i>-butoxide (2 M in THF, 1.04 equiv) at 0 °C was added diethyl cyanomethylphosphonate (1.1 equiv) dropwise. After stirring at 0 °C for 1 h, 3-furancarboxaldehyde (0.50 mL, 5.8 mmol, 1 equiv) was added dropwise and the reaction was allowed to warm to room temperature overnight. The reaction mixture was poured into saturated NH<sub>4</sub>Cl (aq) and diluted with ethyl acetate. The layers were separated, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts from each suspension were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography (4% to 12% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>) to afford 3-(furan-3-yl)acrylonitrile 600 mg (88% yield) as an oil in a 3.3:1 mixture of <i>E</i>:<i>Z</i> isomers. 3-(Furan-3-yl)acrylonitrile was subjected to general procedure C3 using <i>p</i>-anisaldehyde (0.605 mL, 4.98 mmol) to afford 292 mg of <b>10l</b> (22% yield) as a beige solid after purification via automated flash chromatography (3% to 15% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80 (s, 1H), 7.44 (t, <i>J</i> = 1.7 Hz, 1H), 7.18 (d, <i>J</i> = 8.1 Hz, 2H), 6.87 (d, <i>J</i> = 8.5 Hz, 2H), 6.76 (s, 1H), 5.69 (s, 1H), 5.23 (s, 1H), 3.79 (s, 3H), 3.47 (s, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 161.1, 159.2, 145.3, 143.1, 139.0, 130.1, 128.5, 128.1, 120.3, 114.3, 108.8, 89.3, 55.3, 51.3. Mp: 140–142 °C. LC/MS (<i>m</i>/<i>z</i>): 270.176 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.45 min.</div></div><div id="sec5_9_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 3-Methyl-1-(4-methylbenzyl)-1<i>H-</i>pyrazol-5-amine (<b>10m</b>)</h3><div class="NLM_p last">Synthesized using general procedure C3 from crotononitrile (0.70 mL, 8.6 mmol) and <i>p</i>-tolualdehyde (1.0 mL, 8.5 mmol) to afford 610 mg of <b>10m</b> (36% yield) as a yellow solid after purification via automated flash chromatography (5% to 20% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.13 (d, <i>J</i> = 7.9 Hz, 2H), 7.06 (d, <i>J</i> = 7.8 Hz, 2H), 5.37 (s, 1H), 5.11 (s, 2H), 3.29 (s, 2H), 2.32 (s, 3H), 2.19 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 147.4, 145.6, 137.1, 134.0, 129.4, 126.7, 90.9, 50.8, 21.1, 13.9. Mp: 102–104 °C. LC/MS (<i>m</i>/<i>z</i>): 202.158 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.13 min.</div></div><div id="sec5_9_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 3-Methyl-1-(2-methylbenzyl)-1<i>H-</i>pyrazol-5-amine (<b>10n</b>)</h3><div class="NLM_p last">Synthesized using general procedure C1 from (2-methylbenzyl)hydrazine hydrochloride (180 mg, 1.33 mmol) to afford 125 mg of <b>10n</b> (47% yield) as a white solid after purification via automated flash chromatography (5% to 20% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.22–7.08 (m, 3H), 6.74 (d, <i>J</i> = 7.3 Hz, 1H), 5.41 (s, 1H), 5.13 (s, 2H), 3.36–3.18 (m, 2H), 2.33 (s, 3H), 2.20 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 147.6, 145.6, 135.4, 135.0, 130.4, 127.5, 126.5, 126.1, 91.1, 74.1, 49.4, 19.1, 14.0. Mp: 84–87 °C. LC/MS (<i>m</i>/<i>z</i>): 202.202 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.10 min.</div></div><div id="sec5_9_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 1-(2-Chlorobenzyl)-3-methyl-1<i>H-</i>pyrazol-5-amine (<b>10o</b>)</h3><div class="NLM_p last">Synthesized using general procedure C1 from (2-chlorobenzyl)hydrazine dihydrochloride (300 mg, 1.31 mmol) to afford 245 mg of <b>10o</b> (85% yield) as a white solid after purification via automated flash chromatography (3% to 15% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43–7.33 (m, 1H), 7.24–7.15 (m, 2H), 6.85–6.72 (m, 1H), 5.43 (s, 1H), 5.23 (s, 2H), 3.42 (s, 2H), 2.20 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 148.2, 145.6, 134.7, 131.9, 129.3, 128.7, 127.9, 127.3, 91.1, 48.3, 14.0. Mp: 97–99 °C. LC/MS (<i>m</i>/<i>z</i>): 222.14 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.12 min.</div></div><div id="sec5_9_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 1-Methyl-3-phenyl-1<i>H-</i>pyrazol-5-amine (<b>10p</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 from benzoylacetonitrile (250 mg, 1.72 mmol) to afford 221 mg of <b>10p</b> (74% yield) as a white solid after purification via automated flash chromatography (25% to 40% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.78–7.67 (m, 2H), 7.36 (td, <i>J</i> = 7.2, 6.4, 1.3 Hz, 2H), 7.31–7.21 (m, 1H), 5.83 (s, 1H), 3.68 (s, 3H), 3.56 (s, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 149.7, 145.6, 133.8, 128.5, 127.5, 125.3, 88.5, 34.4. Mp: 127–128 °C. LC/MS (<i>m</i>/<i>z</i>): 174.103 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.14 min.</div></div><div id="sec5_9_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 1-(<i>tert</i>-Butyl)-3-phenyl-1<i>H-</i>pyrazol-5-amine (<b>10q</b>)</h3><div class="NLM_p last">Synthesized using general procedure C4 from benzoylacetonitrile (250 mg, 1.72 mmol) and <i>tert</i>-butylhydrazine hydrochloride (429 mg, 3.44 mmol) to afford 278 mg of <b>10q</b> (85% yield) as a yellow solid after purification via automated flash chromatography (7% to 20% ethyl acetate in hexanes). <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 7.62 (d, <i>J</i> = 7.5 Hz, 2H), 7.38–7.27 (m, 2H), 7.26–7.13 (m, 1H), 5.76 (d, <i>J</i> = 1.6 Hz, 1H), 4.95 (s, 2H), 1.55 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 147.5, 145.6, 134.4, 128.5, 127.1, 125.3, 91.3, 58.8, 29.4. Mp: 103–104 °C. LC/MS (<i>m</i>/<i>z</i>): 217.2 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.63 min.</div></div><div id="sec5_9_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 1-Cyclohexyl-3-phenyl-1<i>H-</i>pyrazol-5-amine (<b>10r</b>)</h3><div class="NLM_p last">Synthesized using general procedure C4 from benzoylacetonitrile (250 mg, 1.72 mmol) and cyclohexylhydrazine hydrochloride (519 mg, 3.44 mmol) to afford 326 mg of <b>10r</b> (79% yield) as a yellow solid after purification via automated flash chromatography (7% to 20% ethyl acetate in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77 (d, <i>J</i> = 7.6 Hz, 2H), 7.36 (t, <i>J</i> = 7.5 Hz, 2H), 7.30–7.25 (m, 1H), 5.88 (s, 1H), 3.99 (s, 1H), 3.62 (s, 1H), 2.17–1.84 (m, 7H), 1.72 (d, <i>J</i> = 11.5 Hz, 1H), 1.48–1.11 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 149.3, 144.5, 134.5, 128.5, 127.2, 125.5, 88.9, 56.2, 32.3, 25.8, 25.3. Mp: 126–128 °C. LC/MS (<i>m</i>/<i>z</i>): 243.225 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.68 min.</div></div><div id="sec5_9_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 1-Isobutyl-3-phenyl-1<i>H-</i>pyrazol-5-amine (<b>10s</b>)</h3><div class="NLM_p last">Synthesized using general procedure C4 from benzoylacetonitrile (100 mg, 0.689 mmol) and isobutylhydrazine hydrochloride (172 mg, 1.38 mmol) to afford 102 mg of <b>10s</b> (69% yield) after purification via automated flash chromatography (15% to 40% ethyl acetate in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.70 (m, 2H), 7.41–7.32 (m, 2H), 7.32–7.23 (m, 1H), 5.87 (s, 1H), 3.80 (d, <i>J</i> = 7.5 Hz, 2H), 3.50 (s, 2H), 2.29 (dt, <i>J</i> = 13.8, 6.9 Hz, 1H), 0.97 (d, <i>J</i> = 6.7 Hz, 6H).</div></div><div id="sec5_9_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 3-Isopropyl-1-methyl-1<i>H-</i>pyrazol-5-amine (<b>10t</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 from 4-methyl-3-oxopentanenitrile (200 mg, 1.80 mmol) to afford 205 mg of <b>10s</b> (82% yield) as a purple solid after purification via automated flash chromatography (2% to 6% methanol in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.38 (s, 1H), 3.61 (s, 3H), 3.42 (s, 2H), 2.83 (p, <i>J</i> = 7.0 Hz, 1H), 1.21 (d, <i>J</i> = 7.1 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 157.9, 144.7, 87.8, 33.9, 28.1, 22.9. Mp: 105–107 °C. LC/MS (<i>m</i>/<i>z</i>): 140.358 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.37 min.</div></div><div id="sec5_9_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 3-Cyclohexyl-1-methyl-1<i>H-</i>pyrazol-5-amine (<b>10u</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 from 3-cyclohexyl-3-oxopropanenitrile (253 mg, 1.67 mmol) to afford 161 mg of <b>10u</b> (54% yield) as a clear crystalline solid after recrystallization of the crude material from an ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub> mixture. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 5.27 (s, 1H), 3.51 (s, 3H), 2.47–2.32 (m, 1H), 1.93–1.66 (m, 5H), 1.43–1.12 (m, 5H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 157.1, 144.6, 88.2, 38.0, 33.9, 33.3, 26.4, 26.1. Mp: 170–171 °C. LC/MS (<i>m</i>/<i>z</i>): 181.205 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.16 min.</div></div><div id="sec5_9_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 1-Methyl-3-(<i>o</i>-tolyl)-1<i>H-</i>pyrazol-5-amine (<b>10v</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 from 3-(2-methylphenyl)-3-oxopropanenitrile (256 mg, 1.61 mmol) to afford 186 mg of <b>10v</b> (62% yield) as a brown solid after purification via automated flash chromatography (15% to 40% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.55–7.45 (m, 1H), 7.23–7.17 (m, 3H), 5.73 (s, 1H), 3.74 (s, 3H), 3.51 (s, 2H), 2.45 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 150.1, 144.7, 135.9, 133.8, 130.6, 129.0, 127.4, 125.7, 91.8, 34.2, 21.1. Mp: 69–72 °C. LC/MS (<i>m</i>/<i>z</i>): 189.145 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.14 min.</div></div><div id="sec5_9_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 1-Methyl-3-(<i>m</i>-tolyl)-1<i>H-</i>pyrazol-5-amine (<b>10w</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 from 3-(3-methylphenyl)-3-oxopropanenitrile (278 mg, 1.75 mmol) to afford 258 mg of <b>10w</b> (79% yield) as a white solid after purification via automated flash chromatography (15% to 40% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.58 (s, 1H), 7.49 (d, <i>J</i> = 7.7 Hz, 1H), 7.31–7.20 (m, 1H), 7.14–7.03 (m, 1H), 5.86 (s, 1H), 3.73 (d, <i>J</i> = 0.8 Hz, 3H), 3.53 (s, 2H), 2.37 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 149.8, 145.7, 138.1, 133.7, 128.4, 128.2, 125.9, 122.5, 88.5, 34.3, 21.5. Mp: 103–104 °C. LC/MS (<i>m</i>/<i>z</i>): 188.396 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.27 min.</div></div><div id="sec5_9_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 3-(3-Methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-amine (<b>10x</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 from 3-(3-methoxyphenyl)-3-oxopropanenitrile (306 mg, 1.75 mmol) to afford 279 mg of <b>10x</b> (79% yield) as a yellow solid after purification via automated flash chromatography (15% to 45% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.24 (m, 3H), 6.86–6.80 (m, 1H), 5.86 (s, 1H), 3.85 (s, 3H), 3.73 (s, 3H), 3.53 (s, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.8, 149.5, 145.8, 135.3, 129.5, 117.9, 113.4, 110.3, 88.6, 74.1, 55.3, 34.3. Mp: 91–92 °C. LC/MS (<i>m</i>/<i>z</i>): 205.158 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.21 min.</div></div><div id="sec5_9_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 1-Methyl-3-(3-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-amine (<b>10y</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 from 3-(trifluoromethyl)benzoylacetonitrile (373 mg, 1.75 mmol) to afford 334 mg of <b>10y</b> (79% yield) as a white/beige solid after purification via automated flash chromatography (15% to 40% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.97 (d, <i>J</i> = 2.2 Hz, 1H), 7.89 (d, <i>J</i> = 7.5 Hz, 1H), 7.48 (dt, <i>J</i> = 15.3, 7.7 Hz, 2H), 5.90 (s, 1H), 3.74 (s, 3H), 3.57 (s, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 148.2, 146.0, 134.7, 130.8 (q, <sup>2</sup><i>J</i><sub>C-F</sub> = 31.9 Hz), 129.0, 128.4, 128.4, 124.3 (q, <sup>1</sup><i>J</i><sub>C-F</sub> = 272.4 Hz), 123.9 (q, <sup>3</sup><i>J</i><sub>C-F</sub> = 4.1 Hz), 121.9 (q, <sup>3</sup><i>J</i><sub>C-F</sub> = 4.1 Hz), 88.4, 74.1, 34.3. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −62.7. Mp: 87–88 °C. LC/MS (<i>m</i>/<i>z</i>): 243.137 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.60 min.</div></div><div id="sec5_9_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 1-Methyl-3-(<i>p</i>-tolyl)-1<i>H-</i>pyrazol-5-amine. (<b>10z</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 with 3-(4-methylphenyl)-3-oxopropanenitrile (278 mg, 1.75 mmol) to afford 238 mg of <b>10z</b> (73% yield) as a white solid after purification via automated flash chromatography (15% to 40% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.61 (d, <i>J</i> = 8.2 Hz, 2H), 7.22–7.09 (m, 2H), 5.84 (s, 1H), 3.72 (s, 3H), 3.52 (s, 2H), 2.35 (s, 3H). Mp: 139–140 °C. LC/MS (<i>m</i>/<i>z</i>): 188.396 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.25 min.</div></div><div id="sec5_9_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 3-(4-Methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-amine (<b>10aa</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 with 3-(4-methoxyphenyl)-3-oxopropanenitrile (306 mg, 1.75 mmol) to afford 238 mg of <b>10aa</b> (67% yield) as an off-white/brown crystalline solid after purification via automated flash chromatography (15% to 45% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 7.60–7.47 (m, 2H), 6.91–6.80 (m, 2H), 5.57 (s, 1H), 5.18 (s, 2H), 3.73 (s, 3H), 3.51 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 159.1, 149.6, 145.5, 126.7, 126.5, 113.9, 88.1, 55.3, 34.3. Mp: 139–142 °C. LC/MS (<i>m</i>/<i>z</i>): 204.364 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.15 min.</div></div><div id="sec5_9_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 1-Methyl-3-(4-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-amine (<b>10ab</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 from 4-(trifluoromethyl)benzoylacetonitrile (373 mg, 1.75 mmol) to afford 326 mg of <b>10ab</b> (77% yield) as a white solid after purification via automated flash chromatography (15% to 40% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.84 (d, <i>J</i> = 8.1 Hz, 2H), 7.64 (d, <i>J</i> = 8.1 Hz, 2H), 5.89 (s, 1H), 3.67 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 149.8, 149.7, 138.8, 130.1 (q, <sup>2</sup><i>J</i><sub>C-F</sub> = 32.2 Hz), 126.6, 125.8 (q, <sup>1</sup><i>J</i><sub>C-F</sub> = 271.1 Hz), 126.4 (q, <sup>3</sup><i>J</i><sub>C-F</sub> = 3.9 Hz), 88.5, 34.4. <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −64.0. Mp: 170–172 °C. LC/MS (<i>m</i>/<i>z</i>): 243.137 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.61 min.</div></div><div id="sec5_9_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 3-(4-(<i>tert</i>-Butyl)phenyl)-1-methyl-1<i>H-</i>pyrazol-5-amine (<b>10ac</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 from 3-(4-<i>tert</i>-butylphenyl)-3-oxopropanenitrile (253 mg, 1.26 mmol) to afford 222 mg of <b>10ac</b> (77% yield) as a white solid after purification via automated flash chromatography (15% to 40% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.64 (d, <i>J</i> = 8.5 Hz, 2H), 7.38 (d, <i>J</i> = 8.5 Hz, 2H), 5.85 (s, 1H), 3.72 (s, 3H), 1.33 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 150.4, 149.7, 145.5, 131.1, 125.4, 125.0, 88.4, 74.1, 34.6, 34.3, 31.4. Mp: 143–145 °C. LC/MS (<i>m</i>/<i>z</i>): 231.183 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.59 min.</div></div><div id="sec5_9_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 1-Methyl-3-(4-(trifluoromethoxy)phenyl)-1<i>H-</i>pyrazol-5-amine (<b>10ad</b>)</h3><div class="NLM_p last">Synthesized using general procedure C5 from 4-(trifluoromethoxy)benzoyl acetonitrile (400 mg, 1.75 mmol) to afford 362 mg of <b>10ad</b> (81% yield) as a purple solid after purification via automated flash chromatography (15% to 40% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.73 (d, <i>J</i> = 8.7 Hz, 2H), 7.20 (d, <i>J</i> = 7.8 Hz, 2H), 5.85 (s, 1H), 3.73 (s, 3H), 3.55 (s, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 148.4, 146.0, 132.7, 126.5, 120.5 (q, <sup>1</sup><i>J</i><sub>C-F</sub> = 256.8 Hz) 121.0, 88.3, 34.2. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −57.8. Mp: 97–99 °C. LC/MS (<i>m</i>/<i>z</i>): 259.105 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.62 min.</div></div><div id="sec5_9_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 2-Bromo-4,6-bis(methoxymethoxy)benzoic Acid (<b>12</b>)</h3><div class="NLM_p">To a suspension of 2-bromo-4,6-dimethoxybenzaldehyde (3.0 g, 12 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) was added a freshly prepared solution of boron tribromide (3.5 mL, 37 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) via cannula over 15 min. The reaction was warmed to room temperature and stirred overnight. The reaction mixture was poured into 200 mL of ice water, and the resulting mixture was extracted four times with ethyl acetate. The combined organic layers were washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography (5% to 20% acetone in hexanes) to afford 1.8 g of 2-bromo-4,6-dihydroxybenzaldehyde as a white solid (81% yield). <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 12.18 (s, 1H), 11.33 (s, 1H), 9.96 (s, 1H), 6.69 (d, <i>J</i> = 2.2 Hz, 1H), 6.29 (d, <i>J</i> = 2.2 Hz, 1H). <sup>13</sup>C NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 194.5, 165.6, 165.4, 128.2, 113.9, 111.5, 102.3.</div><div class="NLM_p">To a solution of 2-bromo-4,6-dihydroxybenzaldehyde (1.5 g, 6.9 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (4.8 mL, 28 mmol) in DMF (20 mL) at room temperature was added chloromethyl methyl ether (2.1 mL, 28 mmol) dropwise. The reaction was stirred at room temperature overnight. The reaction mixture was poured into water, and the resulting mixture was extracted four times with Et<sub>2</sub>O. The combined organic layers were washed twice with water and once with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography (5% to 25% ethyl acetate in hexanes) to afford 2.1 g of 2-bromo-4,6-bis(methoxymethoxy)benzaldehyde as a white solid (93% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.34 (s, 1H), 7.01 (d, <i>J</i> = 2.3 Hz, 1H), 6.83 (d, <i>J</i> = 2.2 Hz, 1H), 5.26 (s, 2H), 5.20 (s, 2H), 3.51 (s, 3H), 3.48 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 189.1, 161.9, 161.2, 126.3, 118.3, 115.3, 102.9, 95.0, 94.3, 56.7, 56.5. Mp: 60–64 °C.</div><div class="NLM_p last">To a solution of 2-bromo-4,6-bis(methoxymethoxy)benzaldehyde (350 mg, 1.15 mmol) in <sup><i>t</i></sup>BuOH (3.6 mL) and THF (1.3 mL) at room temperature was added a solution of sodium chlorite (80%, 260 mg, 2.29 mmol) and sodium phosphate monobasic monohydrate (791 mg, 5.74 mmol) in water (1.9 mL) dropwise. To the yellow solution was added 2-methyl-2-butene (90%, 1.08 mL, 9.18 mmol). After 25 min, the orange solution became faint yellow/colorless and was diluted with ethyl acetate. The layers were separated, and the organic layer was washed three times with saturated NH<sub>4</sub>Cl (aq). The organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude carboxylic acid <b>12</b> (364 mg, 99% crude yield) was used in the next step without further purification.</div></div><div id="sec5_9_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (2-Bromo-4,6-bis(methoxymethoxy)phenyl)(isoindolin-2-yl)methanone (<b>13</b>)</h3><div class="NLM_p last">To a suspension of benzoic acid <b>12</b> (320 mg, 0.997 mmol) and isoindoline hydrochloride (156 mg, 1.49 mmol) in THF (2.9 mL) and CH<sub>2</sub>Cl<sub>2</sub> (2.9 mL) at room temperature was added trimethylamine (0.420 mL, 2.99 mmol) followed by HATU (451 mg, 1.20 mmol). After the suspension was stirred at room temperature, the reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>. The resulting mixture was washed with saturated NaHCO<sub>3</sub> (aq), brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography (20% to 50% ethyl acetate in hexanes) to afford 266 mg of <b>13</b> as a white solid (63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.27 (m, 3H), 7.19–7.14 (m, 1H), 6.99 (d, <i>J</i> = 2.1 Hz, 1H), 6.85 (d, <i>J</i> = 2.1 Hz, 1H), 5.21–5.10 (m, 4H), 5.07–4.94 (m, 2H), 4.68–4.48 (m, 2H), 3.49 (s, 3H), 3.42 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 165.6, 158.8, 154.8, 136.3, 136.2, 127.7, 127.5, 123.1, 123.0, 122.5, 119.8, 113.3, 103.1, 94.9, 94.4, 56.4, 56.2, 53.1, 51.7. Mp: 102–104 °C. LC/MS (<i>m</i>/<i>z</i>): 422.128 and 424.133 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.97 min.</div></div><div id="sec5_9_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Isoindolin-2-yl(2-((1-(4-methoxybenzyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)methanone (<b>14a</b>)</h3><div class="NLM_p last">Synthesized using general procedure D1 from <b>13</b> (45 mg, 110 μmol) and <b>10a</b> (25 mg, 170 μmol). Following silica gel flash chromatography (12% to 40% acetone in hexanes), TMT (18 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 52 mg of <b>14a</b> (87% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.24 (m, 3H), 7.16 (d, <i>J</i> = 7.1 Hz, 1H), 7.06 (d, <i>J</i> = 8.6 Hz, 2H), 6.64 (d, <i>J</i> = 8.7 Hz, 2H), 6.44–6.35 (m, 2H), 6.22 (d, <i>J</i> = 2.1 Hz, 1H), 5.85 (s, 1H), 5.15 (q, <i>J</i> = 6.7 Hz, 2H), 5.07 (d, <i>J</i> = 1.3 Hz, 2H), 5.03 (s, 2H), 4.99–4.41 (m, 4H), 3.66 (s, 3H), 3.45 (s, 2H), 3.44 (s, 3H), 2.24 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 159.7, 158.9, 155.3, 147.5, 143.6, 139.3, 136.5, 136.1, 128.6, 128.6, 128.6, 127.7, 127.6, 122.9, 122.5, 113.8, 107.7, 98.5, 96.4, 95.3, 95.0, 94.2, 56.5, 56.2, 55.1, 52.9, 52.0, 51.2, 14.1. LC/MS (<i>m</i>/<i>z</i>): 559.299 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.66 min.</div></div><div id="sec5_9_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Isoindolin-2-yl(2-((1-(4-methoxybenzyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)methanone (<b>14b</b>)</h3><div class="NLM_p last">Synthesized using general procedure D1 from <b>13</b> (40 mg, 95 μmol) and <b>10b</b> (25 mg, 170 μmol). Following silica gel flash chromatography (5% to 30% acetone in hexanes), TMT (18 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 52.6 mg of <b>14b</b> (89% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83–7.76 (m, 2H), 7.43–7.23 (m, 5H), 7.18 (d, <i>J</i> = 7.2 Hz, 1H), 7.16–7.09 (m, 2H), 6.70–6.61 (m, 2H), 6.48 (s, 1H), 6.42 (d, <i>J</i> = 2.1 Hz, 1H), 6.39 (s, 1H), 6.29 (d, <i>J</i> = 2.1 Hz, 1H), 5.16 (d, <i>J</i> = 7.2 Hz, 4H), 5.06 (s, 2H), 5.01–4.49 (m, 4H), 3.67 (s, 3H), 3.45 (s, 3H), 3.45 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 159.8, 159.0, 155.3, 150.0, 143.5, 140.0, 136.5, 136.1, 133.7, 128.7, 128.5, 128.3, 127.7, 127.6, 127.5, 125.3, 122.9, 122.5, 113.8, 107.8, 96.5, 96.3, 95.3, 95.2, 94.2, 56.5, 56.2, 55.1, 52.9, 52.0, 51.8. LC/MS (<i>m</i>/<i>z</i>): 621.311 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.03 min.</div></div><div id="sec5_9_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Isoindolin-2-yl(2-((1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)methanone (<b>14c</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>13</b> (45 mg, 110 μmol) and 1-[(4-methoxyphenyl)methyl]-1<i>H-</i>pyrazol-5-amine (24 mg, 170 μmol). Following silica gel flash chromatography (10% to 45% ethyl acetate in hexanes), TMT (22 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 66 mg of <b>14c</b> (108% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.31 (ddd, <i>J</i> = 16.1, 7.2, 2.0 Hz, 3H), 7.17 (d, <i>J</i> = 7.3 Hz, 1H), 7.09 (d, <i>J</i> = 8.7 Hz, 2H), 6.66 (d, <i>J</i> = 8.7 Hz, 2H), 6.45 (s, 1H), 6.40 (d, <i>J</i> = 2.2 Hz, 1H), 6.19 (d, <i>J</i> = 2.1 Hz, 1H), 6.05 (d, <i>J</i> = 2.0 Hz, 1H), 5.16 (dd, <i>J</i> = 9.7, 5.0 Hz, 2H), 5.11 (s, 2H), 5.07–5.01 (m, 2H), 4.99–4.79 (m, 3H), 4.56 (d, <i>J</i> = 14.6 Hz, 1H), 3.68 (s, 3H), 3.48–3.39 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.9, 159.8, 159.0, 155.4, 143.8, 138.9, 138.8, 136.6, 136.2, 128.9, 128.4, 128.3, 127.7, 127.6, 123.0, 122.5, 114.3, 113.9, 107.7, 99.2, 96.2, 95.3, 95.3, 94.3, 56.5, 56.2, 55.1, 53.0, 52.1, 51.6. LC/MS (<i>m</i>/<i>z</i>): 545.185 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.67 min.</div></div><div id="sec5_9_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Isoindolin-2-yl(2-((1-(4-methoxybenzyl)-4-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)methanone (<b>14d</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>13</b> 45 mg, 110 μmol) and <b>10c</b> (25 mg, 120 μmol). Following silica gel flash chromatography (10% to 40% acetone in hexanes), TMT (17 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite, and the filtrate was concentrated using a rotary evaporator to afford 49 mg of <b>14d</b> (82% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39–7.28 (m, 4H), 7.20 (d, <i>J</i> = 7.2 Hz, 1H), 7.07–7.01 (m, 2H), 6.66–6.54 (m, 2H), 6.36 (d, <i>J</i> = 2.1 Hz, 1H), 6.09 (s, 1H), 5.71 (d, <i>J</i> = 2.1 Hz, 1H), 5.16 (s, 2H), 5.10–4.81 (m, 7H), 4.61 (d, <i>J</i> = 14.7 Hz, 1H), 3.68 (s, 3H), 3.46 (s, 3H), 3.42 (s, 3H), 1.86 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.0, 159.9, 158.9, 155.4, 144.6, 139.2, 136.6, 136.3, 135.5, 128.9, 128.9, 127.8, 127.7, 123.1, 122.6, 113.8, 111.5, 107.1, 95.5, 95.3, 94.5, 94.2, 56.6, 56.2, 55.1, 53.1, 52.1, 51.8, 8.3. LC/MS (<i>m</i>/<i>z</i>): 559.166 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.81 min.</div></div><div id="sec5_9_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Isoindolin-2-yl(2-((4-isopropyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)methanone (<b>14e</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>13</b> (45 mg, 110 μmol) and <b>10d</b> (29 mg, 120 μmol). Following silica gel flash chromatography (10% to 30% acetone in hexanes), TMT (15 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 54 mg of <b>14e</b> (86% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.41 (s, 1H), 7.39–7.27 (m, 3H), 7.21 (d, <i>J</i> = 7.2 Hz, 1H), 7.02 (d, <i>J</i> = 8.1 Hz, 2H), 6.58 (d, <i>J</i> = 8.1 Hz, 2H), 6.35 (d, <i>J</i> = 2.2 Hz, 1H), 6.13 (s, 1H), 5.65 (d, <i>J</i> = 2.1 Hz, 1H), 5.17 (s, 2H), 5.11–4.83 (m, 7H), 4.62 (d, <i>J</i> = 14.7 Hz, 1H), 3.66 (s, 3H), 3.46 (s, 3H), 3.39 (s, 3H), 2.67 (p, <i>J</i> = 6.9 Hz, 1H), 1.13 (d, <i>J</i> = 6.9 Hz, 3H), 1.08 (d, <i>J</i> = 6.9 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.1, 159.9, 158.9, 155.5, 145.4, 136.6, 136.6, 136.3, 133.9, 129.0, 128.9, 127.7, 127.7, 123.7, 123.1, 122.6, 113.7, 106.9, 95.5, 95.3, 94.5, 94.2, 56.6, 56.1, 55.1, 53.1, 52.1, 51.6, 23.7, 23.6, 23.3. LC/MS (<i>m</i>/<i>z</i>): 587.262 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.96 min.</div></div><div id="sec5_9_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Isoindolin-2-yl(2-((1-(4-methoxybenzyl)-4-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)methanone (<b>14f</b>)</h3><div class="NLM_p last">Synthesized using general procedure D1 from <b>13</b> (40 mg, 95 μmol) and <b>10e</b> (29 mg, 100 μmol) for 4 h. Following silica gel flash chromatography (5% to 35% acetone in hexanes), TMT (13 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 25 mg of <b>14f</b> (43% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.79 (s, 1H), 7.41 (dt, <i>J</i> = 6.2, 1.3 Hz, 2H), 7.38–7.26 (m, 3H), 7.22–7.02 (m, 6H), 6.65 (d, <i>J</i> = 8.3 Hz, 2H), 6.47 (s, 1H), 6.36 (d, <i>J</i> = 2.1 Hz, 1H), 5.72 (d, <i>J</i> = 2.1 Hz, 1H), 5.24–4.94 (m, 6H), 4.93–4.81 (m, 3H), 4.58 (d, <i>J</i> = 14.7 Hz, 1H), 3.68 (s, 3H), 3.47 (s, 3H), 3.34 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.0, 159.9, 159.1, 155.5, 144.3, 137.7, 136.6, 136.2, 134.3, 132.1, 129.2, 128.5, 128.4, 127.8, 127.7, 126.3, 126.1, 123.1, 122.5, 116.7, 113.9, 107.3, 95.8, 95.4, 94.8, 94.2, 56.6, 56.2, 55.2, 53.0, 52.2, 51.9. LC/MS (<i>m</i>/<i>z</i>): 621.311 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.92 min</div></div><div id="sec5_9_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> (2-((4-Benzyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)(isoindolin-2-yl)methanone (<b>14g</b>)</h3><div class="NLM_p last">Synthesized using general procedure D1 from <b>13</b> (40 mg, 95 μmol) and <b>10f</b> (31 mg, 100 μmol) for 4 h. Following silica gel flash chromatography (10% to 35% acetone in hexanes), TMT (17 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 45 mg of <b>14g</b> (75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.41–7.27 (m, 4H), 7.23–6.96 (m, 7H), 6.68–6.56 (m, 2H), 6.34 (d, <i>J</i> = 2.1 Hz, 1H), 6.19 (s, 1H), 5.65 (d, <i>J</i> = 2.1 Hz, 1H), 5.16 (d, <i>J</i> = 2.4 Hz, 2H), 5.11–4.82 (m, 7H), 4.53 (d, <i>J</i> = 14.7 Hz, 1H), 3.69 (s, 3H), 3.61 (d, <i>J</i> = 3.5 Hz, 2H), 3.46 (s, 3H), 3.41 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.0, 159.8, 159.0, 155.4, 144.8, 140.2, 139.0, 136.6, 136.3, 135.4, 129.1, 128.7, 128.4, 128.2, 127.7, 127.6, 125.9, 123.0, 122.6, 115.6, 113.8, 106.9, 95.4, 95.3, 94.7, 94.1, 56.6, 56.2, 55.2, 53.0, 52.1, 51.8, 29.8. LC/MS (<i>m</i>/<i>z</i>): 635.292 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.96 min.</div></div><div id="sec5_9_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> (2-((3-(<i>tert</i>-Butyl)-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)(isoindolin-2-yl)methanone (<b>14h</b>)</h3><div class="NLM_p last">Synthesized using general procedure D1 from <b>13</b> (40 mg, 95 μmol) and <b>10i</b> (27 mg, 100 μmol) for 4 h. Following silica gel flash chromatography (5% to 25% acetone in hexanes), TMT (18 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 45 mg of <b>14h</b> (79% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35–7.27 (m, 3H), 7.16 (d, <i>J</i> = 7.2 Hz, 1H), 7.03 (d, <i>J</i> = 8.5 Hz, 2H), 6.64 (d, <i>J</i> = 8.6 Hz, 2H), 6.38 (d, <i>J</i> = 2.1 Hz, 1H), 6.33–6.23 (m, 2H), 5.92 (s, 1H), 5.14 (q, <i>J</i> = 6.5 Hz, 2H), 5.08 (s, 2H), 5.05 (s, 2H), 4.91 (d, <i>J</i> = 14.8 Hz, 1H), 4.84 (s, 2H), 4.51 (d, <i>J</i> = 14.6 Hz, 1H), 3.66 (s, 3H), 3.45 (s, 3H), 3.44 (s, 3H), 1.30 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 160.8, 159.8, 158.8, 155.3, 143.7, 138.8, 136.6, 136.2, 128.9, 128.4, 127.7, 127.6, 123.0, 122.5, 113.8, 107.8, 96.5, 95.3, 95.2, 95.1, 94.4, 56.5, 56.2, 55.1, 53.0, 52.0, 51.4, 32.3, 30.5. LC/MS (<i>m</i>/<i>z</i>): 601.331 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.04 min.</div></div><div id="sec5_9_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> (2,4-Bis(methoxymethoxy)-6-((1-methyl-1<i>H-</i>pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>14i</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>13</b> (45 mg, 110 μmol) and 1-methyl-1<i>H-</i>pyrazol-5-amine (11 mg, 120 μmol). Following silica gel flash chromatography (30% to 70% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>), TMT (19 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 38 mg of <b>14i</b> (82% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43 (d, <i>J</i> = 2.0 Hz, 1H), 7.38–7.27 (m, 3H), 7.19 (d, <i>J</i> = 6.9 Hz, 1H), 6.64 (s, 1H), 6.43 (d, <i>J</i> = 2.2 Hz, 1H), 6.08 (d, <i>J</i> = 2.1 Hz, 1H), 6.01 (d, <i>J</i> = 2.0 Hz, 1H), 5.21–5.10 (m, 3H), 5.08 (s, 2H), 5.05–4.84 (m, 2H), 4.63 (d, <i>J</i> = 14.7 Hz, 1H), 3.68 (s, 3H), 3.45 (s, 3H), 3.45 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.1, 159.9, 155.5, 144.4, 139.3, 138.6, 136.6, 136.1, 127.8, 127.6, 123.1, 122.5, 107.6, 99.1, 96.2, 95.4, 95.2, 94.2, 56.6, 56.3, 53.1, 52.2, 35.0. LC/MS (<i>m</i>/<i>z</i>): 439.33 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.48 min.</div></div><div id="sec5_9_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Isoindolin-2-yl(2-((1-(4-isopropylbenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)methanone (<b>14j</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>13</b> (40 mg, 95 μmol) and 1-([4-(propan-2-yl)phenyl]methyl)-1<i>H-</i>pyrazol-5-amine (22 mg, 100 μmol). Following silica gel flash chromatography (10% to 30% acetone in hexanes), TMT (15 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 42 mg of <b>14j</b> (80% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.48 (d, <i>J</i> = 2.0 Hz, 1H), 7.35–7.28 (m, 3H), 7.18 (d, <i>J</i> = 7.3 Hz, 1H), 7.06 (d, <i>J</i> = 8.1 Hz, 2H), 6.98 (d, <i>J</i> = 8.2 Hz, 2H), 6.43 (s, 1H), 6.40 (d, <i>J</i> = 2.1 Hz, 1H), 6.20 (d, <i>J</i> = 2.1 Hz, 1H), 6.06 (d, <i>J</i> = 2.0 Hz, 1H), 5.23–5.07 (m, 5H), 5.07–5.00 (m, 2H), 5.00–4.76 (m, 3H), 4.57 (d, <i>J</i> = 14.7 Hz, 1H), 3.45 (s, 6H), 2.76 (p, <i>J</i> = 6.9 Hz, 1H), 1.14 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.9, 159.8, 155.4, 148.2, 143.9, 139.0, 138.9, 136.6, 136.2, 133.6, 127.7, 127.6, 127.5, 127.5, 126.7, 123.0, 122.5, 107.7, 99.4, 96.2, 95.3, 95.2, 94.3, 56.6, 56.3, 53.0, 52.1, 51.9, 33.7, 23.9, 23.8. LC/MS (<i>m</i>/<i>z</i>): 557.27 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.93 min</div></div><div id="sec5_9_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (2,4-Bis(methoxymethoxy)-6-((3-methyl-1-(4-methylbenzyl)-1<i>H-</i>pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>14k</b>)</h3><div class="NLM_p last">Synthesized using general procedure D1 from <b>13</b> (45 mg, 110 μmol) and <b>10m</b> (24 mg, 120 μmol) and heated for 3 h. Following silica gel flash chromatography (10% to 35% acetone in hexanes), TMT (15 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 40 mg of <b>14k</b> (70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.27 (m, 3H), 7.16 (d, <i>J</i> = 7.2 Hz, 1H), 6.97 (d, <i>J</i> = 7.8 Hz, 2H), 6.88 (d, <i>J</i> = 7.8 Hz, 2H), 6.39 (d, <i>J</i> = 2.1 Hz, 1H), 6.32 (s, 1H), 6.24 (d, <i>J</i> = 2.1 Hz, 1H), 5.86 (s, 1H), 5.14 (q, <i>J</i> = 6.5 Hz, 2H), 5.07 (d, <i>J</i> = 1.3 Hz, 2H), 5.06 (s, 2H), 4.90 (d, <i>J</i> = 14.7 Hz, 1H), 4.83 (s, 2H), 4.48 (d, <i>J</i> = 14.6 Hz, 1H), 3.46 (s, 3H), 3.43 (s, 3H), 2.24 (s, 3H), 2.17 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 159.8, 155.3, 147.6, 143.7, 139.4, 137.0, 136.6, 136.2, 133.6, 129.2, 127.7, 127.6, 127.0, 122.9, 122.5, 107.8, 98.6, 96.4, 95.3, 95.1, 94.3, 56.5, 56.3, 52.9, 52.0, 51.7, 21.0, 14.2. LC/MS (<i>m</i>/<i>z</i>): 543.332 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.76 min.</div></div><div id="sec5_9_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> (2-((1-(2-Chlorobenzyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)(isoindolin-2-yl)methanone (<b>14l</b>)</h3><div class="NLM_p last">Inside a nitrogen glovebox were combined aryl bromide <b>13</b> (45 mg, 110 μmol), amine <b>10o</b> (26 mg, 170 μmol), tris(dibenzylideneacetone)dipalladium (3.9 mg, 4.3 μmol), Xantphos (6.2 mg, 11 μmol), and sodium phenoxide (19 mg, 160 μmol). Dioxane (0.8 mL) was added to the mixture, and the reaction vessel was capped and removed from the glovebox. The reaction vessel was heated at 60 °C for 90 min, 90 °C for 90 min, and then 120 °C for 2.5 h. After cooling to room temperature, the reaction was diluted with ethyl acetate. The resulting mixture was washed three times with saturated Na<sub>2</sub>CO<sub>3</sub> (aq), brine, then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. Following silica gel flash chromatography (10% to 30% acetone in hexanes), TMT (20 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 47 mg of <b>14l</b> (78% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34–7.27 (m, 3H), 7.16 (s, 1H), 7.09–6.93 (m, 3H), 6.72–6.62 (m, 1H), 6.39 (d, <i>J</i> = 2.1 Hz, 1H), 6.37 (s, 1H), 6.20 (d, <i>J</i> = 2.1 Hz, 1H), 5.93 (s, 1H), 5.28–5.01 (m, 6H), 4.86 (d, <i>J</i> = 14.5 Hz, 1H), 4.77 (s, 2H), 4.38 (d, <i>J</i> = 14.6 Hz, 1H), 3.46 (s, 3H), 3.42 (s, 3H), 2.26 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 159.8, 155.4, 148.4, 143.8, 140.1, 136.6, 136.1, 134.6, 131.8, 129.1, 128.4, 127.7, 127.6, 127.5, 127.0, 122.9, 122.6, 107.9, 99.4, 96.5, 95.3, 95.2, 94.3, 56.5, 56.3, 52.9, 52.0, 49.1, 14.3. LC/MS (<i>m</i>/<i>z</i>): 563.224 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.73 min.</div></div><div id="sec5_9_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> (2,4-Bis(methoxymethoxy)-6-((3-methyl-1-(2-methylbenzyl)-1<i>H-</i>pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>14m</b>)</h3><div class="NLM_p last">Inside a nitrogen glovebox were combined aryl bromide <b>13</b> (45 mg, 110 μmol), amine <b>10n</b> (28 mg, 140 μmol), <sup><i>t</i></sup>BuXPhos Palladacycle Gen. 1 (7.3 mg, 11 μmol), <sup><i>t</i></sup>BuXphos (4.5 mg, 11 μmol), sodium <i>tert</i>-butoxide (22 mg, 220 μmol). <i>tert</i>-Butanol (0.8 mL) was added to the mixture, and the reaction vessel was capped and removed from the glovebox. After stirring at room temperature for 2.5 h, the reaction was quenched with saturated NH<sub>4</sub>Cl (aq). The resulting mixture was extracted four times with ethyl acetate. The combined organic layers were washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts from each suspension were removed via gravity filtration, and volatile materials were condensed in vacuo. Following silica gel flash chromatography (40% to 80% ethyl acetate in hexanes), TMT (21 mg) was added to the isolated residue; the mixture was suspended in toluene (1.5 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 25 mg of <b>14m</b> (52% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35–7.28 (m, 3H), 7.21–7.09 (m, 1H), 7.03–6.88 (m, 3H), 6.65 (d, <i>J</i> = 7.6 Hz, 1H), 6.39 (d, <i>J</i> = 2.1 Hz, 1H), 6.33–6.26 (m, 2H), 5.91 (s, 1H), 5.16–5.03 (m, 7H), 4.85 (d, <i>J</i> = 14.7 Hz, 1H), 4.73 (d, <i>J</i> = 9.2 Hz, 2H), 4.38 (d, <i>J</i> = 14.7 Hz, 1H), 3.46 (s, 3H), 3.42 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.7, 159.7, 155.3, 147.8, 143.6, 140.1, 136.5, 136.2, 135.1, 134.8, 130.2, 127.7, 127.5, 127.2, 126.4, 126.2, 123.0, 122.5, 107.9, 98.3, 96.5, 95.3, 95.2, 94.3, 56.5, 56.3, 52.8, 51.9, 49.6, 19.0, 14.3. LC/MS (<i>m</i>/<i>z</i>): 543.288 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.75 min.</div></div><div id="sec5_9_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> (2,4-Bis(methoxymethoxy)-6-((1-methyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>14n</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>13</b> (60 mg, 140 μmol) and <b>10p</b> (27 mg, 160 μmol) and purified via automated flash chromatography (30% to 80% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). To QuadraPure MPA resin (1.5 mmol/g loading, 68 mg) soaked in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) for 90 min was transferred the purified product using CH<sub>2</sub>Cl<sub>2</sub> (3 mL), and the mixture was shaken overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 65 mg of <b>14n</b> (89% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.79–7.70 (m, 2H), 7.41–7.27 (m, 6H), 7.20 (d, <i>J</i> = 7.1 Hz, 1H), 6.72 (s, 1H), 6.45 (d, <i>J</i> = 2.1 Hz, 1H), 6.34 (s, 1H), 6.18 (d, <i>J</i> = 2.1 Hz, 1H), 5.24–5.11 (m, 3H), 5.09 (s, 2H), 5.06–4.86 (m, 2H), 4.65 (d, <i>J</i> = 14.7 Hz, 1H), 3.73 (s, 3H), 3.46 (d, <i>J</i> = 0.8 Hz, 3H), 3.45 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.1, 160.0, 155.6, 150.0, 144.3, 140.5, 136.6, 136.2, 133.6, 128.6, 128.4, 127.8, 127.6, 127.6, 127.4, 125.2, 123.1, 122.5, 107.7, 96.5, 96.4, 95.4, 95.2, 94.3, 56.6, 56.3, 53.1, 52.3, 35.2. LC/MS (<i>m</i>/<i>z</i>): 516.34 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.88 min.</div></div><div id="sec5_9_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> (2-Bromo-4,6-bis(methoxymethoxy)phenyl)(5-((1-methylpiperidin-4-yl)amino)isoindolin-2-yl)methanone (<b>15a</b>)</h3><div class="NLM_p">Inside a glovebox under a nitrogen atmosphere were combined <i>tert</i>-butyl 5-bromoisoindoline-2-carboxylate (85 mg, 0.29 mmol), tris(dibenzylideneacetone)dipalladium (13 mg, 0.014 mmol), Johnphos (8.5 mg, 0.029 mmol), and sodium <i>tert</i>-butoxide (38 mg, 0.40 mmol), and the mixture was suspended in toluene (4 mL). 4-Amino-1-methylpiperidine (39 mg mL, 0.34 mmol) was added to the mixture, and the reaction vessel was sealed and removed from the glovebox. The reaction mixture was irradiated at 120 °C for 30 min in a microwave reactor. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate, washed with brine, and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via silica gel flash chromatography (95:5:1 CH<sub>2</sub>Cl<sub>2</sub>/methanol/concentrated NH<sub>4</sub>OH (aq)) to afford 47 mg of <i>tert</i>-butyl 5-((1-methylpiperidin-4-yl)amino)isoindoline-2-carboxylate (50% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.01 (dd, <i>J</i> = 20.7, 8.1 Hz, 1H), 6.63–6.40 (m, 2H), 4.65–4.42 (m, 4H), 3.33–3.17 (m, 1H), 2.82 (d, <i>J</i> = 11.3 Hz, 2H), 2.31 (s, 3H), 2.22–2.02 (m, 4H), 1.50 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 154.5, 154.4, 146.6, 146.6, 138.4, 138.0, 125.6, 125.3, 123.3, 123.0, 113.1, 106.6, 106.5, 79.2, 54.4, 52.3, 52.0, 51.6, 51.3, 46.1, 32.3, 28.4. LC/MS (<i>m</i>/<i>z</i>): 332.193 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.19 min</div><div class="NLM_p">To a solution of <i>tert</i>-butyl 5-((1-methylpiperidin-4-yl)amino)isoindoline-2-carboxylate (47 mg, 0.14 mmol) from above in CH<sub>2</sub>Cl<sub>2</sub> (0.28 mL) at room temperature was added HCl (4 M in dioxane, 0.45 mL, 1.8 mmol), and the mixture was stirred overnight. The reaction was then triturated with ether. The suspension was filtered and the resulting solid washed with ether to afford 29 mg of <i>N</i>-(1-methylpiperidin-4-yl)isoindolin-5-amine dihydrogen chloride as a viscous gum (66% based on crude mass).</div><div class="NLM_p last">Benzoic acid <b>12</b> (68 mg, 0.21 mmol), <i>N</i>-(1-methylpiperidin-4-yl)isoindolin-5-amine dihydrogen chloride salt (64 mg, 0.21 mmol) from above, trimethylamine (0.12 mL, 0.84 mmol), and HATU (95 mg, 0.25 mmol) were reacted using the same procedure for the synthesis of amide <b>13</b> to afford 57 mg of <b>15a</b> (51% yield) after purification via automated flash chromatography (1% to 10% methanol in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.15–6.87 (m, 3H), 6.71–6.38 (m, 2H), 5.32–5.13 (m, 4H), 4.89 (s, 3H), 4.86–4.74 (m, 2H), 4.45 (d, <i>J</i> = 14.7 Hz, 2H), 3.48 (d, <i>J</i> = 1.2 Hz, 2H), 3.42–3.38 (m, 3H), 3.35 (s, 1H), 3.02 (t, <i>J</i> = 13.6 Hz, 2H), 2.44 (d, <i>J</i> = 11.0 Hz, 4H), 2.17–1.97 (m, 2H), 1.69–1.42 (m, 2H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 166.7, 166.7, 159.3, 159.3, 155.0, 147.8, 147.6, 136.7, 136.5, 123.5, 123.4, 123.1, 122.9, 122.2, 122.1, 119.2, 113.9, 113.7, 112.9, 112.8, 106.4, 106.3, 102.8, 102.8, 94.8, 94.7, 94.3, 55.4, 55.2, 53.7, 53.3, 52.7, 51.6, 51.0, 44.1, 30.7. LC/MS (<i>m</i>/<i>z</i>): 534.114 and 536.099 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.31 min.</div></div><div id="sec5_9_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> (2-Bromo-4,6-bis(methoxymethoxy)phenyl)(5-(2-(dimethylamino)ethoxy)isoindolin-2-yl)methanone (<b>15b</b>)</h3><div class="NLM_p">A suspension of <i>tert</i>-butyl 5-hydroxyisoindoline-2-carboxylate (250 mg, 1.06 mmol), 2-chloro-<i>N</i>,<i>N</i>-dimethylethylamine hydrochloride (367 mg, 2.55 mmol), and cesium carbonate (1.73 g, 5.31 mmol) in MeCN (4 mL) was heated overnight at 90 °C. The mixture was cooled to room temperature and diluted with 15% methanol in CH<sub>2</sub>Cl<sub>2</sub>. The resulting mixture was washed twice with water and once with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography (5% to 10% methanol in CH<sub>2</sub>Cl<sub>2</sub>) to afford 165 mg of <i>tert</i>-butyl 5-(2-(dimethylamino)ethoxy)isoindoline-2-carboxylate (51% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.12 (dd, <i>J</i> = 20.9, 8.3 Hz, 1H), 6.88–6.72 (m, 2H), 4.60 (t, <i>J</i> = 15.2 Hz, 4H), 4.05 (td, <i>J</i> = 5.7, 2.0 Hz, 2H), 2.74 (t, <i>J</i> = 5.7 Hz, 2H), 2.35 (s, 6H), 1.51 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 158.4, 158.4, 154.3, 154.3, 138.5, 138.1, 129.2, 128.8, 123.2, 123.0, 114.3, 114.0, 108.3, 108.2, 79.4, 66.0, 58.1, 52.2, 52.0, 51.6, 51.2, 45.7, 28.4. LC/MS (<i>m</i>/<i>z</i>): 307.139 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.18 min.</div><div class="NLM_p">To a solution of <i>tert</i>-butyl 5-(2-(dimethylamino)ethoxy)isoindoline-2-carboxylate from above (135 mg, 0.441 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.88 mL) at room temperature was added HCl (4 M in dioxane, 1.4 mL, 5.6 mmol), and the mixture was stirred overnight. The reaction was then triturated with ether. The suspension was filtered and the resulting solid washed with ether to afford 103 mg 2-(isoindolin-5-yloxy)-<i>N</i>,<i>N</i>-dimethylethan-1-amine dihydrochloride as a solid (84% based on crude mass).</div><div class="NLM_p last">Benzoic acid <b>12</b> (38 mg, 0.12 mmol), 2-(isoindolin-5-yloxy)-<i>N</i>,<i>N</i>-dimethylethan-1-amine dihydrochloride salt from above (33 mg, 0.12 mmol), trimethylamine (0.066 mL, 0.47 mmol), and HATU (54 mg, 0.14 mmol) were reacted using the same procedure for the synthesis of amide <b>13</b> to afford 60 mg of <b>15b</b> (75% yield) after purification via automated flash chromatography (1% to 8% methanol in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.14 (dd, <i>J</i> = 75.4, 8.4 Hz, 1H), 6.98 (t, <i>J</i> = 2.0 Hz, 1H), 6.94–6.66 (m, 3H), 5.25–5.05 (m, 4H), 4.92 (dd, <i>J</i> = 7.9, 3.4 Hz, 2H), 4.50 (q, <i>J</i> = 13.3 Hz, 2H), 4.09 (dt, <i>J</i> = 20.4, 5.5 Hz, 2H), 3.57–3.45 (m, 3H), 3.41 (s, 3H), 3.18 (q, <i>J</i> = 7.3 Hz, 4H), 2.87 (dt, <i>J</i> = 16.3, 5.6 Hz, 2H), 2.46 (s, 3H), 2.42 (s, 3H), 1.34 (t, <i>J</i> = 7.3 Hz, 4H). LC/MS (<i>m</i>/<i>z</i>): 509.062 and 511.047 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.29 min.</div></div><div id="sec5_9_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> (2-Bromo-4,6-bis(methoxymethoxy)phenyl)(5-(4-methylpiperazin-1-yl)isoindolin-2-yl)methanone (<b>15c</b>)</h3><div class="NLM_p">The procedure was adapted from ref <a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a>. Inside a glovebox under a nitrogen atmosphere were combined <i>tert</i>-butyl 5-bromoisoindoline-2-carboxylate (300 mg, 1.01 mmol), tris(dibenzylideneacetone)dipalladium (46.1 mg, 0.0503 mmol), Xantphos (29.1 mg, 0.0503 mmol), and sodium <i>tert</i>-butoxide (145 mg, 1.51 mmol) and suspended in toluene (3 mL). 1-Methylpiperazine (0.134 mL, 1.21 mmol) was added to the mixture, and the reaction vessel was sealed and removed from the glovebox. After heating at 100 °C overnight, the reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic mixture was washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography (1% to 7% methanol in CH<sub>2</sub>Cl<sub>2</sub>) to afford 259 mg of <i>tert</i>-butyl 5-(4-methylpiperazin-1-yl)isoindoline-2-carboxylate (81% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.12 (dd, <i>J</i> = 20.8, 8.3 Hz, 1H), 6.92–6.75 (m, 2H), 4.70–4.46 (m, 4H), 3.19 (d, <i>J</i> = 5.1 Hz, 4H), 2.58 (t, <i>J</i> = 5.0 Hz, 4H), 2.35 (s, 3H), 1.51 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 154.3, 154.3, 151.0, 138.1, 137.7, 128.2, 127.9, 122.9, 122.7, 115.8, 115.6, 110.0, 109.8, 79.2, 54.8, 52.3, 52.0, 51.6, 51.3, 49.4, 49.3, 45.9, 28.3. LC/MS (<i>m</i>/<i>z</i>): 318.167 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.04 min.</div><div class="NLM_p">To a solution of <i>tert</i>-butyl 5-(4-methylpiperazin-1-yl)isoindoline-2-carboxylate from above (259 mg, 0.816 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.6 mL) at room temperature was added HCl (4 M in dioxane, 2.59 mL, 10.4 mmol), and the mixture was stirred overnight. The reaction was then triturated with ether. The suspension was filtered and the resulting solid washed with ether to afford 262 mg of crude 5-(4-methylpiperazin-1-yl)isoindoline dihydrochloride salt (110% crude yield).</div><div class="NLM_p last">Benzoic acid <b>12</b> (133 mg, 0.374 mmol), 5-(4-methylpiperazin-1-yl)isoindoline dihydrochloride salt from above (106 mg, 0.365 mmol), trimethylamine (0.208 mL, 1.49 mmol), and HATU (169 mg, 0.448 mmol) were reacted using the same procedure for the synthesis of amide <b>13</b> to afford 132 mg of <b>15c</b> (68% yield) after purification via automated flash chromatography (1% to 8% methanol in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.23 (d, <i>J</i> = 8.6 Hz, 1H), 7.04 (d, <i>J</i> = 8.3 Hz, 1H), 6.98 (dd, <i>J</i> = 2.1, 1.5 Hz, 1H), 6.96–6.82 (m, 3H), 5.30 (s, 1H), 5.23–5.07 (m, 4H), 4.93 (d, <i>J</i> = 13.0 Hz, 2H), 4.61–4.39 (m, 2H), 3.49 (d, <i>J</i> = 0.9 Hz, 3H), 3.41 (d, <i>J</i> = 2.0 Hz, 3H), 3.27–3.12 (m, 5H), 2.64 (dt, <i>J</i> = 9.5, 4.7 Hz, 4H), 2.40 (d, <i>J</i> = 7.0 Hz, 3H), 1.39 (t, <i>J</i> = 7.3 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 165.7, 165.6, 158.8, 154.8, 151.3, 151.2, 137.2, 137.2, 127.1, 127.1, 123.5, 123.0, 122.7, 119.7, 116.5, 116.0, 113.2, 113.2, 110.4, 109.8, 103.1, 103.0, 94.9, 94.8, 94.4, 77.2, 56.4, 56.2, 54.8, 53.4, 52.7, 51.9, 51.2, 49.1, 49.1, 47.0, 47.0, 45.7, 8.7. LC/MS (<i>m</i>/<i>z</i>): 520.089 and 522.073 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.25 min.</div></div><div id="sec5_9_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> <i>N</i>-Benzyl-2-bromo-4,6-bis(methoxymethoxy)-<i>N</i>-methylbenzamide (<b>15d</b>)</h3><div class="NLM_p last">The product was synthesized using the same procedure for the synthesis of amide <b>13</b>. The reaction with benzoic acid <b>12</b> (0.68 g, 2.1 mmol), <i>N</i>-benzylmethylamine (0.41 mL, 3.2 mmol), trimethylamine (0.59 mL, 4.2 mmol), and HATU (0.96 g, 2.5 mmol) afforded 0.55 g of <b>15d</b> as a colorless oil (61% yield) after purification via automated flash chromatography (20% to 40% ethyl acetate in hexanes and 5% to 10% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>). Isomer 1: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42 (d, <i>J</i> = 7.5 Hz, 1H), 7.32 (dt, <i>J</i> = 20.9, 8.2 Hz, 4H), 6.96 (d, <i>J</i> = 2.1 Hz, 1H), 6.79 (d, <i>J</i> = 2.1 Hz, 1H), 5.29–5.08 (m, 6H), 5.03–4.59 (m, 2H), 3.47 (s, 3H), 3.43 (s, 3H), 2.75 (s, 3H). Isomer 2: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42 (d, <i>J</i> = 7.5 Hz, 1H), 7.32 (dt, <i>J</i> = 20.9, 8.2 Hz, 4H), 6.96 (d, <i>J</i> = 2.1 Hz, 1H), 6.82 (d, <i>J</i> = 2.2 Hz, 1H), 5.29–5.08 (m, 5H), 4.52–4.25 (m, 2H), 3.45 (s, 3H), 3.43 (s, 3H), 3.01 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 424.069 and 426.010 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.69 min.</div></div><div id="sec5_9_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> (2-((1-(4-Methoxybenzyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)(5-((1-methylpiperidin-4-yl)amino)isoindolin-2-yl)methanone (<b>16a</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>15a</b> (56.9 mg, 106 μmol) and <b>10a</b> (25.4 mg, 117 μmol) in dioxane. The crude mixture was purified via automated flash chromatography (2% to 10% methanol in CH<sub>2</sub>Cl<sub>2</sub>). To QuadraPure MPA resin (1.5 mmol/g loading, 45 mg) soaked in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) for 30 min was transferred the purified product using CH<sub>2</sub>Cl<sub>2</sub> (3 mL), and the mixture was shaken overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 41.8 mg of <b>16a</b> (59% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.14–6.91 (m, 3H), 6.66 (dd, <i>J</i> = 8.6, 1.5 Hz, 2H), 6.53 (q, <i>J</i> = 8.9, 8.2 Hz, 2H), 6.41–6.16 (m, 3H), 5.84 (s, 1H), 5.23–5.09 (m, 2H), 5.09–4.97 (m, 4H), 4.88–4.67 (m, 3H), 4.43 (t, <i>J</i> = 13.1 Hz, 1H), 3.68 (d, <i>J</i> = 1.5 Hz, 3H), 3.51–3.39 (m, 6H), 3.26 (d, <i>J</i> = 28.2 Hz, 1H), 2.83 (d, <i>J</i> = 13.5 Hz, 2H), 2.30 (d, <i>J</i> = 8.8 Hz, 4H), 2.24 (s, 3H), 2.18–1.95 (m, 4H), 1.49 (d, <i>J</i> = 11.8 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 166.7, 159.7, 158.9, 155.3, 147.6, 147.6, 147.1, 146.9, 143.7, 139.3, 137.8, 137.5, 128.7, 128.7, 128.7, 124.8, 124.5, 123.6, 123.2, 113.9, 113.9, 113.5, 113.4, 108.0, 107.9, 106.8, 106.3, 98.7, 98.6, 96.4, 96.4, 95.3, 95.3, 95.1, 95.0, 94.3, 56.5, 56.5, 56.2, 55.1, 55.1, 54.5, 53.2, 52.6, 52.2, 51.6, 51.3, 49.6, 46.2, 46.2, 32.4, 14.2. LC/MS (<i>m</i>/<i>z</i>): 671.282 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.45 min.</div></div><div id="sec5_9_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> (5-(2-(Dimethylamino)ethoxy)isoindolin-2-yl)(2-((1-(4-methoxybenzyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)methanone (<b>16b</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>15b</b> (41.9 mg, 82.3 μmol) and <b>10a</b> (19.7 mg, 90.5 μmol) in dioxane (0.8 mL). The crude mixture was purified via automated flash chromatography (1% to 8% methanol in CH<sub>2</sub>Cl<sub>2</sub>). To QuadraPure MPA resin (1.5 mmol/g loading, 34 mg) soaked in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) for 30 min was transferred the purified product using CH<sub>2</sub>Cl<sub>2</sub> (3 mL), and the mixture was shaken overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated in vacuo to afford 37.7 mg of <b>16b</b> (71% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.21 (d, <i>J</i> = 8.4 Hz, 1H), 7.05 (t, <i>J</i> = 8.8 Hz, 2H), 6.90–6.79 (m, 2H), 6.72–6.59 (m, 2H), 6.37 (dd, <i>J</i> = 7.7, 3.6 Hz, 2H), 6.22 (d, <i>J</i> = 2.4 Hz, 1H), 5.84 (s, 1H), 5.14 (q, <i>J</i> = 7.1 Hz, 2H), 5.04 (d, <i>J</i> = 12.2 Hz, 4H), 4.92–4.67 (m, 3H), 4.46 (t, <i>J</i> = 12.8 Hz, 1H), 4.05 (dt, <i>J</i> = 18.9, 5.7 Hz, 2H), 3.67 (s, 3H), 3.44 (s, 3H), 3.43 (s, 3H), 2.74 (dt, <i>J</i> = 11.6, 5.6 Hz, 2H), 2.35 (s, 3H), 2.33 (s, 3H), 2.23 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 166.8, 159.7, 158.9, 158.9, 158.8, 155.3, 147.6, 143.7, 139.3, 137.9, 137.5, 128.7, 128.6, 128.5, 128.2, 127.7, 126.4, 125.8, 125.3, 123.7, 123.3, 121.5, 120.7, 114.8, 114.5, 113.9, 108.6, 108.5, 107.8, 98.6, 96.4, 95.3, 95.3, 95.1, 94.3, 66.3, 66.2, 58.2, 58.2, 56.5, 56.5, 56.2, 55.1, 53.1, 52.5, 52.2, 51.5, 51.3, 45.8, 45.8, 14.2. LC/MS (<i>m</i>/<i>z</i>): 646.275 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.47 min.</div></div><div id="sec5_9_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> (2-((1-(4-Methoxybenzyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)phenyl)(5-(4-methylpiperazin-1-yl)isoindolin-2-yl)methanone (<b>16c</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>15c</b> (41 mg, 79 μmol) and <b>10a</b> (19 mg, 87 μmol) in dioxane (0.8 mL). The crude mixture was purified via automated flash chromatography (1% to 7% methanol in CH<sub>2</sub>Cl<sub>2</sub>). To QuadraPure MPA resin (1.5 mmol/g loading, 34 mg) soaked in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) for 30 min was transferred the purified product using CH<sub>2</sub>Cl<sub>2</sub> (3 mL), and the mixture was shaken overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated in vacuo to afford 39 mg of <b>16c</b> (75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.22–6.99 (m, 3H), 6.94–6.82 (m, 2H), 6.71–6.58 (m, 2H), 6.40–6.31 (m, 2H), 6.21 (dd, <i>J</i> = 5.1, 2.1 Hz, 1H), 5.84 (s, 1H), 5.19–5.08 (m, 2H), 5.08–4.97 (m, 4H), 4.91–4.71 (m, 3H), 4.46 (t, <i>J</i> = 13.0 Hz, 1H), 3.67 (d, <i>J</i> = 3.6 Hz, 3H), 3.51–3.40 (m, 6H), 3.29–3.10 (m, 4H), 2.59 (dt, <i>J</i> = 10.0, 4.7 Hz, 4H), 2.36 (d, <i>J</i> = 7.7 Hz, 3H), 2.24 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 166.7, 159.7, 158.9, 155.3, 151.5, 151.4, 147.6, 143.7, 139.3, 137.7, 137.3, 128.7, 128.7, 128.7, 127.5, 127.3, 123.4, 123.0, 116.4, 116.1, 113.9, 110.3, 109.8, 107.9, 107.8, 98.7, 98.6, 96.4, 95.3, 95.3, 95.1, 95.0, 94.3, 56.5, 56.2, 55.1, 55.0, 55.0, 53.2, 52.6, 52.3, 51.6, 51.3, 49.5, 49.5, 46.1, 46.1, 14.2. LC/MS (<i>m</i>/<i>z</i>): 657.301 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.89 min.</div></div><div id="sec5_9_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> <i>N-</i>Benzyl-2-((1-(4-methoxybenzyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)-<i>N</i>-methylbenzamide (<b>16d</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>15d</b> (30 mg, 71 μmol) and <b>10a</b> (17 mg, 78 μmol). Following silica gel flash chromatography (10% to 35% acetone in hexanes), TMT (15 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 39 mg of <b>16d</b> (98% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35–7.07 (m, 8H), 7.06–6.97 (m, 1H), 6.87–6.74 (m, 2H), 6.43–6.30 (m, 1H), 6.23 (dd, <i>J</i> = 15.2, 2.1 Hz, 1H), 5.84 (d, <i>J</i> = 12.4 Hz, 1H), 5.19–4.96 (m, 7H), 4.65–4.17 (m, 1H), 3.72 (d, <i>J</i> = 6.6 Hz, 3H), 3.46–3.35 (m, 6H), 2.91–2.78 (m, 3H), 2.27 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.0, 168.0, 159.6, 159.6, 159.0, 155.2, 155.0, 147.7, 147.6, 144.2, 144.1, 139.9, 139.5, 136.8, 136.4, 128.9, 128.8, 128.7, 128.7, 128.6, 128.6, 128.1, 127.7, 127.6, 127.4, 114.2, 114.1, 114.0, 106.9, 106.5, 98.4, 97.5, 97.0, 96.4, 95.0, 94.9, 94.9, 94.3, 94.3, 94.2, 91.4, 56.5, 56.3, 56.2, 56.2, 55.3, 55.2, 54.8, 51.2, 51.0, 50.9, 50.4, 35.8, 32.4, 14.3. LC/MS (<i>m</i>/<i>z</i>): 561.284 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.80 min.</div></div><div id="sec5_9_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Methyl 2-Bromo-4,6-bis(methoxymethoxy)benzoate (<b>17</b>)</h3><div class="NLM_p last">To a suspension of benzoic acid <b>12</b> (1.26 g, 3.93 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.951 g, 6.88 mmol) in DMF (39 mL) at room temperature was added iodomethane (0.428 mL, 6.88 mmol) dropwise. The suspension was heated to 80 °C and stirred for 1 h. After cooling to room temperature, the reaction was quenched with saturated NH<sub>4</sub>Cl (aq). The resulting mixture was extracted four times with ether. The combined organic layers were washed twice with water, brine and then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography (5% to 20% ethyl acetate in hexanes twice) to afford 1.02 g of <b>17</b> (77% yield) as a clear colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.94 (d, <i>J</i> = 2.1 Hz, 1H), 6.79 (d, <i>J</i> = 2.1 Hz, 1H), 5.15 (s, 2H), 5.14 (s, 2H), 3.92 (s, 3H), 3.46 (s, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.5, 159.0, 155.6, 120.7, 119.9, 113.0, 102.8, 94.7, 94.4, 56.3, 56.2, 52.6. LC/MS (<i>m</i>/<i>z</i>): [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = min (d<i>H-</i>109–763).</div></div><div id="sec5_9_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Methyl 2-((1-(4-Methoxybenzyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18a</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (130 mg, 390 μmol) and <b>10a</b> (93 mg, 430 μmol). Following silica gel flash chromatography (20% to 60% ethyl acetate in hexanes and 15% to 50% ethyl acetate in hexanes), TMT (59 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 161 mg of <b>18a</b> (88% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.64 (s, 1H), 7.17–7.10 (m, 2H), 6.82–6.73 (m, 2H), 6.24 (d, <i>J</i> = 2.3 Hz, 1H), 6.10 (d, <i>J</i> = 2.3 Hz, 1H), 5.88 (s, 1H), 5.17 (s, 2H), 5.06 (s, 2H), 5.03 (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H), 3.52 (s, 3H), 3.42 (s, 3H), 2.27 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.7, 161.3, 159.7, 158.9, 149.2, 147.7, 138.9, 128.9, 128.8, 113.9, 99.9, 99.5, 95.2, 95.0, 95.0, 93.9, 56.4, 56.2, 55.1, 51.8, 51.1, 14.2. LC/MS (<i>m</i>/<i>z</i>): 473.16 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.70 min.</div></div><div id="sec5_9_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Methyl 2-((1-(4-Methoxybenzyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18b</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (203 mg, 606 μmol) and <b>10b</b> (186 mg, 666 μmol). Following silica gel flash chromatography (7% to 25% ethyl acetate in hexanes), TMT (115 mg) was added to the isolated residue; the mixture was suspended in toluene (4 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 270 mg of <b>18b</b> (84% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.70 (s, 1H), 7.85–7.76 (m, 2H), 7.44–7.36 (m, 2H), 7.31 (d, <i>J</i> = 7.4 Hz, 1H), 7.20 (d, <i>J</i> = 8.7 Hz, 2H), 6.80 (d, <i>J</i> = 8.7 Hz, 2H), 6.42 (d, <i>J</i> = 0.7 Hz, 1H), 6.26 (d, <i>J</i> = 2.3 Hz, 1H), 6.15 (d, <i>J</i> = 2.3 Hz, 1H), 5.19 (s, 2H), 5.18 (s, 2H), 5.01 (s, 2H), 3.85 (s, 3H), 3.76 (s, 3H), 3.53 (s, 3H), 3.41 (s, 3H), 1.56 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.7, 161.4, 159.7, 159.0, 150.2, 149.0, 139.6, 133.7, 128.9, 128.5, 128.5, 127.5, 125.3, 113.9, 100.1, 97.3, 95.2, 95.2, 95.1, 93.9, 56.4, 56.3, 55.1, 51.8, 51.6. LC/MS (<i>m</i>/<i>z</i>): 535.438 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.01 min</div></div><div id="sec5_9_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> Methyl 2-((3-Ethyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18c</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (100 mg, 298 μmol) and <b>10g</b> (75.9 mg, 328 μmol). Following silica gel flash chromatography (15% to 40% ethyl acetate in hexanes), TMT (40 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 123 mg of <b>18c</b> (85% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.16 (s, 2H), 6.80 (d, <i>J</i> = 8.3 Hz, 2H), 6.25 (s, 1H), 6.14 (s, 1H), 5.93 (s, 1H), 5.17 (s, 2H), 5.11 (s, 2H), 5.03 (s, 2H), 3.83 (s, 3H), 3.76 (s, 3H), 3.52 (s, 3H), 3.42 (s, 3H), 2.65 (q, <i>J</i> = 7.7 Hz, 2H), 1.25 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.7, 161.4, 159.7, 159.0, 153.9, 149.2, 138.9, 128.9, 128.9, 113.9, 100.0, 98.0, 95.3, 95.1, 94.0, 56.4, 56.3, 55.2, 51.8, 51.2, 22.1, 13.9. LC/MS (<i>m</i>/<i>z</i>): 487.318 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.80 min.</div></div><div id="sec5_9_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Methyl 2-((3-Isopropyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18d</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> 100 mg, 298 μmol) and <b>10h</b> (80.5 mg, 328 μmol). Following silica gel flash chromatography (12% to 35% ethyl acetate in hexanes), TMT (42 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 112 mg of <b>18d</b> (75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.59 (s, 1H), 7.14 (d, <i>J</i> = 8.2 Hz, 2H), 6.86–6.71 (m, 2H), 6.24 (d, <i>J</i> = 2.2 Hz, 1H), 6.13 (s, 1H), 5.93 (s, 1H), 5.17 (s, 2H), 5.10 (s, 2H), 5.01 (s, 2H), 3.82 (s, 3H), 3.76 (s, 3H), 3.51 (s, 3H), 3.42 (s, 3H), 2.97 (p, <i>J</i> = 6.9 Hz, 1H), 1.27 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.6, 161.4, 159.7, 159.0, 158.3, 149.2, 138.8, 129.0, 128.8, 113.9, 100.1, 96.5, 95.3, 95.2, 95.2, 94.0, 56.4, 56.2, 55.2, 51.8, 51.2, 28.3, 22.9. LC/MS (<i>m</i>/<i>z</i>): 501.344 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.89 min.</div></div><div id="sec5_9_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Methyl 2-((3-Cyclopropyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18e</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (100 mg, 298 μmol) and <b>10j</b> (80.0 mg, 328 μmol). Following silica gel flash chromatography (8% to 50% ethyl acetate in hexanes), TMT (44 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 133 mg of <b>18e</b> (89% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 7.15 (d, <i>J</i> = 8.2 Hz, 2H), 6.85–6.73 (m, 2H), 6.24 (d, <i>J</i> = 2.2 Hz, 1H), 6.11 (s, 1H), 5.72 (s, 1H), 5.16 (s, 2H), 5.07 (s, 2H), 5.02 (s, 2H), 3.82 (s, 3H), 3.76 (s, 3H), 3.51 (s, 3H), 3.42 (s, 3H), 1.93 (dq, <i>J</i> = 8.8, 5.1, 4.4 Hz, 1H), 0.90 (dd, <i>J</i> = 7.7, 5.5 Hz, 2H), 0.77–0.63 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.7, 161.4, 159.7, 159.0, 154.3, 149.1, 138.9, 128.9, 128.9, 113.9, 100.0, 95.7, 95.3, 95.2, 94.0, 56.4, 56.3, 55.2, 51.8, 51.2, 9.7, 7.9. LC/MS (<i>m</i>/<i>z</i>): 499.315 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.81 min.</div></div><div id="sec5_9_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> Methyl 2-((3-Cyclopentyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18f</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (81 mg, 240 μmol) and <b>10k</b> (67 mg, 240 μmol) in dioxane (1.2 mL). Following silica gel flash chromatography (8% to 25% ethyl acetate in hexanes), TMT (36 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 90 mg of <b>18f</b> (71% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.60 (s, 1H), 7.15 (d, <i>J</i> = 8.2 Hz, 2H), 6.80 (d, <i>J</i> = 8.6 Hz, 2H), 6.24 (s, 1H), 6.15 (s, 1H), 5.92 (s, 1H), 5.17 (s, 2H), 5.10 (s, 2H), 5.02 (s, 2H), 3.82 (s, 3H), 3.76 (s, 3H), 3.51 (s, 3H), 3.42 (s, 3H), 3.08 (t, <i>J</i> = 8.1 Hz, 1H), 2.06 (s, 2H), 1.83–1.45 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.6, 161.4, 159.7, 159.0, 156.6, 149.2, 138.9, 129.0, 128.8, 113.9, 100.1, 97.0, 95.3, 95.2, 95.2, 94.0, 56.4, 56.3, 55.2, 51.8, 51.2, 39.6, 33.4, 25.4. LC/MS (<i>m</i>/<i>z</i>): 527.366 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.02 min.</div></div><div id="sec5_9_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> Methyl 2-((3-(Furan-3-yl)-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18g</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (88.4 mg, 328 μmol) and <b>10l</b> (88.4 mg, 328 μmol). Following silica gel flash chromatography (12% to 35% ethyl acetate in hexanes), TMT (44 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 111 mg of <b>18g</b> (71% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.68 (s, 1H), 7.77 (dd, <i>J</i> = 1.6, 0.9 Hz, 1H), 7.45 (t, <i>J</i> = 1.7 Hz, 1H), 7.17 (d, <i>J</i> = 8.6 Hz, 2H), 6.85–6.78 (m, 2H), 6.76 (dd, <i>J</i> = 1.9, 0.9 Hz, 1H), 6.26 (d, <i>J</i> = 2.3 Hz, 1H), 6.22–6.18 (m, 1H), 6.14 (d, <i>J</i> = 2.2 Hz, 1H), 5.18 (s, 2H), 5.16 (s, 2H), 5.02 (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H), 3.52 (s, 3H), 3.41 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.7, 161.4, 159.8, 159.1, 149.0, 143.7, 143.2, 139.5, 139.1, 128.9, 128.6, 120.2, 113.9, 108.8, 100.2, 97.6, 95.3, 95.3, 95.2, 94.0, 56.5, 56.3, 55.2, 51.9, 51.6. LC/MS (<i>m</i>/<i>z</i>): 524.279 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.81 min.</div></div><div id="sec5_9_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18h</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (100 mg, 207 μmol) and 1-methyl-1<i>H-</i>pyrazol-5-amine (31.9 mg, 328 μmol). Following silica gel flash chromatography (10% to 35% ethyl acetate in hexanes), TMT (30 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 80.6 mg of <b>18h</b> (77% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.95 (s, 1H), 7.47 (d, <i>J</i> = 2.0 Hz, 1H), 6.27 (d, <i>J</i> = 2.3 Hz, 1H), 6.08 (dd, <i>J</i> = 8.0, 2.1 Hz, 2H), 5.18 (s, 2H), 5.07 (s, 2H), 3.91 (s, 3H), 3.73 (s, 3H), 3.52 (s, 3H), 3.42 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.1, 161.6, 160.0, 149.5, 139.0, 138.6, 99.4, 95.3, 95.2, 94.6, 93.9, 56.5, 56.3, 52.0, 35.0. LC/MS (<i>m</i>/<i>z</i>): 353.233 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.34 min.</div></div><div id="sec5_9_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> Methyl 2-((1-Isopropyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18i</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and 1-(propan-2-yl)-1<i>H-</i>pyrazol-5-amine (61.6 mg, 492 μmol). Following silica gel flash chromatography (10% to 30% ethyl acetate in hexanes), TMT (47 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 124 mg of <b>18i</b> (73% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.84 (s, 1H), 7.53 (d, <i>J</i> = 1.9 Hz, 1H), 6.24 (d, <i>J</i> = 2.3 Hz, 1H), 6.05 (dd, <i>J</i> = 5.1, 2.0 Hz, 2H), 5.18 (s, 2H), 5.05 (s, 2H), 4.48 (p, <i>J</i> = 6.6 Hz, 1H), 3.91 (s, 3H), 3.52 (d, <i>J</i> = 1.2 Hz, 3H), 3.40 (d, <i>J</i> = 0.8 Hz, 3H), 1.45 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.6, 160.0, 150.4, 138.6, 137.4, 100.2, 99.4, 95.3, 95.1, 94.5, 93.9, 56.4, 56.2, 51.9, 48.6, 22.4. LC/MS (<i>m</i>/<i>z</i>): 381.329 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.61 min.</div></div><div id="sec5_9_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Methyl 2-((1-Isobutyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18j</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and 1-(2-methylpropyl)-1<i>H-</i>pyrazol-5-amine (68.3 mg, 492 μmol). Following silica gel flash chromatography (12% to 33% ethyl acetate in hexanes), TMT (50 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 136 mg of <b>18j</b> (77% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.93 (s, 1H), 7.50 (d, <i>J</i> = 2.0 Hz, 1H), 6.25 (d, <i>J</i> = 2.3 Hz, 1H), 6.18 (d, <i>J</i> = 2.3 Hz, 1H), 6.07 (d, <i>J</i> = 1.9 Hz, 1H), 5.18 (s, 2H), 5.06 (s, 2H), 3.90 (s, 3H), 3.80 (d, <i>J</i> = 7.4 Hz, 2H), 3.52 (s, 3H), 3.42 (s, 3H), 2.22 (hept, <i>J</i> = 7.0 Hz, 1H), 0.90 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.1, 161.6, 160.0, 149.7, 138.9, 138.6, 99.6, 99.2, 95.3, 95.2, 94.7, 93.9, 56.4, 56.2, 55.1, 51.9, 29.4, 19.9. LC/MS (<i>m</i>/<i>z</i>): 395.355 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.73 min.</div></div><div id="sec5_9_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Methyl 2-((1-(Cyclohexylmethyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18k</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (139 mg, 415 μmol) and 1-(cyclohexylmethyl)-1<i>H-</i>pyrazol-5-amine (81.8 mg, 456 μmol). Following silica gel flash chromatography (8% to 25% ethyl acetate in hexanes), TMT (44 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 130 mg of <b>18k</b> (72% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.88 (s, 1H), 7.49 (d, <i>J</i> = 2.0 Hz, 1H), 6.25 (d, <i>J</i> = 2.3 Hz, 1H), 6.16 (d, <i>J</i> = 2.3 Hz, 1H), 6.09–5.97 (m, 1H), 5.18 (s, 2H), 5.06 (s, 2H), 3.91 (s, 3H), 3.82 (d, <i>J</i> = 7.3 Hz, 2H), 3.53 (s, 3H), 3.41 (s, 3H), 1.91 (tt, <i>J</i> = 7.5, 3.7 Hz, 1H), 1.75–1.54 (m, 6H), 1.32–1.07 (m, 3H), 0.96 (q, <i>J</i> = 11.8 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.1, 161.6, 159.9, 149.7, 139.0, 138.6, 99.7, 99.1, 95.3, 95.2, 94.7, 93.9, 56.4, 56.3, 53.9, 51.9, 38.5, 30.6, 26.3, 25.7. LC/MS (<i>m</i>/<i>z</i>): 435.405 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.93 min.</div></div><div id="sec5_9_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-phenyl-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18l</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and 1-phenyl-1<i>H-</i>pyrazol-5-amine (78.4 mg, 492 μmol). Following silica gel flash chromatography (12% to 33% ethyl acetate in hexanes), TMT (47 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 132 mg of <b>18l</b> (71% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.99 (s, 1H), 7.66 (d, <i>J</i> = 2.0 Hz, 1H), 7.60–7.53 (m, 2H), 7.49–7.40 (m, 2H), 7.38–7.32 (m, 1H), 6.46 (d, <i>J</i> = 2.3 Hz, 1H), 6.30–6.19 (m, 2H), 5.16 (s, 2H), 5.09 (s, 2H), 3.79 (s, 3H), 3.50 (s, 3H), 3.43 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.6, 161.5, 159.7, 148.2, 140.3, 139.3, 138.5, 129.2, 127.6, 124.0, 100.5, 99.1, 95.7, 95.2, 95.2, 94.0, 56.4, 56.3, 51.9. LC/MS (<i>m</i>/<i>z</i>): 415.292 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.67 min.</div></div><div id="sec5_9_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> Methyl 2-((1-Cyclohexyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18m</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and 1-cyclohexyl-1<i>H-</i>pyrazol-5-amine (81.4 mg, 492 μmol). Following silica gel flash chromatography (10% to 30% ethyl acetate in hexanes), TMT (60 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 152 mg of <b>18m</b> (81% yield) as a clear yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.84 (s, 2H), 7.51 (d, <i>J</i> = 1.9 Hz, 2H), 6.24 (d, <i>J</i> = 2.3 Hz, 2H), 6.13–5.96 (m, 1H), 5.19 (s, 1H), 5.05 (s, 2H), 4.09–3.97 (m, 1H), 3.91 (s, 3H), 3.53 (d, <i>J</i> = 1.0 Hz, 3H), 3.40 (s, 3H), 1.99–1.81 (m, 7H), 1.72–1.64 (m, 1H), 1.46–1.06 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.6, 160.0, 150.4, 138.5, 137.6, 99.9, 99.5, 95.3, 95.1, 94.5, 93.8, 56.4, 56.3, 56.2, 51.9, 32.7, 25.6, 25.2. LC/MS (<i>m</i>/<i>z</i>): 421.379 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.83 min.</div></div><div id="sec5_9_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> Methyl 2-((1-Benzyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18n</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (140 mg, 418 μmol) and 1-benzyl-1<i>H-</i>pyrazol-5-amine (79.6 mg, 460 μmol). Following silica gel flash chromatography (10% to 30% ethyl acetate in hexanes), TMT (44 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 116 mg of <b>18n</b> (65% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.69 (s, 1H), 7.54 (d, <i>J</i> = 2.0 Hz, 1H), 7.31–7.23 (m, 3H), 7.22–7.17 (m, 2H), 6.25 (d, <i>J</i> = 2.3 Hz, 1H), 6.11 (d, <i>J</i> = 2.0 Hz, 1H), 6.09 (d, <i>J</i> = 2.3 Hz, 1H), 5.20 (s, 2H), 5.17 (s, 2H), 5.01 (s, 2H), 3.82 (s, 3H), 3.51 (s, 3H), 3.41 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.7, 161.4, 159.8, 149.3, 139.2, 138.9, 136.5, 128.6, 127.7, 127.6, 100.2, 100.0, 95.3, 95.3, 94.9, 93.9, 56.5, 56.3, 52.0, 51.9. LC/MS (<i>m</i>/<i>z</i>): 429.362 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.71 min.</div></div><div id="sec5_9_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-(pyridin-3-ylmethyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18o</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and 1-(pyridin-3-ylmethyl)-1<i>H-</i>pyrazol-5-amine (85.8 mg, 492 μmol) and purified via silica gel flash chromatography (10% to 30% acetone in CH<sub>2</sub>Cl<sub>2</sub>). To QuadraPure MPA resin (1.5 mmol/g loading, 192 mg) soaked in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) for 30 min was transferred the purified product using CH<sub>2</sub>Cl<sub>2</sub> (2 mL), and the mixture was shaken overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 135 mg of <b>18o</b> (71% yield) as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.61 (s, 1H), 7.31 (dd, <i>J</i> = 8.5, 7.3 Hz, 2H), 7.18 (dd, <i>J</i> = 8.5, 1.3 Hz, 2H), 7.07–6.99 (m, 1H), 6.59 (d, <i>J</i> = 2.2 Hz, 1H), 6.26 (d, <i>J</i> = 2.3 Hz, 1H), 5.18 (s, 2H), 5.08 (s, 2H), 3.88 (s, 3H), 3.52 (s, 3H), 3.43 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.8, 160.9, 159.4, 148.1, 141.1, 129.3, 123.0, 121.5, 101.8, 95.7, 95.2, 95.2, 94.0, 56.4, 56.2, 51.9. LC/MS (<i>m</i>/<i>z</i>): 429.582 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.16 min.</div></div><div id="sec5_9_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> Methyl 2-((1-(Furan-2-ylmethyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18p</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and 1-(furan-2-ylmethyl)-1<i>H-</i>pyrazol-5-amine (80.3 mg, 492 μmol). Following silica gel flash chromatography (12% to 35% ethyl acetate in hexanes), TMT (60 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 145 mg of <b>18p</b> (78% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.85 (s, 1H), 7.51 (d, <i>J</i> = 1.9 Hz, 1H), 7.41–7.33 (m, 1H), 6.35–6.28 (m, 2H), 6.28 (d, <i>J</i> = 2.2 Hz, 1H), 6.17 (d, <i>J</i> = 2.2 Hz, 1H), 6.09 (d, <i>J</i> = 2.0 Hz, 1H), 5.19 (s, 4H), 5.05 (s, 2H), 3.90 (s, 3H), 3.52 (d, <i>J</i> = 0.9 Hz, 3H), 3.42 (d, <i>J</i> = 0.9 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.8, 161.4, 159.8, 149.4, 149.2, 142.8, 139.3, 139.0, 110.4, 108.7, 100.2, 99.9, 95.4, 95.3, 95.0, 93.9, 56.4, 56.3, 51.9, 44.7. LC/MS (<i>m</i>/<i>z</i>): 419.35 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.57 min.</div></div><div id="sec5_9_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> Methyl 2-((1-(4-Isopropylbenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18q</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (80 mg, 240 μmol) and 1-([4-(propan-2-yl)phenyl]methyl)-1<i>H-</i>pyrazol-5-amine (57 mg, 270 μmol). Following silica gel flash chromatography (7% to 25% ethyl acetate in hexanes), TMT (21 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 55 mg of <b>18q</b> (49% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.67 (s, 1H), 7.52 (d, <i>J</i> = 2.0 Hz, 1H), 7.14 (s, 4H), 6.24 (d, <i>J</i> = 2.3 Hz, 1H), 6.10 (t, <i>J</i> = 2.2 Hz, 2H), 5.17 (s, 2H), 5.16 (s, 2H), 5.00 (s, 2H), 3.83 (s, 3H), 3.52 (s, 3H), 3.41 (s, 3H), 2.85 (p, <i>J</i> = 7.0 Hz, 1H), 1.20 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.7, 161.4, 159.8, 149.3, 148.3, 139.1, 138.8, 133.8, 127.7, 126.7, 100.1, 100.0, 95.3, 95.3, 94.9, 93.9, 56.4, 56.3, 51.9, 51.7, 33.8, 23.9. LC/MS (<i>m</i>/<i>z</i>): 470.381 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.96 min.</div></div><div id="sec5_9_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-(4-(trifluoromethyl)benzyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18r</b>)</h3><div class="NLM_p last">Inside a nitrogen glovebox were combined aryl bromide <b>17</b> (145 mg, 432 μmol), 1-([4-(trifluoromethyl)phenyl]methyl)-1<i>H-</i>pyrazol-5-amine hydrochloride (100 mg, 360 μmol), tris(dibenzylideneacetone)dipalladium (16.5 mg, 18.0 μmol). Xantphos (25.0 mg, 43.2, μmol), and sodium phenoxide (155 mg, 1.33 mmol). Dioxane (3.4 mL) was added to the mixture, and the reaction vessel was capped and removed from the glovebox. After the reaction was irradiated at 170 °C for 2 h in a microwave reactor, the reaction cooled to room temperature and diluted with ethyl acetate. The resulting mixture was washed three times with saturated Na<sub>2</sub>CO<sub>3</sub> (aq), brine, then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. Following silica gel flash chromatography (10% to 40% ethyl acetate in hexanes), TMT (30 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 66 mg of <b>18r</b> (37% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.78 (s, 1H), 7.55 (d, <i>J</i> = 1.9 Hz, 1H), 7.53 (d, <i>J</i> = 8.1 Hz, 2H), 7.29 (d, <i>J</i> = 8.0 Hz, 2H), 6.25 (d, <i>J</i> = 2.3 Hz, 1H), 6.13 (d, <i>J</i> = 1.9 Hz, 1H), 6.04 (d, <i>J</i> = 2.3 Hz, 1H), 5.26 (s, 2H), 5.17 (s, 2H), 5.01 (s, 2H), 3.83 (s, 3H), 3.51 (s, 3H), 3.40 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.9, 161.5, 159.9, 149.2, 140.4, 140.4, 139.5, 139.1, 129.9 (q, <sup>2</sup><i>J</i><sub>C-F</sub> = 32.6 Hz), 127.9, 125.6 (q, <sup>3</sup><i>J</i><sub>C-F</sub> = 3.7 Hz), 124.0 (q, <sup>1</sup><i>J</i><sub>C-F</sub> = 272.0 Hz), 100.4, 99.9, 95.4, 95.3, 94.8, 93.9, 56.4, 56.3, 51.9, 51.5. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −62.6. LC/MS (<i>m</i>/<i>z</i>): 497.33 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.88 min.</div></div><div id="sec5_9_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18s</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (50 mg, 150 μmol) and <b>10p</b> (28 mg, 160 μmol). Following silica gel flash chromatography (10% to 35% MTBE in hexanes), TMT (21 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 55 mg of <b>18s</b> (86% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.01 (s, 1H), 7.81–7.72 (m, 2H), 7.48–7.34 (m, 2H), 7.34–7.27 (m, 1H), 6.51–6.36 (m, 1H), 6.29 (d, <i>J</i> = 2.3 Hz, 1H), 6.18 (d, <i>J</i> = 2.2 Hz, 1H), 5.20 (s, 2H), 5.08 (s, 2H), 3.92 (s, 3H), 3.78 (s, 3H), 3.53 (s, 3H), 3.42 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 161.7, 160.1, 150.1, 149.4, 140.1, 133.6, 128.6, 127.6, 125.3, 99.8, 96.6, 95.3, 95.3, 94.9, 94.0, 56.5, 56.3, 52.0, 35.2. LC/MS (<i>m</i>/<i>z</i>): 429.23 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.76 min.</div></div><div id="sec5_9_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> Methyl 2-((1-(<i>tert</i>-Butyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18t</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (69.4 mg, 207 μmol) and <b>10q</b> (49.0 mg, 227 μmol) in dioxane (1.6 mL). Following silica gel flash chromatography (7% to 20% MTBE in hexanes), TMT (29 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 65.5 mg of <b>18t</b> (68% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.91 (s, 1H), 7.83–7.73 (m, 2H), 7.47–7.35 (m, 2H), 7.33–7.22 (m, 1H), 6.47–6.38 (m, 1H), 6.28–6.19 (m, 2H), 5.19 (s, 2H), 5.05 (s, 2H), 3.91 (s, 3H), 3.54 (s, 3H), 3.40 (s, 3H), 1.68 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.3, 161.6, 160.0, 150.4, 147.8, 139.2, 134.1, 128.5, 127.3, 125.2, 100.0, 99.3, 95.4, 95.0, 94.7, 94.0, 59.8, 56.5, 56.3, 51.9, 29.8. LC/MS (<i>m</i>/<i>z</i>): 471.263 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.15 min.</div></div><div id="sec5_9_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> Methyl 2-((1-Cyclohexyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18u</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (100 mg, 298 μmol) and <b>10r</b> (79.2 mg, 323 μmol). Following silica gel flash chromatography (8% to 25% MTBE in hexanes), TMT (44 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 111 mg of <b>18u</b> (75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.89 (s, 1H), 7.84–7.75 (m, 2H), 7.38 (t, <i>J</i> = 7.7 Hz, 2H), 7.30–7.27 (m, 1H), 6.40–6.33 (m, 1H), 6.26 (d, <i>J</i> = 2.3 Hz, 1H), 6.17 (d, <i>J</i> = 2.3 Hz, 1H), 5.20 (s, 2H), 5.05 (s, 2H), 4.07 (td, <i>J</i> = 11.2, 5.5 Hz, 1H), 3.92 (s, 3H), 3.54 (s, 3H), 3.40 (s, 3H), 2.12–1.87 (m, 6H), 1.74–1.66 (m, 1H), 1.47–1.16 (m, 3H).</div></div><div id="sec5_9_77" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Methyl 2-((1-Isobutyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18v</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (100 mg, 298 μmol) and <b>10s</b> (66.4 mg, 308 μmol). Following silica gel flash chromatography (7% to 20% ethyl acetate in hexanes), TMT (42 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 118 mg of <b>18v</b> (84% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.05 (s, 1H), 7.84–7.78 (m, 2H), 7.40 (t, <i>J</i> = 7.6 Hz, 2H), 7.30 (t, <i>J</i> = 7.3 Hz, 1H), 6.40 (s, 1H), 6.29 (d, <i>J</i> = 2.1 Hz, 2H), 5.20 (s, 2H), 5.08 (s, 2H), 3.92 (s, 3H), 3.88 (d, <i>J</i> = 7.4 Hz, 2H), 3.54 (s, 3H), 3.42 (s, 3H), 2.40–2.21 (m, 1H), 0.94 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.6, 160.0, 150.0, 149.6, 140.0, 133.8, 128.6, 127.5, 125.4, 99.7, 96.4, 95.3, 95.2, 95.0, 94.0, 56.5, 56.3, 55.2, 52.0, 29.5, 20.0. LC/MS (<i>m</i>/<i>z</i>): 471.307 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.05 min.</div></div><div id="sec5_9_78" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> Methyl 2-((3-Isopropyl-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18w</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) an amine <b>10t</b> (68.5 mg, 492 μmol). Following silica gel flash chromatography (15% to 45% ethyl acetate in hexanes), TMT (55 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 129 mg of <b>18w</b> (78% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.26 (d, <i>J</i> = 2.3 Hz, 1H), 6.14 (d, <i>J</i> = 2.2 Hz, 1H), 5.89 (s, 1H), 5.18 (s, 2H), 5.08 (s, 2H), 3.89 (d, <i>J</i> = 0.9 Hz, 3H), 3.66 (s, 3H), 3.52 (d, <i>J</i> = 0.6 Hz, 3H), 3.43 (d, <i>J</i> = 0.6 Hz, 3H), 2.92 (p, <i>J</i> = 6.9 Hz, 1H), 1.26 (d, <i>J</i> = 7.0 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.1, 161.6, 159.9, 158.1, 149.5, 139.1, 99.7, 95.8, 95.3, 95.1, 94.9, 94.0, 56.4, 56.2, 51.9, 34.6, 28.3, 22.8. LC/MS (<i>m</i>/<i>z</i>): 395.355 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.68 min.</div></div><div id="sec5_9_79" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Methyl 2-((3-Cyclohexyl-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18x</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) an amine <b>10u</b> (88.3 mg, 492 μmol). Following silica gel flash chromatography (15% to 40% ethyl acetate in hexanes), TMT (42 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 108 mg of <b>18x</b> (56% yield) as a clear yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.87 (s, 1H), 6.26 (d, <i>J</i> = 2.3 Hz, 1H), 6.12 (d, <i>J</i> = 2.3 Hz, 1H), 5.87 (s, 1H), 5.18 (s, 2H), 5.07 (s, 2H), 3.89 (s, 3H), 3.66 (s, 3H), 3.52 (s, 3H), 3.43 (s, 3H), 2.64–2.50 (m, 1H), 2.05–1.90 (m, 2H), 1.86–1.75 (m, 2H), 1.75–1.62 (m, 1H), 1.50–1.15 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.0, 161.6, 159.9, 157.3, 149.5, 139.0, 99.7, 96.1, 95.3, 95.1, 94.9, 94.0, 56.4, 56.2, 51.9, 38.1, 34.6, 33.2, 26.4, 26.1. LC/MS (<i>m</i>/<i>z</i>): 435.405 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.97 min.</div></div><div id="sec5_9_80" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(<i>o</i>-tolyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18y</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and <b>10v</b> (92.2 mg, 492 μmol). Following silica gel flash chromatography 10% to 30% ethyl acetate in hexanes), TMT (48 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 139 mg of <b>18y</b> (70% yield) as a clear yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.59 (s, 1H), 7.27–7.21 (m, 2H), 6.30–6.16 (m, 3H), 5.20 (s, 2H), 5.08 (s, 2H), 3.92 (s, 3H), 3.79 (s, 3H), 3.53 (s, 3H), 3.42 (s, 3H), 2.48 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.7, 160.0, 150.4, 149.5, 139.2, 135.8, 133.5, 130.7, 129.0, 127.6, 125.8, 99.7, 95.3, 95.3, 94.7, 94.0, 56.5, 56.3, 52.0, 35.1, 21.1. LC/MS (<i>m</i>/<i>z</i>): 443.388 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.93 min.</div></div><div id="sec5_9_81" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(<i>m</i>-tolyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18z</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (170 mg, 570 μmol) and <b>10w</b> (104 mg, 558 μmol). Following silica gel flash chromatography (10% to 30% ethyl acetate in hexanes), TMT (66 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 155 mg of <b>18z</b> (69% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.99 (s, 1H), 7.63 (s, 1H), 7.55 (d, <i>J</i> = 7.8 Hz, 1H), 7.29 (d, <i>J</i> = 7.7 Hz, 1H), 7.12 (d, <i>J</i> = 7.6 Hz, 1H), 6.42–6.32 (m, 1H), 6.29 (d, <i>J</i> = 2.3 Hz, 1H), 6.17 (d, <i>J</i> = 2.3 Hz, 1H), 5.20 (s, 2H), 5.08 (s, 2H), 3.92 (s, 3H), 3.77 (s, 3H), 3.53 (s, 3H), 3.42 (s, 3H), 2.39 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.7, 160.1, 150.2, 149.5, 140.1, 138.2, 133.5, 128.5, 128.4, 125.8, 122.5, 99.8, 96.7, 95.3, 95.2, 94.9, 94.0, 56.5, 56.3, 52.0, 35.1, 21.5.</div></div><div id="sec5_9_82" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> Methyl 2,4-Bis(methoxymethoxy)-6-((3-(3-methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18aa</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and <b>10x</b> (100 mg, 492 μmol). Following silica gel flash chromatography (10% to 40% ethyl acetate in hexanes), TMT (64 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 161 mg of <b>18aa</b> (79% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.02 (s, 1H), 7.39–7.29 (m, 3H), 6.86 (dd, <i>J</i> = 7.8, 2.2 Hz, 1H), 6.39 (s, 1H), 6.30 (dd, <i>J</i> = 2.3, 1.0 Hz, 1H), 6.18 (t, <i>J</i> = 2.4 Hz, 1H), 5.20 (s, 2H), 5.08 (s, 2H), 3.92 (s, 3H), 3.87 (s, 3H), 3.78 (d, <i>J</i> = 2.1 Hz, 3H), 3.53 (s, 3H), 3.43 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.7, 160.1, 159.9, 149.9, 149.4, 140.1, 135.0, 129.6, 117.9, 113.7, 110.2, 99.8, 96.8, 95.3, 95.2, 94.9, 93.9, 56.5, 56.3, 55.3, 52.0, 35.2. LC/MS (<i>m</i>/<i>z</i>): 459.399 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.85 min.</div></div><div id="sec5_9_83" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(3-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18ab</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and <b>10y</b> (119 mg, 492 μmol). Following silica gel flash chromatography (10% to 30% ethyl acetate in hexanes), TMT (65 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 165 mg of <b>18ab</b> (74% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.09 (s, 1H), 8.04 (s, 1H), 7.95 (d, <i>J</i> = 7.5 Hz, 1H), 7.58–7.43 (m, 2H), 6.47–6.40 (m, 1H), 6.31 (d, <i>J</i> = 2.3 Hz, 1H), 6.20 (d, <i>J</i> = 2.3 Hz, 1H), 5.20 (s, 2H), 5.09 (s, 2H), 3.92 (s, 3H), 3.79 (s, 3H), 3.53 (s, 3H), 3.43 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.7, 160.1, 149.2, 148.6, 140.6, 134.5, 130.9 (q, <sup>2</sup><i>J</i><sub>C-F</sub> = 32.2 Hz), 129.0, 128.4, 124.2 (q, <sup>1</sup><i>J</i><sub>C-F</sub> = 272.4 Hz), 124.1 (q, <sup>3</sup><i>J</i><sub>C-F</sub> = 3.8 Hz), 122.0 (q, <sup>3</sup><i>J</i><sub>C-F</sub> = 3.9 Hz), 99.8, 96.5, 95.4, 95.3, 94.9, 94.0, 56.4, 56.3, 52.0, 35.2. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −62.7. LC/MS (<i>m</i>/<i>z</i>): 497.286 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.09 min.</div></div><div id="sec5_9_84" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(<i>p</i>-tolyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18ac</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and <b>10z</b> (92.2 mg, 492 μmol). Following silica gel flash chromatography (10% to 30% ethyl acetate in hexanes), TMT (59 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 160 mg of <b>18ac</b> (81% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.98 (s, 1H), 7.66 (d, <i>J</i> = 7.9 Hz, 2H), 7.20 (d, <i>J</i> = 7.9 Hz, 2H), 6.36 (s, 1H), 6.29 (d, <i>J</i> = 2.2 Hz, 1H), 6.18 (d, <i>J</i> = 2.3 Hz, 1H), 5.19 (s, 2H), 5.08 (s, 2H), 3.91 (d, <i>J</i> = 0.9 Hz, 3H), 3.76 (s, 3H), 3.53 (s, 3H), 3.42 (s, 3H), 2.37 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.7, 160.1, 150.2, 149.5, 140.0, 137.3, 130.8, 129.3, 125.2, 99.8, 96.4, 95.3, 95.2, 94.9, 94.0, 56.5, 56.3, 52.0, 35.1, 21.2. LC/MS (<i>m</i>/<i>z</i>): 443.388 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.94 min.</div></div><div id="sec5_9_85" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> Methyl 2,4-Bis(methoxymethoxy)-6-((3-(4-methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18ad</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and <b>10aa</b> (100 mg, 492 μmol). Following silica gel flash chromatography (15% to 45% ethyl acetate in hexanes), TMT (57 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 161 mg of <b>18ad</b> (78% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.98 (s, 1H), 7.70 (d, <i>J</i> = 8.6 Hz, 2H), 6.93 (d, <i>J</i> = 8.6 Hz, 2H), 6.32 (s, 1H), 6.29 (d, <i>J</i> = 2.3 Hz, 1H), 6.18 (d, <i>J</i> = 2.3 Hz, 1H), 5.19 (s, 2H), 5.08 (s, 2H), 3.92 (s, 3H), 3.84 (s, 3H), 3.75 (s, 3H), 3.53 (s, 3H), 3.42 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.1, 161.7, 160.1, 159.3, 150.0, 149.5, 140.0, 126.5, 126.5, 114.0, 99.7, 96.1, 95.3, 95.2, 94.9, 94.0, 56.5, 56.3, 55.3, 52.0, 35.0. LC/MS (<i>m</i>/<i>z</i>): 459.354 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.80 min.</div></div><div id="sec5_9_86" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(4-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18ae</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and <b>10ab</b> (119 mg, 492 μmol). Following silica gel flash chromatography (10% to 30% ethyl acetate in hexanes), TMT (60 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 180 mg of <b>18ae</b> (81% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.09 (s, 1H), 7.88 (d, <i>J</i> = 8.1 Hz, 2H), 7.64 (d, <i>J</i> = 8.1 Hz, 2H), 6.45 (s, 1H), 6.31 (d, <i>J</i> = 2.3 Hz, 1H), 6.19 (d, <i>J</i> = 2.2 Hz, 1H), 5.20 (s, 2H), 5.09 (s, 2H), 3.92 (s, 3H), 3.79 (s, 3H), 3.53 (s, 3H), 3.43 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.7, 160.1, 149.2, 148.6, 140.5, 137.0, 137.0, 129.3 (q, <sup>2</sup><i>J</i><sub>C-F</sub> = 32.3 Hz), 128.8, 125.53 (q, <sup>3</sup><i>J</i><sub>C-F</sub> = 3.8 Hz), 124.3 (q, <sup>1</sup><i>J</i><sub>C-F</sub> = 271.8 Hz), 123.0, 120.3, 99.8, 96.8, 95.4, 95.3, 94.9, 94.0, 56.5, 56.3, 52.0, 35.3. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −62.4. LC/MS (<i>m</i>/<i>z</i>): 497.33 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.06 min.</div></div><div id="sec5_9_87" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Methyl 2-((3-(4-(<i>tert</i>-Butyl)phenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoate (<b>18af</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and <b>10ac</b> (113 mg, 492 μmol). Following silica gel flash chromatography (10% to 30% ethyl acetate in hexanes), TMT (58 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 174 mg of <b>18af</b> (80% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.98 (s, 1H), 7.70 (d, <i>J</i> = 8.2 Hz, 2H), 7.42 (d, <i>J</i> = 8.2 Hz, 2H), 6.37 (s, 1H), 6.28 (d, <i>J</i> = 2.2 Hz, 1H), 5.19 (s, 2H), 5.07 (s, 2H), 3.92 (s, 2H), 3.76 (s, 3H), 3.53 (s, 3H), 3.42 (s, 3H), 1.34 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.7, 160.0, 150.6, 150.1, 149.5, 140.0, 130.8, 129.0, 128.2, 125.5, 125.3, 125.0, 99.7, 96.5, 95.3, 95.2, 94.9, 94.0, 56.5, 56.3, 52.0, 35.1, 34.6, 31.3. LC/MS (<i>m</i>/<i>z</i>): 485.377 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.20 min.</div></div><div id="sec5_9_88" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> Methyl 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(4-(trifluoromethoxy)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoate (<b>18ag</b>)</h3><div class="NLM_p last">Synthesized using general procedure D2 from <b>17</b> (150 mg, 448 μmol) and <b>10ad</b> (127 mg, 492 μmol). Following silica gel flash chromatography (12% to 33% ethyl acetate in hexanes), TMT (66 mg) was added to the isolated residue; the mixture was suspended in toluene (3 mL) and stirred overnight. The suspension was filtered through a plug of Celite and the filtrate was concentrated using a rotary evaporator to afford 183 mg of <b>18ag</b> (80% yield) as a white/yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.04 (s, 1H), 7.83–7.71 (m, 2H), 7.25–7.19 (m, 2H), 6.41–6.34 (m, 1H), 6.30 (d, <i>J</i> = 2.3 Hz, 1H), 6.17 (d, <i>J</i> = 2.2 Hz, 1H), 5.20 (s, 2H), 5.08 (s, 2H), 3.92 (s, 3H), 3.77 (s, 3H), 3.53 (s, 3H), 3.43 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.7, 160.1, 149.3, 148.8, 140.4, 132.5, 126.6, 121.1, 120.5 (q, <i>J</i> = 256.9 Hz), 99.8, 96.5, 95.3, 95.3, 94.9, 94.0, 56.4, 56.3, 52.0, 35.2. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −57.8. LC/MS (<i>m</i>/<i>z</i>): 513.296 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.04 min.</div></div><div id="sec5_9_89" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> 2-((1-(4-Methoxybenzyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(methoxymethoxy)-6-((methoxymethyl)peroxy)benzoic Acid (<b>19a</b>)</h3><div class="NLM_p last">Ester <b>18a</b> (105 mg, 0.222 mmol) was hydrolyzed using general procedure E to afford 95.1 mg of crude acid <b>19a</b> (93% crude yield).</div></div><div id="sec5_9_90" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> 2-((1-(4-Methoxybenzyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(methoxymethoxy)-6-((methoxymethyl)peroxy)benzoic Acid (<b>19b</b>)</h3><div class="NLM_p last">Ester <b>18b</b> (267 mg, 500 μmol) was hydrolyzed using general procedure E to afford 235 mg of crude acid <b>19b</b> (90% crude yield).</div></div><div id="sec5_9_91" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> 2-((3-Ethyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19c</b>)</h3><div class="NLM_p last">Ester <b>18c</b> (123 mg, 253 μmol) was hydrolyzed using general procedure E to afford 112 mg of crude acid <b>19c</b> (94% crude yield).</div></div><div id="sec5_9_92" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> 2-((3-Isopropyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19d</b>)</h3><div class="NLM_p last">Ester <b>18d</b> (112 mg, 224 μmol) was hydrolyzed using general procedure E to afford 111 mg of crude acid <b>19d</b> (102% crude yield).</div></div><div id="sec5_9_93" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> 2-((3-Cyclopropyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19e</b>)</h3><div class="NLM_p last">Ester <b>18e</b> (132 mg, 265 μmol) was hydrolyzed using general procedure E to afford 118 mg of crude acid <b>19e</b> (92% crude yield).</div></div><div id="sec5_9_94" class="NLM_sec NLM_sec_level_2"><div id="ac_i131" class="anchor-spacer"></div><h3 class="article-section__title" id="_i131"> 2-((3-Cyclopentyl-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19f</b>)</h3><div class="NLM_p last">Ester <b>18f</b> (90.1 mg, 171 μmol) was hydrolyzed using general procedure E to afford 90 mg of crude acid <b>19f</b> (103% crude yield).</div></div><div id="sec5_9_95" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> 2-((3-(Furan-3-yl)-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19g</b>)</h3><div class="NLM_p last">Ester <b>18g</b> (110 mg, 210 μmol) was hydrolyzed using general procedure E to afford 104 mg of crude acid <b>19g</b> (97% crude yield).</div></div><div id="sec5_9_96" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> 2,4-Bis(methoxymethoxy)-6-((1-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19h</b>)</h3><div class="NLM_p last">Ester <b>18h</b> (79.8 mg, 227 μmol) was hydrolyzed using general procedure E to afford 27.6 mg of crude acid <b>19h</b> (36% crude yield).</div></div><div id="sec5_9_97" class="NLM_sec NLM_sec_level_2"><div id="ac_i134" class="anchor-spacer"></div><h3 class="article-section__title" id="_i134"> 2-((1-Isopropyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19i</b>)</h3><div class="NLM_p last">Ester <b>18i</b> (124 mg, 327 μmol) was hydrolyzed using general procedure E to afford 98.8 mg of crude acid <b>19i</b> (83% crude yield).</div></div><div id="sec5_9_98" class="NLM_sec NLM_sec_level_2"><div id="ac_i135" class="anchor-spacer"></div><h3 class="article-section__title" id="_i135"> 2-((1-Isobutyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19j</b>)</h3><div class="NLM_p last">Ester <b>18j</b> (135 mg, 343 μmol) was hydrolyzed using general procedure E to afford 119 mg of crude acid <b>19j</b> (91% crude yield).</div></div><div id="sec5_9_99" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> 2-((1-(Cyclohexylmethyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19k</b>)</h3><div class="NLM_p last">Ester <b>18k</b> (125 mg, 288 μmol) was hydrolyzed using general procedure E to afford 105 mg of crude acid <b>19k</b> (87% crude yield).</div></div><div id="sec5_9_100" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> 2,4-Bis(methoxymethoxy)-6-((1-phenyl-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19l</b>)</h3><div class="NLM_p last">Ester <b>18l</b> (131 mg, 317 μmol) was hydrolyzed using general procedure E to afford 114 mg of crude acid <b>19l</b> (90% crude yield).</div></div><div id="sec5_9_101" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> 2-((1-Cyclohexyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19m</b>)</h3><div class="NLM_p last">Ester <b>18m</b> (152 mg, 362 μmol) was hydrolyzed using general procedure E to afford 152 mg of crude acid <b>19m</b> (103% crude yield).</div></div><div id="sec5_9_102" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> 2-((1-Benzyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19n</b>)</h3><div class="NLM_p last">Ester <b>18n</b> (115 mg, 269 μmol) was hydrolyzed using general procedure E to afford 106 mg of crude acid <b>19n</b> (95% crude yield).</div></div><div id="sec5_9_103" class="NLM_sec NLM_sec_level_2"><div id="ac_i140" class="anchor-spacer"></div><h3 class="article-section__title" id="_i140"> 2,4-Bis(methoxymethoxy)-6-((1-(pyridin-3-ylmethyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19o</b>)</h3><div class="NLM_p last">Ester <b>18o</b> (135 mg, 315 μmol) was hydrolyzed using general procedure E to afford 90.1 mg of crude acid <b>19o</b> (69% crude yield).</div></div><div id="sec5_9_104" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> 2-((1-(Furan-2-ylmethyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19p</b>)</h3><div class="NLM_p last">Ester <b>18p</b> (145 mg, 347 μmol) was hydrolyzed using general procedure E to afford 128 mg of crude acid <b>19p</b> (91% crude yield).</div></div><div id="sec5_9_105" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> 2-((1-(4-Isopropylbenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19q</b>)</h3><div class="NLM_p last">Ester <b>18q</b> (55.1 mg, 117 μmol) was hydrolyzed using general procedure E to afford 47.9 mg of crude acid <b>19q</b> (90% crude yield).</div></div><div id="sec5_9_106" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> 2,4-Bis(methoxymethoxy)-6-((1-(4-(trifluoromethyl)benzyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19r</b>)</h3><div class="NLM_p last">Ester <b>18r</b> (66 mg, 133 μmol) was hydrolyzed using general procedure E to afford 57 mg of crude acid <b>19r</b> (89% crude yield).</div></div><div id="sec5_9_107" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19s</b>)</h3><div class="NLM_p last">Ester <b>18s</b> (65.7 mg, 154 μmol) was hydrolyzed using general procedure E to afford 64.1 mg of crude acid <b>19s</b> (101% crude yield).</div></div><div id="sec5_9_108" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> 2-((1-(<i>tert</i>-Butyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19t</b>)</h3><div class="NLM_p last">Ester <b>18t</b> (65.5 mg, 140 μmol) was hydrolyzed using general procedure E to afford 62.2 mg of crude acid <b>19t</b> (98% crude yield).</div></div><div id="sec5_9_109" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> 2-((1-Cyclohexyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19u</b>)</h3><div class="NLM_p last">Ester <b>18u</b> (111 mg, 224 μmol) was hydrolyzed using general procedure E to afford 104 mg of crude acid <b>19u</b> (96% crude yield).</div></div><div id="sec5_9_110" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> 2-((1-Isobutyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19v</b>)</h3><div class="NLM_p last">Ester <b>18v</b> (118 mg, 251 μmol) was hydrolyzed using general procedure E to afford 112 mg of crude acid <b>19v</b> (98% crude yield).</div></div><div id="sec5_9_111" class="NLM_sec NLM_sec_level_2"><div id="ac_i148" class="anchor-spacer"></div><h3 class="article-section__title" id="_i148"> 2-((3-Isopropyl-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19w</b>)</h3><div class="NLM_p last">Ester <b>18w</b> (124 mg, 316 μmol) was hydrolyzed using general procedure E to afford 124 mg of crude acid <b>19w</b> (104% crude yield).</div></div><div id="sec5_9_112" class="NLM_sec NLM_sec_level_2"><div id="ac_i149" class="anchor-spacer"></div><h3 class="article-section__title" id="_i149"> 2-((3-Cyclohexyl-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19x</b>)</h3><div class="NLM_p last">Ester <b>18x</b> (105 mg, 242 μmol) was hydrolyzed using general procedure E to afford 102 mg of crude acid <b>19x</b> (101% crude yield).</div></div><div id="sec5_9_113" class="NLM_sec NLM_sec_level_2"><div id="ac_i150" class="anchor-spacer"></div><h3 class="article-section__title" id="_i150"> 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(<i>o</i>-tolyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19y</b>)</h3><div class="NLM_p last">Ester <b>18y</b> (138 mg, 313 μmol) was hydrolyzed using general procedure E to afford 133 mg of crude acid <b>19y</b> (100% crude yield).</div></div><div id="sec5_9_114" class="NLM_sec NLM_sec_level_2"><div id="ac_i151" class="anchor-spacer"></div><h3 class="article-section__title" id="_i151"> 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(<i>m</i>-tolyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19z</b>)</h3><div class="NLM_p last">Ester <b>18z</b> (154 mg, 349 μmol) was hydrolyzed using general procedure E to afford 166 mg of crude acid <b>19z</b> (112% crude yield).</div></div><div id="sec5_9_115" class="NLM_sec NLM_sec_level_2"><div id="ac_i152" class="anchor-spacer"></div><h3 class="article-section__title" id="_i152"> 2,4-Bis(methoxymethoxy)-6-((3-(3-methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19aa</b>)</h3><div class="NLM_p last">Ester <b>18aa</b> (161 mg, 352 μmol) was hydrolyzed using general procedure E to afford 142 mg of crude acid <b>19aa</b> (91% crude yield).</div></div><div id="sec5_9_116" class="NLM_sec NLM_sec_level_2"><div id="ac_i153" class="anchor-spacer"></div><h3 class="article-section__title" id="_i153"> 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(3-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19ab</b>)</h3><div class="NLM_p last">Ester <b>S6ab</b> (161 mg, 325 μmol) was hydrolyzed using general procedure E to afford 152 mg of crude acid <b>19ab</b> (97% crude yield).</div></div><div id="sec5_9_117" class="NLM_sec NLM_sec_level_2"><div id="ac_i154" class="anchor-spacer"></div><h3 class="article-section__title" id="_i154"> 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(<i>p</i>-tolyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19ac</b>)</h3><div class="NLM_p last">Ester <b>18ac</b> (146 mg, 331 μmol) was hydrolyzed using general procedure E to afford 142 mg of crude acid <b>19ac</b> (100% crude yield).</div></div><div id="sec5_9_118" class="NLM_sec NLM_sec_level_2"><div id="ac_i155" class="anchor-spacer"></div><h3 class="article-section__title" id="_i155"> 2,4-Bis(methoxymethoxy)-6-((3-(4-methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19ad</b>)</h3><div class="NLM_p last">Ester <b>18ad</b> (155 mg, 339 μmol) was hydrolyzed using general procedure E to afford 144 mg of crude acid (96% crude yield).</div></div><div id="sec5_9_119" class="NLM_sec NLM_sec_level_2"><div id="ac_i156" class="anchor-spacer"></div><h3 class="article-section__title" id="_i156"> 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(4-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19ae</b>)</h3><div class="NLM_p last">Ester <b>18ae</b> (174 mg, 351 μmol) was hydrolyzed using general procedure E to afford 174 mg of crude acid <b>19ae</b> (105% crude yield).</div></div><div id="sec5_9_120" class="NLM_sec NLM_sec_level_2"><div id="ac_i157" class="anchor-spacer"></div><h3 class="article-section__title" id="_i157"> 2-((3-(4-(<i>tert</i>-Butyl)phenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4,6-bis(methoxymethoxy)benzoic Acid (<b>19af</b>)</h3><div class="NLM_p last">Ester <b>18af</b> (167 mg, 345 μmol) was hydrolyzed using general procedure E to afford 138 mg of crude acid <b>19af</b> (85% crude yield).</div></div><div id="sec5_9_121" class="NLM_sec NLM_sec_level_2"><div id="ac_i158" class="anchor-spacer"></div><h3 class="article-section__title" id="_i158"> 2,4-Bis(methoxymethoxy)-6-((1-methyl-3-(4-(trifluoromethoxy)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzoic Acid (<b>19ag</b>)</h3><div class="NLM_p last">Ester <b>18ag</b> (175 mg, 342 μmol) was hydrolyzed using general procedure E to afford 156 mg of crude acid <b>19ag</b> (92% crude yield).</div></div><div id="sec5_9_122" class="NLM_sec NLM_sec_level_2"><div id="ac_i159" class="anchor-spacer"></div><h3 class="article-section__title" id="_i159"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>20</b>)</h3><div class="NLM_p last">Amide <b>14a</b> (38 mg, 68 μmol) was deprotected using general procedure F to afford 24 mg of <b>20</b> (74% yield). <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 9.66 (s, 1H), 9.31 (s, 1H), 7.45–7.13 (m, 3H), 7.13–6.92 (m, 3H), 6.68 (d, <i>J</i> = 8.5 Hz, 1H), 5.85 (d, <i>J</i> = 2.1 Hz, 1H), 5.78 (s, 1H), 5.71 (d, <i>J</i> = 2.0 Hz, 1H), 4.89 (s, 2H), 4.72 (s, 2H), 3.62 (s, 3H), 2.03 (s, 3H). <sup>13</sup>C NMR (126 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 166.6, 159.2, 158.4, 155.4, 146.0, 143.8, 143.7, 140.1, 129.3, 128.8, 127.2, 122.8, 113.6, 103.7, 98.0, 94.3, 92.8, 55.0, 50.0, 40.4, 13.9. LC/MS (<i>m</i>/<i>z</i>): 471.207 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.31 min.</div></div><div id="sec5_9_123" class="NLM_sec NLM_sec_level_2"><div id="ac_i160" class="anchor-spacer"></div><h3 class="article-section__title" id="_i160"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>21</b>)</h3><div class="NLM_p last">Amide <b>14b</b> was deprotected using general procedure F (52.6 mg, 84.7 μmol) to afford 25.9 mg of <b>21</b> (57% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.75–7.66 (m, 2H), 7.42–7.32 (m, 3H), 7.32–7.21 (m, 5H), 7.06 (d, <i>J</i> = 8.7 Hz, 2H), 6.65 (d, <i>J</i> = 8.7 Hz, 2H), 6.46 (s, 1H), 5.93 (dd, <i>J</i> = 14.2, 2.1 Hz, 2H), 5.17 (s, 2H), 4.96–4.59 (m, 4H), 3.63 (s, 3H). <sup>13</sup>C NMR (126 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 166.6, 159.4, 158.5, 155.6, 148.7, 143.6, 141.2, 136.6 (br), 133.5, 129.0, 128.8, 128.5, 127.4, 127.3, 124.8, 122.8, 113.7, 104.0, 96.1, 94.6, 93.0, 55.0, 50.6, 40.4. LC/MS (<i>m</i>/<i>z</i>): 533.257 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.63 min.</div></div><div id="sec5_9_124" class="NLM_sec NLM_sec_level_2"><div id="ac_i161" class="anchor-spacer"></div><h3 class="article-section__title" id="_i161"> 5-((1-((4-Methoxyphenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>22</b>)</h3><div class="NLM_p">Crude acid <b>19a</b> (31.7 mg, 69.3 μmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (20.1 mg, 104 μmol) and triethylamine (72 μL, 520 μmol) using general procedure G to give 21.8 mg of MOM-protected intermediate (56% yield) after purification via automated flash chromatography (10% to 50% acetone in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56–8.42 (m, 1H), 7.67–7.43 (m, 1H), 7.21 (ddd, <i>J</i> = 13.1, 7.7, 4.9 Hz, 1H), 7.06 (ddd, <i>J</i> = 9.9, 6.0, 2.6 Hz, 2H), 6.70–6.57 (m, 2H), 6.45 (d, <i>J</i> = 2.5 Hz, 1H), 6.39 (dd, <i>J</i> = 7.5, 2.1 Hz, 1H), 6.23 (dd, <i>J</i> = 13.2, 2.1 Hz, 1H), 5.84 (s, 1H), 5.30–4.72 (m, 9H), 4.61–4.41 (m, 1H), 3.68 (d, <i>J</i> = 2.8 Hz, 3H), 3.44 (dd, <i>J</i> = 4.3, 2.0 Hz, 6H), 2.23 (d, <i>J</i> = 3.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.2, 167.2, 159.9, 159.0, 158.9, 157.6, 157.2, 155.4, 155.4, 149.4, 149.3, 147.6, 147.6, 143.9, 143.8, 139.4, 139.2, 131.0, 130.6, 130.3, 129.9, 128.8, 128.6, 128.5, 122.5, 122.4, 113.9, 113.8, 107.1, 98.5, 98.5, 96.5, 95.4, 95.3, 95.1, 95.1, 94.3, 94.2, 56.6, 56.5, 56.3, 56.2, 55.2, 55.1, 53.8, 53.4, 52.6, 51.4, 51.3, 51.3, 50.5, 29.3, 14.2, 14.2. LC/MS (<i>m</i>/<i>z</i>): 560.225 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.41 min</div><div class="NLM_p last">The MOM-protected intermediate (21.8 mg, 39.0 μmol) was deprotected using general procedure F to afford 3.0 mg of <b>22</b> (16% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.44 (d, <i>J</i> = 5.0 Hz, 1H), 7.76 (s, 1H), 7.40–7.30 (m, 1H), 7.00 (d, <i>J</i> = 8.7 Hz, 2H), 6.66 (d, <i>J</i> = 8.7 Hz, 2H), 5.96–5.85 (m, 2H), 5.83 (d, <i>J</i> = 2.1 Hz, 1H), 5.04 (s, 2H), 4.96–4.43 (m, 4H), 3.65 (s, 3H), 2.13 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 472.234 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.12 min.</div></div><div id="sec5_9_125" class="NLM_sec NLM_sec_level_2"><div id="ac_i162" class="anchor-spacer"></div><h3 class="article-section__title" id="_i162"> 5-((1-((4-Methoxyphenyl)methyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>23</b>)</h3><div class="NLM_p">Acid <b>19b</b> (31.7 mg, 69.3 μmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (20.1 mg, 104 μmol) and triethylamine (72 μL, 520 μmol) using general procedure G to give 43.2 mg of MOM-protected intermediate (77% yield) after purification via automated flash chromatography (4% to 40% acetone in hexanes and 0% to 3% methanol in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.57–8.40 (m, 1H), 7.78 (dq, <i>J</i> = 6.4, 1.4 Hz, 2H), 7.66–7.46 (m, 1H), 7.42–7.34 (m, 2H), 7.33–7.18 (m, 2H), 7.18–7.06 (m, 2H), 6.73–6.58 (m, 2H), 6.53 (d, <i>J</i> = 4.4 Hz, 1H), 6.46–6.34 (m, 2H), 6.30 (dd, <i>J</i> = 18.9, 2.1 Hz, 1H), 5.16 (d, <i>J</i> = 17.6 Hz, 4H), 5.06 (d, <i>J</i> = 3.8 Hz, 2H), 5.02–4.78 (m, 3H), 4.56 (d, <i>J</i> = 16.2 Hz, 1H), 3.69 (d, <i>J</i> = 3.1 Hz, 3H), 3.52–3.40 (m, 6H). LC/MS (<i>m</i>/<i>z</i>): 622.237 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.71 min.</div><div class="NLM_p last">The MOM-protected intermediate (43.2 mg, 69.5 μmol) was deprotected using general procedure F to afford 11.5 mg of <b>23</b> (31% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.40 (d, <i>J</i> = 5.1 Hz, 1H), 7.75 (d, <i>J</i> = 7.5 Hz, 1H), 7.72–7.63 (m, 2H), 7.38–7.30 (m, 2H), 7.30–7.20 (m, 1H), 7.15–7.04 (m, 2H), 6.73–6.66 (m, 2H), 6.45 (s, 1H), 6.01–5.90 (m, 1H), 5.19 (s, 2H), 4.99–4.49 (m, 4H), 3.65 (s, 2H), 2.65 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 535.173 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.40 min.</div></div><div id="sec5_9_126" class="NLM_sec NLM_sec_level_2"><div id="ac_i163" class="anchor-spacer"></div><h3 class="article-section__title" id="_i163"> 5-((1-((4-Methoxyphenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>24</b>)</h3><div class="NLM_p">Acid <b>19a</b> (39 mg, 85 μmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (14 mg, 130 μmol) and triethylamine (24 μL, 170 μmol) using general procedure G to give 28.1 mg of MOM-protected intermediate (60% yield) after purification via automated flash chromatography (15% to 60% acetone in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36–7.17 (m, 2H), 7.13–6.98 (m, 2H), 6.73–6.61 (m, 2H), 6.43–6.31 (m, 2H), 6.20 (d, <i>J</i> = 2.1 Hz, 1H), 5.84 (d, <i>J</i> = 2.3 Hz, 1H), 5.20–5.10 (m, 2H), 5.09–4.97 (m, 4H), 4.77–4.56 (m, 3H), 4.31 (dd, <i>J</i> = 13.6, 7.2 Hz, 1H), 3.68 (d, <i>J</i> = 1.0 Hz, 3H), 3.48–3.38 (m, 6H), 2.23 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.4, 159.8, 159.7, 159.0, 158.9, 155.2, 147.6, 143.6, 139.4, 139.3, 128.7, 128.6, 128.6, 128.6, 113.9, 113.9, 107.7, 107.6, 98.7, 98.6, 96.5, 96.4, 95.2, 95.1, 95.1, 94.2, 56.5, 56.5, 56.2, 55.1, 55.1, 53.7, 51.2, 51.2, 46.6, 46.4, 45.6, 45.3, 29.2, 14.1. LC/MS (<i>m</i>/<i>z</i>): 549.199 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.28 min.</div><div class="NLM_p last">The MOM-protected intermediate (28.1 mg, 51.2 μmol) was deprotected using general procedure F to afford 3.6 mg of <b>24</b> (15% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.44 (s, 1H), 7.06–6.95 (m, 2H), 6.75–6.65 (m, 2H), 5.95–5.87 (m, 2H), 5.82 (d, <i>J</i> = 2.1 Hz, 1H), 5.03 (s, 2H), 4.77–4.22 (m, 4H), 3.68 (s, 3H), 2.65 (s, 3H), 2.15 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 461.207 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.94 min.</div></div><div id="sec5_9_127" class="NLM_sec NLM_sec_level_2"><div id="ac_i164" class="anchor-spacer"></div><h3 class="article-section__title" id="_i164"> 5-((1-((4-Methoxyphenyl)methyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>25</b>)</h3><div class="NLM_p">Acid <b>19b</b> (90 mM in 1:1 CH<sub>2</sub>Cl<sub>2</sub>/THF, 1.0 mL, 90 μmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (15 mg, 140 μmol) and triethylamine (25 μL, 180 μmol) using general procedure G to give 33 mg of MOM-protected intermediate (61% yield) after purification via automated flash chromatography (10% to 40% acetone in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.85–7.75 (m, 2H), 7.39 (t, <i>J</i> = 7.6 Hz, 2H), 7.29 (t, <i>J</i> = 7.5 Hz, 1H), 7.16 (d, <i>J</i> = 8.2 Hz, 2H), 6.76–6.65 (m, 2H), 6.50–6.35 (m, 3H), 6.29 (dd, <i>J</i> = 8.7, 1.9 Hz, 1H), 5.15 (s, 1H), 5.05 (s, 2H), 4.83–4.50 (m, 3H), 4.35 (t, <i>J</i> = 12.4 Hz, 1H), 3.71 (dd, <i>J</i> = 2.1, 0.9 Hz, 3H), 3.45 (s, 3H), 3.44 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.4, 159.8, 159.8, 159.0, 158.9, 155.2, 150.1, 143.4, 143.4, 140.1, 140.0, 133.6, 128.7, 128.5, 128.3, 128.2, 127.6, 125.3, 113.9, 113.9, 107.7, 107.7, 96.6, 96.4, 95.3, 95.2, 94.2, 56.5, 56.5, 56.2, 55.1, 55.1. LC/MS (<i>m</i>/<i>z</i>): 611.255 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.61 min.</div><div class="NLM_p last">The MOM-protected intermediate (33.5 mg, 54.9 μmol) was deprotected using general procedure F to afford 7.2 mg of <b>25</b> (25% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.71 (dd, <i>J</i> = 8.0, 1.4 Hz, 2H), 7.46–7.31 (m, 3H), 7.30–7.21 (m, 1H), 7.13–7.00 (m, 2H), 6.75–6.68 (m, 2H), 6.46 (s, 1H), 5.92 (dd, <i>J</i> = 17.4, 2.1 Hz, 2H), 5.18 (s, 2H), 4.77–4.17 (m, 4H), 3.68 (d, <i>J</i> = 0.6 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>): 523.132 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.31 min.</div></div><div id="sec5_9_128" class="NLM_sec NLM_sec_level_2"><div id="ac_i165" class="anchor-spacer"></div><h3 class="article-section__title" id="_i165"> 4-(4-Fluoro-2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>26</b>)</h3><div class="NLM_p">Acid <b>19a</b> (30 mg, 66 μmol) was coupled with 4-fluoroisoindoline (13 mg, 98 μmol) and triethylamine (18 μL, 130 μmol) using general procedure G to give 38 mg of MOM-protected intermediate (78% yield) after purification via automated flash chromatography (10% to 45% acetone in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.30 (dd, <i>J</i> = 7.9, 5.2 Hz, 1H), 7.17–7.03 (m, 2H), 7.03–6.88 (m, 1H), 6.72–6.61 (m, 2H), 6.46–6.33 (m, 2H), 6.25 (dd, <i>J</i> = 13.2, 2.1 Hz, 1H), 5.85 (d, <i>J</i> = 2.5 Hz, 1H), 5.16 (dd, <i>J</i> = 9.5, 3.3 Hz, 2H), 5.06 (d, <i>J</i> = 10.6 Hz, 4H), 5.00–4.76 (m, 3H), 4.53 (d, <i>J</i> = 14.9 Hz, 1H), 3.68 (d, <i>J</i> = 7.4 Hz, 3H), 3.49–3.38 (m, 6H), 2.24 (s, 3H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −117.44 (dd, <i>J</i> = 9.1, 5.1 Hz), −117.90 (dd, <i>J</i> = 9.1, 5.0 Hz). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.0, 166.8, 159.9, 159.9, 159.0, 158.9, 156.8, 156.5, 155.3, 147.6, 147.6, 143.8, 143.7, 140.0, 139.9, 139.5, 139.5, 139.3, 139.3, 129.9, 129.9, 129.8, 128.7, 128.6, 128.5, 123.4, 118.7, 118.6, 118.2, 114.3, 114.1, 114.1, 114.0, 113.9, 113.9, 107.5, 107.2, 98.5, 98.3, 96.5, 95.4, 95.3, 95.1, 95.1, 94.3, 56.6, 56.3, 55.1, 55.1, 53.0, 52.3, 51.4, 51.3, 50.0, 49.2, 14.2. LC/MS (<i>m</i>/<i>z</i>): 578.22 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.65 min.</div><div class="NLM_p last">The MOM-protected intermediate (27.5 mg, 47.7 μmol) was deprotected using general procedure F to afford 6.9 mg of <b>26</b> (30% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.33 (q, <i>J</i> = 7.7 Hz, 1H), 7.09 (s, 1H), 7.04–6.94 (m, 3H), 6.66 (d, <i>J</i> = 8.7 Hz, 2H), 5.96–5.87 (m, 2H), 5.84 (d, <i>J</i> = 2.1 Hz, 1H), 5.03 (s, 2H), 4.92–4.53 (m, 4H), 3.64 (s, 3H), 2.13 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 489.214 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.36 min.</div></div><div id="sec5_9_129" class="NLM_sec NLM_sec_level_2"><div id="ac_i166" class="anchor-spacer"></div><h3 class="article-section__title" id="_i166"> 4-(4-Fluoro-2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>27</b>)</h3><div class="NLM_p">Acid <b>19b</b> (90 mM in 1:1 CH<sub>2</sub>Cl<sub>2</sub>/THF, 1.0 mL, 90 μmol) was coupled with 4-fluoroisoindoline (17 mg, 140 μmol) and triethylamine (25 μL, 180 μmol) using general procedure G to give 42 mg of MOM-protected intermediate (72% yield) after purification via automated flash chromatography (8% to 30% acetone in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86–7.73 (m, 2H), 7.39 (t, <i>J</i> = 7.7 Hz, 2H), 7.35–7.23 (m, 2H), 7.19–7.08 (m, 3H), 6.98 (dt, <i>J</i> = 12.5, 8.4 Hz, 1H), 6.73–6.65 (m, 2H), 6.52 (d, <i>J</i> = 3.3 Hz, 1H), 6.46–6.37 (m, 2H), 6.32 (dd, <i>J</i> = 16.3, 2.1 Hz, 1H), 5.29 (s, 1H), 5.25–5.11 (m, 4H), 5.07 (s, 2H), 5.03–4.81 (m, 3H), 4.56 (dd, <i>J</i> = 14.7, 5.9 Hz, 1H), 3.69 (d, <i>J</i> = 8.1 Hz, 3H), 3.48–3.43 (m, 6H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −117.44 (dd, <i>J</i> = 9.1, 4.9 Hz), −117.88 (dd, <i>J</i> = 9.4, 5.1 Hz). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.9, 166.8, 160.0, 159.9, 159.3, 159.1, 159.0, 156.8, 155.4, 150.1, 150.1, 143.7, 143.5, 140.0, 140.0, 139.9, 139.5, 133.7, 130.0, 129.9, 129.8, 128.7, 128.7, 128.6, 128.4, 128.2, 127.6, 125.4, 123.6, 123.4, 123.3, 123.1, 118.6, 118.2, 114.3, 114.2, 114.1, 114.0, 113.9, 113.9, 107.6, 107.3, 96.6, 96.3, 96.0, 95.4, 95.3, 95.3, 95.3, 94.3, 94.3, 56.6, 56.3, 55.1, 55.1, 53.1, 52.3, 51.9, 51.8, 50.0, 49.3. LC/MS (<i>m</i>/<i>z</i>): 639.306 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 2.00 min.</div><div class="NLM_p last">The MOM-protected intermediate (41.7 mg, 65.3 μmol) was deprotected using general procedure F to afford 19.2 mg of <b>27</b> (53% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.76–7.52 (m, 3H), 7.41–7.20 (m, 4H), 7.06 (d, <i>J</i> = 8.5 Hz, 3H), 6.98 (t, <i>J</i> = 8.8 Hz, 1H), 6.74–6.62 (m, 2H), 6.46 (d, <i>J</i> = 0.9 Hz, 1H), 5.93 (ddd, <i>J</i> = 14.0, 2.1, 0.9 Hz, 2H), 5.18 (s, 2H), 4.93–4.53 (m, 4H), 3.64 (d, <i>J</i> = 0.9 Hz, 3H). <sup>13</sup>C NMR (126 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 166.6, 159.5, 158.5, 157.2 (d, <sup>1</sup><i>J</i><sub>C–F</sub> = 244.1 Hz), 155.7, 148.7, 143.7, 141.2, 133.5, 129.9 (d, <sup>3</sup><i>J</i><sub>C–F</sub> = 4.8 Hz), 129.0, 128.7, 128.5, 127.3, 124.7, 123.1 (br), 119.1, 113.67 (app d, ovrlp), 113.63, 103.7, 96.2, 94.6, 93.2, 54.9, 50.5, 40.4. LC/MS (<i>m</i>/<i>z</i>): 551.250 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.65 min.</div></div><div id="sec5_9_130" class="NLM_sec NLM_sec_level_2"><div id="ac_i167" class="anchor-spacer"></div><h3 class="article-section__title" id="_i167"> 4-(5-Fluoro-2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>28</b>)</h3><div class="NLM_p">Acid <b>19a</b> (31.1 mg, 68.0 μmol) was coupled with 5-fluoroisoindoline hydrochloride (17.7 mg, 102 μmol) and triethylamine (28 μL, 204 μmol) using general procedure G to give 33.3 mg of MOM-protected intermediate (85% yield) after purification via automated flash chromatography (20% to 50% ethyl acetate in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.17–6.80 (m, 4H), 6.66 (dd, <i>J</i> = 8.6, 1.8 Hz, 2H), 6.43–6.34 (m, 2H), 6.24 (dd, <i>J</i> = 2.1, 0.7 Hz, 1H), 5.85 (s, 1H), 5.15 (q, <i>J</i> = 6.6 Hz, 2H), 5.05 (dd, <i>J</i> = 11.3, 1.7 Hz, 4H), 4.96–4.74 (m, 3H), 4.55–4.40 (m, 1H), 3.68 (s, 3H), 3.51–3.37 (m, 6H), 2.24 (s, 3H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −114.63 to −114.72 (m), −114.72 to −114.83 (m). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.9, 166.8, 163.9, 163.8, 161.4, 161.3, 159.9, 159.9, 158.9, 155.3, 155.3, 147.6, 143.8, 143.7, 139.3, 138.6, 138.6, 138.3, 138.2, 132.0, 131.7, 128.7, 128.7, 128.6, 124.3, 124.2, 123.8, 123.7, 115.1, 115.0, 114.9, 114.8, 113.9, 110.3, 110.1, 109.8, 109.6, 107.5, 107.5, 98.5, 98.4, 96.5, 95.4, 95.3, 95.1, 94.3, 56.6, 56.3, 55.1, 55.1, 52.9, 52.3, 52.0, 52.0, 51.5, 51.3, 14.2. LC/MS (<i>m</i>/<i>z</i>): 577.206 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.71 min.</div><div class="NLM_p last">The MOM-protected intermediate (29.9 mg, 51.9 μmol) was deprotected using general procedure F to afford 9.1 mg of <b>28</b> (36% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.25 (s, 1H), 7.07–6.91 (m, 4H), 6.72–6.57 (m, 2H), 5.93–5.84 (m, 2H), 5.83 (d, <i>J</i> = 2.1 Hz, 1H), 5.03 (s, 2H), 4.91–4.48 (m, 4H), 3.65 (s, 3H), 2.14 (d, <i>J</i> = 6.9 Hz, 4H). LC/MS (<i>m</i>/<i>z</i>): 489.244 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.34 min</div></div><div id="sec5_9_131" class="NLM_sec NLM_sec_level_2"><div id="ac_i168" class="anchor-spacer"></div><h3 class="article-section__title" id="_i168"> 4-(5-Fluoro-2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>29</b>)</h3><div class="NLM_p">Acid <b>19b</b> (90 mM in 1:1 CH<sub>2</sub>Cl<sub>2</sub>/THF, 1.0 mL, 90 μmol) was coupled with 5-fluoroisoindoline hydrochloride (23 mg, 140 μmol) and triethylamine (38 μL, 270 μmol) using general procedure G to give 39 mg of MOM-protected intermediate (68% yield) after purification via automated flash chromatography (8% to 30% acetone in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83–7.74 (m, 2H), 7.38 (dd, <i>J</i> = 8.4, 6.9 Hz, 2H), 7.32–7.27 (m, 1H), 7.12 (ddd, <i>J</i> = 11.7, 7.9, 3.6 Hz, 2H), 7.04–6.80 (m, 2H), 6.72–6.59 (m, 2H), 6.48 (d, <i>J</i> = 5.9 Hz, 1H), 6.43–6.36 (m, 2H), 6.30 (t, <i>J</i> = 1.9 Hz, 1H), 5.16 (d, <i>J</i> = 9.5 Hz, 4H), 5.06 (s, 2H), 4.98–4.73 (m, 3H), 4.57–4.43 (m, 1H), 3.69 (s, 3H), 3.50–3.38 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 166.8, 163.9, 163.8, 161.5, 161.4, 159.9, 159.9, 159.0, 155.4, 155.4, 150.1, 143.6, 143.6, 140.0, 140.0, 138.6, 138.5, 138.3, 138.2, 133.7, 132.0, 132.0, 131.7, 131.7, 128.7, 128.6, 128.6, 128.4, 128.3, 127.6, 125.4, 124.3, 124.2, 123.9, 123.8, 115.1, 115.0, 114.9, 114.8, 113.9, 110.3, 110.1, 109.8, 109.6, 107.6, 107.6, 96.7, 96.2, 96.2, 95.4, 95.4, 95.3, 94.3, 56.6, 56.3, 55.1, 55.1, 52.9, 52.4, 52.0, 51.8, 51.5. LC/MS (<i>m</i>/<i>z</i>): 639.306 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.98 min.</div><div class="NLM_p last">The MOM-protected intermediate (39.3 mg, 61.5 μmol) was deprotected using general procedure F to afford 6.6 mg of <b>29</b> (19% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.72–7.60 (m, 2H), 7.34 (dd, <i>J</i> = 8.4, 6.9 Hz, 2H), 7.28–7.22 (m, 1H), 7.21 (s, 1H), 7.08–7.00 (m, 2H), 6.98 (dd, <i>J</i> = 9.0, 7.0 Hz, 2H), 6.72–6.64 (m, 2H), 6.45 (s, 1H), 5.93 (dd, <i>J</i> = 12.7, 2.1 Hz, 2H), 5.17 (s, 2H), 4.97–4.43 (m, 4H), 3.65 (s, 3H). <sup>13</sup>C NMR (126 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 166.5, 161.8 (d, <sup>1</sup><i>J</i><sub><i>C–F</i></sub> = 241.3 Hz), 159.4, 158.5, 155.6, 148.7, 143.6, 141.2, 133.4, 129.0, 128.8, 128.5, 127.3, 124.7, 124.5 (d, <sup>3</sup><i>J</i><sub><i>C–F</i></sub> = 9.5 Hz), 114.3 (d, <sup>2</sup><i>J</i><sub><i>C–F</i></sub> = 22.9 Hz), 113.6, 110.0 (d, <sup>2</sup><i>J</i><sub><i>C-</i>F</sub> = 22.9 Hz), 103.9, 96.2, 94.6, 93.1, 55.0, 50.5, 40.4. LC/MS (<i>m</i>/<i>z</i>): 551.250 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.64 min.</div></div><div id="sec5_9_132" class="NLM_sec NLM_sec_level_2"><div id="ac_i169" class="anchor-spacer"></div><h3 class="article-section__title" id="_i169"> <i>N</i>-(Cyclopropylmethyl)-2,4-dihydroxy-6-((1-((4-methoxyphenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-<i>N</i>-methylbenzamide (<b>30</b>)</h3><div class="NLM_p">Acid <b>19a</b> (49 mg, 110 μmol) was coupled with (cyclopropylmethyl)methylamine (27 mg, 320 μmol) and triethylamine (30 μL, 210 μmol) using general procedure G to give 43 mg of MOM-protected intermediate (76% yield) after purification via automated flash chromatography (10% to 35% acetone in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.19–7.07 (m, 2H), 6.80 (t, <i>J</i> = 8.6 Hz, 2H), 6.43–6.26 (m, 1H), 6.25–6.15 (m, 1H), 5.84 (d, <i>J</i> = 8.5 Hz, 1H), 5.19–4.92 (m, 6H), 3.75 (d, <i>J</i> = 4.1 Hz, 3H), 3.50–3.30 (m, 7H), 3.10–2.87 (m, 3H), 2.31–2.17 (m, 3H), 1.07 – −0.15 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.5, 167.2, 159.5, 159.4, 159.0, 159.0, 155.0, 154.7, 147.7, 147.6, 143.9, 143.9, 139.7, 139.6, 128.9, 128.8, 128.8, 128.7, 114.0, 113.9, 107.4, 107.2, 98.3, 97.9, 96.6, 96.4, 95.0, 95.0, 94.8, 94.7, 94.3, 94.3, 56.4, 56.3, 56.2, 56.2, 55.4, 55.2, 55.2, 51.1, 51.0, 36.2, 32.4, 14.2, 9.9, 9.2, 3.9, 3.5, 3.4, 3.4. LC/MS (<i>m</i>/<i>z</i>): 525.249 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.66 min</div><div class="NLM_p last">The MOM-protected intermediate (42.7 mg, 81.4 μmol) was deprotected using general procedure F to afford 19.2 mg of <b>30</b> (54% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.07 (d, <i>J</i> = 8.7 Hz, 2H), 6.83 (d, <i>J</i> = 8.7 Hz, 2H), 5.89 (s, 1H), 5.87–5.79 (m, 2H), 5.05 (s, 2H), 3.74 (s, 3H), 3.19 (dd, <i>J</i> = 6.9, 4.6 Hz, 2H), 3.02 (s, 3H), 2.20 (s, 4H), 0.99–0.82 (m, 1H), 0.53–0.32 (m, 2H), 0.12 (ddt, <i>J</i> = 37.2, 9.5, 4.8 Hz, 2H). LC/MS (<i>m</i>/<i>z</i>): 437.213 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.28 min.</div></div><div id="sec5_9_133" class="NLM_sec NLM_sec_level_2"><div id="ac_i170" class="anchor-spacer"></div><h3 class="article-section__title" id="_i170"> <i>N</i>-(Cyclopropylmethyl)-2,4-dihydroxy-6-((1-((4-methoxyphenyl)methyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-<i>N</i>-methylbenzamide (<b>31</b>)</h3><div class="NLM_p">Acid <b>19b</b> (90 mM in 1:1 CH<sub>2</sub>Cl<sub>2</sub>/THF, 1.0 mL, 90 μmol) was coupled with (cyclopropylmethyl)methylamine (23 mg, 270 μmol) and triethylamine (25 μL, 180 μmol) using general procedure G to give 40 mg of MOM-protected intermediate (75% yield) after purification via automated flash chromatography (8% to 30% acetone in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80 (dt, <i>J</i> = 8.2, 1.6 Hz, 2H), 7.39 (t, <i>J</i> = 7.6 Hz, 2H), 7.33–7.27 (m, 1H), 7.22 (dd, <i>J</i> = 8.8, 2.6 Hz, 2H), 6.87–6.71 (m, 2H), 6.41–6.31 (m, 2H), 6.30–6.24 (m, 1H), 5.29–5.09 (m, 4H), 5.03 (s, 2H), 3.76 (d, <i>J</i> = 4.5 Hz, 3H), 3.50–3.30 (m, 7H), 3.17–2.92 (m, 4H), 1.04 to −0.10 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.4, 167.2, 159.5, 159.4, 159.1, 159.1, 155.1, 154.8, 150.1, 150.1, 143.8, 143.7, 140.5, 140.3, 133.8, 133.7, 128.9, 128.9, 128.5, 128.5, 128.4, 127.6, 125.4, 114.0, 114.0, 107.5, 107.3, 96.8, 96.6, 96.0, 95.5, 95.1, 95.0, 94.8, 94.3, 94.3, 56.4, 56.4, 56.3, 56.2, 55.2, 55.2, 51.6, 51.6, 51.1, 36.2, 32.5, 10.0, 9.3, 3.9, 3.5, 3.5, 3.4. LC/MS (<i>m</i>/<i>z</i>): 587.306 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.95 min.</div><div class="NLM_p last">The MOM-protected intermediate (39.8 mg, 54.9 μmol) was deprotected using general procedure F to afford 5.7 mg of <b>19b</b> (17% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.78–7.73 (m, 2H), 7.38 (dd, <i>J</i> = 8.3, 7.0 Hz, 2H), 7.32–7.26 (m, 1H), 7.18–7.12 (m, 2H), 6.87–6.81 (m, 2H), 6.45 (s, 1H), 5.93 (d, <i>J</i> = 2.1 Hz, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.20 (s, 2H), 3.75 (s, 3H), 3.26–3.15 (m, 2H), 3.03 (s, 3H), 0.99–0.84 (m, 1H), 0.50–0.33 (m, 2H), 0.12 (ddq, <i>J</i> = 42.7, 9.6, 4.8 Hz, 2H). LC/MS (<i>m</i>/<i>z</i>): 499.182 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.60 min</div></div><div id="sec5_9_134" class="NLM_sec NLM_sec_level_2"><div id="ac_i171" class="anchor-spacer"></div><h3 class="article-section__title" id="_i171"> 5-((1-((4-Methoxyphenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5-((1-methylpiperidin-4-yl)amino)-2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)benzene-1,3-diol (<b>32</b>)</h3><div class="NLM_p last">Amide <b>16a</b> (41.8 mg, 62.3 μmol) was deprotected using general procedure F to afford 3.3 mg of <b>32</b> (9.1% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.52 (s, 1H), 7.08–6.94 (m, 3H), 6.63 (d, <i>J</i> = 8.7 Hz, 4H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.88 (s, 1H), 5.82 (d, <i>J</i> = 2.0 Hz, 1H), 5.01 (s, 3H), 4.84–4.29 (m, 4H), 3.64 (s, 3H), 3.51 (s, 1H), 3.03–2.81 (m, 4H), 2.72 (s, 3H), 2.65 (s, 1H), 2.14 (s, 5H), 1.66 (s, 1H). LC/MS (<i>m</i>/<i>z</i>): 583.336 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.88 min.</div></div><div id="sec5_9_135" class="NLM_sec NLM_sec_level_2"><div id="ac_i172" class="anchor-spacer"></div><h3 class="article-section__title" id="_i172"> 5-((1-((4-Methoxyphenyl)methyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5-((1-methylpiperidin-4-yl)amino)-2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)benzene-1,3-diol (<b>33</b>)</h3><div class="NLM_p">Acid <b>19b</b> 77 mM in 1:1 CH<sub>2</sub>Cl<sub>2</sub>/THF, 1.0 mL, 77 μmol) was coupled with <i>N</i>-(1-methylpiperidin-4-yl)isoindolin-5-amine dihydrogen chloride (25 mg, 81 μmol) and triethylamine (85 μL, 610 μmol) using general procedure G to give 35 mg of MOM-protected intermediate (59% yield) after purification via silica gel flash chromatography (96:4:1 CH<sub>2</sub>Cl<sub>2</sub>/methanol/conc NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.79 (d, <i>J</i> = 7.6 Hz, 2H), 7.38 (t, <i>J</i> = 7.5 Hz, 2H), 7.30 (d, <i>J</i> = 7.2 Hz, 1H), 7.21–7.05 (m, 2H), 6.71–6.61 (m, 2H), 6.60–6.46 (m, 1H), 6.40 (dd, <i>J</i> = 12.6, 10.4 Hz, 3H), 6.26 (dd, <i>J</i> = 8.6, 2.1 Hz, 1H), 5.15 (d, <i>J</i> = 6.9 Hz, 4H), 5.05 (d, <i>J</i> = 2.0 Hz, 2H), 4.81 (dt, <i>J</i> = 21.1, 14.4 Hz, 3H), 3.68 (d, <i>J</i> = 1.6 Hz, 3H), 3.47–3.35 (m, 6H), 2.81 (s, 1H), 2.30 (d, <i>J</i> = 8.6 Hz, 3H), 2.20–1.92 (m, 3H), 1.49 (d, <i>J</i> = 11.6 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 166.7, 159.7, 159.0, 155.4, 150.1, 147.1, 147.0, 143.5, 140.0, 137.8, 137.5, 133.7, 128.8, 128.5, 128.4, 127.6, 125.4, 124.8, 124.5, 123.7, 123.2, 113.9, 113.6, 113.4, 106.8, 106.3, 96.5, 96.4, 95.3, 94.3, 56.5, 56.3, 55.1, 54.5, 52.6, 52.2, 51.8, 51.6, 46.2, 32.4. LC/MS (<i>m</i>/<i>z</i>): 733.603 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.45 min</div><div class="NLM_p last">The MOM-protected intermediate (34.7 mg, 47.4 μmol) was deprotected using general procedure F to afford 7.7 mg of <b>33</b> (25% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.52 (s, 1H), 7.76–7.63 (m, 2H), 7.42–7.22 (m, 3H), 7.10–6.94 (m, 2H), 6.71–6.60 (m, 3H), 6.55 (s, 1H), 6.44 (s, 1H), 5.92 (dd, <i>J</i> = 16.0, 2.1 Hz, 1H), 5.15 (s, 2H), 4.83–4.43 (m, 4H), 3.64 (s, 3H), 3.52 (s, 1H), 3.36 (d, <i>J</i> = 14.5 Hz, 2H), 2.99 (s, 2H), 2.76 (s, 3H), 2.18 (d, <i>J</i> = 14.2 Hz, 2H), 1.68 (s, 2H). LC/MS (<i>m</i>/<i>z</i>): 645.481 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.21 min.</div></div><div id="sec5_9_136" class="NLM_sec NLM_sec_level_2"><div id="ac_i173" class="anchor-spacer"></div><h3 class="article-section__title" id="_i173"> 4-(5-(2-(Dimethylamino)ethoxy)-2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>34</b>)</h3><div class="NLM_p last">Amide <b>16b</b> (37.7 mg, 58.4 μmol) was deprotected using general procedure F to afford 8.2 mg of <b>34</b> (25% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.52 (s, 1H), 7.19 (s, 1H), 7.02–6.96 (m, 2H), 6.93 (d, <i>J</i> = 8.7 Hz, 2H), 6.65 (d, <i>J</i> = 8.7 Hz, 2H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.88 (s, 1H), 5.83 (d, <i>J</i> = 2.1 Hz, 1H), 5.02 (s, 3H), 4.85–4.45 (m, 3H), 4.22 (t, <i>J</i> = 5.3 Hz, 2H), 3.65 (s, 3H), 3.25–3.18 (m, 2H), 2.70 (s, 7H), 2.65 (s, 5H), 2.13 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 558.328 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.90 min.</div></div><div id="sec5_9_137" class="NLM_sec NLM_sec_level_2"><div id="ac_i174" class="anchor-spacer"></div><h3 class="article-section__title" id="_i174"> 4-(5-(2-(Dimethylamino)ethoxy)-2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>35</b>)</h3><div class="NLM_p">To a suspension of crude carboxylic acid <b>19b</b> (57 mg, 110 μmol) and 2-(isoindolin-5-yloxy)-<i>N</i>,<i>N</i>-dimethylethan-1-amine dihydrochloride (24 mg, 86 μmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.7 mL) and THF (0.7 mL) was added triethylamine (60 μL, 430 μmol) followed by HATU (26 mg, 69 μmol). After the suspension was stirred overnight at room temperature, additional 2-(isoindolin-5-yloxy)-<i>N</i>,<i>N</i>-dimethylethan-1-amine dihydrochloride (12 mg, 43 μmol), triethylamine (60 μL, 430 μmol), and HATU (13 mg, 34 μmol) were added to the reaction. After stirring overnight, the reaction was diluted with CH<sub>2</sub>Cl<sub>2</sub>. The reaction mixture was washed with saturated NaHCO<sub>3</sub> (aq), brine and then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude mixture was purified via automated flash chromatography (2% to 5% methanol in CH<sub>2</sub>Cl<sub>2</sub>) to afford 47 mg of MOM-protected intermediate (60% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.73 (m, 2H), 7.38 (t, <i>J</i> = 7.6 Hz, 2H), 7.30 (d, <i>J</i> = 7.1 Hz, 1H), 7.23–7.01 (m, 3H), 6.91–6.80 (m, 1H), 6.66 (d, <i>J</i> = 8.6 Hz, 2H), 6.45 (d, <i>J</i> = 5.8 Hz, 1H), 6.42–6.33 (m, 2H), 6.28 (dd, <i>J</i> = 3.4, 2.1 Hz, 1H), 5.16 (d, <i>J</i> = 7.4 Hz, 4H), 5.05 (d, <i>J</i> = 1.9 Hz, 2H), 4.95–4.73 (m, 3H), 4.55–4.43 (m, 1H), 4.07 (dt, <i>J</i> = 17.1, 5.6 Hz, 2H), 3.68 (d, <i>J</i> = 1.0 Hz, 3H), 3.44 (t, <i>J</i> = 1.4 Hz, 6H), 2.80 (dt, <i>J</i> = 9.2, 5.5 Hz, 2H), 2.40 (s, 3H), 2.38 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.8, 166.8, 159.8, 159.1, 158.8, 158.7, 155.4, 150.1, 143.6, 140.1, 138.0, 137.6, 133.8, 128.7, 128.5, 128.4, 127.5, 125.4, 123.7, 123.3, 114.8, 114.6, 114.0, 108.8, 108.6, 108.0, 96.7, 96.4, 95.4, 94.4, 66.0, 58.1, 56.5, 56.2, 55.1, 53.1, 52.5, 52.2, 51.8, 51.5, 45.7. LC/MS (<i>m</i>/<i>z</i>): 708.551 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.45 min.</div><div class="NLM_p last">To a solution of the resulting MOM-protected intermediate (46.7 mg, 66.0 μmol) in methanol (6.4 mL) at room temperature was added HCl (aq) (2 M, 0.21 mL, 420 μmol), and the mixture was stirred at 50 °C overnight. Additional HCl (aq) (2 M, 0.21 mL, 420 μmol) was added to the reaction mixture and stirred at 50 °C overnight. The reaction was cooled the room temperature, and volatile materials were condensed in vacuo. The crude residue was purified using mass-guided preparative HPLC to afford 29.2 mg of <b>35</b> (71% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.68 (dt, <i>J</i> = 6.4, 1.3 Hz, 2H), 7.37–7.28 (m, 2H), 7.28–7.20 (m, 1H), 7.16 (d, <i>J</i> = 8.6 Hz, 1H), 7.10–6.99 (m, 2H), 6.97–6.79 (m, 2H), 6.74–6.59 (m, 2H), 6.43 (s, 1H), 5.94 (dd, <i>J</i> = 14.2, 2.0 Hz, 2H), 5.16 (s, 2H), 4.85–4.45 (m, 4H), 4.25 (t, <i>J</i> = 5.1 Hz, 2H), 3.64 (s, 3H), 3.41 (t, <i>J</i> = 4.9 Hz, 2H), 3.34 (s, 1H), 2.84 (s, 6H). LC/MS (<i>m</i>/<i>z</i>): 620.473 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.20 min.</div></div><div id="sec5_9_138" class="NLM_sec NLM_sec_level_2"><div id="ac_i175" class="anchor-spacer"></div><h3 class="article-section__title" id="_i175"> 5-((1-((4-Methoxyphenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-[5-(4-methylpiperazin-1-yl)-2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)benzene-1,3-diol (<b>36</b>)</h3><div class="NLM_p last">Amide <b>16c</b> (38.8 mg, 59.1 μmol) was deprotected using general procedure F to afford 14.6 mg of <b>36</b> (43% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.04–6.92 (m, 4H), 6.68–6.58 (m, 2H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.88 (s, 1H), 5.83 (d, <i>J</i> = 2.1 Hz, 1H), 5.01 (s, 3H), 4.68 (d, <i>J</i> = 59.6 Hz, 4H), 3.63 (s, 3H), 3.30 (dt, <i>J</i> = 3.7, 1.9 Hz, 4H), 3.01 (d, <i>J</i> = 5.1 Hz, 4H), 2.66–2.61 (m, 3H), 2.13 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 569.311 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.77 min.</div></div><div id="sec5_9_139" class="NLM_sec NLM_sec_level_2"><div id="ac_i176" class="anchor-spacer"></div><h3 class="article-section__title" id="_i176"> <i>N</i>-Benzyl-2,4-dihydroxy-6-((1-((4-methoxyphenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-<i>N</i>-methylbenzamide (<b>37</b>)</h3><div class="NLM_p last">Amide <b>16d</b> (39.1 mg, 69.7 μmol) was deprotected using general procedure F to afford 12.6 mg of <b>37</b> (38% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.19 (q, <i>J</i> = 4.2, 3.4 Hz, 5H), 7.10–7.02 (m, 2H), 6.83–6.73 (m, 2H), 5.95–5.82 (m, 3H), 5.04 (s, 2H), 4.53 (d, <i>J</i> = 14.7 Hz, 2H), 3.70 (s, 3H), 2.84 (s, 3H), 2.21 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 473.16 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.49 min.</div></div><div id="sec5_9_140" class="NLM_sec NLM_sec_level_2"><div id="ac_i177" class="anchor-spacer"></div><h3 class="article-section__title" id="_i177"> 5-((1-((4-Methoxyphenyl)methyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(pyrrolidine-1-carbonyl)benzene-1,3-diol (<b>38</b>)</h3><div class="NLM_p">Acid <b>19b</b> (31.5 mg, 60.6 μmol) was coupled with pyrrolidine (6.5 mg, 91 μmol) and triethylamine (17 μL, 120 μmol) using general procedure G to give 22.6 mg of MOM-protected intermediate (65% yield) after purification via automated flash chromatography (30% to 60% ethyl acetate in hexanes, 10% to 20% ethyl acetate in CH<sub>2</sub>Cl<sub>2</sub>, and 10% to 30% acetone in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83–7.76 (m, 2H), 7.39 (t, <i>J</i> = 7.6 Hz, 2H), 7.29 (t, <i>J</i> = 7.3 Hz, 1H), 7.25–7.16 (m, 2H), 6.86–6.74 (m, 2H), 6.69 (s, 1H), 6.40–6.32 (m, 2H), 6.28 (d, <i>J</i> = 2.1 Hz, 1H), 5.26–5.09 (m, 4H), 5.03 (s, 2H), 3.76 (s, 3H), 3.47 (s, 6H), 3.42 (s, 3H), 3.21 (s, 1H), 2.80 (s, 3H), 1.90 (d, <i>J</i> = 6.3 Hz, 3H), 1.76 (s, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.1, 159.5, 159.1, 155.3, 150.1, 143.5, 140.4, 133.8, 129.0, 128.5, 127.6, 125.4, 114.0, 108.5, 96.6, 95.7, 95.3, 95.2, 94.3, 56.4, 56.2, 55.2, 51.6, 47.5, 45.6, 25.8, 24.5. LC/MS (<i>m</i>/<i>z</i>): 573.457 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.87 min</div><div class="NLM_p last">The MOM-protected intermediate (22.6 mg, 39.5 μmol) was deprotected using general procedure F to afford 8.5 mg of <b>38</b> (44% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.82–7.66 (m, 2H), 7.38 (dd, <i>J</i> = 8.2, 6.8 Hz, 2H), 7.32–7.24 (m, 1H), 7.14 (s, 2H), 6.85 (d, <i>J</i> = 8.7 Hz, 2H), 6.45 (s, 1H), 5.89 (d, <i>J</i> = 4.1 Hz, 2H), 5.19 (s, 2H), 3.75 (s, 3H), 3.41–3.23 (m, 5H), 1.98–1.69 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 485.377 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.53 min.</div></div><div id="sec5_9_141" class="NLM_sec NLM_sec_level_2"><div id="ac_i178" class="anchor-spacer"></div><h3 class="article-section__title" id="_i178"> <i>N</i>,<i>N</i>-Diethyl-2,4-dihydroxy-6-((1-((4-methoxyphenyl)methyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)benzamide (<b>39</b>)</h3><div class="NLM_p">Acid <b>19b</b> (35.6 mg, 68.5 μmol) was coupled with diethylamine (7.5 mg, 100 μmol) and triethylamine (19 μL, 140 μmol) using general procedure G to give 25.2 mg of MOM-protected intermediate (64% yield) after purification via automated flash chromatography (20% to 50% ethyl acetate in hexanes and 10% to 30% ethyl acetate in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.85–7.76 (m, 2H), 7.43–7.36 (m, 2H), 7.33–7.28 (m, 1H), 7.24–7.14 (m, 2H), 6.81 (d, <i>J</i> = 8.7 Hz, 2H), 6.38–6.36 (m, 1H), 6.35 (d, <i>J</i> = 2.1 Hz, 1H), 6.27 (d, <i>J</i> = 2.1 Hz, 1H), 6.11 (s, 1H), 5.29–5.10 (m, 4H), 5.02 (s, 2H), 3.76 (s, 3H), 3.64 (dq, <i>J</i> = 13.7, 6.9 Hz, 1H), 3.46 (s, 3H), 3.42 (s, 3H), 3.33 (dp, <i>J</i> = 14.3, 7.1 Hz, 2H), 3.18 (dq, <i>J</i> = 14.3, 7.1 Hz, 1H), 1.14 (t, <i>J</i> = 7.1 Hz, 3H), 1.02 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 166.9, 159.3, 159.1, 154.7, 150.2, 143.4, 140.5, 133.7, 128.8, 128.5, 128.5, 127.6, 125.4, 114.1, 108.2, 96.8, 95.8, 95.1, 95.0, 94.3, 56.4, 56.2, 55.2, 51.5, 43.0, 39.0, 14.3, 12.9. LC/MS (<i>m</i>/<i>z</i>): 575.485 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.95 min.</div><div class="NLM_p last">The MOM-protected intermediate (25.4 mg, 44.2 μmol) was deprotected using general procedure F to afford 13.5 mg of <b>39</b> (63% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.79–7.71 (m, 2H), 7.38 (td, <i>J</i> = 7.3, 6.4, 1.3 Hz, 2H), 7.32–7.26 (m, 1H), 7.21–7.10 (m, 2H), 6.94–6.78 (m, 2H), 6.44 (s, 1H), 5.91 (dd, <i>J</i> = 14.7, 2.1 Hz, 2H), 5.19 (s, 2H), 3.75 (s, 3H), 3.43 (dq, <i>J</i> = 14.1, 7.1 Hz, 2H), 3.36–3.24 (m, 2H), 1.07 (t, <i>J</i> = 7.1 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 487.406 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.61 min.</div></div><div id="sec5_9_142" class="NLM_sec NLM_sec_level_2"><div id="ac_i179" class="anchor-spacer"></div><h3 class="article-section__title" id="_i179"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>40</b>)</h3><div class="NLM_p last">Amide <b>14c</b> (62.4 mg, 114 μmol) was deprotected using general procedure F to afford 23.8 mg of <b>40</b> (46% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.43 (d, <i>J</i> = 2.1 Hz, 1H), 7.28 (s, 4H), 7.02–6.96 (m, 2H), 6.67–6.59 (m, 2H), 6.10 (d, <i>J</i> = 2.1 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.77 (d, <i>J</i> = 2.1 Hz, 1H), 5.10 (s, 2H), 4.98–4.56 (m, 4H), 3.63 (s, 3H). <sup>13</sup>C NMR (126 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 166.6, 159.3, 158.5, 155.5, 143.7, 143.6, 139.73, 139.66, 138.1, 129.1, 128.8, 127.3, 122.8, 122.8, 113.6, 103.3, 98.8, 94.4, 92.6, 55.0, 50.4, 40.4. LC/MS (<i>m</i>/<i>z</i>): 457.227 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.30 min.</div></div><div id="sec5_9_143" class="NLM_sec NLM_sec_level_2"><div id="ac_i180" class="anchor-spacer"></div><h3 class="article-section__title" id="_i180"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-4-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>41</b>)</h3><div class="NLM_p last">Amide <b>14d</b> (49.1 mg, 87.9 μmol) was deprotected using general procedure F to afford 12.2 mg of <b>41</b> (30% yield) after purification using mass-guided preparative HPLC <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.31 (d, <i>J</i> = 14.5 Hz, 5H), 6.98 (d, <i>J</i> = 8.6 Hz, 2H), 6.65–6.54 (m, 3H), 5.87 (d, <i>J</i> = 2.1 Hz, 1H), 5.34 (d, <i>J</i> = 2.0 Hz, 1H), 5.03 (s, 2H), 4.94–4.73 (m, 4H), 3.63 (s, 3H), 1.90 (s, 3H). <sup>13</sup>C NMR (126 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 166.6, 159.3, 158.4, 155.5, 144.4, 138.4, 136.7 (br), 136.6, 129.4, 128.9, 127.3, 122.9, 113.5, 109.9, 103.4, 93.8, 91.6, 55.0, 50.5, 40.4, 8.3. LC/MS (<i>m</i>/<i>z</i>): 471.251 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.34 min.</div></div><div id="sec5_9_144" class="NLM_sec NLM_sec_level_2"><div id="ac_i181" class="anchor-spacer"></div><h3 class="article-section__title" id="_i181"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-4-(propan-2-yl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>42</b>)</h3><div class="NLM_p last">Amide <b>14e</b> (53.7 mg, 91.5 μmol) was deprotected using general procedure F to afford 22.4 mg of <b>42</b> (49% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.39 (s, 1H), 7.29 (s, 4H), 6.98 (d, <i>J</i> = 8.2 Hz, 2H), 6.62–6.50 (m, 3H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.31 (d, <i>J</i> = 2.1 Hz, 1H), 5.00 (s, 2H), 4.97–4.70 (m, 4H), 3.61 (s, 3H), 2.73 (p, <i>J</i> = 6.9 Hz, 1H), 1.14 (d, <i>J</i> = 6.9 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 499.255 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.47 min.</div></div><div id="sec5_9_145" class="NLM_sec NLM_sec_level_2"><div id="ac_i182" class="anchor-spacer"></div><h3 class="article-section__title" id="_i182"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((4-methoxyphenyl)methyl)-4-phenyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>43</b>)</h3><div class="NLM_p last">Amide <b>14f</b> (25.4 mg, 40.9 μmol) was deprotected using general procedure F to afford 15.0 mg of <b>43</b> (69% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.81 (s, 1H), 7.50–7.44 (m, 2H), 7.33–7.16 (m, 9H), 7.10 (dd, <i>J</i> = 13.6, 7.6 Hz, 3H), 6.65 (d, <i>J</i> = 8.2 Hz, 2H), 5.87 (d, <i>J</i> = 2.1 Hz, 1H), 5.37 (d, <i>J</i> = 2.1 Hz, 1H), 5.12 (s, 2H), 3.65 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 533.257 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.53 min.</div></div><div id="sec5_9_146" class="NLM_sec NLM_sec_level_2"><div id="ac_i183" class="anchor-spacer"></div><h3 class="article-section__title" id="_i183"> 5-((4-Benzyl-1-((4-methoxyphenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)benzene-1,3-diol (<b>44</b>)</h3><div class="NLM_p last">Amide <b>14g</b> (45.3 mg, 71.4 μmol) was deprotected using general procedure F to afford 23.5 mg of <b>44</b> (60% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.29 (d, <i>J</i> = 4.5 Hz, 5H), 7.09 (d, <i>J</i> = 5.6 Hz, 4H), 7.04–6.95 (m, 3H), 6.67–6.56 (m, 3H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.36 (d, <i>J</i> = 2.1 Hz, 1H), 5.05 (s, 2H), 4.96–4.57 (m, 4H), 3.68–3.59 (m, 5H). LC/MS (<i>m</i>/<i>z</i>): 547.17 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.70 min.</div></div><div id="sec5_9_147" class="NLM_sec NLM_sec_level_2"><div id="ac_i184" class="anchor-spacer"></div><h3 class="article-section__title" id="_i184"> (5,7-Dihydro-6<i>H</i>-pyrrolo[3,4-<i>b</i>]pyridin-6-yl)(2-((3-ethyl-1-(4-methoxybenzyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)methanone (<b>45</b>)</h3><div class="NLM_p">Acid <b>19c</b> (51.7 mg, 110 μmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (31.7 mg, 164 μmol) and triethylamine (115 μL, 822 μmol) using general procedure G to give 33.2 mg of MOM-protected intermediate (53% yield) after purification via silica gel flash chromatography (1% to 4% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (20:80:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/conc NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.57–8.41 (m, 1H), 7.21 (ddd, <i>J</i> = 13.4, 7.6, 4.9 Hz, 1H), 7.08 (dd, <i>J</i> = 8.4, 5.9 Hz, 2H), 6.67 (dd, <i>J</i> = 8.7, 3.2 Hz, 2H), 6.47 (d, <i>J</i> = 2.8 Hz, 1H), 6.40 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.26 (dd, <i>J</i> = 11.8, 2.1 Hz, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.22–5.00 (m, 6H), 4.99–4.78 (m, 3H), 4.52 (d, <i>J</i> = 15.5 Hz, 1H), 3.69 (d, <i>J</i> = 2.6 Hz, 3H), 3.45 (dd, <i>J</i> = 4.4, 1.7 Hz, 6H), 2.61 (qd, <i>J</i> = 7.7, 1.9 Hz, 2H), 1.29–1.14 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.2, 167.1, 159.9, 159.0, 158.9, 157.6, 157.2, 155.4, 155.3, 153.7, 153.7, 149.4, 149.3, 143.8, 143.7, 139.4, 139.2, 131.0, 130.6, 130.3, 129.9, 128.8, 128.6, 128.6, 128.5, 122.5, 122.4, 113.9, 113.8, 107.1, 96.9, 96.8, 96.6, 95.4, 95.2, 95.2, 95.1, 94.3, 94.3, 56.6, 56.5, 56.2, 56.2, 55.2, 55.1, 53.4, 52.5, 51.4, 51.4, 51.3, 50.5, 22.0, 13.9. LC/MS (<i>m</i>/<i>z</i>): 574.383 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.51 min.</div><div class="NLM_p last">The MOM-protected intermediate (33.2 mg, 57.9 μmol) was deprotected using general procedure F to afford 22.9 mg of <b>45</b> (81% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.43 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.74 (s, 1H), 7.33 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 7.06–6.95 (m, 2H), 6.65 (d, <i>J</i> = 8.7 Hz, 2H), 5.93 (d, <i>J</i> = 3.1 Hz, 2H), 5.83 (d, <i>J</i> = 2.1 Hz, 1H), 5.05 (s, 2H), 4.97–4.48 (m, 4H), 3.64 (s, 3H), 2.51 (q, <i>J</i> = 7.6 Hz, 2H), 1.17 (t, <i>J</i> = 7.6 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>): 486.259 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.16 min.</div></div><div id="sec5_9_148" class="NLM_sec NLM_sec_level_2"><div id="ac_i185" class="anchor-spacer"></div><h3 class="article-section__title" id="_i185"> 5-((3-Ethyl-1-((4-methoxyphenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>46</b>)</h3><div class="NLM_p">Acid <b>19c</b> (54.0 mg, 115 μmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (18.8 mg, 172 μmol) and triethylamine (32 μL, 230 μmol) using general procedure G to give 26.9 mg of MOM-protected intermediate (42% yield) after purification via silica gel flash chromatography (12% to 35% acetone in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (96:4 CH<sub>2</sub>Cl<sub>2</sub>/methanol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.08 (d, <i>J</i> = 8.6 Hz, 2H), 6.70 (d, <i>J</i> = 8.7 Hz, 2H), 6.38 (dd, <i>J</i> = 7.1, 2.1 Hz, 1H), 6.32 (d, <i>J</i> = 13.6 Hz, 1H), 6.24 (dd, <i>J</i> = 4.2, 2.1 Hz, 1H), 5.88 (d, <i>J</i> = 1.7 Hz, 1H), 5.15 (td, <i>J</i> = 7.3, 5.2 Hz, 2H), 5.06 (d, <i>J</i> = 2.5 Hz, 4H), 4.82–4.59 (m, 3H), 4.32 (t, <i>J</i> = 12.4 Hz, 1H), 3.71 (d, <i>J</i> = 1.8 Hz, 3H), 3.50–3.39 (m, 6H), 2.62 (q, <i>J</i> = 7.6 Hz, 2H), 1.23 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.4, 159.8, 159.8, 159.0, 158.9, 155.2, 153.8, 143.6, 139.3, 139.2, 128.8, 128.6, 128.6, 118.3, 117.8, 113.9, 113.9, 107.7, 107.6, 97.1, 97.0, 96.6, 95.3, 95.2, 94.3, 56.5, 56.2, 55.2, 55.2, 51.3, 46.6, 46.4, 45.6, 45.3, 22.0, 13.9. LC/MS (<i>m</i>/<i>z</i>): 563.401 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.39 min.</div><div class="NLM_p last">The MOM-protected intermediate (26.9 mg, 47.8 μmol) was deprotected using general procedure F to afford 15.3 mg of <b>46</b> (67% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.43 (s, 1H), 7.00 (d, <i>J</i> = 8.7 Hz, 2H), 6.69 (d, <i>J</i> = 8.7 Hz, 2H), 5.98–5.89 (m, 2H), 5.82 (d, <i>J</i> = 2.1 Hz, 1H), 5.04 (s, 2H), 4.83–4.28 (m, 4H), 3.67 (s, 3H), 2.53 (q, <i>J</i> = 7.6 Hz, 2H), 1.19 (t, <i>J</i> = 7.6 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>): 475.321 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.04 min.</div></div><div id="sec5_9_149" class="NLM_sec NLM_sec_level_2"><div id="ac_i186" class="anchor-spacer"></div><h3 class="article-section__title" id="_i186"> 5-((1-((4-Methoxyphenyl)methyl)-3-(propan-2-yl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H,</i>6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>47</b>)</h3><div class="NLM_p">Acid <b>19d</b> (53.2 mg, 110 μmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (31.7 mg, 164 μmol) and triethylamine (115 μL, 822 μmol) using general procedure G to give 44.1 mg of MOM-protected intermediate (68% yield) after purification via silica gel flash chromatography (1% to 4% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (20:80:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/conc NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.59–8.42 (m, 1H), 7.56 (dd, <i>J</i> = 66.5, 7.7 Hz, 1H), 7.25–7.17 (m, 1H), 7.08 (dd, <i>J</i> = 8.3, 5.8 Hz, 2H), 6.68 (dd, <i>J</i> = 8.7, 2.9 Hz, 2H), 6.48 (d, <i>J</i> = 9.5 Hz, 1H), 6.40 (dd, <i>J</i> = 9.2, 2.1 Hz, 1H), 6.29 (dd, <i>J</i> = 10.5, 2.0 Hz, 1H), 5.89 (d, <i>J</i> = 3.2 Hz, 1H), 5.24–5.01 (m, 6H), 5.01–4.71 (m, 3H), 4.52 (d, <i>J</i> = 15.3 Hz, 1H), 3.69 (d, <i>J</i> = 2.7 Hz, 3H), 3.45 (d, <i>J</i> = 1.4 Hz, 3H), 3.44 (d, <i>J</i> = 1.9 Hz, 3H), 2.94 (p, <i>J</i> = 6.9 Hz, 1H), 1.25 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.2, 167.1, 160.0, 159.0, 158.8, 158.2, 158.2, 157.6, 157.2, 155.4, 155.3, 149.4, 149.3, 143.8, 143.7, 139.2, 139.0, 131.0, 130.6, 129.9, 128.8, 128.6, 128.5, 128.5, 122.5, 122.4, 113.9, 113.8, 107.2, 107.2, 96.7, 95.4, 95.3, 95.2, 95.2, 95.1, 94.4, 94.3, 56.6, 56.5, 56.2, 56.2, 55.2, 55.1, 53.4, 52.5, 51.4, 51.4, 51.3, 50.5, 28.3, 22.8. LC/MS (<i>m</i>/<i>z</i>): 588.408 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.61 min.</div><div class="NLM_p last">The MOM-protected intermediate (44.1 mg, 71.0 μmol) was deprotected using general procedure F to afford 24.8 mg of <b>47</b> (66% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.43 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.74 (s, 1H), 7.33 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 6.98 (d, <i>J</i> = 8.7 Hz, 2H), 6.65 (d, <i>J</i> = 8.7 Hz, 2H), 5.99–5.87 (m, 2H), 5.83 (d, <i>J</i> = 2.1 Hz, 1H), 5.06 (s, 2H), 4.97–4.49 (m, 4H), 3.63 (s, 3H), 2.84 (hept, <i>J</i> = 6.9 Hz, 1H), 1.20 (d, <i>J</i> = 6.9 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 500.285 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.25 min.</div></div><div id="sec5_9_150" class="NLM_sec NLM_sec_level_2"><div id="ac_i187" class="anchor-spacer"></div><h3 class="article-section__title" id="_i187"> 5-((1-((4-Methoxyphenyl)methyl)-3-(propan-2-yl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>48</b>)</h3><div class="NLM_p">Acid <b>19d</b> (57.5 mg, 118 μmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (19.4 mg, 178 μmol) and triethylamine (33 μL, 240 μmol) using general procedure G to give 23.2 mg of MOM-protected intermediate (34% yield) after purification via silica gel flash chromatography (12% to 35% acetone in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (96:4 CH<sub>2</sub>Cl<sub>2</sub>/methanol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.40–7.19 (m, 1H), 7.09 (d, <i>J</i> = 8.1 Hz, 2H), 6.70 (d, <i>J</i> = 8.4 Hz, 2H), 6.44–6.27 (m, 2H), 6.26 (t, <i>J</i> = 2.1 Hz, 1H), 5.89 (d, <i>J</i> = 2.2 Hz, 1H), 5.21–5.00 (m, 6H), 4.78–4.57 (m, 3H), 4.38–4.22 (m, 1H), 3.71 (d, <i>J</i> = 1.4 Hz, 3H), 3.44 (d, <i>J</i> = 1.3 Hz, 6H), 2.94 (p, <i>J</i> = 6.9 Hz, 1H), 1.25 (dd, <i>J</i> = 7.0, 2.2 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.4, 159.8, 159.8, 159.0, 158.9, 158.2, 155.2, 143.5, 143.4, 139.3, 139.2, 128.7, 128.6, 113.9, 113.9, 107.8, 107.7, 96.7, 96.6, 95.5, 95.4, 95.3, 95.2, 94.4, 56.5, 56.2, 55.2, 55.1, 51.3, 51.3, 46.6, 46.4, 45.6, 45.3, 28.3, 22.8. LC/MS (<i>m</i>/<i>z</i>): 577.382 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.47 min.</div><div class="NLM_p last">The MOM-protected intermediate (23.2 mg, 40.2 μmol) was deprotected using general procedure F to afford 15.3 mg of <b>48</b> (78% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.43 (s, 1H), 7.05–6.92 (m, 2H), 6.74–6.63 (m, 2H), 5.99–5.88 (m, 2H), 5.82 (d, <i>J</i> = 2.1 Hz, 1H), 5.05 (s, 2H), 4.79–4.22 (m, 4H), 3.67 (s, 3H), 2.85 (h, <i>J</i> = 6.9 Hz, 1H), 1.21 (d, <i>J</i> = 6.9 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 489.303 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.13 min.</div></div><div id="sec5_9_151" class="NLM_sec NLM_sec_level_2"><div id="ac_i188" class="anchor-spacer"></div><h3 class="article-section__title" id="_i188"> (2-((3-(<i>tert</i>-Butyl)-1-(4-methoxybenzyl)-1<i>H-</i>pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>49</b>)</h3><div class="NLM_p last">Amide <b>14h</b> (45.0 mg, 74.9 μmol) was deprotected using general procedure F to afford 12.5 mg of <b>49</b> (33% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.33–7.17 (m, 4H), 6.93 (d, <i>J</i> = 8.7 Hz, 2H), 6.61 (d, <i>J</i> = 8.7 Hz, 2H), 5.98 (s, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.82 (d, <i>J</i> = 2.1 Hz, 1H), 5.07 (s, 2H), 4.93–4.56 (m, 4H), 3.61 (s, 3H), 1.26 (s, 9H). <sup>13</sup>C NMR (126 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 166.6, 159.32, 159.27, 158.4, 155.5, 143.7, 139.8, 136.7 (br), 129.4, 128.5, 127.2, 122.8, 113.6, 103.8, 94.6, 94.4, 92.9, 54.9, 50.2, 40.4, 31.9, 30.3. LC/MS (<i>m</i>/<i>z</i>): 513.208 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.73 min.</div></div><div id="sec5_9_152" class="NLM_sec NLM_sec_level_2"><div id="ac_i189" class="anchor-spacer"></div><h3 class="article-section__title" id="_i189"> (2-((3-Cyclopropyl-1-(4-methoxybenzyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(5,7-dihydro-6<i>H</i>-pyrrolo[3,4-<i>b</i>]pyridin-6-yl)methanone (<b>50</b>)</h3><div class="NLM_p">Acid <b>19e</b> (52.5 mg, 109 μmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (31.5 mg, 163 μmol) and triethylamine (114 μL, 814 μmol) using general procedure G to give 43.7 mg of MOM-protected intermediate (69% yield) after purification via automated flash system (1% to 4% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (20:80:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/conc NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56–8.44 (m, 1H), 7.68–7.40 (m, 1H), 7.25–7.16 (m, 1H), 7.08 (dd, <i>J</i> = 8.5, 5.0 Hz, 2H), 6.67 (dd, <i>J</i> = 8.7, 2.6 Hz, 2H), 6.48 (d, <i>J</i> = 7.3 Hz, 1H), 6.40 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.29–6.20 (m, 1H), 5.69 (s, 1H), 5.24–4.97 (m, 7H), 5.00–4.79 (m, 3H), 4.51 (d, <i>J</i> = 15.8 Hz, 1H), 3.69 (d, <i>J</i> = 2.2 Hz, 3H), 3.45 (d, <i>J</i> = 1.5 Hz, 3H), 3.44 (d, <i>J</i> = 1.8 Hz, 3H), 1.89 (dtd, <i>J</i> = 8.9, 5.6, 5.2, 2.8 Hz, 1H), 0.89 (dd, <i>J</i> = 8.6, 2.0 Hz, 2H), 0.68 (dd, <i>J</i> = 5.2, 2.4 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.2, 167.1, 159.9, 159.0, 158.9, 157.5, 157.2, 155.4, 155.3, 154.2, 154.1, 149.4, 149.3, 143.6, 143.6, 139.5, 139.3, 131.0, 130.6, 130.3, 129.9, 128.7, 128.6, 128.5, 128.5, 122.5, 122.4, 113.9, 113.8, 107.2, 107.2, 96.7, 95.4, 95.3, 95.2, 95.2, 94.6, 94.5, 94.3, 94.3, 56.6, 56.5, 56.3, 56.2, 55.2, 55.1, 53.4, 52.5, 51.4, 51.4, 51.3, 50.5, 9.6, 7.9. LC/MS (<i>m</i>/<i>z</i>): 586.38 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.46 min.</div><div class="NLM_p last">The MOM-protected intermediate (43.7 mg, 74.6 μmol) was deprotected using general procedure F to afford 25.3 mg of <b>50</b> (68% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.43 (dd, <i>J</i> = 5.1, 1.5 Hz, 1H), 7.74 (s, 1H), 7.33 (dd, <i>J</i> = 7.7, 5.0 Hz, 1H), 7.03–6.90 (m, 2H), 6.72–6.57 (m, 2H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.81 (d, <i>J</i> = 2.1 Hz, 1H), 5.74 (s, 1H), 5.03 (s, 2H), 4.94–4.44 (m, 4H), 3.64 (s, 4H), 1.78 (tt, <i>J</i> = 8.4, 5.0 Hz, 1H), 0.83 (dd, <i>J</i> = 8.5, 2.1 Hz, 2H), 0.61 (dd, <i>J</i> = 5.1, 2.0 Hz, 2H). LC/MS (<i>m</i>/<i>z</i>): 498.3 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.19 min.</div></div><div id="sec5_9_153" class="NLM_sec NLM_sec_level_2"><div id="ac_i190" class="anchor-spacer"></div><h3 class="article-section__title" id="_i190"> 5-((3-Cyclopropyl-1-((4-methoxyphenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>51</b>)</h3><div class="NLM_p">Acid <b>19e</b> (59.7 mg, 123 μmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (20.2 mg, 185 μmol) and triethylamine (34 μL, 250 μmol) using general procedure G to give 31.4 mg of MOM-protected intermediate (44% yield) after purification via automated flash system (12% to 35% acetone in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (96:4 CH<sub>2</sub>Cl<sub>2</sub>/methanol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.08 (d, <i>J</i> = 8.4 Hz, 2H), 6.75–6.63 (m, 2H), 6.38 (dd, <i>J</i> = 7.1, 2.1 Hz, 1H), 6.29 (d, <i>J</i> = 15.5 Hz, 1H), 6.22 (dd, <i>J</i> = 5.2, 2.1 Hz, 1H), 5.69 (s, 1H), 5.21–5.09 (m, 2H), 5.04 (d, <i>J</i> = 4.3 Hz, 5H), 4.78–4.65 (m, 2H), 4.64 (s, 1H), 4.30 (t, <i>J</i> = 12.6 Hz, 1H), 3.71 (d, <i>J</i> = 2.1 Hz, 3H), 3.48–3.37 (m, 6H), 1.89 (td, <i>J</i> = 8.6, 4.3 Hz, 1H), 0.89 (dd, <i>J</i> = 8.5, 2.2 Hz, 2H), 0.76–0.57 (m, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.4, 159.8, 159.8, 159.0, 158.9, 155.2, 154.2, 143.5, 139.4, 139.3, 128.7, 128.6, 128.6, 128.6, 118.2, 117.7, 113.9, 113.9, 107.7, 107.7, 96.6, 95.3, 95.2, 94.9, 94.8, 94.3, 56.5, 56.5, 56.2, 55.2, 55.1, 51.3, 46.6, 46.4, 45.6, 45.3, 9.7, 7.9. LC/MS (<i>m</i>/<i>z</i>): 575.397 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.41 min.</div><div class="NLM_p last">The MOM-protected intermediate (31.4 mg, 54.6 μmol) was deprotected using general procedure F to afford 17.7 mg of <b>51</b> (67% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.43 (s, 1H), 6.99 (d, <i>J</i> = 8.7 Hz, 2H), 6.69 (d, <i>J</i> = 8.7 Hz, 2H), 5.90 (d, <i>J</i> = 2.1 Hz, 1H), 5.80 (d, <i>J</i> = 2.1 Hz, 1H), 5.74 (s, 1H), 5.02 (s, 2H), 4.77–4.18 (m, 4H), 3.67 (s, 4H), 1.82 (tt, <i>J</i> = 8.4, 5.0 Hz, 1H), 0.86 (dd, <i>J</i> = 8.5, 2.1 Hz, 2H), 0.64 (dd, <i>J</i> = 5.1, 2.1 Hz, 2H). LC/MS (<i>m</i>/<i>z</i>): 487.318 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.08 min.</div></div><div id="sec5_9_154" class="NLM_sec NLM_sec_level_2"><div id="ac_i191" class="anchor-spacer"></div><h3 class="article-section__title" id="_i191"> 5-((3-Cyclopentyl-1-((4-methoxyphenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>52</b>)</h3><div class="NLM_p">Acid <b>19f</b> (44.7 mg, 87.4 μmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (25.3 mg, 131 μmol) and triethylamine (91.4 μL, 655 μmol) using general procedure G to give 41.2 mg of MOM-protected intermediate (77% yield) after purification via automated flash system (1% to 4% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (55:45:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/conc NH<sub>4</sub>OH (aq) to 40:60:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/conc NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.58–8.38 (m, 1H), 7.68–7.38 (m, 1H), 7.24–7.15 (m, 1H), 7.08 (dd, <i>J</i> = 8.4, 5.7 Hz, 2H), 6.67 (dd, <i>J</i> = 8.7, 3.0 Hz, 2H), 6.46 (d, <i>J</i> = 6.2 Hz, 1H), 6.40 (dd, <i>J</i> = 8.6, 2.1 Hz, 1H), 6.29 (dd, <i>J</i> = 11.1, 2.1 Hz, 1H), 5.88 (d, <i>J</i> = 2.7 Hz, 1H), 5.27–4.98 (m, 6H), 4.98–4.78 (m, 3H), 4.51 (d, <i>J</i> = 15.6 Hz, 1H), 3.69 (d, <i>J</i> = 2.7 Hz, 3H), 3.45 (dd, <i>J</i> = 5.0, 1.7 Hz, 6H), 3.04 (t, <i>J</i> = 8.2 Hz, 1H), 2.03 (d, <i>J</i> = 9.1 Hz, 2H), 1.85–1.33 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.2, 159.9, 158.8, 157.6, 157.2, 156.5, 156.5, 155.4, 155.3, 149.4, 149.3, 143.8, 143.7, 139.3, 139.1, 131.0, 130.6, 130.3, 129.9, 128.8, 128.6, 128.6, 128.5, 122.5, 122.4, 113.9, 113.8, 107.1, 96.6, 95.8, 95.7, 95.4, 95.2, 95.2, 95.1, 94.4, 94.3, 56.6, 56.5, 56.2, 56.2, 55.2, 55.1, 53.4, 51.4, 51.3, 50.5, 39.5, 33.4, 25.4. LC/MS (<i>m</i>/<i>z</i>): 614.431 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.72 min.</div><div class="NLM_p last">The MOM-protected intermediate (40.8 mg, 66.5 μmol) was deprotected using general procedure F to afford 22.9 mg of <b>52</b> (66% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.43 (dd, <i>J</i> = 4.9, 1.5 Hz, 1H), 7.74 (s, 1H), 7.33 (dd, <i>J</i> = 7.8, 5.1 Hz, 1H), 6.98 (d, <i>J</i> = 8.7 Hz, 2H), 6.65 (d, <i>J</i> = 8.7 Hz, 2H), 5.92 (d, <i>J</i> = 2.6 Hz, 2H), 5.83 (d, <i>J</i> = 2.1 Hz, 1H), 5.05 (s, 2H), 4.88 (s, 9H), 3.64 (s, 3H), 2.92 (d, <i>J</i> = 8.1 Hz, 1H), 1.96 (s, 2H), 1.80–1.48 (m, 6H). <sup>13</sup>C NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 166.8, 159.5, 158.4, 157.3, 155.6, 154.8, 148.8, 143.9, 140.0, 131.3, 129.4, 128.7, 122.4, 113.6, 103.4, 95.8, 94.4, 93.0, 55.0, 50.1, 40.4, 32.7, 24.9 LC/MS (<i>m</i>/<i>z</i>): 526.308 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.36 min.</div></div><div id="sec5_9_155" class="NLM_sec NLM_sec_level_2"><div id="ac_i192" class="anchor-spacer"></div><h3 class="article-section__title" id="_i192"> 5-((3-Cyclopentyl-1-((4-methoxyphenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4H,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>53</b>)</h3><div class="NLM_p">Acid <b>19f</b> (45.3 mg, 88.6 μmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (14.5 mg, 133 μmol) and triethylamine (35 μL, 180 μmol) using general procedure G to give 27.1 mg of MOM-protected intermediate (51% yield) after purification via automated flash system (12% to 35% acetone in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (96:4 CH<sub>2</sub>Cl<sub>2</sub>/methanol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.15–6.99 (m, 2H), 6.70 (d, <i>J</i> = 8.2 Hz, 2H), 6.44–6.29 (m, 2H), 6.27 (q, <i>J</i> = 1.9 Hz, 1H), 5.88 (d, <i>J</i> = 2.2 Hz, 1H), 5.24–4.95 (m, 6H), 4.78–4.58 (m, 3H), 4.31 (t, <i>J</i> = 12.4 Hz, 1H), 3.71 (t, <i>J</i> = 1.4 Hz, 3H), 3.44 (d, <i>J</i> = 1.5 Hz, 6H), 3.06 (q, <i>J</i> = 8.1 Hz, 1H), 2.04 (s, 2H), 1.82–1.48 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.4, 159.8, 159.8, 159.0, 158.9, 156.5, 156.5, 155.2, 143.4, 139.4, 139.3, 128.7, 128.6, 113.9, 113.9, 107.8, 107.7, 96.7, 96.7, 95.9, 95.8, 95.3, 95.3, 94.4, 56.5, 56.2, 55.2, 55.1, 51.3, 51.3, 46.6, 46.4, 45.6, 45.3, 39.5, 33.4, 33.4, 25.4. LC/MS (<i>m</i>/<i>z</i>): 603.404 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.59 min.</div><div class="NLM_p last">The MOM-protected intermediate (27.1 mg, 45.0 μmol) was deprotected using general procedure F to afford 16.1 mg of <b>53</b> (70% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.42 (s, 1H), 6.99 (d, <i>J</i> = 8.7 Hz, 2H), 6.69 (d, <i>J</i> = 8.7 Hz, 2H), 6.01–5.87 (m, 2H), 5.82 (d, <i>J</i> = 2.1 Hz, 1H), 5.05 (s, 2H), 4.82–4.24 (m, 4H), 3.67 (s, 3H), 2.92 (s, 1H), 1.98 (d, <i>J</i> = 10.7 Hz, 2H), 1.87–1.43 (m, 6H). LC/MS (<i>m</i>/<i>z</i>): 515.325 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.25 min.</div></div><div id="sec5_9_156" class="NLM_sec NLM_sec_level_2"><div id="ac_i193" class="anchor-spacer"></div><h3 class="article-section__title" id="_i193"> 5-((3-(Furan-3-yl)-1-((4-methoxyphenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>54</b>)</h3><div class="NLM_p">Acid <b>19g</b> (52.5 mg, 103 μmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (29.8 mg, 155 μmol) and triethylamine (108 μL, 773 μmol) using general procedure G to give 48.6 mg of MOM-protected intermediate (77% yield) after purification via automated flash system (0% to 3% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (55:45:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/conc NH<sub>4</sub>OH (aq) to 40:60:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/conc NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.51 (dd, <i>J</i> = 21.5, 4.9 Hz, 1H), 7.75 (q, <i>J</i> = 1.2 Hz, 1H), 7.70–7.61 (m, 1H), 7.48 (d, <i>J</i> = 7.8 Hz, 1H), 7.44 (q, <i>J</i> = 1.7 Hz, 1H), 7.24–7.16 (m, 1H), 7.12 (dd, <i>J</i> = 8.7, 6.7 Hz, 2H), 6.74 (dd, <i>J</i> = 1.9, 0.9 Hz, 1H), 6.73–6.59 (m, 2H), 6.53 (d, <i>J</i> = 5.5 Hz, 1H), 6.42 (dd, <i>J</i> = 7.9, 2.1 Hz, 1H), 6.29 (dd, <i>J</i> = 15.9, 2.1 Hz, 1H), 6.16 (d, <i>J</i> = 2.0 Hz, 1H), 5.16 (dd, <i>J</i> = 11.1, 7.1 Hz, 5H), 5.07 (d, <i>J</i> = 2.5 Hz, 3H), 5.01–4.78 (m, 4H), 4.53 (d, <i>J</i> = 15.1 Hz, 1H), 3.69 (d, <i>J</i> = 3.1 Hz, 4H), 3.47–3.42 (m, 6H), 2.80 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.2, 167.1, 160.0, 159.1, 159.0, 157.4, 157.1, 155.5, 155.4, 149.3, 149.2, 143.5, 143.5, 143.5, 143.2, 143.2, 140.0, 139.8, 139.1, 131.1, 130.7, 130.3, 129.9, 128.6, 128.6, 128.4, 128.2, 122.5, 122.5, 120.1, 113.9, 113.9, 108.7, 107.2, 96.7, 96.3, 95.4, 95.3, 95.3, 94.3, 94.2, 56.6, 56.6, 56.3, 56.3, 55.2, 55.2, 53.4, 52.5, 51.7, 51.6, 51.4, 50.6, 47.4, 38.6, 8.7. LC/MS (<i>m</i>/<i>z</i>): 612.358 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.55 min.</div><div class="NLM_p last">The MOM-protected intermediate (48.6 mg, 79.5 μmol) was deprotected using general procedure F to afford 28.7 mg of <b>54</b> (69% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.39 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.76 (dd, <i>J</i> = 1.6, 0.8 Hz, 1H), 7.70 (s, 1H), 7.46 (t, <i>J</i> = 1.7 Hz, 1H), 7.29 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 7.04 (d, <i>J</i> = 8.7 Hz, 2H), 6.72–6.59 (m, 3H), 6.26 (s, 1H), 5.95 (d, <i>J</i> = 2.1 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.14 (s, 2H), 5.02–4.45 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 524.279 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.25 min.</div></div><div id="sec5_9_157" class="NLM_sec NLM_sec_level_2"><div id="ac_i194" class="anchor-spacer"></div><h3 class="article-section__title" id="_i194"> 5-((3-(Furan-3-yl)-1-((4-methoxyphenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>55</b>)</h3><div class="NLM_p">Acid <b>19g</b> (51.7 mg, 101 μmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (16.6 mg, 152 μmol) and triethylamine (28 μL, 200 μmol) using general procedure G to give 33.3 mg of MOM-protected intermediate (55% yield) after purification via automated flash system (10% to 30% acetone in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (96:4 CH<sub>2</sub>Cl<sub>2</sub>/methanol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81 (s, 1H), 7.48–7.31 (m, 1H), 7.17 (d, <i>J</i> = 7.8 Hz, 2H), 6.80–6.66 (m, 3H), 6.43 (d, <i>J</i> = 8.6 Hz, 1H), 6.31 (s, 1H), 6.16 (d, <i>J</i> = 2.4 Hz, 1H), 5.16 (d, <i>J</i> = 11.2 Hz, 4H), 5.06 (s, 2H), 4.86–4.55 (m, 3H), 4.33 (s, 1H), 3.72 (d, <i>J</i> = 1.9 Hz, 3H), 3.51–3.35 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.4, 159.8, 159.8, 159.1, 159.0, 155.3, 143.5, 143.3, 143.3, 140.0, 140.0, 139.1, 139.1, 128.7, 128.3, 128.2, 120.1, 114.0, 113.9, 108.8, 107.9, 107.8, 96.7, 96.6, 96.5, 95.4, 95.3, 94.3, 56.5, 56.3, 55.2, 55.2, 51.6, 46.6, 46.5, 45.6, 45.4. LC/MS (<i>m</i>/<i>z</i>): 601.331 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.35 min.</div><div class="NLM_p last">The MOM-protected intermediate (32.9 mg, 55.8 μmol) was deprotected using general procedure F to afford 18.9 mg of <b>55</b> (67% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.84–7.78 (m, 1H), 7.49 (t, <i>J</i> = 1.7 Hz, 1H), 7.41 (s, 1H), 7.05 (d, <i>J</i> = 8.7 Hz, 2H), 6.76–6.66 (m, 3H), 6.27 (s, 1H), 5.93 (d, <i>J</i> = 2.1 Hz, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.14 (s, 2H), 4.79–4.27 (m, 4H), 3.67 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 513.296 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.15 min.</div></div><div id="sec5_9_158" class="NLM_sec NLM_sec_level_2"><div id="ac_i195" class="anchor-spacer"></div><h3 class="article-section__title" id="_i195"> (2,4-Dihydroxy-6-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>56</b>)</h3><div class="NLM_p last">Amide <b>14i</b> (37.0 mg, 84.4 μmol) was deprotected using general procedure F to afford 17.1 mg of <b>56</b> (58% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.36 (d, <i>J</i> = 2.0 Hz, 1H), 7.28 (s, 4H), 6.03 (d, <i>J</i> = 2.1 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.61 (d, <i>J</i> = 2.1 Hz, 1H), 5.07–4.70 (m, 4H), 3.64 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 351.292 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.09 min.</div></div><div id="sec5_9_159" class="NLM_sec NLM_sec_level_2"><div id="ac_i196" class="anchor-spacer"></div><h3 class="article-section__title" id="_i196"> 5-((1-Methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H,</i>6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>57</b>)</h3><div class="NLM_p">Acid <b>19h</b> (27.6 mg, 81.8 μmmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (23.7 mg, 123 μmol) and triethylamine (86 μL, 610 μmol) using general procedure G to give 13.3 mg of MOM-protected intermediate (37% yield) after purification via an automated flash system (1% to 5% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (60:40:1 CH<sub>2</sub>Cl<sub>2</sub>/acetone/conc NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.52 (dd, <i>J</i> = 19.1, 5.0 Hz, 1H), 7.77–7.50 (m, 1H), 7.44 (d, <i>J</i> = 2.0 Hz, 1H), 7.26 (s, 1H), 6.79 (d, <i>J</i> = 15.3 Hz, 1H), 6.45 (dd, <i>J</i> = 10.5, 2.1 Hz, 1H), 6.13 (dd, <i>J</i> = 4.4, 2.1 Hz, 1H), 6.03 (d, <i>J</i> = 2.2 Hz, 1H), 5.18 (d, <i>J</i> = 9.2 Hz, 3H), 5.11–4.81 (m, 4H), 4.79–4.53 (m, 1H), 3.70 (s, 3H), 3.46 (s, 3H), 3.45 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.5, 160.1, 160.1, 157.6, 157.2, 155.7, 155.6, 149.5, 149.3, 144.6, 144.4, 138.6, 131.1, 130.6, 129.9, 122.6, 122.4, 106.9, 99.0, 96.3, 96.2, 95.5, 95.3, 95.3, 95.2, 94.3, 94.2, 56.6, 56.6, 56.3, 56.2, 53.5, 52.7, 51.5, 50.7, 35.1. LC/MS (<i>m</i>/<i>z</i>): 440.426 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.13 min.</div><div class="NLM_p last">The MOM-protected intermediate (13.3 mg, 30.3 μmol) was deprotected using general procedure F to afford 5.1 mg of <b>57</b> (48% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.44 (dd, <i>J</i> = 5.1, 1.5 Hz, 1H), 7.80 (d, <i>J</i> = 7.7 Hz, 1H), 7.36 (d, <i>J</i> = 2.0 Hz, 2H), 6.03 (d, <i>J</i> = 2.1 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.62 (d, <i>J</i> = 2.1 Hz, 1H), 4.90 (s, 4H), 3.65 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 352.218 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.77 min.</div></div><div id="sec5_9_160" class="NLM_sec NLM_sec_level_2"><div id="ac_i197" class="anchor-spacer"></div><h3 class="article-section__title" id="_i197"> 5-((1-Methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>58</b>)</h3><div class="NLM_p">Acid <b>19h</b> (16.8 mg, 49.8 μmmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (8.2 mg, 75 μmol) and triethylamine (14 μL, 100 μmol) using general procedure G to afford 4.2 mg of MOM-protected intermediate (20% yield) after purification via automated flash system (1% to 5% methanol in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43 (d, <i>J</i> = 2.0 Hz, 1H), 7.34 (d, <i>J</i> = 46.2 Hz, 1H), 6.59 (d, <i>J</i> = 7.2 Hz, 1H), 6.42 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 6.07 (d, <i>J</i> = 2.1 Hz, 1H), 6.01 (t, <i>J</i> = 1.9 Hz, 1H), 5.16 (q, <i>J</i> = 6.3, 4.9 Hz, 2H), 5.07 (d, <i>J</i> = 2.5 Hz, 2H), 4.98–4.64 (m, 3H), 4.42 (dd, <i>J</i> = 13.5, 6.5 Hz, 1H), 3.67 (s, 3H), 3.45 (s, 3H), 3.43 (d, <i>J</i> = 1.6 Hz, 3H). LC/MS (<i>m</i>/<i>z</i>): 429.318 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.03 min.</div><div class="NLM_p last">The MOM-protected intermediate (4.2 mg, 9.8 μmol) was deprotected using general procedure F to afford 2.3 mg of <b>58</b> (69% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.45 (s, 1H), 7.38 (d, <i>J</i> = 2.1 Hz, 1H), 6.04 (d, <i>J</i> = 2.1 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.60 (d, <i>J</i> = 2.1 Hz, 1H), 4.80–4.43 (m, 4H), 3.65 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 341.235 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.66 min.</div></div><div id="sec5_9_161" class="NLM_sec NLM_sec_level_2"><div id="ac_i198" class="anchor-spacer"></div><h3 class="article-section__title" id="_i198"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-(propan-2-yl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>59</b>)</h3><div class="NLM_p last">To a mixture of carboxylic acid <b>19i</b> (34.9 mg, 95.5 μmmol) and isoindoline hydrochloride (22.3 mg, 143 μmol) in THF (0.62 mL) and CH<sub>2</sub>Cl<sub>2</sub> (0.62 mL) was added triethylamine (53 μL, 380 μmol) followed by PyBOP (59.7, 115 μmol). After the reaction was stirred at room temperature overnight, the reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>. The reaction mixture was washed twice with saturated NaHCO<sub>3</sub> (aq), once with brine and then dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The salts were removed via gravity filtration, and volatile materials were condensed in vacuo. The crude residue was dissolved in methanol (4.8), and HCl (2 M, 310 μL, 620 μmol) was added to the resulting mixture. The reaction was stirred at 50 °C overnight. After cooling to room temperature, volatile materials were condensed in vacuo. The crude residue was purified using mass-guided preparative HPLC to afford 8.7 mg of <b>59</b> (24% yield over 2 steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.43 (d, <i>J</i> = 2.0 Hz, 1H), 7.29 (d, <i>J</i> = 1.7 Hz, 4H), 6.03 (d, <i>J</i> = 2.0 Hz, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.60–5.55 (m, 1H), 4.90 (s, 4H), 4.55 (p, <i>J</i> = 6.7 Hz, 1H), 1.36 (d, <i>J</i> = 6.7 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 379.344 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.25 min.</div></div><div id="sec5_9_162" class="NLM_sec NLM_sec_level_2"><div id="ac_i199" class="anchor-spacer"></div><h3 class="article-section__title" id="_i199"> (5,7-Dihydro-6<i>H</i>-pyrrolo[3,4-<i>b</i>]pyridin-6-yl)(2,4-dihydroxy-6-((1-isopropyl-1<i>H</i>-pyrazol-5-yl)amino)phenyl)methanone (<b>60</b>)</h3><div class="NLM_p last">Synthesized using the same procedure for the synthesis of <b>59</b> with <b>19i</b> (37.6 mg, 103 μmol), 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (29.8 mg, 154 μmol) and triethylamine (110 μL, 770 μmol) followed by MOM deprotection with HCl (2 M, 330 μL, 670 μmol) in methanol at 50 °C overnight to afford 6.6 mg of <b>60</b> (17% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.55 (s, 1H), 8.45 (d, <i>J</i> = 4.8 Hz, 1H), 7.82 (d, <i>J</i> = 7.4 Hz, 1H), 7.43 (d, <i>J</i> = 1.6 Hz, 1H), 7.36 (dd, <i>J</i> = 7.4, 4.8 Hz, 1H), 6.04 (d, <i>J</i> = 1.6 Hz, 1H), 5.90 (d, <i>J</i> = 2.0 Hz, 1H), 5.59 (d, <i>J</i> = 2.0 Hz, 1H), 4.65–4.53 (m, 2H), 1.67 (d, <i>J</i> = 6.6 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 380.359 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.93 min.</div></div><div id="sec5_9_163" class="NLM_sec NLM_sec_level_2"><div id="ac_i200" class="anchor-spacer"></div><h3 class="article-section__title" id="_i200"> 5-((1-(Propan-2-yl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>61</b>)</h3><div class="NLM_p last">Synthesized using the same procedure for the synthesis of <b>59</b> with <b>19i</b> (36.7 mg, 100 μmol), 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (16.4 mg, 151 μmol) and triethylamine (28 μL, 200 μmol) followed by MOM deprotection with HCl (2 M, 330 μL, 650 μmol) in methanol at 50 °C overnight to afford 11.7 mg of <b>61</b> (32% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.45 (t, <i>J</i> = 2.8 Hz, 2H), 6.04 (d, <i>J</i> = 2.0 Hz, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.56 (d, <i>J</i> = 2.1 Hz, 1H), 4.80–4.42 (m, 5H), 1.37 (d, <i>J</i> = 6.6 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 369.332 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.82 min.</div></div><div id="sec5_9_164" class="NLM_sec NLM_sec_level_2"><div id="ac_i201" class="anchor-spacer"></div><h3 class="article-section__title" id="_i201"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-(2-methylpropyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>62</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19j</b> (45 mg, 120 μmol) was subjected to general procedure H1 to afford 17 mg of <b>62</b> (37% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.40 (d, <i>J</i> = 2.0 Hz, 1H), 7.28 (s, 4H), 6.06 (d, <i>J</i> = 2.0 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.74 (d, <i>J</i> = 2.1 Hz, 1H), 5.14–4.69 (m, 4H), 3.75 (d, <i>J</i> = 7.6 Hz, 2H), 3.34 (s, 2H), 2.09 (dh, <i>J</i> = 12.5, 6.3, 5.9 Hz, 1H), 0.79 (d, <i>J</i> = 6.7 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 393.238 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.38 min.</div></div><div id="sec5_9_165" class="NLM_sec NLM_sec_level_2"><div id="ac_i202" class="anchor-spacer"></div><h3 class="article-section__title" id="_i202"> 5-((1-(2-Methylpropyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>63</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19j</b> (46 mg, 120 μmol) was subjected to general procedure H2 to afford 4.7 mg of <b>63</b> (9.9% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.44 (dd, <i>J</i> = 5.2, 1.5 Hz, 1H), 7.80 (d, <i>J</i> = 7.7 Hz, 1H), 7.40 (d, <i>J</i> = 2.0 Hz, 1H), 7.35 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 6.06 (d, <i>J</i> = 2.0 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.75 (d, <i>J</i> = 2.1 Hz, 1H), 5.04–4.57 (m, 4H), 3.77 (d, <i>J</i> = 7.5 Hz, 2H), 2.12 (hept, <i>J</i> = 7.0 Hz, 1H), 0.81 (d, <i>J</i> = 6.7 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 394.341 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.08 min.</div></div><div id="sec5_9_166" class="NLM_sec NLM_sec_level_2"><div id="ac_i203" class="anchor-spacer"></div><h3 class="article-section__title" id="_i203"> 5-((1-(2-Methylpropyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>64</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19j</b> (46 mg, 120 μmol) was subjected to general procedure H3 to afford 13.2 mg of <b>64</b> (28% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.46 (s, 1H), 7.42 (d, <i>J</i> = 2.0 Hz, 1H), 6.06 (d, <i>J</i> = 2.1 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.72 (d, <i>J</i> = 2.1 Hz, 1H), 4.88 (s, 4H), 3.76 (d, <i>J</i> = 7.5 Hz, 2H), 2.12 (p, <i>J</i> = 6.9 Hz, 1H), 0.81 (d, <i>J</i> = 6.7 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 383.27 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.95 min.</div></div><div id="sec5_9_167" class="NLM_sec NLM_sec_level_2"><div id="ac_i204" class="anchor-spacer"></div><h3 class="article-section__title" id="_i204"> 5-((1-(Cyclohexylmethyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)benzene-1,3-diol (<b>65</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19k</b> (30.9 mg, 73.4 μmol) was subjected to general procedure H1 to afford 12.4 mg of <b>65</b> (39% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.40 (d, <i>J</i> = 2.1 Hz, 1H), 7.29 (s, 5H), 6.06 (d, <i>J</i> = 2.1 Hz, 1H), 5.92 (d, <i>J</i> = 2.0 Hz, 1H), 5.69 (d, <i>J</i> = 2.0 Hz, 1H), 5.10–4.65 (m, 4H), 3.75 (d, <i>J</i> = 7.4 Hz, 2H), 1.77 (ddd, <i>J</i> = 11.1, 7.5, 3.6 Hz, 1H), 1.63–1.40 (m, 5H), 1.16–0.72 (m, 5H). <sup>13</sup>C NMR (126 MHz, 2:1 (CD<sub>3</sub>)<sub>2</sub>SO: CD<sub>3</sub>OD) δ 167.6, 159.8, 155.8, 144.4, 140.4, 138.1, 136.9, 127.7, 123.1, 104.0, 99.5, 94.6, 92.9, 53.7, 40.4, 38.3, 30.4, 26.1, 25.5. LC/MS (<i>m</i>/<i>z</i>): 433.596 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.46 min.</div></div><div id="sec5_9_168" class="NLM_sec NLM_sec_level_2"><div id="ac_i205" class="anchor-spacer"></div><h3 class="article-section__title" id="_i205"> 5-((1-(Cyclohexylmethyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>66</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19k</b> (36.4 mg, 86.8 μmol) was subjected to general procedure H2 to afford 13.8 mg of <b>66</b> (37% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.44 (dd, <i>J</i> = 5.0, 1.4 Hz, 1H), 7.81 (d, <i>J</i> = 7.7 Hz, 1H), 7.40 (d, <i>J</i> = 2.0 Hz, 1H), 7.36 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 6.06 (d, <i>J</i> = 2.0 Hz, 1H), 5.93 (d, <i>J</i> = 2.0 Hz, 1H), 5.71 (d, <i>J</i> = 2.1 Hz, 1H), 4.89 (s, 4H), 3.77 (d, <i>J</i> = 7.4 Hz, 2H), 1.86–1.72 (m, 1H), 1.68–1.39 (m, 5H), 1.18–0.74 (m, 5H). LC/MS (<i>m</i>/<i>z</i>): 434.39 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.22 min.</div></div><div id="sec5_9_169" class="NLM_sec NLM_sec_level_2"><div id="ac_i206" class="anchor-spacer"></div><h3 class="article-section__title" id="_i206"> 5-((1-(Cyclohexylmethyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>67</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19k</b> (37.2 mg, 88.7 μmol) was subjected to general procedure H3 to afford 14.8 mg of <b>67</b> (40% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.46 (s, 1H), 7.41 (d, <i>J</i> = 2.0 Hz, 1H), 6.06 (d, <i>J</i> = 2.0 Hz, 1H), 5.92 (d, <i>J</i> = 2.0 Hz, 1H), 5.69 (d, <i>J</i> = 2.1 Hz, 1H), 5.04–4.38 (m, 4H), 3.76 (d, <i>J</i> = 7.4 Hz, 2H), 1.79 (ddq, <i>J</i> = 11.3, 7.4, 3.7 Hz, 1H), 1.67–1.43 (m, 5H), 1.18–0.76 (m, 5H). LC/MS (<i>m</i>/<i>z</i>): 423.363 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.08 min.</div></div><div id="sec5_9_170" class="NLM_sec NLM_sec_level_2"><div id="ac_i207" class="anchor-spacer"></div><h3 class="article-section__title" id="_i207"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-phenyl-1<i>H-</i>pyrazol-5-yl)amino]benzene-1,3-diol (<b>68</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19l</b> (42 mg, 110 μmol) was subjected to general procedure H1 to afford 2.4 mg of <b>68</b> (5.5% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.61 (d, <i>J</i> = 2.0 Hz, 1H), 7.49–7.40 (m, 2H), 7.34–7.16 (m, 8H), 6.26 (d, <i>J</i> = 2.0 Hz, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.85 (d, <i>J</i> = 2.1 Hz, 1H), 4.98–4.42 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 413.307 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.39 min.</div></div><div id="sec5_9_171" class="NLM_sec NLM_sec_level_2"><div id="ac_i208" class="anchor-spacer"></div><h3 class="article-section__title" id="_i208"> 5-((1-Phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>69</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19l</b> (43 mg, 110 μmol) was subjected to general procedure H2 to afford 5.1 mg of <b>69</b> (11% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.45 (d, <i>J</i> = 5.0 Hz, 1H), 7.77 (s, 1H), 7.61 (d, <i>J</i> = 2.0 Hz, 1H), 7.50–7.41 (m, 2H), 7.39–7.29 (m, 3H), 7.29–7.18 (m, 1H), 6.26 (d, <i>J</i> = 2.0 Hz, 1H), 5.91–5.84 (m, 2H), 5.12–4.44 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 414.277 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.08 min.</div></div><div id="sec5_9_172" class="NLM_sec NLM_sec_level_2"><div id="ac_i209" class="anchor-spacer"></div><h3 class="article-section__title" id="_i209"> 5-((1-Phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>70</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19l</b> (44 mg, 110 μmol) was subjected to general procedure H3 to afford 6.6 mg of <b>70</b> (15% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.62 (d, <i>J</i> = 2.0 Hz, 1H), 7.52–7.41 (m, 3H), 7.39–7.24 (m, 3H), 6.26 (d, <i>J</i> = 2.0 Hz, 1H), 5.85 (dd, <i>J</i> = 17.7, 2.1 Hz, 2H), 4.73–4.07 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 403.295 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.97 min.</div></div><div id="sec5_9_173" class="NLM_sec NLM_sec_level_2"><div id="ac_i210" class="anchor-spacer"></div><h3 class="article-section__title" id="_i210"> 5-((1-Cyclohexyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)benzene-1,3-diol (<b>71</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19m</b> (48.8 mg, 120 μmol) was subjected to general procedure H1 to afford 18.3 mg of <b>71</b> (36% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.41 (d, <i>J</i> = 2.0 Hz, 1H), 7.37–7.20 (m, 4H), 6.03 (d, <i>J</i> = 2.0 Hz, 1H), 5.90 (d, <i>J</i> = 2.1 Hz, 1H), 5.59 (d, <i>J</i> = 2.1 Hz, 1H), 5.03–4.76 (m, 4H), 4.09 (d, <i>J</i> = 11.4 Hz, 1H), 1.98–1.71 (m, 9H), 1.63 (d, <i>J</i> = 10.8 Hz, 1H), 1.23 (dd, <i>J</i> = 26.4, 15.1 Hz, 2H). LC/MS (<i>m</i>/<i>z</i>): 419.041 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.46 min.</div></div><div id="sec5_9_174" class="NLM_sec NLM_sec_level_2"><div id="ac_i211" class="anchor-spacer"></div><h3 class="article-section__title" id="_i211"> 5-((1-Cyclohexyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>72</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19m</b> (54.4 mg, 134 μmol) was subjected to general procedure H2 to afford 14.3 mg of <b>72</b> (25% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.44 (dd, <i>J</i> = 5.1, 1.5 Hz, 1H), 7.86–7.74 (m, 1H), 7.40 (d, <i>J</i> = 2.0 Hz, 1H), 7.36 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 6.03 (d, <i>J</i> = 2.0 Hz, 1H), 5.90 (d, <i>J</i> = 2.1 Hz, 1H), 5.61 (d, <i>J</i> = 2.1 Hz, 1H), 4.88 (s, 4H), 4.12 (dt, <i>J</i> = 11.3, 6.4 Hz, 1H), 1.96–1.71 (m, 7H), 1.71–1.59 (m, 1H), 1.44–1.08 (m, 3H). LC/MS (<i>m</i>/<i>z</i>): 420.32 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.18 min.</div></div><div id="sec5_9_175" class="NLM_sec NLM_sec_level_2"><div id="ac_i212" class="anchor-spacer"></div><h3 class="article-section__title" id="_i212"> 5-((1-Cyclohexyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>73</b>)</h3><div class="NLM_p last">Carboxylic acid <b>19m</b> (58.8 mg, 145 μmol) was subjected to general procedure H3 to afford 22.5 mg of <b>73</b> (38% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.46 (s, 1H), 7.43 (d, <i>J</i> = 2.0 Hz, 1H), 6.04 (d, <i>J</i> = 2.0 Hz, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.58 (d, <i>J</i> = 2.1 Hz, 1H), 4.80–4.43 (m, 4H), 4.11 (dt, <i>J</i> = 10.9, 6.4 Hz, 1H), 1.92–1.72 (m, 7H), 1.71–1.61 (m, 1H), 1.44–1.12 (m, 3H). LC/MS (<i>m</i>/<i>z</i>): 409.337 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.05 min.</div></div><div id="sec5_9_176" class="NLM_sec NLM_sec_level_2"><div id="ac_i213" class="anchor-spacer"></div><h3 class="article-section__title" id="_i213"> 5-((1-Benzyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)benzene-1,3-diol (<b>74</b>)</h3><div class="NLM_p last">Acid <b>19n</b> (42.1 mg, 102 μmol) was subjected to general procedure H1 to afford 3.3 mg of <b>74</b> (7.6% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.45 (d, <i>J</i> = 2.0 Hz, 1H), 7.34–7.18 (m, 4H), 7.10 (dd, <i>J</i> = 4.0, 2.5 Hz, 3H), 7.03 (dd, <i>J</i> = 6.8, 3.0 Hz, 2H), 6.12 (d, <i>J</i> = 2.1 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.79 (d, <i>J</i> = 2.1 Hz, 1H), 5.18 (s, 2H), 5.01–4.52 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 427.333 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.37 min.</div></div><div id="sec5_9_177" class="NLM_sec NLM_sec_level_2"><div id="ac_i214" class="anchor-spacer"></div><h3 class="article-section__title" id="_i214"> 5-((1-Benzyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>75</b>)</h3><div class="NLM_p last">Acid <b>19n</b> (42.6 mg, 103 μmol) was subjected to general procedure H2 to afford 2.9 mg of <b>75</b> (6.6% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.44 (d, <i>J</i> = 5.1 Hz, 1H), 7.76 (s, 1H), 7.45 (d, <i>J</i> = 2.0 Hz, 1H), 7.41–7.31 (m, 1H), 7.17–6.99 (m, 5H), 6.13 (d, <i>J</i> = 2.1 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.79 (d, <i>J</i> = 2.1 Hz, 1H), 5.19 (s, 2H), 5.05–4.11 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 428.347 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.08 min.</div></div><div id="sec5_9_178" class="NLM_sec NLM_sec_level_2"><div id="ac_i215" class="anchor-spacer"></div><h3 class="article-section__title" id="_i215"> 5-((1-Benzyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>76</b>)</h3><div class="NLM_p last">Acid <b>19n</b> (43 mg, 100 μmol) was subjected to general procedure H3 to afford 5.0 mg of <b>76</b> (12% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.51–7.33 (m, 2H), 7.15 (dd, <i>J</i> = 5.2, 1.9 Hz, 4H), 7.06 (dd, <i>J</i> = 6.9, 2.7 Hz, 2H), 6.12 (d, <i>J</i> = 2.0 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.78 (d, <i>J</i> = 2.1 Hz, 1H), 5.19 (s, 3H), 4.80–4.21 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 417.321 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.96 min.</div></div><div id="sec5_9_179" class="NLM_sec NLM_sec_level_2"><div id="ac_i216" class="anchor-spacer"></div><h3 class="article-section__title" id="_i216"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((pyridin-3-yl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>77</b>)</h3><div class="NLM_p last">Acid <b>19o</b> (41.5 mg, 100 μmol) was subjected to general procedure H1 to afford 4.0 mg of <b>77</b> (9.3% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.32 (d, <i>J</i> = 6.5 Hz, 2H), 7.61 (d, <i>J</i> = 1.9 Hz, 1H), 7.47 (d, <i>J</i> = 2.0 Hz, 1H), 7.25 (d, <i>J</i> = 18.7 Hz, 6H), 6.13 (d, <i>J</i> = 2.0 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.64 (d, <i>J</i> = 2.1 Hz, 1H), 5.25 (s, 2H), 5.00–4.41 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 428.347 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.98 min.</div></div><div id="sec5_9_180" class="NLM_sec NLM_sec_level_2"><div id="ac_i217" class="anchor-spacer"></div><h3 class="article-section__title" id="_i217"> 5-((1-((Pyridin-3-yl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>78</b>)</h3><div class="NLM_p last">Acid <b>19o</b> (42.4 mg, 102 μmol) was subjected to general procedure H2 to afford 2.5 mg of <b>78</b> (5.7% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.44 (d, <i>J</i> = 5.1 Hz, 1H), 8.38–8.29 (m, 2H), 7.75–7.59 (m, 2H), 7.46 (d, <i>J</i> = 2.1 Hz, 1H), 7.41–7.32 (m, 1H), 7.32–7.19 (m, 2H), 6.13 (d, <i>J</i> = 2.0 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.64 (d, <i>J</i> = 2.0 Hz, 1H), 5.27 (s, 2H), 5.04–4.49 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 429.362 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.76 min.</div></div><div id="sec5_9_181" class="NLM_sec NLM_sec_level_2"><div id="ac_i218" class="anchor-spacer"></div><h3 class="article-section__title" id="_i218"> 5-((1-((Pyridin-3-yl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>79</b>)</h3><div class="NLM_p last">Acid <b>19o</b> (46.6 mg, 112 μmol) was subjected to general procedure H3 to afford 4.2 mg of <b>79</b> (9.0% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.40 (dd, <i>J</i> = 5.0, 1.6 Hz, 1H), 8.39–8.31 (m, 2H), 7.67–7.56 (m, 1H), 7.49 (d, <i>J</i> = 2.1 Hz, 1H), 7.36 (ddd, <i>J</i> = 7.9, 4.9, 0.9 Hz, 1H), 6.09 (d, <i>J</i> = 2.0 Hz, 1H), 5.77 (s, 2H), 5.27 (s, 2H), 5.01–4.45 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 418.335 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.63 min.</div></div><div id="sec5_9_182" class="NLM_sec NLM_sec_level_2"><div id="ac_i219" class="anchor-spacer"></div><h3 class="article-section__title" id="_i219"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-((furan-2-yl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>80</b>)</h3><div class="NLM_p last">Acid <b>19p</b> (47.1 mg, 117 μmol) was subjected to general procedure H1 to afford 12.7 mg of <b>80</b> (26% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.40 (d, <i>J</i> = 2.0 Hz, 1H), 7.26 (d, <i>J</i> = 11.9 Hz, 5H), 6.23 (t, <i>J</i> = 1.6 Hz, 2H), 6.08 (d, <i>J</i> = 2.0 Hz, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.15 (s, 2H), 5.00–4.65 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 417.321 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.29 min.</div></div><div id="sec5_9_183" class="NLM_sec NLM_sec_level_2"><div id="ac_i220" class="anchor-spacer"></div><h3 class="article-section__title" id="_i220"> 5-((1-((Furan-2-yl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>81</b>)</h3><div class="NLM_p last">Acid <b>19p</b> (49.6 mg, 123 μmol) was subjected to general procedure H2 to afford 7.6 mg of <b>81</b> (15% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.44 (dd, <i>J</i> = 5.1, 1.4 Hz, 1H), 7.85–7.70 (m, 1H), 7.40 (d, <i>J</i> = 2.1 Hz, 1H), 7.35 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 7.28 (dd, <i>J</i> = 1.8, 0.9 Hz, 1H), 6.25 (dd, <i>J</i> = 3.2, 1.3 Hz, 2H), 6.08 (d, <i>J</i> = 2.1 Hz, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.79 (d, <i>J</i> = 2.1 Hz, 1H), 5.16 (s, 2H), 5.03–4.72 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 418.291 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.98 min.</div></div><div id="sec5_9_184" class="NLM_sec NLM_sec_level_2"><div id="ac_i221" class="anchor-spacer"></div><h3 class="article-section__title" id="_i221"> 5-((1-((Furan-2-yl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>82</b>)</h3><div class="NLM_p last">Acid <b>19p</b> (55.5 mg, 138 μmol) was subjected to general procedure H3 to afford 8.5 mg of <b>82</b> (15% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.45 (s, 1H), 7.41 (d, <i>J</i> = 2.1 Hz, 1H), 7.34–7.27 (m, 1H), 6.26 (t, <i>J</i> = 1.4 Hz, 2H), 6.08 (d, <i>J</i> = 2.0 Hz, 1H), 5.93 (d, <i>J</i> = 2.1 Hz, 1H), 5.78 (d, <i>J</i> = 2.1 Hz, 1H), 5.16 (s, 2H), 4.80–4.33 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 407.308 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.89 min.</div></div><div id="sec5_9_185" class="NLM_sec NLM_sec_level_2"><div id="ac_i222" class="anchor-spacer"></div><h3 class="article-section__title" id="_i222"> (2,4-Dihydroxy-6-((1-(4-isopropylbenzyl)-1<i>H-</i>pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>83</b>)</h3><div class="NLM_p last">Amide <b>14j</b> (42.1 mg, 75.6 μmol) was deprotected using general procedure F to afford 7.8 mg of <b>83</b> (22% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.45 (d, <i>J</i> = 2.1 Hz, 1H), 7.29 (s, 4H), 6.96 (d, <i>J</i> = 1.0 Hz, 4H), 6.11 (d, <i>J</i> = 2.1 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.75 (d, <i>J</i> = 2.1 Hz, 1H), 5.13 (s, 2H), 4.95–4.59 (m, 4H), 2.72 (p, <i>J</i> = 6.9 Hz, 1H), 1.11 (d, <i>J</i> = 6.9 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 469.234 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.59 min.</div></div><div id="sec5_9_186" class="NLM_sec NLM_sec_level_2"><div id="ac_i223" class="anchor-spacer"></div><h3 class="article-section__title" id="_i223"> 5-((1-((4-(Propan-2-yl)phenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>84</b>)</h3><div class="NLM_p">Acid <b>19q</b> (24.6 mg, 54.0 μmmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (15.6 mg, 81.0 μmol) and triethylamine (57 μL, 410 μmol) using general procedure G to give 20.7 mg of MOM-protected intermediate (69% yield) after purification via an automated flash system (25% to 70% ethyl acetate in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.51 (ddd, <i>J</i> = 19.6, 5.0, 1.5 Hz, 1H), 7.67–7.44 (m, 2H), 7.21 (ddd, <i>J</i> = 12.8, 7.7, 4.9 Hz, 1H), 7.07 (dd, <i>J</i> = 8.2, 3.7 Hz, 2H), 7.00 (dd, <i>J</i> = 8.2, 3.3 Hz, 2H), 6.51 (d, <i>J</i> = 6.0 Hz, 1H), 6.40 (dd, <i>J</i> = 6.7, 2.1 Hz, 1H), 6.20 (dd, <i>J</i> = 17.0, 2.1 Hz, 1H), 6.12–6.01 (m, 1H), 5.24–5.09 (m, 4H), 5.05 (d, <i>J</i> = 3.9 Hz, 2H), 4.93 (dt, <i>J</i> = 25.1, 13.4 Hz, 3H), 4.57 (dd, <i>J</i> = 15.1, 7.2 Hz, 1H), 3.44 (t, <i>J</i> = 1.9 Hz, 6H), 2.83–2.71 (m, 1H), 1.14 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.3, 167.2, 160.0, 157.6, 157.2, 155.5, 155.4, 149.4, 149.3, 148.5, 148.2, 144.0, 139.0, 138.9, 133.7, 133.6, 130.9, 130.6, 130.3, 129.9, 127.5, 126.7, 126.7, 126.6, 122.5, 122.4, 106.9, 99.3, 99.2, 96.3, 96.2, 95.4, 95.3, 95.3, 95.2, 94.3, 94.2, 56.6, 56.6, 56.3, 56.2, 53.4, 52.6, 51.9, 51.9, 51.5, 50.6, 33.7, 23.9. LC/MS (<i>m</i>/<i>z</i>): 558.417 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.60 min.</div><div class="NLM_p last">The MOM-protected intermediate (20 mg, 36 μmol) was deprotected using general procedure F to afford 8.5 mg of <b>84</b> (50% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.44 (dd, <i>J</i> = 5.1, 1.5 Hz, 1H), 7.77 (s, 1H), 7.44 (d, <i>J</i> = 2.1 Hz, 1H), 7.35 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 6.99 (s, 4H), 6.11 (d, <i>J</i> = 2.1 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.73 (d, <i>J</i> = 2.1 Hz, 1H), 5.14 (s, 2H), 4.89 (s, 25H), 2.73 (p, <i>J</i> = 6.9 Hz, 1H), 1.11 (d, <i>J</i> = 6.9 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 470.381 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.36 min.</div></div><div id="sec5_9_187" class="NLM_sec NLM_sec_level_2"><div id="ac_i224" class="anchor-spacer"></div><h3 class="article-section__title" id="_i224"> 5-((1-((4-(Propan-2-yl)phenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>85</b>)</h3><div class="NLM_p">Acid <b>19q</b> (27.7 mg, 60.8 μmmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (10 mg, 109 μmol) and triethylamine (17 μL, 120 μmol) using general procedure G to give 17.2 mg of MOM-protected intermediate (52% yield) after purification via automated flash system (2% to 5% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual flash chromatography (40:59:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/saturated NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.49 (d, <i>J</i> = 2.0 Hz, 1H), 7.32 (d, <i>J</i> = 43.7 Hz, 1H), 7.09 (d, <i>J</i> = 7.8 Hz, 2H), 7.04 (d, <i>J</i> = 8.1 Hz, 2H), 6.45–6.31 (m, 2H), 6.20 (dd, <i>J</i> = 3.7, 2.1 Hz, 1H), 6.07 (d, <i>J</i> = 1.9 Hz, 1H), 5.24–5.08 (m, 4H), 5.04 (s, 2H), 4.69 (d, <i>J</i> = 20.0 Hz, 2H), 4.36 (dd, <i>J</i> = 13.5, 8.5 Hz, 1H), 3.50–3.33 (m, 6H), 2.80 (q, <i>J</i> = 7.0, 6.5 Hz, 1H), 1.16 (dd, <i>J</i> = 7.0, 1.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.4, 159.9, 159.8, 155.3, 148.4, 148.2, 143.8, 139.1, 139.0, 138.9, 133.6, 133.6, 127.5, 126.7, 126.7, 107.6, 99.4, 99.3, 96.3, 95.3, 95.3, 94.2, 56.5, 56.2, 51.8, 46.6, 33.7, 23.9, 23.9. LC/MS (<i>m</i>/<i>z</i>): 547.434 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.53 min.</div><div class="NLM_p last">The MOM-protected intermediate (17.2 mg, 31.5 μmol) was deprotected using general procedure F to afford 7.5 mg of <b>85</b> (52% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.45 (d, <i>J</i> = 2.0 Hz, 2H), 7.08–6.91 (m, 4H), 6.11 (d, <i>J</i> = 2.0 Hz, 1H), 5.91 (t, <i>J</i> = 1.4 Hz, 1H), 5.74 (d, <i>J</i> = 2.0 Hz, 1H), 5.14 (s, 2H), 4.80–4.36 (m, 4H), 2.77 (p, <i>J</i> = 6.9 Hz, 1H), 1.14 (d, <i>J</i> = 6.9 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 459.354 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.23 min.</div></div><div id="sec5_9_188" class="NLM_sec NLM_sec_level_2"><div id="ac_i225" class="anchor-spacer"></div><h3 class="article-section__title" id="_i225"> 4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>Pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)-5-((1-((4-(trifluoromethyl)phenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino]benzene-1,3-diol (<b>86</b>)</h3><div class="NLM_p last">Acid <b>19r</b> (35.1 mg, 65 μmol) was subjected to general procedure H2 to afford 10.3 mg of <b>86</b> (32% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.43 (dd, <i>J</i> = 5.0, 1.4 Hz, 1H), 7.75 (s, 1H), 7.52–7.42 (m, 3H), 7.34 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 7.25 (d, <i>J</i> = 8.0 Hz, 2H), 6.14 (d, <i>J</i> = 2.1 Hz, 1H), 5.92 (d, <i>J</i> = 2.0 Hz, 1H), 5.68 (d, <i>J</i> = 2.1 Hz, 1H), 5.28 (s, 2H), 5.07–4.44 (m, 4H). LC/MS (<i>m</i>/<i>z</i>): 496.316 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.31 min.</div></div><div id="sec5_9_189" class="NLM_sec NLM_sec_level_2"><div id="ac_i226" class="anchor-spacer"></div><h3 class="article-section__title" id="_i226"> 4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>Pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)-5-((1-((4-(trifluoromethyl)phenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino]benzene-1,3-diol (<b>87</b>)</h3><div class="NLM_p last">Acid <b>19r</b> (31.6 mg, 66 μmol) was subjected to general procedure H3 to afford 10.6 mg of <b>87</b> (33% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.54–7.38 (m, 4H), 7.25 (d, <i>J</i> = 8.0 Hz, 2H), 6.14 (d, <i>J</i> = 2.0 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.67 (d, <i>J</i> = 2.1 Hz, 1H), 5.28 (s, 2H), 4.82–4.20 (m, 4H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −64.1. LC/MS (<i>m</i>/<i>z</i>): 485.289 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.20 min.</div></div><div id="sec5_9_190" class="NLM_sec NLM_sec_level_2"><div id="ac_i227" class="anchor-spacer"></div><h3 class="article-section__title" id="_i227"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((3-methyl-1-((4-methylphenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>88</b>)</h3><div class="NLM_p last">Amide <b>14k</b> (40.4 mg, 74.5 μmol) was deprotected using general procedure F to afford 28.8 mg of <b>88</b> (85% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.29 (d, <i>J</i> = 8.8 Hz, 4H), 6.89 (s, 4H), 5.96–5.88 (m, 2H), 5.85 (d, <i>J</i> = 2.1 Hz, 1H), 5.05 (s, 2H), 4.95–4.46 (m, 4H), 2.14 (s, 3H), 2.13 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 455.208 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.55 min.</div></div><div id="sec5_9_191" class="NLM_sec NLM_sec_level_2"><div id="ac_i228" class="anchor-spacer"></div><h3 class="article-section__title" id="_i228"> 5-((1-((2-Chlorophenyl)methyl)-3-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)benzene-1,3-diol (<b>89</b>)</h3><div class="NLM_p last">Amide <b>14l</b> (46.5 mg, 82.3 μmol) was deprotected using general procedure F to afford 30.4 mg of <b>89</b> (78% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.31–7.19 (m, 4H), 7.17–7.11 (m, 1H), 7.10–6.99 (m, 2H), 6.64–6.53 (m, 1H), 5.97 (s, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.20 (s, 2H), 4.85–4.29 (m, 4H), 2.14 (s, 3H). <sup>13</sup>C NMR (126 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 166.4, 159.2, 155.5, 146.7, 143.7, 141.3, 136.5, 135.0, 131.3, 129.0, 128.8, 128.6, 127.2, 127.1, 122.8, 104.1, 98.4, 94.5, 93.1, 48.0, 40.4, 13.9. LC/MS (<i>m</i>/<i>z</i>): 475.573 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.41 min.</div></div><div id="sec5_9_192" class="NLM_sec NLM_sec_level_2"><div id="ac_i229" class="anchor-spacer"></div><h3 class="article-section__title" id="_i229"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((3-methyl-1-((2-methylphenyl)methyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>90</b>)</h3><div class="NLM_p last">Amide <b>14m</b> (21.3 mg, 39.3 μmol) was deprotected using general procedure F to afford 9.7 mg of <b>90</b> (54% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.28 (dt, <i>J</i> = 7.1, 3.6 Hz, 2H), 7.22 (d, <i>J</i> = 7.4 Hz, 2H), 7.01–6.94 (m, 2H), 6.91–6.83 (m, 1H), 6.49 (d, <i>J</i> = 7.6 Hz, 1H), 5.97–5.93 (m, 2H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.11 (s, 2H), 4.82–4.32 (m, 4H), 2.16 (s, 3H), 2.14 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 455.164 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.51 min.</div></div><div id="sec5_9_193" class="NLM_sec NLM_sec_level_2"><div id="ac_i230" class="anchor-spacer"></div><h3 class="article-section__title" id="_i230"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-methyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino]benzene-1,3-diol (<b>91</b>)</h3><div class="NLM_p last">Amide <b>14n</b> (65.0 mg, 126 μmol) was deprotected using general procedure F to afford 32.8 mg of <b>91</b> (61% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.70–7.53 (m, 2H), 7.34–7.27 (m, 2H), 7.24 (s, 5H), 6.35 (s, 1H), 5.95 (d, <i>J</i> = 2.1 Hz, 1H), 5.78 (d, <i>J</i> = 2.1 Hz, 1H), 5.03–4.71 (m, 4H), 3.69 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.2, 161.6, 157.5, 151.6, 145.8, 143.7, 137.7, 134.7, 129.7, 128.9, 128.8, 126.4, 123.9, 105.3, 98.3, 95.9, 95.2, 40.6, 35.3. LC/MS (<i>m</i>/<i>z</i>): 428.347 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.58 min.</div></div><div id="sec5_9_194" class="NLM_sec NLM_sec_level_2"><div id="ac_i231" class="anchor-spacer"></div><h3 class="article-section__title" id="_i231"> 5-((1-Methyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>92</b>)</h3><div class="NLM_p">Acid <b>19s</b> (44.1 mg, 107 μmmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (30.9 mg, 160 μmol) and triethylamine (110 μL, 800 μmol) using general procedure G to give 48.3 mg of MOM-protected intermediate (88% yield) after purification via an automated flash system (0% to 4% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual chromatography (70:30:1 CH<sub>2</sub>Cl<sub>2</sub>/acetone/saturated NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.61–8.46 (m, 1H), 7.75 (ddd, <i>J</i> = 8.3, 2.5, 1.3 Hz, 2H), 7.63 (dd, <i>J</i> = 51.9, 7.7 Hz, 1H), 7.38 (ddd, <i>J</i> = 7.9, 6.8, 2.1 Hz, 2H), 7.32–7.27 (m, 1H), 6.81 (s, 1H), 6.47 (dd, <i>J</i> = 7.4, 2.1 Hz, 1H), 6.34 (s, 1H), 6.26–6.16 (m, 1H), 5.19 (d, <i>J</i> = 10.6 Hz, 3H), 5.10 (d, <i>J</i> = 0.9 Hz, 3H), 4.99–4.83 (m, 1H), 4.75–4.51 (m, 1H), 3.74 (s, 3H), 3.47 (s, 3H), 3.46–3.42 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 169.2, 161.6, 160.0, 150.4, 149.7, 138.6, 134.1, 128.5, 127.3, 125.4, 99.6, 97.2, 95.4, 95.1, 94.8, 93.9, 56.7, 56.5, 56.3, 52.0, 32.7, 25.7, 25.2. LC/MS (<i>m</i>/<i>z</i>): 516.251 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.43 min.</div><div class="NLM_p last">The MOM-protected intermediate (48.3 mg, 94 μmol) was deprotected using general procedure F to afford 25 mg of <b>92</b> (62% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.34 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.68 (dd, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.61–7.53 (m, 2H), 7.34–7.14 (m, 4H), 6.35 (s, 1H), 5.96 (d, <i>J</i> = 2.1 Hz, 1H), 5.82 (d, <i>J</i> = 2.1 Hz, 1H), 5.01–4.60 (m, 4H), 3.72 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.4, 161.8, 158.2, 157.6, 151.4, 149.6, 146.1, 144.0, 134.6, 133.4, 129.7, 128.8, 126.3, 124.3, 111.5, 104.9, 98.2, 96.0, 95.7, 40.6, 35.3. LC/MS (<i>m</i>/<i>z</i>): 428.259 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.11 min.</div></div><div id="sec5_9_195" class="NLM_sec NLM_sec_level_2"><div id="ac_i232" class="anchor-spacer"></div><h3 class="article-section__title" id="_i232"> 5-((1-Methyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>93</b>)</h3><div class="NLM_p">Acid <b>19s</b> (64.1 mg, 155 μmmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (25 mg, 230 μmol) and triethylamine (43 μL, 310 μmol) using general procedure G to give 17.2 mg of MOM-protected intermediate (52% yield) as a solid after purification via automated flash system (20% to 60% acetone in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.88–7.77 (m, 2H), 7.51 (d, <i>J</i> = 24.4 Hz, 1H), 7.43–7.32 (m, 2H), 7.30–6.88 (m, 1H), 6.49 (d, <i>J</i> = 5.2 Hz, 1H), 6.45 (dd, <i>J</i> = 5.0, 2.1 Hz, 1H), 6.18 (q, <i>J</i> = 2.1 Hz, 1H), 5.32–5.15 (m, 2H), 5.13 (d, <i>J</i> = 2.3 Hz, 2H), 4.82–4.48 (m, 3H), 4.43 (d, <i>J</i> = 13.0 Hz, 1H), 3.70 (d, <i>J</i> = 3.3 Hz, 3H), 3.43 (d, <i>J</i> = 2.5 Hz, 3H), 3.40 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 505.269 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.34 min.</div><div class="NLM_p last">The MOM-protected intermediate (41.6 mg, 82 μmol) was deprotected using general procedure F to afford 24.5 mg of <b>93</b> (71% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.67–7.61 (m, 2H), 7.38 (s, 1H), 7.36–7.28 (m, 2H), 7.28–7.22 (m, 1H), 6.37 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.77 (d, <i>J</i> = 2.1 Hz, 1H), 4.78–4.44 (m, 4H), 3.71 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 417.233 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.01 min.</div></div><div id="sec5_9_196" class="NLM_sec NLM_sec_level_2"><div id="ac_i233" class="anchor-spacer"></div><h3 class="article-section__title" id="_i233"> 5-((1-<i>tert</i>-Butyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>94</b>)</h3><div class="NLM_p">Acid <b>19t</b> (41.5 mg, 91.1 μmmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (26.4 mg, 140 μmol) and triethylamine (100 μL, 680 μmol) using general procedure G to give 39.9 mg of MOM-protected intermediate (79% yield) after purification via an automated flash system (0% to 3% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual chromatography (70:30:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/saturated NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.52 (dd, <i>J</i> = 18.4, 4.9 Hz, 1H), 7.84–7.74 (m, 2H), 7.60 (dd, <i>J</i> = 59.2, 7.8 Hz, 1H), 7.36 (t, <i>J</i> = 7.7 Hz, 2H), 7.27–7.17 (m, 2H), 6.75 (d, <i>J</i> = 7.3 Hz, 1H), 6.51–6.36 (m, 2H), 6.30 (dd, <i>J</i> = 9.4, 2.1 Hz, 1H), 5.32–5.01 (m, 6H), 4.94 (d, <i>J</i> = 16.5 Hz, 1H), 4.68 (d, <i>J</i> = 14.7 Hz, 1H), 3.47 (s, 3H), 3.44 (d, <i>J</i> = 1.9 Hz, 3H), 2.80 (s, 3H), 1.64 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.7, 167.6, 160.1, 160.1, 157.7, 157.2, 155.7, 155.6, 149.4, 149.3, 147.7, 147.7, 145.2, 145.2, 139.5, 139.4, 134.0, 131.1, 130.6, 129.9, 128.5, 127.2, 125.2, 122.5, 122.4, 106.5, 106.4, 99.3, 99.1, 96.5, 96.3, 95.5, 95.4, 94.6, 94.5, 94.3, 94.2, 59.7, 59.7, 56.7, 56.6, 56.3, 56.2, 53.5, 52.7, 51.5, 50.8, 38.6, 29.7. LC/MS (<i>m</i>/<i>z</i>): 558.328 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.84 min.</div><div class="NLM_p last">The MOM-protected intermediate (39.9 mg, 72 μmol) was deprotected using general procedure F to afford 24.3 mg of <b>94</b> (72% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.42 (dd, <i>J</i> = 5.1, 1.5 Hz, 1H), 7.78 (d, <i>J</i> = 7.7 Hz, 1H), 7.74–7.65 (m, 2H), 7.41–7.26 (m, 3H), 7.26–7.18 (m, 1H), 6.45 (s, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.80 (d, <i>J</i> = 2.0 Hz, 1H), 5.08–4.70 (m, 4H), 1.63 (s, 9H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.7, 161.8, 158.3, 157.4, 149.7, 149.5, 147.3, 142.2, 135.5, 133.4, 132.6, 129.6, 128.5, 126.3, 124.3, 103.8, 101.9, 95.1, 94.5, 61.2, 40.6, 30.4. LC/MS (<i>m</i>/<i>z</i>): 470.337 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.51 min.</div></div><div id="sec5_9_197" class="NLM_sec NLM_sec_level_2"><div id="ac_i234" class="anchor-spacer"></div><h3 class="article-section__title" id="_i234"> 5-((1-<i>tert</i>-Butyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>95</b>)</h3><div class="NLM_p">Acid <b>19t</b> (62.2 mg, 137 μmmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (22.3 mg, 205 μmol) and triethylamine (38 μL, 270 μmol) using general procedure G to give 44.4 mg of MOM-protected intermediate (59% yield) as a solid after purification via automated flash system (10% to 30% acetone in CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 12.70 (s, 1H), 7.80–7.71 (m, 3H), 7.71–7.62 (m, 1H), 7.53 (d, <i>J</i> = 31.5 Hz, 1H), 7.45–7.30 (m, 3H), 7.28–7.20 (m, 1H), 7.04 (d, <i>J</i> = 2.7 Hz, 1H), 6.60 (d, <i>J</i> = 9.9 Hz, 1H), 6.27 (t, <i>J</i> = 2.5 Hz, 1H), 5.85 (dd, <i>J</i> = 10.4, 2.1 Hz, 1H), 5.24–5.11 (m, 3H), 5.10–4.99 (m, 3H), 4.66 (dd, <i>J</i> = 14.4, 6.5 Hz, 1H), 4.56–4.39 (m, 3H), 4.34 (d, <i>J</i> = 12.9 Hz, 1H), 3.28 (s, 6H), 2.87 (s, 3H), 1.54 (d, <i>J</i> = 1.1 Hz, 9H). LC/MS (<i>m</i>/<i>z</i>): 547.346 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.60 min.</div><div class="NLM_p last">The MOM-protected intermediate (43.4 mg, 79 μmol) was deprotected using general procedure F to afford 15.5 mg of <b>95</b> (43% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.78–7.70 (m, 2H), 7.45 (s, 1H), 7.39–7.29 (m, 2H), 7.27–7.21 (m, 1H), 6.46 (s, 1H), 5.87 (d, <i>J</i> = 2.1 Hz, 1H), 5.77 (t, <i>J</i> = 1.9 Hz, 1H), 4.84–4.44 (m, 4H), 1.63 (s, 9H). LC/MS (<i>m</i>/<i>z</i>): 459.266 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.40 min.</div></div><div id="sec5_9_198" class="NLM_sec NLM_sec_level_2"><div id="ac_i235" class="anchor-spacer"></div><h3 class="article-section__title" id="_i235"> 5-((1-Cyclohexyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>96</b>)</h3><div class="NLM_p">Acid <b>19u</b> (51.9 mg, 108 μmmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (31.2 mg, 162 μmol) and triethylamine (110 μL, 810 μmol) using general procedure G to give 39.5 mg of MOM-protected intermediate (63% yield) after purification via an automated flash system (0% to 3% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual chromatography (65:35:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/saturated NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.58–8.44 (m, 1H), 7.83–7.74 (m, 2H), 7.61 (dd, <i>J</i> = 59.5, 7.7 Hz, 1H), 7.42–7.30 (m, 2H), 7.31–7.17 (m, 3H), 6.62 (d, <i>J</i> = 3.9 Hz, 1H), 6.43 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 6.32 (d, <i>J</i> = 3.0 Hz, 1H), 6.22 (dd, <i>J</i> = 7.2, 2.1 Hz, 1H), 5.19 (d, <i>J</i> = 5.7 Hz, 3H), 5.08 (s, 3H), 4.96 (d, <i>J</i> = 14.1 Hz, 1H), 4.69 (d, <i>J</i> = 14.1 Hz, 1H), 4.03 (td, <i>J</i> = 11.2, 4.1 Hz, 1H), 3.47 (d, <i>J</i> = 1.0 Hz, 3H), 3.43 (d, <i>J</i> = 1.3 Hz, 3H), 2.80 (s, 3H), 2.09–1.75 (m, 6H), 1.75–1.57 (m, 1H), 1.25 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.6, 167.5, 160.0, 157.6, 155.6, 155.5, 149.6, 149.5, 149.3, 145.1, 145.0, 138.9, 138.8, 134.0, 131.1, 130.6, 128.5, 127.3, 127.3, 125.3, 122.5, 106.9, 106.8, 96.8, 96.7, 96.5, 96.4, 95.5, 95.4, 95.1, 95.0, 94.2, 94.2, 56.8, 56.8, 56.6, 56.6, 56.2, 56.2, 53.6, 52.7, 51.6, 50.7, 38.6, 32.8, 32.4, 25.6, 25.2. LC/MS (<i>m</i>/<i>z</i>): 584.351 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.88 min.</div><div class="NLM_p last">The MOM-protected intermediate (43.4 mg, 79 μmol) was deprotected using general procedure F to afford 15.5 mg of <b>96</b> (43% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.36 (dd, <i>J</i> = 5.1, 1.5 Hz, 1H), 7.71 (d, <i>J</i> = 7.7 Hz, 1H), 7.67–7.55 (m, 2H), 7.39–7.05 (m, 4H), 6.33 (s, 1H), 5.93 (d, <i>J</i> = 2.1 Hz, 1H), 5.79 (d, <i>J</i> = 2.1 Hz, 1H), 5.21–4.68 (m, 4H), 4.19 (p, <i>J</i> = 7.9 Hz, 1H), 2.08–1.76 (m, 6H), 1.72–1.59 (m, 1H), 1.49–1.20 (m, 3H). LC/MS (<i>m</i>/<i>z</i>): 496.271 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.54 min.</div></div><div id="sec5_9_199" class="NLM_sec NLM_sec_level_2"><div id="ac_i236" class="anchor-spacer"></div><h3 class="article-section__title" id="_i236"> 5-((1-Cyclohexyl-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>97</b>)</h3><div class="NLM_p">Acid <b>19u</b> (54.8 mg, 114 μmmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (18.6 mg, 172 μmol) and triethylamine (32 μL, 230 μmol) using general procedure G1. The resulting suspension was diluted with CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub> (aq). The layers were separated and the organic layer was washed with brine. The organic layer was dried with anhydrous sodium sulfate. The desired amide was collected along with sodium sulfate following vacuum filtration through Celite. The desired product and residual Celite was separated from sodium sulfate and used without purification.</div><div class="NLM_p last">To a mixture of the intermediate amide and residual Celite in methanol (8.3 mL) was add HCl (2 M, 0.37 μL, 740 μmol). The resulting mixture was stirred at 50 °C for three nights. Additional HCl (2 M, 0.37 μL, 740 μmol) was added to the mixture and stirred at 50 °C overnight. The mixture was cooled to room temperature, and volatile material was condensed in vacuo. The residue was dissolved in DMSO, and the residual Celite was removed via filtration. The crude mixture was purified using mass-guided preparative HPLC to afford 13.7 mg of <b>97</b> (25% yield over 2 steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.73–7.61 (m, 2H), 7.41 (s, 1H), 7.33 (dd, <i>J</i> = 8.3, 6.7 Hz, 2H), 7.28–7.12 (m, 1H), 6.36 (s, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.73 (d, <i>J</i> = 2.1 Hz, 1H), 4.81–4.45 (m, 4H), 4.16 (p, <i>J</i> = 9.3, 8.7 Hz, 1H), 2.04–1.78 (m, 6H), 1.67 (d, <i>J</i> = 10.9 Hz, 1H), 1.48–1.10 (m, 3H). LC/MS (<i>m</i>/<i>z</i>): 485.245 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.41 min.</div></div><div id="sec5_9_200" class="NLM_sec NLM_sec_level_2"><div id="ac_i237" class="anchor-spacer"></div><h3 class="article-section__title" id="_i237"> 5-((1-(2-Methylpropyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>98</b>)</h3><div class="NLM_p">Acid <b>19v</b> (52.5 mg, 115 μmmol) was coupled with 6,7-dihydro-5<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine dihydrochloride (33.4 mg, 173 μmol) and triethylamine (120 μL, 860 μmol) using general procedure G to give 46.6 mg of MOM-protected intermediate (73% yield) after purification via an automated flash system (1% to 4% methanol in CH<sub>2</sub>Cl<sub>2</sub>) and manual chromatography (20:80:1 CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate/saturated NH<sub>4</sub>OH (aq)). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.51 (dd, <i>J</i> = 21.5, 4.8 Hz, 1H), 7.80–7.71 (m, 2H), 7.71–7.45 (m, 1H), 7.37 (td, <i>J</i> = 7.4, 1.3 Hz, 2H), 7.33–7.15 (m, 2H), 6.79 (d, <i>J</i> = 7.2 Hz, 1H), 6.45 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 6.38–6.30 (m, 2H), 5.14 (d, <i>J</i> = 32.1 Hz, 6H), 4.94 (d, <i>J</i> = 15.8 Hz, 1H), 4.67 (d, <i>J</i> = 14.2 Hz, 1H), 3.82 (dd, <i>J</i> = 7.5, 2.4 Hz, 2H), 3.47 (d, <i>J</i> = 0.9 Hz, 3H), 3.45 (d, <i>J</i> = 1.0 Hz, 3H), 2.80 (s, 3H), 2.32–2.17 (m, 1H), 0.88 (d, <i>J</i> = 6.4 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 167.6, 167.4, 160.1, 157.6, 157.2, 155.7, 155.6, 149.9, 149.5, 149.3, 144.4, 144.3, 140.3, 140.2, 133.8, 131.1, 130.6, 130.3, 129.8, 128.5, 127.5, 127.5, 125.3, 122.5, 122.5, 107.0, 106.9, 96.7, 96.6, 95.8, 95.7, 95.5, 95.4, 95.2, 95.1, 94.3, 94.3, 56.6, 56.6, 56.3, 56.2, 55.3, 55.2, 53.5, 52.7, 51.6, 50.8, 38.6, 29.4, 20.0. LC/MS (<i>m</i>/<i>z</i>): 558.372 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.72 min.</div><div class="NLM_p last">The MOM-protected intermediate (46.6 mg, 79 μmol) was deprotected using general procedure F to afford 26.0 mg of <b>98</b> (66% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.37 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.71 (d, <i>J</i> = 7.7 Hz, 1H), 7.66–7.56 (m, 2H), 7.38–7.19 (m, 4H), 6.39 (s, 1H), 5.94 (dd, <i>J</i> = 12.6, 2.1 Hz, 2H), 5.16–4.61 (m, 4H), 3.83 (d, <i>J</i> = 7.5 Hz, 2H), 2.19 (hept, <i>J</i> = 6.9 Hz, 1H), 0.86 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.5, 161.8, 158.2, 157.6, 151.5, 149.7, 146.1, 143.6, 134.8, 133.4, 132.5, 129.7, 128.8, 126.5, 124.3, 104.8, 98.1, 96.0, 95.4, 56.3, 40.6, 30.7, 20.4. LC/MS (<i>m</i>/<i>z</i>): 470.293 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.38 min.</div></div><div id="sec5_9_201" class="NLM_sec NLM_sec_level_2"><div id="ac_i238" class="anchor-spacer"></div><h3 class="article-section__title" id="_i238"> 5-((1-(2-Methylpropyl)-3-phenyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>99</b>)</h3><div class="NLM_p">Acid <b>19v</b> (59.0 mg, 130 μmmol) was coupled with 1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole (21.2 mg, 195 μmol) and triethylamine (36 μL, 260 μmol) using general procedure G1. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub> (aq). The layers were separated, and brine was added to the organic layer. The combined mixture was filtered through a Celite plug, and the plug was washed with water, methanol, and CH<sub>2</sub>Cl<sub>2</sub>. The organic layer from the combined filtrate evaporated to leave a fine powder. The remaining water layer was decanted from the solid. The solid was dried to afford 33.9 mg of impure MOM-protected amide which was used without further purification.</div><div class="NLM_p last">The impure MOM-protected amide from above was deprotected using general procedure F to afford 15.3 mg of <b>99</b> (59% overall yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.73–7.64 (m, 2H), 7.41 (s, 1H), 7.38–7.31 (m, 2H), 7.30–7.17 (m, 1H), 5.93 (d, <i>J</i> = 2.1 Hz, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 4.67 (s, 4H), 3.82 (d, <i>J</i> = 7.5 Hz, 2H), 2.19 (hept, <i>J</i> = 6.9 Hz, 1H), 0.87 (d, <i>J</i> = 6.7 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 459.31 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.27 min.</div></div><div id="sec5_9_202" class="NLM_sec NLM_sec_level_2"><div id="ac_i239" class="anchor-spacer"></div><h3 class="article-section__title" id="_i239"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-methyl-3-(propan-2-yl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>100</b>)</h3><div class="NLM_p last">Acid <b>19w</b> (45 mg, 120 μmol) was subjected to general procedure H1 to afford 15.3 mg of <b>100</b> (33% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.28 (s, 4H), 5.93 (dd, <i>J</i> = 12.6, 2.0 Hz, 1H), 5.84 (s, 1H), 5.67 (d, <i>J</i> = 2.1 Hz, 1H), 5.06–4.67 (m, 4H), 3.58 (s, 4H), 2.76 (p, <i>J</i> = 7.0 Hz, 1H), 1.15 (d, <i>J</i> = 7.0 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 393.106 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.30 min.</div></div><div id="sec5_9_203" class="NLM_sec NLM_sec_level_2"><div id="ac_i240" class="anchor-spacer"></div><h3 class="article-section__title" id="_i240"> 5-((1-Methyl-3-(propan-2-yl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>101</b>)</h3><div class="NLM_p last">Acid <b>19w</b> (45 mg, 120 μmol) was subjected to general procedure H2 to afford 9.9 mg of <b>101</b> (21% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.44 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.80 (d, <i>J</i> = 7.7 Hz, 1H), 7.35 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.85 (s, 1H), 5.68 (d, <i>J</i> = 2.1 Hz, 1H), 5.09–4.72 (m, 4H), 3.59 (s, 3H), 2.76 (hept, <i>J</i> = 6.6 Hz, 1H), 1.14 (d, <i>J</i> = 6.9 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 394.253 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.29 min.</div></div><div id="sec5_9_204" class="NLM_sec NLM_sec_level_2"><div id="ac_i241" class="anchor-spacer"></div><h3 class="article-section__title" id="_i241"> 5-((1-Methyl-3-(propan-2-yl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>102</b>)</h3><div class="NLM_p last">Acid <b>19w</b> (45 mg, 120 μmol) was subjected to general procedure H3 to afford 12.5 mg of <b>102</b> (28% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.45 (s, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.85 (s, 1H), 5.66 (d, <i>J</i> = 2.1 Hz, 1H), 4.85–4.44 (m, 4H), 3.59 (s, 3H), 2.78 (dq, <i>J</i> = 13.9, 6.9 Hz, 1H), 1.17 (d, <i>J</i> = 6.9 Hz, 6H). LC/MS (<i>m</i>/<i>z</i>): 383.314 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.92 min.</div></div><div id="sec5_9_205" class="NLM_sec NLM_sec_level_2"><div id="ac_i242" class="anchor-spacer"></div><h3 class="article-section__title" id="_i242"> 5-((3-Cyclohexyl-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)benzene-1,3-diol (<b>103</b>)</h3><div class="NLM_p last">Acid <b>19x</b> (38.9 mg, 92.7 μmol) was subjected to general procedure H1 to afford 16.1 mg of <b>103</b> (40% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.28 (s, 4H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.80 (s, 1H), 5.69 (d, <i>J</i> = 2.1 Hz, 1H), 5.09–4.64 (m, 4H), 3.58 (s, 3H), 2.44–2.21 (m, 1H), 1.99–1.62 (m, 5H), 1.48–1.09 (m, 5H). LC/MS (<i>m</i>/<i>z</i>): 433.376 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.51 min.</div></div><div id="sec5_9_206" class="NLM_sec NLM_sec_level_2"><div id="ac_i243" class="anchor-spacer"></div><h3 class="article-section__title" id="_i243"> 5-((3-Cyclohexyl-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>104</b>)</h3><div class="NLM_p last">Acid <b>19x</b> (39.9 mg, 95.1 μmol) was subjected to general procedure H2 to afford 3.3 mg of <b>104</b> (8.0% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.54 (s, 1H), 8.44 (dd, <i>J</i> = 5.1, 1.5 Hz, 1H), 7.79 (d, <i>J</i> = 7.7 Hz, 1H), 7.35 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.81 (s, 1H), 5.71 (d, <i>J</i> = 2.1 Hz, 1H), 5.04–4.38 (m, 4H), 3.59 (s, 4H), 2.39 (d, <i>J</i> = 10.8 Hz, 1H), 1.73 (dq, <i>J</i> = 23.1, 11.6, 8.8 Hz, 6H), 1.27 (hept, <i>J</i> = 11.6 Hz, 4H). LC/MS (<i>m</i>/<i>z</i>): 434.346 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.32 min.</div></div><div id="sec5_9_207" class="NLM_sec NLM_sec_level_2"><div id="ac_i244" class="anchor-spacer"></div><h3 class="article-section__title" id="_i244"> 5-((3-Cyclohexyl-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>105</b>)</h3><div class="NLM_p last">Acid <b>19x</b> (44 mg, 100 μmol) was subjected to general procedure H3 to afford 12.5 mg of <b>105</b> (28% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.44 (s, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.81 (s, 1H), 5.68 (d, <i>J</i> = 2.1 Hz, 1H), 4.78–4.36 (m, 4H), 3.59 (s, 3H), 2.51–2.27 (m, 1H), 1.89–1.61 (m, 5H), 1.43–1.09 (m, 5H). LC/MS (<i>m</i>/<i>z</i>): 423.363 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.15 min.</div></div><div id="sec5_9_208" class="NLM_sec NLM_sec_level_2"><div id="ac_i245" class="anchor-spacer"></div><h3 class="article-section__title" id="_i245"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-methyl-3-(2-methylphenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>106</b>)</h3><div class="NLM_p last">Acid <b>19y</b> (50.3 mg, 118 μmol) was subjected to general procedure H1 to afford 18.8 mg of <b>106</b> (36% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.34 (dd, <i>J</i> = 7.1, 1.3 Hz, 1H), 7.27 (s, 4H), 7.22–7.17 (m, 2H), 7.17–7.09 (m, 1H), 6.17 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.75 (d, <i>J</i> = 2.1 Hz, 1H), 5.01–4.72 (m, 4H), 3.70 (s, 3H), 2.37 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.2, 161.6, 157.5, 151.9, 145.9, 142.8, 137.7, 137.2, 134.7, 131.7, 130.3, 129.0, 128.8, 126.9, 123.9, 105.3, 101.6, 95.9, 94.9, 40.6, 35.3, 21.3. LC/MS (<i>m</i>/<i>z</i>): 441.315 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.65 min.</div></div><div id="sec5_9_209" class="NLM_sec NLM_sec_level_2"><div id="ac_i246" class="anchor-spacer"></div><h3 class="article-section__title" id="_i246"> 5-((1-Methyl-3-(2-methylphenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>107</b>)</h3><div class="NLM_p last">Acid <b>19y</b> (50.4 mg, 118 μmol) was subjected to general procedure H2 to afford 14.6 mg of <b>107</b> (28% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.40 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.75 (d, <i>J</i> = 7.7 Hz, 1H), 7.44–7.27 (m, 2H), 7.27–7.16 (m, 2H), 7.16–7.08 (m, 1H), 6.17 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.77 (d, <i>J</i> = 2.1 Hz, 1H), 5.02–4.65 (m, 4H), 3.72 (s, 3H), 2.37 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 442.329 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.40 min.</div></div><div id="sec5_9_210" class="NLM_sec NLM_sec_level_2"><div id="ac_i247" class="anchor-spacer"></div><h3 class="article-section__title" id="_i247"> 5-((1-Methyl-3-(2-methylphenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>108</b>)</h3><div class="NLM_p last">Acid <b>19y</b> (50.4 mg, 118 μmol) was subjected to general procedure H3 to afford 14.6 mg of <b>108</b> (28% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.42 (s, 1H), 7.36 (dd, <i>J</i> = 7.0, 1.6 Hz, 1H), 7.25–7.11 (m, 3H), 6.18 (s, 1H), 5.93 (d, <i>J</i> = 2.1 Hz, 1H), 5.74 (d, <i>J</i> = 2.1 Hz, 1H), 4.80–4.47 (m, 4H), 3.71 (s, 3H), 2.39 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.7, 161.6, 157.4, 152.0, 145.9, 142.9, 137.2, 134.7, 131.7, 130.3, 129.0, 126.9, 105.2, 101.7, 95.9, 95.0, 40.6, 35.3, 21.3. LC/MS (<i>m</i>/<i>z</i>): 431.347 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.31 min.</div></div><div id="sec5_9_211" class="NLM_sec NLM_sec_level_2"><div id="ac_i248" class="anchor-spacer"></div><h3 class="article-section__title" id="_i248"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-methyl-3-(3-methylphenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>109</b>)</h3><div class="NLM_p last">Acid <b>19z</b> (54.1 mg, 127 μmol) was subjected to general procedure H1 to afford 20.2 mg of <b>109</b> (36% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.49–7.36 (m, 2H), 7.24 (s, 4H), 7.18 (t, <i>J</i> = 7.6 Hz, 1H), 7.06 (d, <i>J</i> = 7.6 Hz, 1H), 6.34 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.78 (d, <i>J</i> = 2.1 Hz, 1H), 4.96–4.70 (m, 4H), 3.69 (s, 3H), 2.31 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 441.094 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.57 min.</div></div><div id="sec5_9_212" class="NLM_sec NLM_sec_level_2"><div id="ac_i249" class="anchor-spacer"></div><h3 class="article-section__title" id="_i249"> 5-((1-Methyl-3-(3-methylphenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>110</b>)</h3><div class="NLM_p last">Acid <b>19z</b> (56.7 mg, 133 μmol) was subjected to general procedure H2 to afford 16.2 mg of <b>110</b> (28% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.34 (dd, <i>J</i> = 4.9, 1.4 Hz, 1H), 7.73–7.62 (m, 1H), 7.46–7.29 (m, 2H), 7.24 (dd, <i>J</i> = 7.7, 5.0 Hz, 1H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 7.04 (d, <i>J</i> = 7.6 Hz, 1H), 6.33 (s, 1H), 5.95 (d, <i>J</i> = 2.1 Hz, 1H), 5.83 (d, <i>J</i> = 2.1 Hz, 1H), 5.02–4.65 (m, 4H), 3.72 (s, 3H), 2.31 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 442.329 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.29 min.</div></div><div id="sec5_9_213" class="NLM_sec NLM_sec_level_2"><div id="ac_i250" class="anchor-spacer"></div><h3 class="article-section__title" id="_i250"> 5-((1-Methyl-3-(3-methylphenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>111</b>)</h3><div class="NLM_p last">Acid <b>19z</b> (57.6 mg, 135 μmol) was subjected to general procedure H3 to afford 20.3 mg of <b>111</b> (35% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.51–7.40 (m, 2H), 7.38 (s, 1H), 7.20 (t, <i>J</i> = 7.6 Hz, 1H), 7.13–7.05 (m, 1H), 6.34 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.78 (d, <i>J</i> = 2.1 Hz, 1H), 4.79–4.45 (m, 4H), 3.70 (s, 3H), 2.33 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.6, 161.6, 157.4, 151.7, 145.8, 143.7, 139.4, 134.6, 129.6, 127.0, 123.6, 105.2, 98.4, 95.9, 95.3, 40.6, 35.3, 21.7. LC/MS (<i>m</i>/<i>z</i>): 431.347 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.22 min.</div></div><div id="sec5_9_214" class="NLM_sec NLM_sec_level_2"><div id="ac_i251" class="anchor-spacer"></div><h3 class="article-section__title" id="_i251"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((3-(3-methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>112</b>)</h3><div class="NLM_p last">Acid <b>19aa</b> (48.6 mg, 110 μmol) was subjected to general procedure H1 to afford 18.2 mg of <b>112</b> (36% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.54 (s, 1H), 7.34–7.09 (m, 7H), 6.82 (s, 1H), 6.36 (s, 1H), 5.94 (s, 1H), 5.77 (s, 1H), 5.17–4.70 (m, 4H), 3.80 (s, 3H), 3.70 (s, 3H). <sup>13</sup>C NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) δ 166.4, 159.5, 159.3, 155.5, 148.1, 143.9, 143.8, 141.5, 141.4, 135.0, 129.6, 127.2, 122.9, 117.1, 113.1, 109.6, 104.0, 96.9, 94.3, 92.7, 55.0, 40.4, 35.0. LC/MS (<i>m</i>/<i>z</i>): 457.061 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.58 min.</div></div><div id="sec5_9_215" class="NLM_sec NLM_sec_level_2"><div id="ac_i252" class="anchor-spacer"></div><h3 class="article-section__title" id="_i252"> 5-((3-(3-Methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>113</b>)</h3><div class="NLM_p last">Acid <b>19aa</b> (52.6 mg, 119 μmol) was subjected to general procedure H2 to afford 6.7 mg of <b>113</b> (12% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.34 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.67 (dd, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.23 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 7.21–7.07 (m, 3H), 6.78 (ddd, <i>J</i> = 7.9, 2.6, 1.3 Hz, 1H), 6.34 (s, 1H), 5.95 (d, <i>J</i> = 2.1 Hz, 1H), 5.83 (d, <i>J</i> = 2.1 Hz, 1H), 4.98–4.63 (m, 4H), 3.79 (s, 3H), 3.72 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.4, 161.8, 161.5, 158.1, 157.6, 151.2, 149.6, 146.2, 144.0, 135.9, 133.3, 132.5, 130.7, 124.2, 118.8, 114.6, 111.4, 104.9, 98.3, 96.0, 95.9, 55.8, 40.6, 35.4. LC/MS (<i>m</i>/<i>z</i>): 458.296 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.30 min.</div></div><div id="sec5_9_216" class="NLM_sec NLM_sec_level_2"><div id="ac_i253" class="anchor-spacer"></div><h3 class="article-section__title" id="_i253"> 5-((3-(3-Methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>114</b>)</h3><div class="NLM_p last">Acid <b>19aa</b> (55.5 mg, 125 μmol) was subjected to general procedure H3 to afford 21.6 mg of <b>114</b> (37% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.38 (s, 1H), 7.30–7.15 (m, 3H), 6.82 (ddd, <i>J</i> = 7.6, 2.6, 1.7 Hz, 1H), 6.37 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.77 (d, <i>J</i> = 2.1 Hz, 1H), 4.80–4.47 (m, 4H), 3.80 (s, 3H), 3.71 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.7, 161.6, 161.5, 157.4, 151.4, 145.8, 143.7, 136.0, 130.8, 119.0, 114.7, 111.5, 98.6, 95.9, 95.3, 55.8, 40.6, 35.3. LC/MS (<i>m</i>/<i>z</i>): 447.313 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.25 min.</div></div><div id="sec5_9_217" class="NLM_sec NLM_sec_level_2"><div id="ac_i254" class="anchor-spacer"></div><h3 class="article-section__title" id="_i254"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-methyl-3-(3-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>115</b>)</h3><div class="NLM_p last">Acid <b>19ab</b> (50.5 mg, 105 μmol) was subjected to general procedure H1 to afford 22 mg of <b>115</b> (42% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.94 (s, 1H), 7.81 (d, <i>J</i> = 7.6 Hz, 1H), 7.49 (dt, <i>J</i> = 15.4, 7.8 Hz, 2H), 7.20 (s, 4H), 6.44 (s, 1H), 5.96 (d, <i>J</i> = 2.1 Hz, 1H), 5.81 (d, <i>J</i> = 2.1 Hz, 1H), 4.98–4.65 (m, 4H), 3.72 (s, 3H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 170.1, 161.6, 157.6, 149.7, 145.73, 145.66, 144.2, 137.6, 135.8, 132.0 (q, <sup>2</sup><i>J</i><sub>C–F</sub> = 32.5 Hz), 130.6, 129.9, 128.8, 125.8 (q, <sup>1</sup><i>J</i><sub>C–F</sub> = 270.0 Hz), 125.1 (q, <sup>3</sup><i>J</i><sub>C–F</sub> = 3.8 Hz), 123.8, 122.6 (q, <sup>3</sup><i>J</i><sub>C–F</sub> = 3.7 Hz), 105.5, 98.5, 96.1, 95.6, 40.6, 35.5. <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −64.2. LC/MS (<i>m</i>/<i>z</i>): 495.301 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.78 min.</div></div><div id="sec5_9_218" class="NLM_sec NLM_sec_level_2"><div id="ac_i255" class="anchor-spacer"></div><h3 class="article-section__title" id="_i255"> 5-((1-Methyl-3-(3-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>116</b>)</h3><div class="NLM_p last">Acid <b>19ab</b> (56.4 mg, 117 μmol) was subjected to general procedure H2 to afford 18.7 mg of <b>116</b> (32% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.30 (dd, <i>J</i> = 5.0, 1.4 Hz, 1H), 7.89 (d, <i>J</i> = 2.2 Hz, 1H), 7.79 (d, <i>J</i> = 7.5 Hz, 1H), 7.66 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.54–7.40 (m, 2H), 7.20 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 6.45 (s, 1H), 5.97 (d, <i>J</i> = 2.1 Hz, 1H), 5.85 (d, <i>J</i> = 2.1 Hz, 1H), 4.98–4.63 (m, 4H), 3.75 (s, 3H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 170.4, 161.8, 158.2, 157.7, 149.62, 149.59, 146.1, 144.5, 135.7, 133.3, 132.0 (q, <sup>2</sup><i>J</i><sub>C–F</sub> = 31.5 Hz), 130.6, 129.8, 125.8 (q, <sup>1</sup><i>J</i><sub>C–F</sub> = 267.0 Hz), 125.1 (q, <sup>3</sup><i>J</i><sub>C–F</sub> = 3.8 Hz), 124.2, 122.5 (q, <sup>3</sup><i>J</i><sub>C–F</sub> = 4.8 Hz), 105.1, 98.3, 96.2, 96.1, 40.6, 35.6. <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −64.2. LC/MS (<i>m</i>/<i>z</i>): 496.316 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.52 min.</div></div><div id="sec5_9_219" class="NLM_sec NLM_sec_level_2"><div id="ac_i256" class="anchor-spacer"></div><h3 class="article-section__title" id="_i256"> 5-((1-Methyl-3-(3-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>117</b>)</h3><div class="NLM_p last">Acid <b>19ab</b> (57.2 mg, 119 μmol) was subjected to general procedure H3 to afford 18.9 mg of <b>117</b> (33% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.97 (s, 1H), 7.86 (d, <i>J</i> = 7.3 Hz, 1H), 7.60–7.47 (m, 2H), 7.36 (s, 1H), 6.47 (s, 1H), 5.95 (d, <i>J</i> = 2.1 Hz, 1H), 5.80 (d, <i>J</i> = 2.1 Hz, 1H), 4.82–4.45 (m, 4H), 3.73 (s, 3H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 170.6, 161.6, 157.4, 149.8, 145.7, 144.2, 135.9, 132.1 (q, <sup>2</sup><i>J</i><sub>C–F</sub> = 31.5 Hz), 130.6, 129.9, 125.8 (q, <sup>1</sup><i>J</i><sub>C–F</sub> = 270.8 Hz), 125.2 (q, <sup>3</sup><i>J</i><sub>C–F</sub> = 4.8 Hz), 122.7 (q, <sup>3</sup><i>J</i><sub>C–F</sub> = 3.8 Hz), 105.4, 98.5, 96.1, 95.6, 40.6, 35.6. <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −64.2. LC/MS (<i>m</i>/<i>z</i>): 485.289 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.45 min.</div></div><div id="sec5_9_220" class="NLM_sec NLM_sec_level_2"><div id="ac_i257" class="anchor-spacer"></div><h3 class="article-section__title" id="_i257"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-methyl-3-(4-methylphenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>118</b>)</h3><div class="NLM_p last">Acid <b>19ac</b> (44.5 mg, 104 μmol) was subjected to general procedure H1 to afford 18.2 mg of <b>118</b> (40% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.58–7.43 (m, 2H), 7.24 (s, 4H), 7.12 (d, <i>J</i> = 8.0 Hz, 2H), 6.31 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.76 (d, <i>J</i> = 2.1 Hz, 1H), 4.96–4.69 (m, 4H), 3.68 (s, 3H), 2.31 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.2, 161.6, 157.5, 151.7, 145.8, 143.6, 138.8, 137.7, 131.9, 130.3, 128.8, 126.4, 123.9, 105.2, 98.1, 95.9, 95.1, 40.6, 35.3, 21.4. LC/MS (<i>m</i>/<i>z</i>): 441.094 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.66 min.</div></div><div id="sec5_9_221" class="NLM_sec NLM_sec_level_2"><div id="ac_i258" class="anchor-spacer"></div><h3 class="article-section__title" id="_i258"> 5-((1-Methyl-3-(4-methylphenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>119</b>)</h3><div class="NLM_p last">Acid <b>19ac</b> (46.6 mg, 109 μmol) was subjected to general procedure H2 to afford 14.2 mg of <b>119</b> (30% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.35 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.69 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.52–7.42 (m, 2H), 7.25 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 7.09 (d, <i>J</i> = 7.9 Hz, 2H), 6.30 (s, 1H), 5.95 (d, <i>J</i> = 2.1 Hz, 1H), 5.81 (d, <i>J</i> = 2.1 Hz, 1H), 4.99–4.64 (m, 4H), 3.70 (s, 3H), 2.31 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 442.329 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.40 min.</div></div><div id="sec5_9_222" class="NLM_sec NLM_sec_level_2"><div id="ac_i259" class="anchor-spacer"></div><h3 class="article-section__title" id="_i259"> 5-((1-Methyl-3-(4-methylphenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>120</b>)</h3><div class="NLM_p last">Acid <b>19ac</b> (50.8 mg, 119 μmol) was subjected to general procedure H3 to afford 16.5 mg of <b>120</b> (32% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.58–7.46 (m, 2H), 7.38 (s, 1H), 7.14 (d, <i>J</i> = 7.9 Hz, 2H), 6.32 (s, 1H), 5.93 (d, <i>J</i> = 2.1 Hz, 1H), 5.76 (d, <i>J</i> = 2.1 Hz, 1H), 4.79–4.45 (m, 4H), 3.69 (s, 3H), 2.32 (s, 3H). LC/MS (<i>m</i>/<i>z</i>): 431.303 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.32 min.</div></div><div id="sec5_9_223" class="NLM_sec NLM_sec_level_2"><div id="ac_i260" class="anchor-spacer"></div><h3 class="article-section__title" id="_i260"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((3-(4-methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>121</b>)</h3><div class="NLM_p last">Acid <b>19ad</b> (54.2 mg, 122 μmol) was subjected to general procedure H1 to afford 21.4 mg of <b>121</b> (38% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.58–7.47 (m, 2H), 7.24 (s, 4H), 6.93–6.81 (m, 2H), 6.27 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.77 (d, <i>J</i> = 2.1 Hz, 1H), 4.99–4.72 (m, 4H), 3.78 (s, 3H), 3.67 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.2, 161.6, 161.0, 157.5, 151.5, 145.9, 143.6, 137.7, 128.8, 128.1, 127.7, 127.4, 123.9, 115.1, 105.3, 97.8, 95.9, 95.2, 55.8, 40.6, 35.2. LC/MS (<i>m</i>/<i>z</i>): 457.105 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.47 min.</div></div><div id="sec5_9_224" class="NLM_sec NLM_sec_level_2"><div id="ac_i261" class="anchor-spacer"></div><h3 class="article-section__title" id="_i261"> 5-((3-(4-Methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>122</b>)</h3><div class="NLM_p last">Acid <b>19ad</b> (55.4 mg, 125 μmol) was subjected to general procedure H2 to afford 14.4 mg of <b>122</b> (25% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.36 (dd, <i>J</i> = 5.1, 1.5 Hz, 1H), 7.69 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.58–7.42 (m, 2H), 7.26 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 6.88–6.74 (m, 2H), 6.26 (s, 1H), 5.95 (d, <i>J</i> = 2.1 Hz, 1H), 5.82 (d, <i>J</i> = 2.1 Hz, 1H), 5.09–4.66 (m, 4H), 3.79 (s, 3H), 3.70 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 170.4, 161.8, 161.0, 158.2, 157.6, 151.4, 149.6, 146.2, 143.9, 133.4, 127.6, 127.3, 124.3, 115.1, 104.9, 97.7, 96.0, 95.7, 55.9, 40.6, 35.2. LC/MS (<i>m</i>/<i>z</i>): 458.241 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.04 min.</div></div><div id="sec5_9_225" class="NLM_sec NLM_sec_level_2"><div id="ac_i262" class="anchor-spacer"></div><h3 class="article-section__title" id="_i262"> 5-((3-(4-Methoxyphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>123</b>)</h3><div class="NLM_p last">Acid <b>19ad</b> (55.6 mg, 125 μmol) was subjected to general procedure H3 to afford 12.9 mg of <b>123</b> (23% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.61–7.51 (m, 2H), 7.39 (s, 1H), 6.93–6.82 (m, 2H), 6.28 (s, 1H), 5.93 (d, <i>J</i> = 2.1 Hz, 1H), 5.76 (d, <i>J</i> = 2.1 Hz, 1H), 4.85–4.41 (m, 4H), 3.79 (s, 3H), 3.68 (s, 3H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 170.7, 161.6, 161.1, 157.4, 151.6, 145.9, 143.7, 127.7, 127.4, 115.1, 105.3, 97.9, 95.9, 95.3, 55.9, 40.6, 35.2. LC/MS (<i>m</i>/<i>z</i>): 447.216 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 0.98 min.</div></div><div id="sec5_9_226" class="NLM_sec NLM_sec_level_2"><div id="ac_i263" class="anchor-spacer"></div><h3 class="article-section__title" id="_i263"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-methyl-3-(4-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>124</b>)</h3><div class="NLM_p last">Acid <b>19ae</b> (61.4 mg, 128 μmol) was subjected to general procedure H1 to afford 20.5 mg of <b>124</b> (32% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.81–7.71 (m, 2H), 7.56 (d, <i>J</i> = 8.2 Hz, 2H), 7.21 (s, 4H), 6.45 (s, 1H), 5.96 (d, <i>J</i> = 2.1 Hz, 1H), 5.81 (d, <i>J</i> = 2.1 Hz, 1H), 4.98–4.68 (m, 4H), 3.73 (s, 3H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −64.1. LC/MS (<i>m</i>/<i>z</i>): 495.301 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.78 min.</div></div><div id="sec5_9_227" class="NLM_sec NLM_sec_level_2"><div id="ac_i264" class="anchor-spacer"></div><h3 class="article-section__title" id="_i264"> 5-((1-Methyl-3-(4-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5H,6H,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>125</b>)</h3><div class="NLM_p last">Acid <b>19ae</b> (61.5 mg, 128 μmol) was subjected to general procedure H2 to afford 15.2 mg of <b>125</b> (24% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.30 (d, <i>J</i> = 5.0 Hz, 1H), 7.76–7.69 (m, 2H), 7.65 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 7.54 (d, <i>J</i> = 8.2 Hz, 2H), 7.20 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 6.45 (s, 1H), 5.97 (d, <i>J</i> = 2.1 Hz, 1H), 5.85 (d, <i>J</i> = 2.1 Hz, 1H), 4.96–4.59 (m, 4H), 3.75 (s, 3H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −64.0. LC/MS (<i>m</i>/<i>z</i>): 496.271 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.53 min.</div></div><div id="sec5_9_228" class="NLM_sec NLM_sec_level_2"><div id="ac_i265" class="anchor-spacer"></div><h3 class="article-section__title" id="_i265"> 5-((1-Methyl-3-(4-(trifluoromethyl)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>126</b>)</h3><div class="NLM_p last">Acid <b>19ae</b> (62.2 mg, 129 μmol) was subjected to general procedure H3 to afford 15 mg of <b>126</b> (24% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.81 (d, <i>J</i> = 8.1 Hz, 2H), 7.61 (d, <i>J</i> = 8.1 Hz, 2H), 7.37 (s, 1H), 6.47 (s, 1H), 5.95 (d, <i>J</i> = 2.1 Hz, 1H), 5.79 (d, <i>J</i> = 2.1 Hz, 1H), 4.79–4.41 (m, 4H), 3.74 (s, 3H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −64.0. LC/MS (<i>m</i>/<i>z</i>): 485.289 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.47 min.</div></div><div id="sec5_9_229" class="NLM_sec NLM_sec_level_2"><div id="ac_i266" class="anchor-spacer"></div><h3 class="article-section__title" id="_i266"> 5-((3-(4-<i>tert</i>-Butylphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(2,3-dihydro-1<i>H-</i>isoindole-2-carbonyl)benzene-1,3-diol (<b>127</b>)</h3><div class="NLM_p last">Acid <b>19af</b> (59 mg, 130 μmol) was subjected to general procedure H1 to afford 18.4 mg of <b>127</b> (30% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.62–7.47 (m, 2H), 7.38–7.30 (m, 2H), 7.23 (s, 4H), 6.32 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.78 (d, <i>J</i> = 2.1 Hz, 1H), 5.05–4.68 (m, 4H), 3.69 (s, 3H), 1.31 (s, 9H). LC/MS (<i>m</i>/<i>z</i>): 483.392 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.90 min.</div></div><div id="sec5_9_230" class="NLM_sec NLM_sec_level_2"><div id="ac_i267" class="anchor-spacer"></div><h3 class="article-section__title" id="_i267"> 5-((3-(4-<i>tert</i>-Butylphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>128</b>)</h3><div class="NLM_p last">Acid <b>19af</b> (59.8 mg, 127 μmol) was subjected to general procedure H2 to afford 18.1 mg of <b>128</b> (29% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.33 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.68 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.54–7.42 (m, 2H), 7.36–7.28 (m, 2H), 7.23 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 6.32 (s, 1H), 5.95 (d, <i>J</i> = 2.1 Hz, 1H), 5.83 (d, <i>J</i> = 2.1 Hz, 1H), 4.93–4.66 (m, 4H), 3.72 (s, 3H), 1.31 (s, 9H). LC/MS (<i>m</i>/<i>z</i>): 484.363 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.64 min.</div></div><div id="sec5_9_231" class="NLM_sec NLM_sec_level_2"><div id="ac_i268" class="anchor-spacer"></div><h3 class="article-section__title" id="_i268"> 5-((3-(4-<i>tert</i>-Butylphenyl)-1-methyl-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>129</b>)</h3><div class="NLM_p last">Acid <b>19af</b> (61.7 mg, 131 μmol) was subjected to general procedure H3 to afford 18.1 mg of <b>129</b> (29% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.57 (d, <i>J</i> = 8.5 Hz, 2H), 7.42–7.31 (m, 3H), 6.34 (s, 1H), 5.93 (d, <i>J</i> = 2.1 Hz, 1H), 5.76 (d, <i>J</i> = 2.1 Hz, 1H), 4.81–4.47 (m, 4H), 3.70 (s, 3H), 1.32 (s, 9H). LC/MS (<i>m</i>/<i>z</i>): 473.336 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.57 min.</div></div><div id="sec5_9_232" class="NLM_sec NLM_sec_level_2"><div id="ac_i269" class="anchor-spacer"></div><h3 class="article-section__title" id="_i269"> 4-(2,3-Dihydro-1<i>H-</i>isoindole-2-carbonyl)-5-((1-methyl-3-(4-(trifluoromethoxy)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)benzene-1,3-diol (<b>130</b>)</h3><div class="NLM_p last">Acid <b>19ag</b> (51.3 mg, 103 μmol) was subjected to general procedure H1 to afford 21.3 mg of <b>130</b> (40% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.72–7.55 (m, 2H), 7.21 (s, 4H), 7.20–7.12 (m, 2H), 6.36 (s, 1H), 5.96 (d, <i>J</i> = 2.1 Hz, 1H), 5.80 (d, <i>J</i> = 2.1 Hz, 1H), 4.99–4.66 (m, 4H), 3.71 (s, 3H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 170.2, 161.6, 157.5, 150.0, 149.9, 145.8, 144.1, 137.7, 134.0, 128.8, 127.9, 123.9, 122.3, 122.1 (q, <sup>1</sup><i>J</i><sub>C–F</sub> = 253.8 Hz), 105.5, 98.3, 96.1, 95.7, 40.6, 35.4. <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −59.5. LC/MS (<i>m</i>/<i>z</i>): 511.162 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.61 min.</div></div><div id="sec5_9_233" class="NLM_sec NLM_sec_level_2"><div id="ac_i270" class="anchor-spacer"></div><h3 class="article-section__title" id="_i270"> 5-((1-Methyl-3-(4-(trifluoromethoxy)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(5<i>H</i>,6<i>H</i>,7<i>H-</i>pyrrolo[3,4-<i>b</i>]pyridine-6-carbonyl)benzene-1,3-diol (<b>131</b>)</h3><div class="NLM_p last">Acid <b>19ag</b> (53.1 mg, 107 μmol) was subjected to general procedure H2 to afford 18.6 mg of <b>131</b> (34% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.31 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.69–7.59 (m, 3H), 7.21 (dd, <i>J</i> = 7.8, 5.0 Hz, 1H), 7.19–7.11 (m, 2H), 6.37 (s, 1H), 5.96 (d, <i>J</i> = 2.1 Hz, 1H), 5.85 (d, <i>J</i> = 2.1 Hz, 1H), 4.97–4.64 (m, 4H), 3.73 (s, 3H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 170.4, 161.7, 158.1, 157.6, 149.9, 149.7, 149.4, 133.8, 133.5, 132.6, 127.7, 124.7, 122.1 (q, <sup>1</sup><i>J</i><sub>C–F</sub> = 253.8 Hz), 105.1, 98.2, 96.24, 96.17, 40.6, 35.4. <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −59.4. LC/MS (<i>m</i>/<i>z</i>): 512.326 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.48 min.</div></div><div id="sec5_9_234" class="NLM_sec NLM_sec_level_2"><div id="ac_i271" class="anchor-spacer"></div><h3 class="article-section__title" id="_i271"> 5-((1-Methyl-3-(4-(trifluoromethoxy)phenyl)-1<i>H-</i>pyrazol-5-yl)amino)-4-(1<i>H</i>,4<i>H</i>,5<i>H</i>,6<i>H-</i>pyrrolo[3,4-<i>c</i>]pyrazole-5-carbonyl)benzene-1,3-diol (<b>132</b>)</h3><div class="NLM_p last">Acid <b>19ag</b> (54.4 mg, 109 μmol) was subjected to general procedure H3 to afford 17 mg of <b>132</b> (31% yield) after purification using mass-guided preparative HPLC. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.77–7.67 (m, 2H), 7.37 (s, 1H), 7.28–7.17 (m, 2H), 6.39 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.78 (d, <i>J</i> = 2.1 Hz, 1H), 4.79–4.45 (m, 4H), 3.72 (s, 3H). <sup>13</sup>C NMR (126 MHz, CD<sub>3</sub>OD) δ 170.6, 161.5, 157.4, 150.0, 149.9, 145.6, 144.1, 134.0, 127.9, 124.1, 122.3, 122.1 (q, <sup>1</sup><i>J</i><sub>C–F</sub> = 255.0 Hz), 105.4, 98.2, 96.1, 95.6, 40.6, 35.4. <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ −59.5. LC/MS (<i>m</i>/<i>z</i>): 501.151 [M + H<sup>+</sup>]; UPLC <i>t</i><sub>R</sub> = 1.28 min.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i272"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00826" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15828" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15828" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00826" class="ext-link">10.1021/acs.jmedchem.9b00826</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Figures S1 and S2 and Supplementary Tables 1–5 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and associated biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf">jm9b00826_si_001.pdf (737.6 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_002.csv">jm9b00826_si_002.csv (10.68 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00826" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81476" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81476" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luke Whitesell</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3b574e505e154c53524f5e485e57577b4e4f544954554f5415585a"><span class="__cf_email__" data-cfemail="90fce5fbf5bee7f8f9e4f5e3f5fcfcd0e5e4ffe2fffee4ffbef3f1">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leah E. Cowen</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9bf7fefaf3b5f8f4ecfef5dbeeeff4e9f4f5eff4b5f8fa"><span class="__cf_email__" data-cfemail="08646d6960266b677f6d66487d7c677a67667c67266b69">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lauren E. Brown</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9489-484X" title="Orcid link">http://orcid.org/0000-0001-9489-484X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7f1d0d100811131a3f1d0a511a1b0a"><span class="__cf_email__" data-cfemail="f193839e869f9d94b19384df949584">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David S. Huang</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</span>; 
    <span>Present Address:
                        D.S.H.: Foghorn Therapeutics, 100 Binney Street, Cambridge, MA 02142, U.S</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0256-5307" title="Orcid link">http://orcid.org/0000-0003-0256-5307</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emmanuelle V. LeBlanc</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tanvi Shekhar-Guturja</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole Robbins</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Damian J. Krysan</span> - <span class="hlFld-Affiliation affiliation">Departments
of Pediatrics and Microbiology/Immunology, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6330-3365" title="Orcid link">http://orcid.org/0000-0001-6330-3365</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan Pizarro</span> - <span class="hlFld-Affiliation affiliation">Department
of Tropical Medicine, School of Public Health and Tropical Medicine
and Vector-Borne Infectious Disease Research Center, Tulane University, New Orleans, Louisiana 70112, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0643-518X" title="Orcid link">http://orcid.org/0000-0003-0643-518X</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>D.S.H. and E.V.L. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): L.E.C. is a cofounder, Chief Scientific Officer, and shareholder of Bright Angel Therapeutics, a platform company for the development of novel antifungal therapeutics. L.E.C. is a consultant for Boragen, a small molecule development company focused on leveraging the unique chemical properties of boron chemistry for crop protection and animal health. L.W. is a co-founder and shareholder of Bright Angel Therapeutics. L.E.B., D.S.H., L.E.C. and L.W. are named as inventors on a provisional patent application pertaining to findings reported here.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e19221-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i275">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44128" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44128" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by a grant from the National Institutes of Health (Grant R01AI120958 to L.E.C., L.E.B., and D.J.K). L.E.C. holds a Canada Research Chair in Microbial Genomics & Infectious Disease and is Co-Director of the CIFAR Program, Fungal Kingdom: Threats & Opportunities. The authors thank Dr. Han Yueh for assistance in acquiring LC/MS purity data, Dr. Paul Ralifo for assistance with NMR analysis, Gaurang Patel and Adrian Sheldon (Charles River Laboratories) for assistance with microsomal stability assays, and the Ontario Institute for Cancer Research (M. Mohammed and R. Marcellus) for assistance with SPR assays.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Hsp90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">Trap1</td><td class="NLM_def"><p class="first last">TNF receptor associated protein 1</p></td></tr><tr><td class="NLM_term">Grp94</td><td class="NLM_def"><p class="first last">94 kDa glucose-regulated protein</p></td></tr><tr><td class="NLM_term">NBD</td><td class="NLM_def"><p class="first last">nucleotide binding domain</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyluronium</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">UPLC</td><td class="NLM_def"><p class="first last">ultraperformance liquid chromatography</p></td></tr><tr><td class="NLM_term">PS-CDI</td><td class="NLM_def"><p class="first last">polymer-supported carbonyldiimidazole;</p></td></tr><tr><td class="NLM_term">TMT</td><td class="NLM_def"><p class="first last">trithiocyanuric acid</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i277">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77408" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77408" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 66 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denning, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitz, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netea, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, T. C.</span></span> <span> </span><span class="NLM_article-title">Hidden killers: human fungal infections</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">165</span>),  <span class="NLM_fpage">165rv13</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3004404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1126%2Fscitranslmed.3004404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=23253612" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=165rv13&issue=165&author=G.+D.+Brownauthor=D.+W.+Denningauthor=N.+A.+Gowauthor=S.+M.+Levitzauthor=M.+G.+Neteaauthor=T.+C.+White&title=Hidden+killers%3A+human+fungal+infections&doi=10.1126%2Fscitranslmed.3004404"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004404%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DG.%2BD.%26aulast%3DDenning%26aufirst%3DD.%2BW.%26aulast%3DGow%26aufirst%3DN.%2BA.%26aulast%3DLevitz%26aufirst%3DS.%2BM.%26aulast%3DNetea%26aufirst%3DM.%2BG.%26aulast%3DWhite%26aufirst%3DT.%2BC.%26atitle%3DHidden%2520killers%253A%2520human%2520fungal%2520infections%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26issue%3D165%26spage%3D165rv13%26doi%3D10.1126%2Fscitranslmed.3004404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span>; <span class="NLM_string-name">Wright, G. D.</span>; <span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Antifungal drugs: the current armamentarium and development of new agents</span>. In  <i>The Fungal Kingdom</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, J.</span>, <span class="NLM_string-name">Howlett, B.</span>, <span class="NLM_string-name">Crous, P.</span>, <span class="NLM_string-name">Stukenbrock, E.</span>, <span class="NLM_string-name">James, T.</span>, <span class="NLM_string-name">Gow, N.</span></span>, Eds.; <span class="NLM_publisher-name">ASM Press</span>: <span class="NLM_publisher-loc">Washington DC</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">4</span>, pp  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">922</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1128%2F9781555819583.ch44" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=903-922&author=N.+Robbins&author=G.+D.+Wright&author=L.+E.+Cowenauthor=J.+Heitman&author=B.+Howlett&author=P.+Crous&author=E.+Stukenbrock&author=T.+James&author=N.+Gow&title=The+Fungal+Kingdom"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1128%2F9781555819583.ch44&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1128%252F9781555819583.ch44%26sid%3Dliteratum%253Aachs%26aulast%3DRobbins%26aufirst%3DN.%26atitle%3DAntifungal%2520drugs%253A%2520the%2520current%2520armamentarium%2520and%2520development%2520of%2520new%2520agents%26btitle%3DThe%2520Fungal%2520Kingdom%26aulast%3DHeitman%26aufirst%3DJ.%26pub%3DASM%2520Press%26date%3D2017%26volume%3D4%26spage%3D903%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora-Montes, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erwig, L. P.</span></span> <span> </span><span class="NLM_article-title">Contribution of Candida albicans cell wall components to recognition by and escape from murine macrophages</span>. <i>Infect. Immun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1650</span>– <span class="NLM_lpage">1658</span>, <span class="refDoi"> DOI: 10.1128/IAI.00001-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1128%2FIAI.00001-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=20123707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt12gtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=1650-1658&issue=4&author=C.+G.+McKenzieauthor=U.+Koserauthor=L.+E.+Lewisauthor=J.+M.+Bainauthor=H.+M.+Mora-Montesauthor=R.+N.+Barkerauthor=N.+A.+Gowauthor=L.+P.+Erwig&title=Contribution+of+Candida+albicans+cell+wall+components+to+recognition+by+and+escape+from+murine+macrophages&doi=10.1128%2FIAI.00001-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of Candida albicans cell wall components to recognition by and escape from murine macrophages</span></div><div class="casAuthors">McKenzie, C. G. J.; Koser, U.; Lewis, L. E.; Bain, J. M.; Mora-Montes, H. M.; Barker, R. N.; Gow, N. A. R.; Erwig, L. P.</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Immunity</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1650-1658</span>CODEN:
                <span class="NLM_cas:coden">INFIBR</span>;
        ISSN:<span class="NLM_cas:issn">0019-9567</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The pathogenicity of the opportunistic human fungal pathogen Candida albicans depends on its ability to escape destruction by the host immune system.  Using mutant strains that are defective in cell surface glycosylation, cell wall protein synthesis, and yeast-hypha morphogenesis, the authors have investigated three important aspects of C. albicans innate immune interactions: phagocytosis by primary macrophages and macrophage cell lines, hyphal formation within macrophage phagosomes, and the ability to escape from and kill macrophages.  The authors show that cell wall glycosylation is critically important for the recognition and ingestion of C. albicans by macrophages.  Phagocytosis was significantly reduced for mutants deficient in phosphomannan biosynthesis (mmn4Δ, pmr1Δ, and mnt3 mnt5Δ), whereas O- and N-linked mannan defects (mnt1Δ mnt2Δ and mns1Δ) were assocd. with increased ingestion, compared to the parent wild-type strains and genetically complemented controls.  In contrast, macrophage uptake of mutants deficient in cell wall proteins such as adhesins (ece1Δ, hwp1Δ, and als3Δ) and yeast-locked mutants (clb2Δ, hgc1Δ, cph1Δ, efg1Δ, and efg1Δ cph1Δ), was similar to that obsd. for wild-type C. albicans.  Killing of macrophages was abrogated in hypha-deficient strains, significantly reduced in all glycosylation mutants, and comparable to wild type in cell wall protein mutants.  The diminished ability of glycosylation mutants to kill macrophages was not a consequence of impaired hyphal formation within macrophage phagosomes.  Therefore, cell wall compn. and the ability to undergo yeast-hypha morphogenesis are crit. determinants of the macrophage's ability to ingest and process C. albicans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5E710wN4SdbVg90H21EOLACvtfcHk0lh9q62UzjN2FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt12gtLc%253D&md5=c0fd80f2331d012cdeec203301f2a588</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FIAI.00001-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FIAI.00001-10%26sid%3Dliteratum%253Aachs%26aulast%3DMcKenzie%26aufirst%3DC.%2BG.%26aulast%3DKoser%26aufirst%3DU.%26aulast%3DLewis%26aufirst%3DL.%2BE.%26aulast%3DBain%26aufirst%3DJ.%2BM.%26aulast%3DMora-Montes%26aufirst%3DH.%2BM.%26aulast%3DBarker%26aufirst%3DR.%2BN.%26aulast%3DGow%26aufirst%3DN.%2BA.%26aulast%3DErwig%26aufirst%3DL.%2BP.%26atitle%3DContribution%2520of%2520Candida%2520albicans%2520cell%2520wall%2520components%2520to%2520recognition%2520by%2520and%2520escape%2520from%2520murine%2520macrophages%26jtitle%3DInfect.%2520Immun.%26date%3D2010%26volume%3D78%26issue%3D4%26spage%3D1650%26epage%3D1658%26doi%3D10.1128%2FIAI.00001-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mylonakis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2818</span>– <span class="NLM_lpage">2823</span>, <span class="refDoi"> DOI: 10.1073/pnas.0813394106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1073%2Fpnas.0813394106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=19196973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislaht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=2818-2823&issue=8&author=L.+E.+Cowenauthor=S.+D.+Singhauthor=J.+R.+Kohlerauthor=C.+Collinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=H.+Azizauthor=E.+Mylonakisauthor=J.+R.+Perfectauthor=L.+Whitesellauthor=S.+Lindquist&title=Harnessing+Hsp90+function+as+a+powerful%2C+broadly+effective+therapeutic+strategy+for+fungal+infectious+disease&doi=10.1073%2Fpnas.0813394106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease</span></div><div class="casAuthors">Cowen, Leah E.; Singh, Sheena D.; Kohler, Julia R.; Collins, Cathy; Zaas, Aimee; Schell, Wiley A.; Aziz, Hamza; Mylonakis, Eleftherios; Perfect, John R.; Whitesell, Luke; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2818-2823</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Invasive fungal infections are a leading cause of mortality among immunocompromised individuals.  Treatment is notoriously difficult with the limited armamentarium of antifungal drugs, whose efficacy is compromised by host toxicity, a limited activity spectrum, or the emergence of drug resistance.  We previously established that the mol. chaperone Hsp90 enables the emergence and maintenance of fungal drug resistance.  For the most prevalent fungal pathogen of humans, Candida albicans, Hsp90 mediates resistance to azoles, which inhibit ergosterol biosynthesis and are the most widely deployed antifungals in the clinic.  For the emerging opportunistic pathogen Aspergillus terreus, Hsp90 is required for basal resistance to echinocandins, which inhibit β(1, 3)-glucan synthesis and are the only new class of antifungals to reach the clinic in decades.  Here, we explore the therapeutic potential of Hsp90 inhibitors in fungal disease using a tractable host-model system, larvae of the greater wax moth Galleria mellonella, and a murine model of disseminated disease.  Combination therapy with Hsp90 inhibitors that are well tolerated in humans and an azole rescued larvae from lethal C. albicans infections.  Combination therapy with an Hsp90 inhibitor and an echinocandin rescued larvae from infections with the most lethal mold, Aspergillus fumigatus.  In a murine model of disseminated candidiasis, genetic compromise of C. albicans HSP90 expression enhanced the therapeutic efficacy of an azole.  Thus, harnessing Hsp90 provides a much-needed strategy for improving the treatment of fungal disease because it enhances the efficacy of existing antifungals, blocks the emergence of drug resistance, and exerts broad-spectrum activity against diverse fungal pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtMf02gFiLZLVg90H21EOLACvtfcHk0lh9q62UzjN2FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislaht7s%253D&md5=a0bf89b9285831333d619bb9edc8f4ef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0813394106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0813394106%26sid%3Dliteratum%253Aachs%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DSingh%26aufirst%3DS.%2BD.%26aulast%3DKohler%26aufirst%3DJ.%2BR.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DAziz%26aufirst%3DH.%26aulast%3DMylonakis%26aufirst%3DE.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHarnessing%2520Hsp90%2520function%2520as%2520a%2520powerful%252C%2520broadly%2520effective%2520therapeutic%2520strategy%2520for%2520fungal%2520infectious%2520disease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D8%26spage%3D2818%26epage%3D2823%26doi%3D10.1073%2Fpnas.0813394106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>309</i></span> (<span class="NLM_issue">5744</span>),  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2189</span>, <span class="refDoi"> DOI: 10.1126/science.1118370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1126%2Fscience.1118370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=16195452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeksbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2005&pages=2185-2189&issue=5744&author=L.+E.+Cowenauthor=S.+Lindquist&title=Hsp90+potentiates+the+rapid+evolution+of+new+traits%3A+drug+resistance+in+diverse+fungi&doi=10.1126%2Fscience.1118370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi</span></div><div class="casAuthors">Cowen, Leah E.; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">5744</span>),
    <span class="NLM_cas:pages">2185-2189</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Hsp90 is a mol. chaperone for many signal transducers and may influence evolution by releasing previously silent genetic variation in response to environmental change.  In fungi sepd. by ∼800 million years of evolution, Hsp90 potentiated the evolution of drug resistance in a different way, by enabling new mutations to have immediate phenotypic consequences.  Resistance was abrogated by Hsp90 inhibitors and by febrile temps., suggesting new therapeutic strategies and a clin. benefit of fever.  During selection in a human host, drug resistance that was initially Hsp90-dependent evolved toward independence.  Thus, Hsp90 can act in diverse ways to couple environmental contingency to the emergence and fixation of new traits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiYEERY_9yw7Vg90H21EOLACvtfcHk0lh9q62UzjN2FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeksbbI&md5=153bda853d501270402f5e18ab14b5d8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1118370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1118370%26sid%3Dliteratum%253Aachs%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHsp90%2520potentiates%2520the%2520rapid%2520evolution%2520of%2520new%2520traits%253A%2520drug%2520resistance%2520in%2520diverse%2520fungi%26jtitle%3DScience%26date%3D2005%26volume%3D309%26issue%3D5744%26spage%3D2185%26epage%3D2189%26doi%3D10.1126%2Fscience.1118370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">e1000532</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1000532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1371%2Fjournal.ppat.1000532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=19649312" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=e1000532&issue=7&author=S.+D.+Singhauthor=N.+Robbinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=J.+R.+Perfectauthor=L.+E.+Cowen&title=Hsp90+governs+echinocandin+resistance+in+the+pathogenic+yeast+Candida+albicans+via+calcineurin&doi=10.1371%2Fjournal.ppat.1000532"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000532%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%2BD.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DHsp90%2520governs%2520echinocandin%2520resistance%2520in%2520the%2520pathogenic%2520yeast%2520Candida%2520albicans%2520via%2520calcineurin%26jtitle%3DPLoS%2520Pathog.%26date%3D2009%26volume%3D5%26issue%3D7%26spage%3De1000532%26doi%3D10.1371%2Fjournal.ppat.1000532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatu, U.</span></span> <span> </span><span class="NLM_article-title">Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">e0005836</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0005836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1371%2Fjournal.pntd.0005836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=28783748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCltbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=e0005836&issue=8&author=S.+Chatterjeeauthor=U.+Tatu&title=Heat+shock+protein+90+localizes+to+the+surface+and+augments+virulence+factors+of+Cryptococcus+neoformans&doi=10.1371%2Fjournal.pntd.0005836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans</span></div><div class="casAuthors">Chatterjee, Sharanya; Tatu, Utpal</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0005836/1-e0005836/20</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Thermotolerance is an essential attribute for pathogenesis of Cryptococcus as exemplified by the fact that only two species in the genus, which can grow at 37°C, are human pathogens.  Species which have other virulence factors including capsule formation and melanisation, but lack the ability to propagate at 37°C are not pathogenic.  In another related fungal pathogen, Candida albicans, heat shock protein 90 has been implicated to be a central player in commanding pathogenicity by governing yeast to hyphal transition and drug resistance.  Exploring Hsp90 biol. in Cryptococcus in context of thermotolerance may thus highlight important regulatory principles of virulence and open new therapeutic avenues.  Methodol./Principal findings Hsp90 is involved in regulating thermotolerance in Cryptococcus as indicated by growth hypersensitivity at 37°C upon mild compromise of Hsp90 function relative to 25°C.  Biochem. studies revealed a more potent inhibition of ATPase activity by pharmacol. inhibitor 17-AAG at 37°C as compared to 25°C.  Catalytic efficiency of the protein at 37°C was found to be 6.39 × 10-5μM-1.  Furthermore, indirect immunofluorescence anal. using a specific antibody revealed cell surface localization of Hsp90 via ER Golgi classical secretory pathway.  Hsp90 was found to be induced under capsule inducing conditions and Hsp90 inhibition led to decrease in capsular vol.  Finally compromising Hsp90 function improved anidulafungin tolerance in Cryptococcus.  Conclusions/Significance Our findings highlight that Hsp90 regulates pathogenicity of the fungus by myriad ways.  Firstly, it is involved in mediating thermotolerance which implies targeting Hsp90 can abrogate thermotolerance and hence growth of the fungus.  Secondly, this study provides the first report of biochem. properties of Hsp90 of a pathogenic fungus.  Finally, since Hsp90 is localised at the cell wall, targeting cell surface Hsp90 can represent a novel strategy to combat this lethal infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox--VK--z5SLVg90H21EOLACvtfcHk0liFdUdd_FE_2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCltbjF&md5=d268755893a680cd9ef4f3e35e88690c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005836%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DTatu%26aufirst%3DU.%26atitle%3DHeat%2520shock%2520protein%252090%2520localizes%2520to%2520the%2520surface%2520and%2520augments%2520virulence%2520factors%2520of%2520Cryptococcus%2520neoformans%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26issue%3D8%26spage%3De0005836%26doi%3D10.1371%2Fjournal.pntd.0005836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Aguiar Cordeiro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Evangelista, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serpa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Farias Marques, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Melo, C. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva Franco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Alencar, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Pinheiro Gomes
Bandeira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brilhante, R. S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidrim, J. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, M. F. G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of Cryptococcus neoformans/Cryptococcus gattii species complex</span>. <i>Microbiology (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1099/mic.0.000222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1099%2Fmic.0.000222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=26645478" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2016&pages=309-317&issue=2&author=R.+de%0AAguiar+Cordeiroauthor=A.+J.+de+Jesus+Evangelistaauthor=R.+Serpaauthor=F.+J.+de+Farias+Marquesauthor=C.+V.+S.+de+Meloauthor=J.+S.+de+Oliveiraauthor=J.+da+Silva+Francoauthor=L.+P.+de+Alencarauthor=T.+de+Jesus+Pinheiro+Gomes%0ABandeiraauthor=R.+S.+N.+Brilhanteauthor=J.+J.+C.+Sidrimauthor=M.+F.+G.+Rocha&title=Inhibition+of+heat-shock+protein+90+enhances+the+susceptibility+to+antifungals+and+reduces+the+virulence+of+Cryptococcus+neoformans%2FCryptococcus+gattii+species+complex&doi=10.1099%2Fmic.0.000222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1099%2Fmic.0.000222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fmic.0.000222%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BAguiar%2BCordeiro%26aufirst%3DR.%26aulast%3Dde%2BJesus%2BEvangelista%26aufirst%3DA.%2BJ.%26aulast%3DSerpa%26aufirst%3DR.%26aulast%3Dde%2BFarias%2BMarques%26aufirst%3DF.%2BJ.%26aulast%3Dde%2BMelo%26aufirst%3DC.%2BV.%2BS.%26aulast%3Dde%2BOliveira%26aufirst%3DJ.%2BS.%26aulast%3Dda%2BSilva%2BFranco%26aufirst%3DJ.%26aulast%3Dde%2BAlencar%26aufirst%3DL.%2BP.%26aulast%3Dde%2BJesus%2BPinheiro%2BGomes%2BBandeira%26aufirst%3DT.%26aulast%3DBrilhante%26aufirst%3DR.%2BS.%2BN.%26aulast%3DSidrim%26aufirst%3DJ.%2BJ.%2BC.%26aulast%3DRocha%26aufirst%3DM.%2BF.%2BG.%26atitle%3DInhibition%2520of%2520heat-shock%2520protein%252090%2520enhances%2520the%2520susceptibility%2520to%2520antifungals%2520and%2520reduces%2520the%2520virulence%2520of%2520Cryptococcus%2520neoformans%252FCryptococcus%2520gattii%2520species%2520complex%26jtitle%3DMicrobiology%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2016%26volume%3D162%26issue%3D2%26spage%3D309%26epage%3D317%26doi%3D10.1099%2Fmic.0.000222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Annessa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compostella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, G.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulators of HSP90 and HSP70: dynamics meets function through structure-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00825</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlykurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=60-87&issue=1&author=M.+Ferraroauthor=I.+D%E2%80%99Annessaauthor=E.+Moroniauthor=G.+Morraauthor=A.+Paladinoauthor=S.+Rinaldiauthor=F.+Compostellaauthor=G.+Colombo&title=Allosteric+modulators+of+HSP90+and+HSP70%3A+dynamics+meets+function+through+structure-based+drug+design&doi=10.1021%2Facs.jmedchem.8b00825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design</span></div><div class="casAuthors">Ferraro, Mariarosaria; DAnnessa, Ilda; Moroni, Elisabetta; Morra, Giulia; Paladino, Antonella; Rinaldi, Silvia; Compostella, Federica; Colombo, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-87</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Mol. chaperones HSP90 and HSP70 are essential regulators of the folding and activation of a disparate ensemble of client proteins.  They function through ATP hydrolysis and the assembly of multiprotein complexes with co-chaperones and clients.  While their therapeutic relevance is recognized, important details underlying the links between ATP-dependent conformational dynamics and clients/co-chaperones recruitment remain elusive.  Allosteric modulators represent fundamental tools to obtain mol. insights into functional regulation.  By selectively perturbing different aspect of HSP90/HSP70 activities, allosteric drugs can tune rather than completely inhibit signaling cascades, providing information on the relationships between structure-dynamics and function.  Herein, the authors review advances in the design of HSP90 and HSP70 allosteric modulators.  The authors consider inhibitors and activators in different biochem. and disease models.  The authors discuss these compds. as probes to decipher the complexity of the chaperone machinery that at the same time represent starting leads for the development of drugs against cancer and neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl2ddWfMChFbVg90H21EOLACvtfcHk0liFdUdd_FE_2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlykurvF&md5=0e8378f0f6d03fb976e82088bca82f21</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00825%26sid%3Dliteratum%253Aachs%26aulast%3DFerraro%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Annessa%26aufirst%3DI.%26aulast%3DMoroni%26aufirst%3DE.%26aulast%3DMorra%26aufirst%3DG.%26aulast%3DPaladino%26aufirst%3DA.%26aulast%3DRinaldi%26aufirst%3DS.%26aulast%3DCompostella%26aufirst%3DF.%26aulast%3DColombo%26aufirst%3DG.%26atitle%3DAllosteric%2520modulators%2520of%2520HSP90%2520and%2520HSP70%253A%2520dynamics%2520meets%2520function%2520through%2520structure-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D60%26epage%3D87%26doi%3D10.1021%2Facs.jmedchem.8b00825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taipale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosz, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">HSP90 at the hub of protein homeostasis: emerging mechanistic insights</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1038/nrm2918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fnrm2918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=20531426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFSmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=515-528&author=M.+Taipaleauthor=D.+F.+Jaroszauthor=S.+Lindquist&title=HSP90+at+the+hub+of+protein+homeostasis%3A+emerging+mechanistic+insights&doi=10.1038%2Fnrm2918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 at the hub of protein homeostasis: emerging mechanistic insights</span></div><div class="casAuthors">Taipale, Mikko; Jarosz, Daniel F.; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">515-528</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Heat-shock protein 90 (HSP90) is a highly conserved mol. chaperone that facilitates the maturation of a wide range of proteins (known as clients).  Clients are enriched in signal transducers, including kinases and transcription factors.  Therefore, HSP90 regulates diverse cellular functions and exerts marked effects on normal biol., disease, and evolutionary processes.  Recent structural and functional analyses have provided new insights on the transcriptional and biochem. regulation of HSP90 and the structural dynamics it uses to act on a diverse client repertoire.  A comprehensive understanding of how HSP90 functions promises not only to provide new avenues for therapeutic intervention, but to shed light on fundamental biol. questions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuMRSaY8uzGbVg90H21EOLACvtfcHk0lhi13QK2DbdWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFSmt7c%253D&md5=492dca92cea32384d2ab4145230f53dd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrm2918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2918%26sid%3Dliteratum%253Aachs%26aulast%3DTaipale%26aufirst%3DM.%26aulast%3DJarosz%26aufirst%3DD.%2BF.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHSP90%2520at%2520the%2520hub%2520of%2520protein%2520homeostasis%253A%2520emerging%2520mechanistic%2520insights%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D515%26epage%3D528%26doi%3D10.1038%2Fnrm2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar-Guturja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nation, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trilles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizarro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">402</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-08248-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fs41467-018-08248-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=30679438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFersrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=402&issue=1&author=L.+Whitesellauthor=N.+Robbinsauthor=D.+S.+Huangauthor=C.+A.+McLellanauthor=T.+Shekhar-Guturjaauthor=E.+V.+LeBlancauthor=C.+S.+Nationauthor=R.+Huiauthor=A.+Hutchinsonauthor=C.+Collinsauthor=S.+Chatterjeeauthor=R.+Trillesauthor=J.+L.+Xieauthor=D.+J.+Krysanauthor=S.+Lindquistauthor=J.+A.+Porcoauthor=U.+Tatuauthor=L.+E.+Brownauthor=J.+Pizarroauthor=L.+E.+Cowen&title=Structural+basis+for+species-selective+targeting+of+Hsp90+in+a+pathogenic+fungus&doi=10.1038%2Fs41467-018-08248-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus</span></div><div class="casAuthors">Whitesell, Luke; Robbins, Nicole; Huang, David S.; McLellan, Catherine A.; Shekhar-Guturja, Tanvi; LeBlanc, Emmanuelle V.; Nation, Catherine S.; Hui, Raymond; Hutchinson, Ashley; Collins, Cathy; Chatterjee, Sharanya; Trilles, Richard; Xie, Jinglin L.; Krysan, Damian J.; Lindquist, Susan; Porco, John A., Jr.; Tatu, Utpal; Brown, Lauren E.; Pizarro, Juan; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">402</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">New strategies are needed to counter the escalating threat posed by drug-resistant fungi.  The mol. chaperone Hsp90 affords a promising target because it supports survival, virulence and drug-resistance across diverse pathogens.  Inhibitors of human Hsp90 under development as anticancer therapeutics, however, exert host toxicities that preclude their use as antifungals.  Seeking a route to species-selectivity, we investigate the nucleotide-binding domain (NBD) of Hsp90 from the most common human fungal pathogen, Candida albicans.  Here we report structures for this NBD alone, in complex with ADP or in complex with known Hsp90 inhibitors.  Encouraged by the conformational flexibility revealed by these structures, we synthesize an inhibitor with >25-fold binding-selectivity for fungal Hsp90 NBD.  Comparing co-crystals occupied by this probe vs. anticancer Hsp90 inhibitors revealed major, previously unreported conformational rearrangements.  These insights and our probe's species-selectivity in culture support the feasibility of targeting Hsp90 as a promising antifungal strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc0j6rgX3IDrVg90H21EOLACvtfcHk0lhi13QK2DbdWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFersrg%253D&md5=ee973dc62c7912479f26d2ad26f024bc</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08248-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08248-w%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DD.%2BS.%26aulast%3DMcLellan%26aufirst%3DC.%2BA.%26aulast%3DShekhar-Guturja%26aufirst%3DT.%26aulast%3DLeBlanc%26aufirst%3DE.%2BV.%26aulast%3DNation%26aufirst%3DC.%2BS.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DHutchinson%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DTrilles%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DJ.%2BL.%26aulast%3DKrysan%26aufirst%3DD.%2BJ.%26aulast%3DLindquist%26aufirst%3DS.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DTatu%26aufirst%3DU.%26aulast%3DBrown%26aufirst%3DL.%2BE.%26aulast%3DPizarro%26aufirst%3DJ.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DStructural%2520basis%2520for%2520species-selective%2520targeting%2520of%2520Hsp90%2520in%2520a%2520pathogenic%2520fungus%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D402%26doi%3D10.1038%2Fs41467-018-08248-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rehn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zierer, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tippel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchner, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric regulation points control the conformational dynamics of the molecular chaperone Hsp90</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>428</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4559</span>– <span class="NLM_lpage">4571</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2016.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.jmb.2016.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=27663270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKmurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2016&pages=4559-4571&issue=22&author=A.+Rehnauthor=E.+Moroniauthor=B.+K.+Ziererauthor=F.+Tippelauthor=G.+Morraauthor=C.+Johnauthor=K.+Richterauthor=G.+Colomboauthor=J.+Buchner&title=Allosteric+regulation+points+control+the+conformational+dynamics+of+the+molecular+chaperone+Hsp90&doi=10.1016%2Fj.jmb.2016.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric regulation points control the conformational dynamics of the molecular chaperone Hsp90</span></div><div class="casAuthors">Rehn, Alexandra; Moroni, Elisabetta; Zierer, Bettina K.; Tippel, Franziska; Morra, Giulia; John, Christine; Richter, Klaus; Colombo, Giorgio; Buchner, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4559-4571</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Heat-shock protein 90 (Hsp90) is an ATP-dependent mol. chaperone responsible for the activation, maturation, and trafficking of several hundred client proteins in the cell.  It is well known that (but not understood how) residues far away from Hsp90's nucleotide binding pocket can regulate its ATPase activity, a phenomenon called allosteric regulation.  Here, the computational design of allosteric mutations was combined with in vitro and in vivo expts. to unravel nucleotide-responsive hot spots in the regulation of Hsp90.  With this approach, the authors identified both activating and inhibiting regulation points and showed that changes in those amino acids affect the conformational dynamics and ATPase activity of Hsp90 in vitro.  These observations that activating mutations loosen and inhibiting mutations rigidify the protein explain for the 1st time how Hsp90 changes in response to allosteric mutations.  Addnl., mutations of these allosteric regulation points can be controlled by the interplay with Hsp90 co-chaperones, thus providing cells with an efficient mechanism of modifying Hsp90's intrinsic properties via different layers of regulation.  Altogether, these results show that a framework for transmitting conformational information exists in the Hsp90 structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6oPpgyNANF7Vg90H21EOLACvtfcHk0lgnwm5Ab8Yt8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKmurrF&md5=131cd1d14b7204c1071f7291e557edf1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2016.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2016.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DRehn%26aufirst%3DA.%26aulast%3DMoroni%26aufirst%3DE.%26aulast%3DZierer%26aufirst%3DB.%2BK.%26aulast%3DTippel%26aufirst%3DF.%26aulast%3DMorra%26aufirst%3DG.%26aulast%3DJohn%26aufirst%3DC.%26aulast%3DRichter%26aufirst%3DK.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DBuchner%26aufirst%3DJ.%26atitle%3DAllosteric%2520regulation%2520points%2520control%2520the%2520conformational%2520dynamics%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D428%26issue%3D22%26spage%3D4559%26epage%3D4571%26doi%3D10.1016%2Fj.jmb.2016.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gewirth, D. T.</span></span> <span> </span><span class="NLM_article-title">Paralog specific Hsp90 inhibitors - a brief history and a bright future</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">2779</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160413141154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.2174%2F1568026616666160413141154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=27072700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2779-2791&issue=25&author=D.+T.+Gewirth&title=Paralog+specific+Hsp90+inhibitors+-+a+brief+history+and+a+bright+future&doi=10.2174%2F1568026616666160413141154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future</span></div><div class="casAuthors">Gewirth, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2779-2791</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background. The high sequence and structural homol. among the hsp90 paralogs - Hsp90α, Hsp90β, Grp94, and Trap-1 - has made the development of paralog-specific inhibitors a challenging proposition.  Objective. This review surveys the state of developments in structural anal., compd. screening, and structure-based design that have been brought to bear on this problem.  Results. First generation compds. that selectively bind to Hsp90, Grp94, or Trap-1 have been identified.  Conclusion. With the proof of principle firmly established, the prospects for further progress are bright.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdyZyrXOyou7Vg90H21EOLACvtfcHk0lgnwm5Ab8Yt8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrzN&md5=208025ff36aa6e2d92d3ee107b20ab5f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160413141154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160413141154%26sid%3Dliteratum%253Aachs%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26atitle%3DParalog%2520specific%2520Hsp90%2520inhibitors%2520-%2520a%2520brief%2520history%2520and%2520a%2520bright%2520future%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26issue%3D25%26spage%3D2779%26epage%3D2791%26doi%3D10.2174%2F1568026616666160413141154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, B. H.</span></span> <span> </span><span class="NLM_article-title">Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4358</span>– <span class="NLM_lpage">4367</span>, <span class="refDoi"> DOI: 10.1021/ja511893n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja511893n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2htrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=4358-4367&issue=13&author=C.+Leeauthor=H.+K.+Parkauthor=H.+Jeongauthor=J.+Limauthor=A.+J.+Leeauthor=K.+Y.+Cheonauthor=C.+S.+Kimauthor=A.+P.+Thomasauthor=B.+Baeauthor=N.+D.+Kimauthor=S.+H.+Kimauthor=P.+G.+Suhauthor=J.+H.+Ryuauthor=B.+H.+Kang&title=Development+of+a+mitochondria-targeted+Hsp90+inhibitor+based+on+the+crystal+structures+of+human+TRAP1&doi=10.1021%2Fja511893n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Mitochondria-Targeted Hsp90 Inhibitor Based on the Crystal Structures of Human TRAP1</span></div><div class="casAuthors">Lee, Changwook; Park, Hye-Kyung; Jeong, Hanbin; Lim, Jaehwa; Lee, An-Jung; Cheon, Keun Young; Kim, Chul-Su; Thomas, Ajesh P.; Bae, Boram; Kim, Nam Doo; Kim, Seong Heon; Suh, Pann-Ghill; Ryu, Ja-Hyoung; Kang, Byoung Heon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4358-4367</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mitochondrial pool of Hsp90 and its mitochondrial paralog, TRAP1, suppresses cell death and reprograms energy metab. in cancer cells; therefore, Hsp90 and TRAP1 have been suggested as target proteins for anticancer drug development.  Here, the authors report that the actual target protein in cancer cell mitochondria is TRAP1, and current Hsp90 inhibitors cannot effectively inactivate TRAP1 because of their insufficient accumulation in the mitochondria.  To develop mitochondrial TRAP1 inhibitors, the authors detd. the crystal structures of human TRAP1 complexed with Hsp90 inhibitors.  The iso-Pr amine of the Hsp90 inhibitor PU-H71 was replaced with the mitochondria-targeting moiety triphenylphosphonium to produce SMTIN-P01.  SMTIN-P01 showed a different mode of action from the nontargeted PU-H71, as well as much improved cytotoxicity to cancer cells.  In addn., the authors detd. the structure of a TRAP1-adenylyl-imidodiphosphate (AMP-PNP) complex.  On the basis of comparative anal. of TRAP1 structures, the authors propose a mol. mechanism of ATP hydrolysis that is crucial for chaperone function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN-VB5CkPi2LVg90H21EOLACvtfcHk0lgnwm5Ab8Yt8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2htrs%253D&md5=c1142149eaa5f4157377ce64662fcfc1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fja511893n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja511893n%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DH.%2BK.%26aulast%3DJeong%26aufirst%3DH.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DA.%2BJ.%26aulast%3DCheon%26aufirst%3DK.%2BY.%26aulast%3DKim%26aufirst%3DC.%2BS.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DBae%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSuh%26aufirst%3DP.%2BG.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DKang%26aufirst%3DB.%2BH.%26atitle%3DDevelopment%2520of%2520a%2520mitochondria-targeted%2520Hsp90%2520inhibitor%2520based%2520on%2520the%2520crystal%2520structures%2520of%2520human%2520TRAP1%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26issue%3D13%26spage%3D4358%26epage%3D4367%26doi%3D10.1021%2Fja511893n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stothert, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, D. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerfeldt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizziah, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Development of glucose regulated protein 94-selective inhibitors based on the BnIm and radamide scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3471</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFGrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3471-3488&issue=7&author=V.+M.+Crowleyauthor=A.+Khandelwalauthor=S.+Mishraauthor=A.+R.+Stothertauthor=D.+J.+E.+Huardauthor=J.+Zhaoauthor=A.+Muthauthor=A.+S.+Duerfeldtauthor=J.+L.+Kizziahauthor=R.+L.+Liebermanauthor=C.+A.+Dickeyauthor=B.+S.+J.+Blagg&title=Development+of+glucose+regulated+protein+94-selective+inhibitors+based+on+the+BnIm+and+radamide+scaffold&doi=10.1021%2Facs.jmedchem.6b00085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold</span></div><div class="casAuthors">Crowley, Vincent M.; Khandelwal, Anuj; Mishra, Sanket; Stothert, Andrew R.; Huard, Dustin J. E.; Zhao, Jinbo; Muth, Aaron; Duerfeldt, Adam S.; Kizziah, James L.; Lieberman, Raquel L.; Dickey, Chad A.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3471-3488</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(Arylmethyl)imidazolylethyl chlorodihydroxybenzoates I (R = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-IC6H4, 4-MeC6H4, 4-EtC6H4, 4-i-PrC6H4, 4-NCC6H4, 4-HC≡CC6H4, 4-F3CC6H4, 4-PhC6H4, 4-MeOC6H4, 3,4-Cl2C6H3, 1-naphthyl, 2-naphthyl, 5-quinolinyl, 3-FC6H4, 3-ClC6H4, 3-BrC6H4, 3-IC6H4, 3-MeOC6H4, 3-MeC6H4, 3-PhC6H4, 2-FC6H4, 2-ClC6H4, 2-BrC6H4, 2-MeC6H4, 2-H2NC6H4, 2-MeOC6H4, 2-EtC6H4, 2-EtOC6H4, 2-i-PrOC6H4, 2-n-PrOC6H4, 2-F3CC6H4, 2-MeO-4-MeC6H3, 3-furanyl, 2-furanyl, 5-Me-2-furanyl, 5-Cl-2-furanyl, 3,5-dimethyl-2-furanyl, 2-thienyl, 3-thienyl, 5-Me-2-thienyl, 5-Cl-2-thienyl, 4-Cl-2-thienyl, 3-Cl-2-thienyl, 5-isoxazolyl, 2-thiazolyl, 3-vinyl-2-thienyl, 3-vinyl-2-furanyl, 3-Et-2-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 5-pyrimidinyl) were prepd. as selective inhibitors of glucose regulated protein 94 (Grp94), the endoplasmic reticulum-resident isoform of the heat shock protein 90 (Hsp90), for potential use in the treatment of glaucoma and cancer; the effect of the aryl substituents on Grp94 binding and selectivity was detd.  I were prepd. by the cyclocondensation of a bissilylated chloro(oxopropyl)dihydroxybenzoate with glyoxal and arylmethylamines RCH2NH2 (R = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-IC6H4, 4-MeC6H4, 4-EtC6H4, 4-i-PrC6H4, 4-NCC6H4, 4-HC≡CC6H4, 4-F3CC6H4, 4-PhC6H4, 4-MeOC6H4, 3,4-Cl2C6H3, 1-naphthyl, 2-naphthyl, 5-quinolinyl, 3-FC6H4, 3-ClC6H4, 3-BrC6H4, 3-IC6H4, 3-MeOC6H4, 3-MeC6H4, 3-PhC6H4, 2-FC6H4, 2-ClC6H4, 2-BrC6H4, 2-MeC6H4, 2-H2NC6H4, 2-MeOC6H4, 2-EtC6H4, 2-EtOC6H4, 2-i-PrOC6H4, 2-n-PrOC6H4, 2-F3CC6H4, 2-MeO-4-MeC6H3, 3-furanyl, 2-furanyl, 5-Me-2-furanyl, 5-Cl-2-furanyl, 3,5-dimethyl-2-furanyl, 2-thienyl, 3-thienyl, 5-Me-2-thienyl, 5-Cl-2-thienyl, 4-Cl-2-thienyl, 3-Cl-2-thienyl, 5-isoxazolyl, 2-thiazolyl, 3-vinyl-2-thienyl, 3-vinyl-2-furanyl, 3-Et-2-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 5-pyrimidinyl) followed by desilylation.  I (R = 2-MeO-4-MeC6H3CH2, 5-chloro-2-furanylmethyl) were tested as inhibitors of cell migration in a cancer metastasis model and for their enhancement of the degrdn. of mutants of the protein myocilin in a glaucoma model.  The structures of the lead compd. radamide bound to Hsp82 and Grp94 and of I (R = 5-chloro-2-furanyl) bound to the N-terminal domain of Hsp94 lacking its acidic linker were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3v_0NEYj1Z7Vg90H21EOLACvtfcHk0lg82syep12WWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFGrs7k%253D&md5=c73bbf30c243e281aae197689162c9e1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00085%26sid%3Dliteratum%253Aachs%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DStothert%26aufirst%3DA.%2BR.%26aulast%3DHuard%26aufirst%3DD.%2BJ.%2BE.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DKizziah%26aufirst%3DJ.%2BL.%26aulast%3DLieberman%26aufirst%3DR.%2BL.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520glucose%2520regulated%2520protein%252094-selective%2520inhibitors%2520based%2520on%2520the%2520BnIm%2520and%2520radamide%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D7%26spage%3D3471%26epage%3D3488%26doi%3D10.1021%2Facs.jmedchem.6b00085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidler, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Que, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taldone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephani, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gewirth, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span> <span> </span><span class="NLM_article-title">Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fnchembio.1335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=23995768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGltb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=677-684&author=P.+D.+Patelauthor=P.+Yanauthor=P.+M.+Seidlerauthor=H.+J.+Patelauthor=W.+Sunauthor=C.+Yangauthor=N.+S.+Queauthor=T.+Taldoneauthor=P.+Finottiauthor=R.+A.+Stephaniauthor=D.+T.+Gewirthauthor=G.+Chiosis&title=Paralog-selective+Hsp90+inhibitors+define+tumor-specific+regulation+of+HER2&doi=10.1038%2Fnchembio.1335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2</span></div><div class="casAuthors">Patel, Pallav D.; Yan, Pengrong; Seidler, Paul M.; Patel, Hardik J.; Sun, Weilin; Yang, Chenghua; Que, Nanette S.; Taldone, Tony; Finotti, Paola; Stephani, Ralph A.; Gewirth, Daniel T.; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">677-684</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy, the contribution of each paralog to the cancer phenotype is poorly understood.  This is in large part because reagents to study paralog-specific functions in cancer cells have been unavailable.  Here the authors combine compd. library screening with structural and computational analyses to identify purine-based chem. tools that are specific for Hsp90 paralogs.  The authors show that Grp94 selectivity is due to the insertion of these compds. into a new allosteric pocket.  The authors use these tools to demonstrate that cancer cells use individual Hsp90 paralogs to regulate a client protein in a tumor-specific manner and in response to proteome alterations.  Finally, the authors provide new mechanistic evidence explaining why selective Grp94 inhibition is particularly efficacious in certain breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAIwIoA9btZLVg90H21EOLACvtfcHk0lg82syep12WWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGltb7J&md5=8bdfb2c60b4171bbdd6046e455e413bb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1335%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%2BD.%26aulast%3DYan%26aufirst%3DP.%26aulast%3DSeidler%26aufirst%3DP.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BJ.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DQue%26aufirst%3DN.%2BS.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DFinotti%26aufirst%3DP.%26aulast%3DStephani%26aufirst%3DR.%2BA.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DParalog-selective%2520Hsp90%2520inhibitors%2520define%2520tumor-specific%2520regulation%2520of%2520HER2%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D677%26epage%3D684%26doi%3D10.1038%2Fnchembio.1335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duerfeldt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eletto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrovsky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinogle, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicchitta, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S.</span></span> <span> </span><span class="NLM_article-title">Development of a Grp94 inhibitor</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">9796</span>– <span class="NLM_lpage">9804</span>, <span class="refDoi"> DOI: 10.1021/ja303477g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja303477g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslGqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=9796-9804&author=A.+S.+Duerfeldtauthor=L.+B.+Petersonauthor=J.+C.+Maynardauthor=C.+L.+Ngauthor=D.+Elettoauthor=O.+Ostrovskyauthor=H.+E.+Shinogleauthor=D.+S.+Mooreauthor=Y.+Argonauthor=C.+V.+Nicchittaauthor=B.+S.+Blagg&title=Development+of+a+Grp94+inhibitor&doi=10.1021%2Fja303477g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Grp94 inhibitor</span></div><div class="casAuthors">Duerfeldt, Adam S.; Peterson, Laura B.; Maynard, Jason C.; Ng, Chun Leung; Eletto, Davide; Ostrovsky, Olga; Shinogle, Heather E.; Moore, David S.; Argon, Yair; Nicchitta, Christopher V.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9796-9804</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) represents a promising therapeutic target for the treatment of cancer and other diseases.  Unfortunately, results from clin. trials have been disappointing as off-target effects and toxicities have been obsd.  These detriments may be a consequence of pan-Hsp90 inhibition, as all clin. evaluated Hsp90 inhibitors simultaneously disrupt all four human Hsp90 isoforms.  Using a structure-based approach, we designed an inhibitor of Grp94, the ER-resident Hsp90.  The effect manifested by compd. (I) on several Grp94 and Hsp90α/β (cytosolic isoforms) clients were investigated.  Compd. I prevented intracellular trafficking of the Toll receptor, inhibited the secretion of IGF-II, affected the conformation of Grp94, and suppressed Drosophila larval growth, all Grp94-dependent processes.  In contrast, compd. I had no effect on cell viability or cytosolic Hsp90α/β client proteins at similar concns.  The design, synthesis, and evaluation of I are described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoayCAvZU_mzrVg90H21EOLACvtfcHk0lg82syep12WWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslGqsLw%253D&md5=00c0b3f15f2cfd04658225c8a6fb708d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fja303477g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja303477g%26sid%3Dliteratum%253Aachs%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DMaynard%26aufirst%3DJ.%2BC.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DEletto%26aufirst%3DD.%26aulast%3DOstrovsky%26aufirst%3DO.%26aulast%3DShinogle%26aufirst%3DH.%2BE.%26aulast%3DMoore%26aufirst%3DD.%2BS.%26aulast%3DArgon%26aufirst%3DY.%26aulast%3DNicchitta%26aufirst%3DC.%2BV.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%26atitle%3DDevelopment%2520of%2520a%2520Grp94%2520inhibitor%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D9796%26epage%3D9804%26doi%3D10.1021%2Fja303477g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stothert, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordhues, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, D. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passaglia, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, C. A.</span></span> <span> </span><span class="NLM_article-title">Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">17951</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-18344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fs41598-017-18344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=29263415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A280%3ADC%252BC1MzjslWisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=17951&issue=1&author=A.+R.+Stothertauthor=A.+Suntharalingamauthor=X.+Tangauthor=V.+M.+Crowleyauthor=S.+J.+Mishraauthor=J.+M.+Websterauthor=B.+A.+Nordhuesauthor=D.+J.+E.+Huardauthor=C.+L.+Passagliaauthor=R.+L.+Liebermanauthor=B.+S.+J.+Blaggauthor=L.+J.+Blairauthor=J.+Korenauthor=C.+A.+Dickey&title=Isoform-selective+Hsp90+inhibition+rescues+model+of+hereditary+open-angle+glaucoma&doi=10.1038%2Fs41598-017-18344-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma</span></div><div class="casAuthors">Stothert Andrew R; Suntharalingam Amirthaa; Tang Xiaolan; Webster Jack M; Nordhues Bryce A; Blair Laura J; Koren John 3rd; Dickey Chad A; Tang Xiaolan; Passaglia Christopher L; Crowley Vincent M; Mishra Sanket J; Blagg Brian S J; Huard Dustin J E; Lieberman Raquel L</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17951</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The heat shock protein 90 (Hsp90) family of molecular chaperones regulates protein homeostasis, folding, and degradation.  The ER-resident Hsp90 isoform, glucose-regulated protein 94 (Grp94), promotes the aggregation of mutant forms of myocilin, a protein associated with primary open-angle glaucoma.  While inhibition of Grp94 promotes the degradation of mutant myocilin in vitro, to date no Grp94-selective inhibitors have been investigated in vivo.  Here, a Grp94-selective inhibitor facilitated mutant myocilin degradation and rescued phenotypes in a transgenic mouse model of hereditary primary open-angle glaucoma.  Ocular toxicities previously associated with pan-Hsp90 inhibitors were not evident with our Grp94-selective inhibitor, 4-Br-BnIm.  Our study suggests that selective inhibition of a distinct Hsp90 family member holds translational promise for ocular and other diseases associated with cell stress and protein misfolding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREMjSSm_naSNhSDZx9hyjKfW6udTcc2eY7CiRsL7ly07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzjslWisQ%253D%253D&md5=2d2b50528853d6b6d6a5704655da3c56</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-18344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-18344-4%26sid%3Dliteratum%253Aachs%26aulast%3DStothert%26aufirst%3DA.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DWebster%26aufirst%3DJ.%2BM.%26aulast%3DNordhues%26aufirst%3DB.%2BA.%26aulast%3DHuard%26aufirst%3DD.%2BJ.%2BE.%26aulast%3DPassaglia%26aufirst%3DC.%2BL.%26aulast%3DLieberman%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26aulast%3DBlair%26aufirst%3DL.%2BJ.%26aulast%3DKoren%26aufirst%3DJ.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26atitle%3DIsoform-selective%2520Hsp90%2520inhibition%2520rescues%2520model%2520of%2520hereditary%2520open-angle%2520glaucoma%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D17951%26doi%3D10.1038%2Fs41598-017-18344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Development of radamide analogs as Grp94 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4083</span>– <span class="NLM_lpage">4098</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.05.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.bmc.2014.05.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=25027801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGru7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4083-4098&issue=15&author=A.+Muthauthor=V.+Crowleyauthor=A.+Khandelwalauthor=S.+Mishraauthor=J.+Zhaoauthor=J.+Hallauthor=B.+S.+J.+Blagg&title=Development+of+radamide+analogs+as+Grp94+inhibitors&doi=10.1016%2Fj.bmc.2014.05.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Development of radamide analogs as Grp94 inhibitors</span></div><div class="casAuthors">Muth, Aaron; Crowley, Vincent; Khandelwal, Anuj; Mishra, Sanket; Zhao, Jinbo; Hall, Jessica; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4083-4098</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hsp90 isoform-selective inhibition is highly desired as it can potentially avoid the toxic side-effects of pan-inhibition.  The current study developed selective inhibitors of one such isoform, Grp94, predicated on the chimeric and pan-Hsp90 inhibitor, radamide (RDA).  Replacement of the quinone moiety of RDA with a Ph ring (2) was found to be better suited for Grp94 inhibition as it can fully interact with a unique hydrophobic pocket present in Grp94.  An extensive SAR for this scaffold showed that substitutions at the 2- and 4-positions (8 and 27, resp.) manifested excellent Grp94 affinity and selectivity.  Introduction of heteroatoms into the ring also proved beneficial, with a 2-pyridine deriv. (38) exhibiting the highest Grp94 affinity (Kd = 820 nM).  Subsequent cell-based assays showed that these Grp94 inhibitors inhibit migration of the metastatic breast cancer cell line, MDA-MB-231, as well as exhibit an anti-proliferative affect against the multiple myeloma cell line, RPMI 8226.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxdbHibsHh3rVg90H21EOLACvtfcHk0ljJLxSpJGp8Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGru7bK&md5=6025c533f1c107eb5c54a559c679c8d2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.05.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.05.075%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DCrowley%26aufirst%3DV.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DJ.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520radamide%2520analogs%2520as%2520Grp94%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26issue%3D15%26spage%3D4083%26epage%3D4098%26doi%3D10.1016%2Fj.bmc.2014.05.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzbeierlein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">425</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02013-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fs41467-017-02013-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=29382832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=425&issue=1&author=A.+Khandelwalauthor=C.+N.+Kentauthor=M.+Balchauthor=S.+Pengauthor=S.+J.+Mishraauthor=J.+Dengauthor=V.+W.+Dayauthor=W.+Liuauthor=C.+Subramanianauthor=M.+Cohenauthor=J.+M.+Holzbeierleinauthor=R.+Mattsauthor=B.+S.+J.+Blagg&title=Structure-guided+design+of+an+Hsp90%CE%B2+N-terminal+isoform-selective+inhibitor&doi=10.1038%2Fs41467-017-02013-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor</span></div><div class="casAuthors">Khandelwal Anuj; Mishra Sanket J; Kent Caitlin N; Blagg Brian S J; Balch Maurie; Peng Shuxia; Deng Junpeng; Matts Robert; Day Victor W; Liu Weiya; Holzbeierlein Jeffery M; Subramanian Chitra; Cohen Mark</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">425</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 90 kDa heat shock protein (Hsp90) is a molecular chaperone responsible for folding proteins that are directly associated with cancer progression.  Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways.  Seventeen small-molecule inhibitors of Hsp90 have entered clinical trials, all of which bind the Hsp90 N-terminus and exhibit pan-inhibitory activity against all four Hsp90 isoforms. pan-Inhibition of Hsp90 appears to be detrimental as toxicities have been reported alongside induction of the pro-survival heat shock response.  The development of Hsp90 isoform-selective inhibitors represents an alternative approach towards the treatment of cancer that may limit some of the detriments.  Described herein is a structure-based approach to design isoform-selective inhibitors of Hsp90β, which induces the degradation of select Hsp90 clients without concomitant induction of Hsp90 levels.  Together, these initial studies support the development of Hsp90β-selective inhibitors as a method to overcome the detriments associated with pan-inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmyRre9-yoQBpyrDyM_m9cfW6udTcc2eY7CiRsL7ly07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D&md5=cfa47e314c9bdbc1c38802108330cba7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02013-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02013-1%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DKent%26aufirst%3DC.%2BN.%26aulast%3DBalch%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DDay%26aufirst%3DV.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSubramanian%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DMatts%26aufirst%3DR.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DStructure-guided%2520design%2520of%2520an%2520Hsp90%25CE%25B2%2520N-terminal%2520isoform-selective%2520inhibitor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D425%26doi%3D10.1038%2Fs41467-017-02013-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitotsumachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekura, K.</span></span> <span> </span><span class="NLM_article-title">TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1158%2F1535-7163.MCT-14-0219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=25416789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=14-22&issue=1&author=S.+Ohkuboauthor=Y.+Kodamaauthor=H.+Muraokaauthor=H.+Hitotsumachiauthor=C.+Yoshimuraauthor=M.+Kitadeauthor=A.+Hashimotoauthor=K.+Itoauthor=A.+Gomoriauthor=K.+Takahashiauthor=Y.+Shibataauthor=A.+Kanohauthor=K.+Yonekura&title=TAS-116%2C+a+highly+selective+inhibitor+of+heat+shock+protein+90%CE%B1+and+%CE%B2%2C+demonstrates+potent+antitumor+activity+and+minimal+ocular+toxicity+in+preclinical+models&doi=10.1158%2F1535-7163.MCT-14-0219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span></div><div class="casAuthors">Ohkubo, Shuichi; Kodama, Yasuo; Muraoka, Hiromi; Hitotsumachi, Hiroko; Yoshimura, Chihoko; Kitade, Makoto; Hashimoto, Akihiro; Ito, Kenjiro; Gomori, Akira; Takahashi, Koichi; Shibata, Yoshihiro; Kanoh, Akira; Yonekura, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-22</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mol. chaperone HSP90 plays a crucial role in cancer cell growth and survival by stabilizing cancer-related proteins.  A no. of HSP90 inhibitors have been developed clin. for cancer therapy; however, potential off-target and/or HSP90-related toxicities have proved problematic.  The 4-(1H-pyrazolo[3,4-b]pyridine-1-yl)benzamide TAS-116 is a selective inhibitor of cytosolic HSP90α and β that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1.  Oral administration of TAS-116 led to tumor shrinkage in human tumor xenograft mouse models accompanied by depletion of multiple HSP90 clients, demonstrating that the inhibition of HSP90α and β alone was sufficient to exert antitumor activity in certain tumor models.  One of the most notable HSP90-related adverse events universally obsd. to differing degrees in the clin. setting is visual disturbance.  A two-week administration of the isoxazole resorcinol NVP-AUY922, an HSP90 inhibitor, caused marked degeneration and disarrangement of the outer nuclear layer of the retina and induced photoreceptor cell death in rats.  In contrast, TAS-116 did not produce detectable photoreceptor injury in rats, probably due to its lower distribution in retinal tissue.  Importantly, in a rat model, the antitumor activity of TAS-116 was accompanied by a higher distribution of the compd. in s.c. xenografted NCI-H1975 non-small cell lung carcinoma tumors than in retina.  Moreover, TAS-116 showed activity against orthotopically transplanted NCI-H1975 lung tumors.  Together, these data suggest that TAS-116 has a potential to maximize antitumor activity while minimizing adverse effects such as visual disturbances that are obsd. with other compds. of this class.  Mol Cancer Ther; 14(1); 14-22. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB25Txc_IcKbVg90H21EOLACvtfcHk0ljQNZCkf8SG3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D&md5=3ffdc26a7f0178d4e44413e22c003f77</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0219%26sid%3Dliteratum%253Aachs%26aulast%3DOhkubo%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DHitotsumachi%26aufirst%3DH.%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DKitade%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DGomori%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DKanoh%26aufirst%3DA.%26aulast%3DYonekura%26aufirst%3DK.%26atitle%3DTAS-116%252C%2520a%2520highly%2520selective%2520inhibitor%2520of%2520heat%2520shock%2520protein%252090%25CE%25B1%2520and%2520%25CE%25B2%252C%2520demonstrates%2520potent%2520antitumor%2520activity%2520and%2520minimal%2520ocular%2520toxicity%2520in%2520preclinical%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D1%26spage%3D14%26epage%3D22%26doi%3D10.1158%2F1535-7163.MCT-14-0219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woody, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcacio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nezami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, D.</span></span> <span> </span><span class="NLM_article-title">Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3382</span>– <span class="NLM_lpage">3400</span>, <span class="refDoi"> DOI: 10.1021/jm500042s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500042s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3382-3400&issue=8&author=J.+T.+Ernstauthor=T.+Neubertauthor=M.+Liuauthor=S.+Sperryauthor=H.+Zuccolaauthor=A.+Turnbullauthor=B.+Fleckauthor=W.+Kargoauthor=L.+Woodyauthor=P.+Chiangauthor=D.+Tranauthor=W.+Chenauthor=P.+Snyderauthor=T.+Alcacioauthor=A.+Nezamiauthor=J.+Reynoldsauthor=K.+Alviauthor=L.+Gouletauthor=D.+Stamos&title=Identification+of+novel+HSP90%CE%B1%2F%CE%B2+isoform+selective+inhibitors+using+structure-based+drug+design.+Demonstration+of+potential+utility+in+treating+CNS+disorders+such+as+Huntington%E2%80%99s+Disease&doi=10.1021%2Fjm500042s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease</span></div><div class="casAuthors">Ernst, Justin T.; Neubert, Timothy; Liu, Michael; Sperry, Samuel; Zuccola, Harmon; Turnbull, Amy; Fleck, Beth; Kargo, William; Woody, Lisa; Chiang, Peggy; Tran, Dao; Chen, Weichao; Snyder, Phillip; Alcacio, Timothy; Nezami, Azin; Reynolds, James; Alvi, Khisal; Goulet, Lance; Stamos, Dean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3382-3400</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based drug design strategy was used to optimize a novel benzolactam series of HSP90α/β inhibitors to achieve >1000-fold selectivity vs. the HSP90 endoplasmic reticulum and mitochondrial isoforms (GRP94 and TRAP1, resp.).  Selective HSP90α/β inhibitors were found to be equipotent to pan-HSP90 inhibitors in promoting the clearance of mutant huntington protein (mHtt) in vitro, however with less cellular toxicity.  Improved tolerability profiles may enable the use of HSP90α/β selective inhibitors in treating chronic neurodegenerative indications such as Huntington's disease (HD).  A potent, selective, orally available HSP90α/β inhibitor, 8-Cyclopentyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one, was identified that crosses the blood-brain barrier and demonstrated proof of concept by successfully reducing brain Htt levels following oral dosing in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKpHcuphxPXbVg90H21EOLACvtfcHk0ljQNZCkf8SG3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGlsLY%253D&md5=0d55fb738fc0f0615b5336b8dc17056a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm500042s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500042s%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DNeubert%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DZuccola%26aufirst%3DH.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DFleck%26aufirst%3DB.%26aulast%3DKargo%26aufirst%3DW.%26aulast%3DWoody%26aufirst%3DL.%26aulast%3DChiang%26aufirst%3DP.%26aulast%3DTran%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSnyder%26aufirst%3DP.%26aulast%3DAlcacio%26aufirst%3DT.%26aulast%3DNezami%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DJ.%26aulast%3DAlvi%26aufirst%3DK.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DStamos%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520novel%2520HSP90%25CE%25B1%252F%25CE%25B2%2520isoform%2520selective%2520inhibitors%2520using%2520structure-based%2520drug%2520design.%2520Demonstration%2520of%2520potential%2520utility%2520in%2520treating%2520CNS%2520disorders%2520such%2520as%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D8%26spage%3D3382%26epage%3D3400%26doi%3D10.1021%2Fjm500042s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vought, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, D.</span></span> <span> </span><span class="NLM_article-title">Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity—Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.bmcl.2013.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=24332488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOlt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=204-208&issue=1&author=J.+T.+Ernstauthor=M.+Liuauthor=H.+Zuccolaauthor=T.+Neubertauthor=K.+Beaumontauthor=A.+Turnbullauthor=A.+Kallelauthor=B.+Voughtauthor=D.+Stamos&title=Correlation+between+chemotype-dependent+binding+conformations+of+HSP90%CE%B1%2F%CE%B2+and+isoform+selectivity%E2%80%94Implications+for+the+structure-based+design+of+HSP90%CE%B1%2F%CE%B2+selective+inhibitors+for+treating+neurodegenerative+diseases&doi=10.1016%2Fj.bmcl.2013.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases</span></div><div class="casAuthors">Ernst, Justin T.; Liu, Michael; Zuccola, Harmon; Neubert, Timothy; Beaumont, Kevin; Turnbull, Amy; Kallel, Adam; Vought, Bryan; Stamos, Dean</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">204-208</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HSP90 continues to be a target of interest for neurodegeneration indications.  Selective knockdown of the HSP90 cytosolic isoforms α and β is sufficient to reduce mutant huntingtin protein levels in vitro.  Chemotype-dependent binding conformations of HSP90α/β appear to strongly influence isoform selectivity.  The rational design of HSP90α/β inhibitors selective vs. the mitochondrial (TRAP1) and endoplasmic reticulum (GRP94) isoforms offers a potential mitigating strategy for mechanism-based toxicities.  Better tolerated HSP90 inhibitors would be attractive for targeting chronic neurodegenerative diseases such as Huntington's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq64ZOr5JsRerVg90H21EOLACvtfcHk0liQcSZmz2pEQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOlt7jO&md5=6799a46090ee297d70700f7c42b79f80</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZuccola%26aufirst%3DH.%26aulast%3DNeubert%26aufirst%3DT.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DKallel%26aufirst%3DA.%26aulast%3DVought%26aufirst%3DB.%26aulast%3DStamos%26aufirst%3DD.%26atitle%3DCorrelation%2520between%2520chemotype-dependent%2520binding%2520conformations%2520of%2520HSP90%25CE%25B1%252F%25CE%25B2%2520and%2520isoform%2520selectivity%25E2%2580%2594Implications%2520for%2520the%2520structure-based%2520design%2520of%2520HSP90%25CE%25B1%252F%25CE%25B2%2520selective%2520inhibitors%2520for%2520treating%2520neurodegenerative%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D204%26epage%3D208%26doi%3D10.1016%2Fj.bmcl.2013.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angove, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewartha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5956</span>– <span class="NLM_lpage">5969</span>, <span class="refDoi"> DOI: 10.1021/jm100060b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100060b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5956-5969&author=A.+J.+Woodheadauthor=H.+Angoveauthor=M.+G.+Carrauthor=G.+Chessariauthor=M.+Congreveauthor=J.+E.+Coyleauthor=J.+Cosmeauthor=B.+Grahamauthor=P.+J.+Dayauthor=R.+Downhamauthor=L.+Fazalauthor=R.+Feltellauthor=E.+Figueroaauthor=M.+Fredericksonauthor=J.+Lewisauthor=R.+McMenaminauthor=C.+W.+Murrayauthor=M.+A.+O%E2%80%99Brienauthor=L.+Parraauthor=S.+Patelauthor=T.+Phillipsauthor=D.+C.+Reesauthor=S.+Richauthor=D.+M.+Smithauthor=G.+Trewarthaauthor=M.+Vinkovicauthor=B.+Williamsauthor=A.+J.+Woolford&title=Discovery+of+%282%2C4-dihydroxy-5-isopropylphenyl%29-%5B5-%284-methylpiperazin-1-ylmethyl%29-1%2C3-dihydrois+oindol-2-yl%5Dmethanone+%28AT13387%29%2C+a+novel+inhibitor+of+the+molecular+chaperone+Hsp90+by+fragment+based+drug+design&doi=10.1021%2Fjm100060b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design</span></div><div class="casAuthors">Woodhead, Andrew J.; Angove, Hayley; Carr, Maria G.; Chessari, Gianni; Congreve, Miles; Coyle, Joseph E.; Cosme, Jose; Graham, Brent; Day, Philip J.; Downham, Robert; Fazal, Lynsey; Feltell, Ruth; Figueroa, Eva; Frederickson, Martyn; Lewis, Jonathan; McMenamin, Rachel; Murray, Christopher W.; O'Brien, M. Alistair; Parra, Lina; Patel, Sahil; Phillips, Theresa; Rees, David C.; Rich, Sharna; Smith, Donna-Michelle; Trewartha, Gary; Vinkovic, Mladen; Williams, Brian; Woolford, Alison J.-A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5956-5969</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the mol. chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clin. development as potential treatments for cancer.  In a preceding publication (DOI: 10.1021/jm100059d) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range.  This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead mol. 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclin. development and is currently being tested in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEEtcgAmkVk7Vg90H21EOLACvtfcHk0liQcSZmz2pEQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D&md5=a2d2ac6dd9e9ba4cb89f83c32727a1d8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm100060b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100060b%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DParra%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520%25282%252C4-dihydroxy-5-isopropylphenyl%2529-%255B5-%25284-methylpiperazin-1-ylmethyl%2529-1%252C3-dihydrois%2520oindol-2-yl%255Dmethanone%2520%2528AT13387%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%2520by%2520fragment%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5956%26epage%3D5969%26doi%3D10.1021%2Fjm100060b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speranza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polley, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinders, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antony, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span> <span> </span><span class="NLM_article-title">Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0255-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1007%2Fs10637-015-0255-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=26082332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVektLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=921-930&issue=4&author=K.+Doauthor=G.+Speranzaauthor=L.-C.+Changauthor=E.+C.+Polleyauthor=R.+Bishopauthor=W.+Zhuauthor=J.+B.+Trepelauthor=S.+Leeauthor=M.-J.+Leeauthor=R.+J.+Kindersauthor=L.+Phillipsauthor=J.+Collinsauthor=J.+Lyonsauthor=W.+Jeongauthor=R.+Antonyauthor=A.+P.+Chenauthor=L.+Neckersauthor=J.+H.+Doroshowauthor=S.+Kummar&title=Phase+I+study+of+the+heat+shock+protein+90+%28Hsp90%29+inhibitor+onalespib+%28AT13387%29+administered+on+a+daily+for+2+consecutive+days+per+week+dosing+schedule+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-015-0255-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Do, Khanh; Speranza, Giovanna; Chang, Lun-Ching; Polley, Eric C.; Bishop, Rachel; Zhu, Weimin; Trepel, Jane B.; Lee, Sunmin; Lee, Min-Jung; Kinders, Robert J.; Phillips, Larry; Collins, Jerry; Lyons, John; Jeong, Woondong; Antony, Ramya; Chen, Alice P.; Neckers, Len; Doroshow, James H.; Kummar, Shivaani</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">921-930</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Inhibition of heat shock 90 (Hsp90) mol. chaperones allows targeting of multiple proteins involved in tumorigenesis.  We investigated the safety, recommended phase 2 dose (RP2D), and pharmacokinetic and pharmacodynamic profile of onalespib (AT13387), a potent synthetic Hsp90 inhibitor, administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/wk) in a phase I trial.  This study followed an accelerated titrn. design with a starting dose of 20 mg/m2/dose and a std. 3 + 3 dose escalation design for dose level 4 (120 mg/m2/dose) and above.  Addnl. patients were enrolled at the RP2D with mandatory paired tumor biopsies to assess modulation of 210 client proteins using reverse phase protein array anal.  Thirty-one patients were treated; RP2D was established at 160 mg/m2/dose on the QDx2/wk schedule.  Common toxicities were gastrointestinal, hepatic, and hematol.  Pharmacokinetic profile was linear and plasma levels increased proportionally with dose (T1/2 ∼8 h).  No responses were obsd.; eight patients had stable disease for > 2 cycles with one patient remaining on study for 6 cycles.  Target engagement was demonstrated by transcriptional upregulation of Hsp70 and Hsp27 in PBMCs.  Statistically significant modulation of client proteins was not achieved in the 9 paired tumor biopsies evaluated; however, hierarchical clustering revealed two subgroups of patients with differential patterns of protein expression.  Further combination studies are needed in order to target prospective driver oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCXt8s5_XMBLVg90H21EOLACvtfcHk0ljjp9mkwa-DMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVektLfJ&md5=624adbaad8dad65d69ea9318a96e984e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0255-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0255-1%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DK.%26aulast%3DSperanza%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DL.-C.%26aulast%3DPolley%26aufirst%3DE.%2BC.%26aulast%3DBishop%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.-J.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DPhillips%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DJeong%26aufirst%3DW.%26aulast%3DAntony%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%2BP.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DKummar%26aufirst%3DS.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitor%2520onalespib%2520%2528AT13387%2529%2520administered%2520on%2520a%2520daily%2520for%25202%2520consecutive%2520days%2520per%2520week%2520dosing%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26issue%3D4%26spage%3D921%26epage%3D930%26doi%3D10.1007%2Fs10637-015-0255-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agulnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedel, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oganesian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keer, H.</span></span> <span> </span><span class="NLM_article-title">Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2016.03.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.ejca.2016.03.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=27156227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslKqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=94-101&author=A.+J.+Wagnerauthor=M.+Agulnikauthor=M.+C.+Heinrichauthor=D.+Mahadevanauthor=R.+F.+Riedelauthor=M.+von+Mehrenauthor=J.+Trentauthor=G.+D.+Demetriauthor=C.+L.+Corlessauthor=M.+Yuleauthor=J.+F.+Lyonsauthor=A.+Oganesianauthor=H.+Keer&title=Dose-escalation+study+of+a+second-generation+non-ansamycin+HSP90+inhibitor%2C+onalespib+%28AT13387%29%2C+in+combination+with+imatinib+in+patients+with+metastatic+gastrointestinal+stromal+tumour&doi=10.1016%2Fj.ejca.2016.03.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour</span></div><div class="casAuthors">Wagner, Andrew J.; Agulnik, Mark; Heinrich, Michael C.; Mahadevan, Daruka; Riedel, Richard F.; von Mehren, Margaret; Trent, Jonathan; Demetri, George D.; Corless, Christopher L.; Yule, Murray; Lyons, John F.; Oganesian, Aram; Keer, Harold</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94-101</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) treated with the tyrosine kinase inhibitor (TKI) imatinib can become resistant when addnl. mutations in the receptor tyrosine kinases KIT or PDGFRA block imatinib activity.  Mutated KIT requires the mol. chaperone heat-shock protein 90 (HSP90) to maintain stability and activity.  Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor.  We hypothesised that the combination of onalespib and imatinib may be safe and effective in managing TKI-resistant GIST.In this dose-escalation study, we evaluated the safety and efficacy of combination once-weekly i.v. onalespib for 3 wk and daily oral imatinib in 28-d cycles.  Twenty-six patients with TKI-resistant GIST were enrolled into four sequential dose cohorts of onalespib (dose range, 150-220 mg/m2) and imatinib 400 mg.  The relationship between tumor mutational status (KIT/PDGFRA) and efficacy of treatment was explored.Common onalespib-related adverse events were diarrhea (58%), nausea (50%), injection site events (46%), vomiting (39%), fatigue (27%), and muscle spasms (23%).  Overall, 81% of patients reported more than one onalespib-related gastrointestinal disorder.  Nine patients (35%) had a best response of stable disease, including two patients who had KIT mutations known to be assocd. with resistance to imatinib and sunitinib.  Disease control at 4 mo was achieved in five patients (19%), and median progression-free survival was 112 d (95% confidence interval 43-165).  One patient with PDGFRA-mutant GIST had a partial response for more than 376 d.The combination of onalespib plus imatinib was well tolerated but exhibited limited antitumor activity as dosed in this TKI-resistant GIST patient population.Trial registration ID: clinicaltrials.gov: NCT01294202.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0EPUydR0h8bVg90H21EOLACvtfcHk0ljjp9mkwa-DMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslKqs7s%253D&md5=53b38c85eb3a83c174f28347d985ecf9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2016.03.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2016.03.076%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DAgulnik%26aufirst%3DM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DRiedel%26aufirst%3DR.%2BF.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DTrent%26aufirst%3DJ.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DOganesian%26aufirst%3DA.%26aulast%3DKeer%26aufirst%3DH.%26atitle%3DDose-escalation%2520study%2520of%2520a%2520second-generation%2520non-ansamycin%2520HSP90%2520inhibitor%252C%2520onalespib%2520%2528AT13387%2529%252C%2520in%2520combination%2520with%2520imatinib%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumour%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D61%26spage%3D94%26epage%3D101%26doi%3D10.1016%2Fj.ejca.2016.03.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welker, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesanakurti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulman, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurcan, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puduvalli, V. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy of onalespib, a long-acting second-generation HSP90 inhibitor, as a single agent and in combination with temozolomide against malignant gliomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6215</span>– <span class="NLM_lpage">6226</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-3151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1158%2F1078-0432.CCR-16-3151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=28679777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6215-6226&issue=20&author=A.+Canellaauthor=A.+M.+Welkerauthor=J.+Y.+Yooauthor=J.+Xuauthor=F.+S.+Abasauthor=D.+Kesanakurtiauthor=P.+Nagarajanauthor=C.+E.+Beattieauthor=E.+P.+Sulmanauthor=J.+Liuauthor=J.+Guminauthor=F.+F.+Langauthor=M.+N.+Gurcanauthor=B.+Kaurauthor=D.+Sampathauthor=V.+K.+Puduvalli&title=Efficacy+of+onalespib%2C+a+long-acting+second-generation+HSP90+inhibitor%2C+as+a+single+agent+and+in+combination+with+temozolomide+against+malignant+gliomas&doi=10.1158%2F1078-0432.CCR-16-3151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas</span></div><div class="casAuthors">Canella, Alessandro; Welker, Alessandra M.; Yoo, Ji Young; Xu, Jihong; Abas, Fazly S.; Kesanakurti, Divya; Nagarajan, Prabakaran; Beattie, Christine E.; Sulman, Erik P.; Liu, Joseph; Gumin, Joy; Lang, Frederick F.; Gurcan, Metin N.; Kaur, Balveen; Sampath, Deepa; Puduvalli, Vinay K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6215-6226</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: HSP90, a highly conserved mol. chaperone that regulates the function of several oncogenic client proteins, is altered in glioblastoma.  However, HSP90 inhibitors currently in clin. trials are short-acting, have unacceptable toxicities, or are unable to cross the blood-brain barrier (BBB).  We examd. the efficacy of onalespib, a potent, long-acting novel HSP90 inhibitor as a single agent and in combination with temozolomide (TMZ) against gliomas in vitro and in vivo.  Exptl. Design: The effect of onalespib on HSP90, its client proteins, and on the biol. of glioma cell lines and patient-derived glioma-initiating cells (GSC) was detd.  Brain and plasma pharmacokinetics of onalespib and its ability to inhibit HSP90 in vivo were assessed in non-tumor-bearing mice.  Its efficacy as a single agent or in combination with TMZ was assessed in vitro and in vivo using zebrafish and patient-derived GSC xenograft mouse glioma models.  Results: Onalespib-mediated HSP90 inhibition depleted several survival-promoting client proteins such as EGFR, EGFRvIII, and AKT, disrupted their downstream signaling, and decreased the proliferation, migration, angiogenesis, and survival of glioma cell lines and GSCs.  Onalespib effectively crossed the BBB to inhibit HSP90 in vivo and extended survival as a single agent in zebrafish xenografts and in combination with TMZ in both zebrafish and GSC mouse xenografts.  Conclusions: Our results demonstrate the long-acting effects of onalespib against gliomas in vitro and in vivo, which combined with its ability to cross the BBB support its development as a potential therapeutic agent in combination with TMZ against gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqiyFYlY0U3bVg90H21EOLACvtfcHk0liYcZTldw9Mhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrfO&md5=ad3c936d44737c257889bbd4602c4dc3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-3151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-3151%26sid%3Dliteratum%253Aachs%26aulast%3DCanella%26aufirst%3DA.%26aulast%3DWelker%26aufirst%3DA.%2BM.%26aulast%3DYoo%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DAbas%26aufirst%3DF.%2BS.%26aulast%3DKesanakurti%26aufirst%3DD.%26aulast%3DNagarajan%26aufirst%3DP.%26aulast%3DBeattie%26aufirst%3DC.%2BE.%26aulast%3DSulman%26aufirst%3DE.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGumin%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DF.%2BF.%26aulast%3DGurcan%26aufirst%3DM.%2BN.%26aulast%3DKaur%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DPuduvalli%26aufirst%3DV.%2BK.%26atitle%3DEfficacy%2520of%2520onalespib%252C%2520a%2520long-acting%2520second-generation%2520HSP90%2520inhibitor%252C%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520with%2520temozolomide%2520against%2520malignant%2520gliomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D20%26spage%3D6215%26epage%3D6226%26doi%3D10.1158%2F1078-0432.CCR-16-3151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stühmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zöllinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knop, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortüm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzicker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chène, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Echeverría, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wajant, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargou, R. C.</span></span> <span> </span><span class="NLM_article-title">Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1604</span>– <span class="NLM_lpage">1612</span>, <span class="refDoi"> DOI: 10.1038/leu.2008.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fleu.2008.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=18480838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslSntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=1604-1612&author=T.+St%C3%BChmerauthor=A.+Z%C3%B6llingerauthor=D.+Siegmundauthor=M.+Chatterjeeauthor=E.+Grellaauthor=S.+Knopauthor=M.+Kort%C3%BCmauthor=C.+Unzickerauthor=M.+R.+Jensenauthor=C.+Quadtauthor=P.+Ch%C3%A8neauthor=J.+Schoepferauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=H.+Einseleauthor=H.+Wajantauthor=R.+C.+Bargou&title=Signalling+profile+and+antitumour+activity+of+the+novel+Hsp90+inhibitor+NVP-AUY922+in+multiple+myeloma&doi=10.1038%2Fleu.2008.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma</span></div><div class="casAuthors">Stuehmer, T.; Zoellinger, A.; Siegmund, D.; Chatterjee, M.; Grella, E.; Knop, S.; Kortuem, M.; Unzicker, C.; Jensen, M. R.; Quadt, C.; Chene, P.; Schoepfer, J.; Garcia-Echeverria, C.; Einsele, H.; Wajant, H.; Bargou, R. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1604-1612</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We as well as others have recently shown that Hsp90 is overexpressed in multiple myeloma (MM) and critically contributes to tumor cell survival.  Pharmacol. blockade of Hsp90 has consistently been found to induce MM cell death.  However, most data have been obtained with MM cell lines whereas knowledge about the mol. effects of pharmacol. Hsp90 blockade in primary tumor cells is limited.  Furthermore, these investigations have so far focused on geldanamycin derivs.  We analyzed the biochem. effects of a novel diarylisoxazole-based Hsp90 inhibitor (NVP-AUY922) on signalling pathways and cell death in a large set of primary MM tumor samples and in MM cell lines.  Treated cells displayed the mol. signature and pharmacodynamic properties for abrogation of Hsp90 function, such as downregulation of multiple survival pathways and strong upregulation of Hsp70.  NVP-AUY922 treatment efficiently induced MM cell apoptosis and revealed both sensitive and resistant subgroups.  Sensitivity was not correlated with TP53 mutation or Hsp70 induction levels and stromal cells from the bone marrow microenvironment were unable to abrogate NVP-AUY922-induced apoptosis of MM cells.  Thus, NVP-AUY922 may be a promising drug for treatment of MM and clin. studies are warranted.  Leukemia (2008) 22, 1604-1612; doi:10.1038/leu.2008.111; published online 15 May 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY5_BOjQZtgLVg90H21EOLACvtfcHk0liYcZTldw9Mhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslSntL8%253D&md5=5a83e6c4e8d05b3ad9fddd3b0d55a63f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.111%26sid%3Dliteratum%253Aachs%26aulast%3DSt%25C3%25BChmer%26aufirst%3DT.%26aulast%3DZ%25C3%25B6llinger%26aufirst%3DA.%26aulast%3DSiegmund%26aufirst%3DD.%26aulast%3DChatterjee%26aufirst%3DM.%26aulast%3DGrella%26aufirst%3DE.%26aulast%3DKnop%26aufirst%3DS.%26aulast%3DKort%25C3%25BCm%26aufirst%3DM.%26aulast%3DUnzicker%26aufirst%3DC.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DWajant%26aufirst%3DH.%26aulast%3DBargou%26aufirst%3DR.%2BC.%26atitle%3DSignalling%2520profile%2520and%2520antitumour%2520activity%2520of%2520the%2520novel%2520Hsp90%2520inhibitor%2520NVP-AUY922%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D1604%26epage%3D1612%26doi%3D10.1038%2Fleu.2008.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radimerski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chène, P.</span></span> <span> </span><span class="NLM_article-title">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">R33</span>, <span class="refDoi"> DOI: 10.1186/bcr1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1186%2Fbcr1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=18430202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=R33&issue=2&author=M.+R.+Jensenauthor=J.+Schoepferauthor=T.+Radimerskiauthor=A.+Masseyauthor=C.+T.+Guyauthor=J.+Brueggenauthor=C.+Quadtauthor=A.+Bucklerauthor=R.+Cozensauthor=M.+J.+Drysdaleauthor=C.+Garcia-Echeverriaauthor=P.+Ch%C3%A8ne&title=NVP-AUY922%3A+a+small+molecule+HSP90+inhibitor+with+potent+antitumor+activity+in+preclinical+breast+cancer+models&doi=10.1186%2Fbcr1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span></div><div class="casAuthors">Jensen Michael Rugaard; Schoepfer Joseph; Radimerski Thomas; Massey Andrew; Guy Chantale T; Brueggen Josef; Quadt Cornelia; Buckler Alan; Cozens Robert; Drysdale Martin J; Garcia-Echeverria Carlos; Chene Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">R33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Heat shock protein 90 (HSP90) is a key component of a multichaperone complex involved in the post-translational folding of a large number of client proteins, many of which play essential roles in tumorigenesis.  HSP90 has emerged in recent years as a promising new target for anticancer therapies.  METHODS:  The concentrations of the HSP90 inhibitor NVP-AUY922 required to reduce cell numbers by 50% (GI50 values) were established in a panel of breast cancer cell lines and patient-derived human breast tumors.  To investigate the properties of the compound in vivo, the pharmacokinetic profile, antitumor effect, and dose regimen were established in a BT-474 breast cancer xenograft model.  The effect on HSP90-p23 complexes, client protein degradation, and heat shock response was investigated in cell culture and breast cancer xenografts by immunohistochemistry, Western blot analysis, and immunoprecipitation.  RESULTS:  We show that the novel small molecule HSP90 inhibitor NVP-AUY922 potently inhibits the proliferation of human breast cancer cell lines with GI50 values in the range of 3 to 126 nM.  NVP-AUY922 induced proliferative inhibition concurrent with HSP70 upregulation and client protein depletion--hallmarks of HSP90 inhibition.  Intravenous acute administration of NVP-AUY922 to athymic mice (30 mg/kg) bearing subcutaneous BT-474 breast tumors resulted in drug levels in excess of 1,000 times the cellular GI50 value for about 2 days.  Significant growth inhibition and good tolerability were observed when the compound was administered once per week.  Therapeutic effects were concordant with changes in pharmacodynamic markers, including HSP90-p23 dissociation, decreases in ERBB2 and P-AKT, and increased HSP70 protein levels.  CONCLUSION:  NVP-AUY922 is a potent small molecule HSP90 inhibitor showing significant activity against breast cancer cells in cellular and in vivo settings.  On the basis of its mechanism of action, preclinical activity profile, tolerability, and pharmaceutical properties, the compound recently has entered clinical phase I breast cancer trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRY3cZ5prrYd1QT_1O5WBYfW6udTcc2ebh3pjxy04ZHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D&md5=2779e042ee1da49407fc813cca82305e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2Fbcr1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr1996%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DGuy%26aufirst%3DC.%2BT.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBuckler%26aufirst%3DA.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26atitle%3DNVP-AUY922%253A%2520a%2520small%2520molecule%2520HSP90%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520breast%2520cancer%2520models%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2008%26volume%3D10%26issue%3D2%26spage%3DR33%26doi%3D10.1186%2Fbcr1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onozawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuse, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, A.</span></span> <span> </span><span class="NLM_article-title">Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1007/s00280-014-2521-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1007%2Fs00280-014-2521-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=25059319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=629-636&issue=3&author=T.+Doiauthor=Y.+Onozawaauthor=N.+Fuseauthor=T.+Yoshinoauthor=K.+Yamazakiauthor=J.+Watanabeauthor=M.+Akimovauthor=M.+Robsonauthor=N.+Bokuauthor=A.+Ohtsu&title=Phase+I+dose-escalation+study+of+the+HSP90+inhibitor+AUY922+in+Japanese+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-014-2521-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span></div><div class="casAuthors">Doi, Toshihiko; Onozawa, Yusuke; Fuse, Nozomu; Yoshino, Takayuki; Yamazaki, Kentaro; Watanabe, Junichiro; Akimov, Mikhail; Robson, Matthew; Boku, Narikazu; Ohtsu, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-636</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: AUY922 is a potent non-geldanamycin inhibitor of heat-shock protein 90.  This study was carried out in Japanese patients to det. the max. tolerated dose (MTD), and to characterize safety, tolerability and pharmacokinetics of single-agent AUY922.  Methods: Japanese patients with advanced solid tumors whose disease had progressed on at least one line of std. therapy, or for whom no std. therapy existed, were treated with AUY922 (i.v., once-weekly, 28-day cycle, starting dose 8 mg/m2).  Results: Thirty-one patients were treated.  Two DLTs were reported in one patient of the 54 mg/m2 cohort; fatigue and decreased appetite (both Grade 3, resolving to Grade 1 within 8 days).  No MTD was detd., and the dose recommended for Phase II studies was detd. to be 70 mg/m2 once-weekly.  Most common drug-related toxicities were diarrhea, night blindness and nausea.  Grade 1 and 2 visual toxicities at high AUY922 doses ≥22 mg/m2 were obsd.  Ten patients (32 %) achieved a best overall response of stable disease, and one patient (3 %) achieved a confirmed partial response.  Conclusion: Overall, AUY922 exhibited acceptable toxicities and demonstrated potential clin. activity in Japanese patients, with similar safety and pharmacokinetic profiles to those reported in a preceding global Phase I study in Western patients (CAUY922A2101).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpBWf7yeQ6rVg90H21EOLACvtfcHk0lgaGW089BfKFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI&md5=b45329cadb86c932a68ced6951b796db</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs00280-014-2521-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-014-2521-x%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DOnozawa%26aufirst%3DY.%26aulast%3DFuse%26aufirst%3DN.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DBoku%26aufirst%3DN.%26aulast%3DOhtsu%26aufirst%3DA.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520AUY922%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2014%26volume%3D74%26issue%3D3%26spage%3D629%26epage%3D636%26doi%3D10.1007%2Fs00280-014-2521-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargou, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alegre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bladé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ibarra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. P.</span></span> <span> </span><span class="NLM_article-title">Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2192</span>, <span class="refDoi"> DOI: 10.1002/cncr.29339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1002%2Fcncr.29339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=25809731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKntL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=2185-2192&issue=13&author=R.+Seggewiss-Bernhardtauthor=R.+C.+Bargouauthor=Y.+T.+Gohauthor=A.+K.+Stewartauthor=A.+Spencerauthor=A.+Alegreauthor=J.+Blad%C3%A9author=O.+G.+Ottmannauthor=C.+Fernandez-Ibarraauthor=H.+Luauthor=S.+Painauthor=M.+Akimovauthor=S.+P.+Iyer&title=Phase+1%2F1B+trial+of+the+heat+shock+protein+90+inhibitor+NVP-AUY922+as+monotherapy+or+in+combination+with+bortezomib+in+patients+with+relapsed+or+refractory+multiple+myeloma&doi=10.1002%2Fcncr.29339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma</span></div><div class="casAuthors">Seggewiss-Bernhardt, Ruth; Bargou, Ralf C.; Goh, Yeow Tee; Stewart, A. Keith; Spencer, Andrew; Alegre, Adrian; Blade, Joan; Ottmann, Oliver G.; Fernandez-Ibarra, Cristina; Lu, Hong; Pain, Scott; Akimov, Mikhail; Iyer, Swaminathan Padmanabhan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2185-2192</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : NVP-AUY922 (AUY; Luminespib) with or without bortezomib showed preclin. activity against multiple myeloma (MM) cells.  This phase 1/1B study assessed NVP-AUY922 alone and with bortezomib in patients with relapsed or refractory MM.  METHODS : Dose escalation was guided by an adaptive Bayesian logistic regression model.  In phase 1, patients who progressed after 2 to 4 prior therapies received NVP-AUY922 i.v. once weekly.  In phase 1B, patients who progressed after 2 or fewer prior therapies received NVP-AUY922 plus bortezomib.  The primary objective was to det. the max. tolerated dose (MTD) of NVP-AUY922.  RESULTS : Twenty-four patients received NVP-AUY922 monotherapy at doses of 8 to 70 mg/m2.  One dose-limiting toxicity (DLT) was obsd. (grade 3 blurred vision at 70 mg/m2); no MTD was reached.  The recommended phase 2 dose was 70 mg/m2.  The most frequent drug-related adverse events (AEs) were diarrhea, nausea, and ocular toxicities.  Grade 3/4 AEs were uncommon (<10%).  Eight patients discontinued treatment because of AEs; 5 had ocular toxicities (≥45 mg/m2).  The best response was stable disease in 66.7% of the patients.  There were no partial or complete responses.  Five patients received NVP-AUY922 (which was started at 50 mg/m2) plus bortezomib (1.3 mg/m2).  Three of these patients experienced DLT.  No further dose escalation was performed; the MTD for NVP-AUY922 plus bortezomib was not established.  CONCLUSIONS : This study showed disease stabilization with NVP-AUY922 in patients with relapsed or refractory MM.  The MTD for NVP-AUY922 was not reached, but reversible ocular toxicity has been reported at high dose levels.  Bortezomib at the std. recommended dose plus NVP-AUY922 was not tolerated.  Cancer 2015;121:2185-2192. © 2015 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV8J1qkTHQbbVg90H21EOLACvtfcHk0lgaGW089BfKFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKntL3L&md5=5ecc6c0563033e7449a8bda4490354ce</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29339%26sid%3Dliteratum%253Aachs%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DBargou%26aufirst%3DR.%2BC.%26aulast%3DGoh%26aufirst%3DY.%2BT.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DSpencer%26aufirst%3DA.%26aulast%3DAlegre%26aufirst%3DA.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DFernandez-Ibarra%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPain%26aufirst%3DS.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26atitle%3DPhase%25201%252F1B%2520trial%2520of%2520the%2520heat%2520shock%2520protein%252090%2520inhibitor%2520NVP-AUY922%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520bortezomib%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26issue%3D13%26spage%3D2185%26epage%3D2192%26doi%3D10.1002%2Fcncr.29339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renouf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzyzanowska, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmuck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. J.</span></span> <span> </span><span class="NLM_article-title">A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1007/s00280-016-3102-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1007%2Fs00280-016-3102-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=27422303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ejtLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2016&pages=541-545&issue=3&author=D.+J.+Renoufauthor=D.+Hedleyauthor=M.+K.+Krzyzanowskaauthor=M.+Schmuckauthor=L.+Wangauthor=M.+J.+Moore&title=A+phase+II+study+of+the+HSP90+inhibitor+AUY922+in+chemotherapy+refractory+advanced+pancreatic+cancer&doi=10.1007%2Fs00280-016-3102-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer</span></div><div class="casAuthors">Renouf, D. J.; Hedley, D.; Krzyzanowska, M. K.; Schmuck, M.; Wang, L.; Moore, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">541-545</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Objectives: AUY922 is a novel heat shock protein inhibitor with preclin. activity in pancreatic cancer.  This phase II study evaluated the efficacy of AUY922 in patients with advanced pancreatic cancer previously treated with chemotherapy.  Methods: In this single-arm, Simon two-stage phase II trial, patients with metastatic or locally advanced pancreatic ductal adenocarcinoma who had progressed on at least one line of chemotherapy and were of good performances status (ECOG 0 or 1) were treated with AUY922 at a dose of 70 mg/m2 IV weekly.  The primary endpoint was disease control rate (objective response and stable disease ≥16 wk).  Results: Twelve patients were accrued, all of whom received treatment.  At least possibly related ≥grade 3 adverse events included fatigue (8 %) and AST elevation (8 %).  Ten patients were evaluable for response with 1 (10 %) having stable disease and 9 (90 %) progressive disease.  The median progression-free survival was 1.6 mo, and the median overall survival was 2.9 mo.  Conclusions: AUY922 was not assocd. with significant efficacy in previously treated patients with advanced pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCYdfJvebVGLVg90H21EOLACvtfcHk0lghW13_m79tiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ejtLrJ&md5=e34132dfb40cc97ab41c169c59612e8a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3102-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3102-y%26sid%3Dliteratum%253Aachs%26aulast%3DRenouf%26aufirst%3DD.%2BJ.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DKrzyzanowska%26aufirst%3DM.%2BK.%26aulast%3DSchmuck%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DM.%2BJ.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520AUY922%2520in%2520chemotherapy%2520refractory%2520advanced%2520pancreatic%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D78%26issue%3D3%26spage%3D541%26epage%3D545%26doi%3D10.1007%2Fs00280-016-3102-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earwood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors</span>. <i>Cancer Invest.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1080/07357907.2016.1193746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1080%2F07357907.2016.1193746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=27379708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCrsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=265-270&issue=6&author=J.+C.+Bendellauthor=T.+M.+Bauerauthor=R.+Lamarauthor=M.+Josephauthor=W.+Penleyauthor=D.+S.+Thompsonauthor=D.+R.+Spigelauthor=R.+Oweraauthor=C.+M.+Laneauthor=C.+Earwoodauthor=H.+A.+Burris&title=A+phase+2+study+of+the+Hsp90+inhibitor+AUY922+as+treatment+for+patients+with+refractory+gastrointestinal+stromal+tumors&doi=10.1080%2F07357907.2016.1193746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Bendell, Johanna C.; Bauer, Todd M.; Lamar, Ruth; Joseph, Mathew; Penley, William; Thompson, Dana S.; Spigel, David R.; Owera, Rami; Lane, Cassie M.; Earwood, Chris; Burris, Howard A., III</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Investigation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">265-270</span>CODEN:
                <span class="NLM_cas:coden">CINVD7</span>;
        ISSN:<span class="NLM_cas:issn">0735-7907</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Background: AUY922 is an inhibitor of heat shock protein 90 (Hsp90).  Hsp90 inhibitors induce kit degrdn. in preclin. gastrointestinal stromal tumor (GIST) models.  This trial was designed to det. the progression-free survival (PFS) of patients with GIST refractory to or intolerant of imatinib and sunitinib.  Methods: Eligible patients received AUY922 70 mg/mg2 by i.v. (IV) infusion on days 1, 8, and 15 of 21-day cycles.  Treatment continued until progression or unacceptable toxicity.  Results: Between Dec. 2011 and Jan. 2015, 25 patients were enrolled (median age, 63 years; 56% male) and received a median of 2 cycles (range: 1-12) of AUY922 treatment.  Thirty-four patients were planned, but enrollment was stopped early due to slow accrual.  Median PFS was 3.9 mo (95% CI: 2.5, 5.3) and median OS was 8.5 mo (95% CI: 5.2, 16.7).  Radiog. response was evaluated in 21 patients; one patient achieved PR (4%) with another 15 having best response of stable disease (60%).  The most common treatment-related adverse event was diarrhea (60% all grades).  Reversible ocular toxicities that resulted in drug hold (24%) or redn. (8%) were also obsd.  Conclusion: AUY922 produced a median PFS which compares favorably to historical controls of placebo (6 wk) for patients refractory to treatment with imatinib.  While diarrhea and ocular toxicities were common, the majority of patients received treatment until disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmYmW82WPEprVg90H21EOLACvtfcHk0lghW13_m79tiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCrsr%252FE&md5=5dfc57d92a51bc78c5765387cac0393c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1080%2F07357907.2016.1193746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07357907.2016.1193746%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DLamar%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DM.%26aulast%3DPenley%26aufirst%3DW.%26aulast%3DThompson%26aufirst%3DD.%2BS.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DOwera%26aufirst%3DR.%26aulast%3DLane%26aufirst%3DC.%2BM.%26aulast%3DEarwood%26aufirst%3DC.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DA%2520phase%25202%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520as%2520treatment%2520for%2520patients%2520with%2520refractory%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Invest.%26date%3D2016%26volume%3D34%26issue%3D6%26spage%3D265%26epage%3D270%26doi%3D10.1080%2F07357907.2016.1193746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bear, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, C.</span></span> <span> </span><span class="NLM_article-title">The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1016/j.exphem.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.exphem.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=18657349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1266-1277&issue=10&author=T.-Y.+Linauthor=M.+Bearauthor=Z.+Duauthor=K.+P.+Foleyauthor=W.+Yingauthor=J.+Barsoumauthor=C.+London&title=The+novel+HSP90+inhibitor+STA-9090+exhibits+activity+against+Kit-dependent+and+-independent+malignant+mast+cell+tumors&doi=10.1016%2Fj.exphem.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors</span></div><div class="casAuthors">Lin, Tzu-Yin; Bear, Misty; Du, Zhenjian; Foley, Kevin P.; Ying, Weiwen; Barsoum, James; London, Cheryl</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1266-1277</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers.  While Kit inhibitors have activity in the clin. setting, they possess variable efficacy against particular forms of mutant Kit and drug resistance often develops over time.  Inhibitors of heat shock protein 90 (HSP90), a chaperone for which Kit is a client protein, have demonstrated activity against human cancers and evidence suggests they downregulate several mutated and imatinib-resistant forms of Kit.  The purpose of this study was to evaluate a novel HSP90 inhibitor, STA-9090, against wild-type (WT) and mutant Kit in canine bone marrow-derived cultured mast cells (BMCMCs), malignant mast cell lines, and fresh malignant mast cells.  BMCMCs, cell lines, and fresh malignant mast cells were treated with STA-9090, 17-AAG, and SU11654 and evaluated for loss in cell viability, cell death, alterations in HSP90 and Kit expression/signaling, and Kit mutation.  STA-9090 activity was tested in a canine mastocytoma xenograft model.  Treatment of BMCMCs, cell lines, and fresh malignant cells with STA-9090 induced growth inhibition, apoptosis that was caspase-3/7-dependent, and downregulation of phospho/total Kit and Akt, but not extracellular signal-regulated kinase (ERK) or phosphoinositide-3 kinase (PI-3K).  Loss of Kit cell-surface expression was also obsd.  Furthermore, STA-9090 exhibited superior activity to 17-AAG and SU11654, and was effective against malignant mast cells expressing either WT or mutant Kit.  Lastly, STA-9090 inhibited tumor growth in a canine mastocytoma mouse xenograft model.  STA-9090 exhibits broad activity against mast cells expressing WT or mutant Kit, suggesting it may be an effective agent in the clin. setting against mast cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzWCSaAah6lrVg90H21EOLACvtfcHk0lghW13_m79tiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK&md5=0ded2a0f878a699b895088651fc47913</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.-Y.%26aulast%3DBear%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DYing%26aufirst%3DW.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DLondon%26aufirst%3DC.%26atitle%3DThe%2520novel%2520HSP90%2520inhibitor%2520STA-9090%2520exhibits%2520activity%2520against%2520Kit-dependent%2520and%2520-independent%2520malignant%2520mast%2520cell%2520tumors%26jtitle%3DExp.%2520Hematol.%26date%3D2008%26volume%3D36%26issue%3D10%26spage%3D1266%26epage%3D1277%26doi%3D10.1016%2Fj.exphem.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackman, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acquaviva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, K.</span></span> <span> </span><span class="NLM_article-title">Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1158%2F1535-7163.MCT-11-0755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=22144665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=475-484&issue=2&author=W.+W.+Yingauthor=Z.+J.+Duauthor=L.+J.+Sunauthor=K.+P.+Foleyauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=D.+Zhouauthor=T.+Inoueauthor=N.+Tatsutaauthor=J.+Sangauthor=S.+X.+Yeauthor=J.+Acquavivaauthor=L.+S.+Ogawaauthor=Y.+Wadaauthor=J.+Barsoumauthor=K.+Koya&title=Ganetespib%2C+a+unique+triazolone-containing+Hsp90+inhibitor%2C+exhibits+potent+antitumor+activity+and+a+superior+safety+profile+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-11-0755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy</span></div><div class="casAuthors">Ying, Weiwen; Du, Zhenjian; Sun, Lijun; Foley, Kevin P.; Proia, David A.; Blackman, Ronald K.; Zhou, Dan; Inoue, Takayo; Tatsuta, Noriaki; Sang, Jim; Ye, Shuxia; Acquaviva, Jamie; Ogawa, Luisa Shin; Wada, Yumiko; Barsoum, James; Koya, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of the mol. chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics.  Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clin. trials for a no. of human cancers.  In the present study, we showed that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematol. tumor cell lines, including those that express mutated kinases that confer resistance to small-mol. tyrosine kinase inhibitors.  Ganetespib treatment rapidly induced the degrdn. of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times.  In vivo, ganetespib showed potent antitumor efficacy in solid and hematol. xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions.  Notably, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib was efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis.  Importantly, ganetespib showed no evidence of cardiac or liver toxicity.  Taken together, this preclin. activity profile indicates that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.  Mol Cancer Ther; 11(2); 475-84.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhzG1TPr4lbVg90H21EOLACvtfcHk0ljSEvv-QkENpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D&md5=269d41b30e5add9b9503cb43a98b0157</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0755%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%2BW.%26aulast%3DDu%26aufirst%3DZ.%2BJ.%26aulast%3DSun%26aufirst%3DL.%2BJ.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DS.%2BX.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26atitle%3DGanetespib%252C%2520a%2520unique%2520triazolone-containing%2520Hsp90%2520inhibitor%252C%2520exhibits%2520potent%2520antitumor%2520activity%2520and%2520a%2520superior%2520safety%2520profile%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D2%26spage%3D475%26epage%3D484%26doi%3D10.1158%2F1535-7163.MCT-11-0755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billups, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurmasheva, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span> <span> </span><span class="NLM_article-title">Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">E42</span>– <span class="NLM_lpage">E45</span>, <span class="refDoi"> DOI: 10.1002/pbc.24451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1002%2Fpbc.24451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=23303741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWhu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2013&pages=E42-E45&issue=7&author=R.+B.+Lockauthor=H.+Carolauthor=J.+M.+Marisauthor=M.+H.+Kangauthor=C.+P.+Reynoldsauthor=E.+A.+Kolbauthor=R.+Gorlickauthor=S.+T.+Keirauthor=C.+A.+Billupsauthor=R.+T.+Kurmashevaauthor=P.+J.+Houghtonauthor=M.+A.+Smith&title=Initial+testing+%28stage+1%29+of+ganetespib%2C+an+Hsp90+inhibitor%2C+by+the+pediatric+preclinical+testing+program&doi=10.1002%2Fpbc.24451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program</span></div><div class="casAuthors">Lock, Richard B.; Carol, Hernan; Maris, John M.; Kang, Min H.; Reynolds, C. Patrick; Kolb, E. Anders; Gorlick, Richard; Keir, Stephen T.; Billups, Catherine A.; Kurmasheva, Raushan T.; Houghton, Peter J.; Smith, Malcolm A.</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Blood & Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">E42-E45, 4</span>CODEN:
                <span class="NLM_cas:coden">PBCEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1545-5017</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Ganetespib, an Hsp90 inhibitor, was tested against the PPTP in vitro cell line panel and selected xenografts in vivo, including JAK2- and BRAF-mutated models.  Ganetespib demonstrated potent in vitro cytotoxic activity (median rIC50 8.8 nM, range 4.4- 27.1 nM).  In vivo, ganetespib induced significant differences in EFS distribution for 4 of 11 xenografts.  Intermediate activity (EFS T/C > 2) was noted only for the MV4;11 xenograft, and there were no objective responses.  Administered as single agents, Hsp90 inhibitors examd. by the PPTP have shown limited evidence for a therapeutic window against both solid tumor and leukemia pediatric preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxyDM0rHGFS7Vg90H21EOLACvtfcHk0ljSEvv-QkENpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWhu7bJ&md5=20c807fb3c0f989ef4825d486764032f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fpbc.24451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.24451%26sid%3Dliteratum%253Aachs%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DKang%26aufirst%3DM.%2BH.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DBillups%26aufirst%3DC.%2BA.%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DInitial%2520testing%2520%2528stage%25201%2529%2520of%2520ganetespib%252C%2520an%2520Hsp90%2520inhibitor%252C%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2013%26volume%3D60%26issue%3D7%26spage%3DE42%26epage%3DE45%26doi%3D10.1002%2Fpbc.24451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplinsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteva, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.1186/s13058-017-0879-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1186%2Fs13058-017-0879-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=28764748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGju7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=89&issue=1&author=K.+Jhaveriauthor=R.+Wangauthor=E.+Teplinskyauthor=S.+Chandarlapatyauthor=D.+Solitauthor=K.+Cadooauthor=J.+Speyerauthor=G.+D%E2%80%99Andreaauthor=S.+Adamsauthor=S.+Patilauthor=S.+Haqueauthor=T.+O%E2%80%99Neillauthor=K.+Friedmanauthor=F.+J.+Estevaauthor=C.+Hudisauthor=S.+Modi&title=A+phase+I+trial+of+ganetespib+in+combination+with+paclitaxel+and+trastuzumab+in+patients+with+human+epidermal+growth+factor+receptor-2+%28HER2%29-positive+metastatic+breast+cancer&doi=10.1186%2Fs13058-017-0879-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer</span></div><div class="casAuthors">Jhaveri, Komal; Wang, Rui; Teplinsky, Eleonora; Chandarlapaty, Sarat; Solit, David; Cadoo, Karen; Speyer, James; D'Andrea, Gabriella; Adams, Sylvia; Patil, Sujata; Haque, Sofia; O'Neill, Tara; Friedman, Kent; Esteva, Francisco J.; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89/1-89/8</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Targeted therapies in HER2-pos. metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance.  HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance.  Preclin. data suggest that HSP90 inhibition is synergistic with taxanes with the potential for significant clin. activity.  We therefore tested ganetespib, a HSP90 inhibitor, in combination with paclitaxel and trastuzumab in patients with trastuzumab-refractory HER2-pos. metastatic breast cancer.  Methods: In this phase I dose-escalation study, patients with trastuzumab-resistant HER2-pos. metastatic breast cancer received weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m2) on days 1, 8, 15, and 22 of a 28-day cycle with escalating doses of ganetespib (100 mg/m2, 150 mg/m2, and a third cohort of 125 mg/m2 if needed) on days 1, 8, and 15.  Therapy was continued until disease progression or toxicity.  The primary objective was to establish the safety and max. tolerated dose and/or recommended phase II dose (RP2D) of this therapy.  The secondary objectives included evaluation of the effects of ganetespib on the pharmacokinetics of paclitaxel, and to make a preliminary assessment of the efficacy of the combination therapy.  Results: Dose escalation was completed for the two main cohorts without any obsd. dose-limiting toxicities.  Nine patients received treatment.  The median prior lines of anti-HER2 therapy numbered three (range 2-4), including prior pertuzumab in 9/9 patients and ado-trastuzumab emtansine (T-DM1) in 8/9 patients.  The most common grade 1/2 adverse events (AEs) were diarrhea, fatigue, anemia, and rash.  There were no grade 4 AEs related to ganetespib.  The overall response rate was 22% (2/9 patients had partial response) and stable disease was seen in 56% (5/9 patients).  The clin. benefit rate was 44% (4/9 patients).  The median progression-free survival was 20 wk (range 8-55).  Conclusion: The RP2D of ganetespib is 150 mg/m2 in combination with weekly paclitaxel plus trastuzumab.  The combination was safe and well tolerated.  Despite prior taxanes, pertuzumab, and T-DM1, clin. activity of this triplet regimen in this heavily pretreated cohort is promising and warrants further study in HER2-pos. metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUSvrm6d3_trVg90H21EOLACvtfcHk0ljSEvv-QkENpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGju7zO&md5=7e725dae322c9d5b8cf3967665da5c82</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1186%2Fs13058-017-0879-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-017-0879-5%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DTeplinsky%26aufirst%3DE.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DCadoo%26aufirst%3DK.%26aulast%3DSpeyer%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DHaque%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DT.%26aulast%3DFriedman%26aufirst%3DK.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520ganetespib%2520in%2520combination%2520with%2520paclitaxel%2520and%2520trastuzumab%2520in%2520patients%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER2%2529-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2017%26volume%3D19%26issue%3D1%26spage%3D89%26doi%3D10.1186%2Fs13058-017-0879-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilbrun, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishampayan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzinic, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0307-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1007%2Fs10637-015-0307-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=26581400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWlsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=112-118&issue=1&author=M.+K.+Thakurauthor=L.+K.+Heilbrunauthor=S.+Shengauthor=M.+Steinauthor=G.+Liuauthor=E.+S.+Antonarakisauthor=U.+Vaishampayanauthor=S.+H.+Dzinicauthor=X.+Liauthor=S.+Freemanauthor=D.+Smithauthor=E.+I.+Heath&title=A+phase+II+trial+of+ganetespib%2C+a+heat+shock+protein+90+Hsp90%29+inhibitor%2C+in+patients+with+docetaxel-pretreated+metastatic+castrate-resistant+prostate+cancer+%28CRPC%29-a+prostate+cancer+clinical+trials+consortium+%28PCCTC%29+study&doi=10.1007%2Fs10637-015-0307-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study</span></div><div class="casAuthors">Thakur, Manish K.; Heilbrun, Lance K.; Sheng, Shijie; Stein, Mark; Liu, Glenn; Antonarakis, Emmanuel S.; Vaishampayan, Ulka; Dzinic, Sijana H.; Li, Xiaohua; Freeman, Stacy; Smith, Daryn; Heath, Elisabeth I.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-118</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Introduction Heat shock protein 90 (Hsp90) has been studied as a therapeutic target in many cancers.  In preclin. trials, the Hsp90 ATPase inhibitor ganetespib demonstrated potent inhibition of solid tumor growth, with superior potency than prior Hsp90 inhibitors.  Given the promising preclin. outcome and favorable pharmacol. properties of ganetespib, we conducted a phase II trial of single-agent ganetespib in patients with metastatic, castrate-resistant prostate cancer (mCRPC).  The primary objective of the study was to det. the 6-mo progression-free survival (PFS) rate.  Methods Patients with mCRPC who had been previously treated with docetaxel were enrolled after meeting eligibility criteria.  All patients received ganetespib at 200 mg/m2 on days 1, 8, and 15 of every 28 days (one cycle).  Subjects who tolerated therapy were continued on ganetespib until disease progression.  Considering that Hsp90 acetylation may confer insensitivity to Hsp90 inhibitors and maspin inhibits protein deacetylation, maspin-assocd. mol. markers were evaluated.  Results Eighteen patients were recruited into the trial; most were Caucasian, had performance status 1, had received prior docetaxel, and were heavily pretreated.  Of the 17 patients who were treated, none attained 6-mo PFS.  Only 2 patients achieved PFS > 4 mo.  The median PFS was 1.9 mo.  As per the study design, the trial was terminated after the interim anal.  The most frequent types of Grade 3 toxicity were dehydration, diarrhea, and fatigue.  Mol. markers provided little addnl. insight regarding drug activity.  Conclusions Ganetespib demonstrated minimal clin. activity in men with mCRPC.  The true 6-mo PFS rate was, at most, 0.20.  Possible reasons for this include selection of a heavily pretreated patient population and lack of agent potency in patients with mCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEc_FjjTbGprVg90H21EOLACvtfcHk0lgeZ82c9MbzrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWlsLjN&md5=08f9e46b0d9880d2caa2395be001ce8e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0307-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0307-6%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DM.%2BK.%26aulast%3DHeilbrun%26aufirst%3DL.%2BK.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DStein%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DVaishampayan%26aufirst%3DU.%26aulast%3DDzinic%26aufirst%3DS.%2BH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520ganetespib%252C%2520a%2520heat%2520shock%2520protein%252090%2520Hsp90%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520docetaxel-pretreated%2520metastatic%2520castrate-resistant%2520prostate%2520cancer%2520%2528CRPC%2529-a%2520prostate%2520cancer%2520clinical%2520trials%2520consortium%2520%2528PCCTC%2529%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2016%26volume%3D34%26issue%3D1%26spage%3D112%26epage%3D118%26doi%3D10.1007%2Fs10637-015-0307-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadlow, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaszkowsky, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolpin, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCleary, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karol, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, A. X.</span></span> <span> </span><span class="NLM_article-title">A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0164-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1007%2Fs10637-014-0164-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=25248753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=128-137&issue=1&author=L.+Goyalauthor=R.+C.+Wadlowauthor=L.+S.+Blaszkowskyauthor=B.+M.+Wolpinauthor=T.+A.+Abramsauthor=N.+J.+McClearyauthor=S.+Sheehanauthor=E.+Sundaramauthor=M.+D.+Karolauthor=J.+Chenauthor=A.+X.+Zhu&title=A+phase+I+and+pharmacokinetic+study+of+ganetespib+%28STA-9090%29+in+advanced+hepatocellular+carcinoma&doi=10.1007%2Fs10637-014-0164-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma</span></div><div class="casAuthors">Goyal, Lipika; Wadlow, Raymond C.; Blaszkowsky, Lawrence S.; Wolpin, Brian M.; Abrams, Thomas A.; McCleary, Nadine Jackson; Sheehan, Susan; Sundaram, Eamala; Karol, Michael D.; Chen, John; Zhu, Andrew X.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-137</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other Hsp90 client proteins involved in hepatocarcinogenesis, thereby making it an attractive therapy for HCC.  This Phase I study was performed to establish the safety, tolerability, recommended Phase 2 dose (RP2D), and preliminary clin. activity of ganetespib in previously treated patients with advanced HCC.  Methods: Patients with advanced HCC, Child-Pugh A cirrhosis, progression on or intolerance to sorafenib, and ECOG PS ≤ 1 were enrolled in a std. 3x3 dose escalation study at doses of 100 mg/m2, 150 mg/m2, and 200 mg/m2 IV given on days 1, 8, and 15 of each 28-day cycle.  Objective response by RECIST version 1.1 criteria was evaluated by CT/MRI every 8 wk.  Results: Fourteen patients were enrolled in this trial and received at least one dose of the study drug.  Of the 14 patients: median age, 57 years old; male 71 %; Asian 36 %; HCC etiol. (HBV 36 %, HCV 43 %, Hemachromatosis 7 %, unknown 21 %); Child Pugh Class (A 93 %, B 7 %); median no. of prior treatments 2; median baseline AFP 70.1 ng/mL.  The RP2D was detd. to be 200 mg/m2.  The most commonly seen AEs were diarrhea (93 %), fatigue (71 %), AST elevation (64 %), and hyperglycemia (64 %).  The most common Gr 3/4 AEs were hyperglycemia (21 %) and lipasemia (21 %).  One (7 %) patient had a fatal AE, septic shock, within 30 days of receiving the study drug.  One dose-limiting toxicity, grade 3 lipasemia, was obsd. at the 100 mg/m2 dose.  Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m2), 0.76 h, and 191 L (100.4 L/m2), resp.  No objective responses were seen; one patient (7 %) had stable disease at 16 wk.  Median time to progression was 1.8 mo, and median overall survival was 7.2 mo.  Conclusion: Ganetespib had a manageable safety profile in patients with advanced HCC who had progressed on at least one line of systemic therapy.  The pharmacokinetic profile showed that ganetespib exposure in patients with mild hepatic dysfunction is similar to that seen in patients with normal liver function.  Ganetespib showed limited clin. benefit in patients with advanced HCC in this phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr57teDffjuSrVg90H21EOLACvtfcHk0lgeZ82c9MbzrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSru7c%253D&md5=c55ec15b28353dea4e1aca73525f7e9b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0164-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0164-8%26sid%3Dliteratum%253Aachs%26aulast%3DGoyal%26aufirst%3DL.%26aulast%3DWadlow%26aufirst%3DR.%2BC.%26aulast%3DBlaszkowsky%26aufirst%3DL.%2BS.%26aulast%3DWolpin%26aufirst%3DB.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BA.%26aulast%3DMcCleary%26aufirst%3DN.%2BJ.%26aulast%3DSheehan%26aufirst%3DS.%26aulast%3DSundaram%26aufirst%3DE.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520ganetespib%2520%2528STA-9090%2529%2520in%2520advanced%2520hepatocellular%2520carcinoma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26issue%3D1%26spage%3D128%26epage%3D137%26doi%3D10.1007%2Fs10637-014-0164-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Socinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koczywas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonomi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belani, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huberman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teofilovici, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3068</span>– <span class="NLM_lpage">3077</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1158%2F1078-0432.CCR-12-3381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=23553849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3068-3077&issue=11&author=M.+A.+Socinskiauthor=J.+Goldmanauthor=I.+El-Hariryauthor=M.+Koczywasauthor=V.+Vukovicauthor=L.+Hornauthor=E.+Pascholdauthor=R.+Salgiaauthor=H.+Westauthor=L.+V.+Sequistauthor=P.+Bonomiauthor=J.+Brahmerauthor=L.-C.+Chenauthor=A.+Sandlerauthor=C.+P.+Belaniauthor=T.+Webbauthor=H.+Harperauthor=M.+Hubermanauthor=S.+Ramalingamauthor=K.-K.+Wongauthor=F.+Teofiloviciauthor=W.+Guoauthor=G.+I.+Shapiro&title=A+multicenter+phase+II+study+of+ganetespib+monotherapy+in+patients+with+genotypically+defined+advanced+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-12-3381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Socinski, Mark A.; Goldman, Jonathan; El-Hariry, Iman; Koczywas, Marianna; Vukovic, Vojo; Horn, Leora; Paschold, Eugene; Salgia, Ravi; West, Howard; Sequist, Lecia V.; Bonomi, Philip; Brahmer, Julie; Chen, Lin-Chi; Sandler, Alan; Belani, Chandra P.; Webb, Timothy; Harper, Harry; Huberman, Mark; Ramalingam, Suresh; Wong, Kwok-Kin; Teofilovici, Florentina; Guo, Wei; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3068-3077</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone protein crit. to tumor growth and proliferation.  In this phase II study, we evaluated the activity and tolerability of ganetespib in previously treated patients with non-small cell lung cancer (NSCLC).  Exptl. Design: Patients were enrolled into cohort A (mutant EGFR), B (mutant KRAS), or C (no EGFR or KRAS mutations).  Patients were treated with 200 mg/m2 ganetespib by i.v. infusion once weekly for 3 wk followed by 1 wk of rest, until disease progression.  The primary endpoint was progression-free survival (PFS) at 16 wk.  Secondary endpoints included objective response (ORR), duration of treatment, tolerability, median PFS, overall survival (OS), and correlative studies.  Results: Ninety-nine patients with a median of 2 prior systemic therapies were enrolled; 98 were assigned to cohort A (n = 15), B (n = 17), or C (n = 66), with PFS rates at 16 wk of 13.3%, 5.9%, and 19.7%, resp.  Four patients (4%) achieved partial response (PR); all had disease that harbored anaplastic lymphoma kinase (ALK) gene rearrangement, retrospectively detected by FISH (n = 1) or PCR-based assays (n = 3), in crizotinib-naive patients enrolled to cohort C. Eight patients (8.1%) experienced treatment-related serious adverse events (AE); 2 of these (cardiac arrest and renal failure) resulted in death.  The most common AEs were diarrhea, fatigue, nausea, and anorexia.  Conclusions: Ganetespib monotherapy showed a manageable side effect profile as well as clin. activity in heavily pretreated patients with advanced NSCLCs, particularly in patients with tumors harboring ALK gene rearrangement.  Clin Cancer Res; 19(11); 3068-77. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFukeZlyNCmbVg90H21EOLACvtfcHk0lh-5SJUFxjcrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D&md5=7fe5177633a6f003a7412431e6fb492d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3381%26sid%3Dliteratum%253Aachs%26aulast%3DSocinski%26aufirst%3DM.%2BA.%26aulast%3DGoldman%26aufirst%3DJ.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DKoczywas%26aufirst%3DM.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DPaschold%26aufirst%3DE.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBonomi%26aufirst%3DP.%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.-C.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DWebb%26aufirst%3DT.%26aulast%3DHarper%26aufirst%3DH.%26aulast%3DHuberman%26aufirst%3DM.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DA%2520multicenter%2520phase%2520II%2520study%2520of%2520ganetespib%2520monotherapy%2520in%2520patients%2520with%2520genotypically%2520defined%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D11%26spage%3D3068%26epage%3D3077%26doi%3D10.1158%2F1078-0432.CCR-12-3381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lake, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilewski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drullinsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserheit-Leiblich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynahan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span> <span> </span><span class="NLM_article-title">A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2013.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.clbc.2013.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=24512858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=154-160&issue=3&author=K.+Jhaveriauthor=S.+Chandarlapatyauthor=D.+Lakeauthor=T.+Gilewskiauthor=M.+Robsonauthor=S.+Goldfarbauthor=P.+Drullinskyauthor=S.+Sugarmanauthor=C.+Wasserheit-Leiblichauthor=J.+Fasanoauthor=M.+E.+Moynahanauthor=G.+D%E2%80%99Andreaauthor=K.+Limauthor=L.+Reddingtonauthor=S.+Haqueauthor=S.+Patilauthor=L.+Baumanauthor=V.+Vukovicauthor=I.+El-Hariryauthor=C.+Hudisauthor=S.+Modi&title=A+phase+II+open-label+study+of+ganetespib%2C+a+novel+heat+shock+protein+90+inhibitor+for+patients+with+metastatic+breast+cancer&doi=10.1016%2Fj.clbc.2013.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer</span></div><div class="casAuthors">Jhaveri, Komal; Chandarlapaty, Sarat; Lake, Diana; Gilewski, Teresa; Robson, Mark; Goldfarb, Shari; Drullinsky, Pamela; Sugarman, Steven; Wasserheit-Leiblich, Carolyn; Fasano, Julie; Moynahan, Mary Ellen; D'Andrea, Gabriella; Lim, Kristina; Reddington, Laura; Haque, Sofia; Patil, Sujata; Bauman, Lynne; Vukovic, Vojo; El-Hariry, Iman; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">154-160</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background:Ganetespib is a small mol., nongeldanamycin HSP90 inhibitor with potent inhibitory effects on HSP90-dependent oncoproteins of relevance to breast cancer pathogenesis.  We therefore tested ganetespib in an unselected cohort of patients with MBC.  Patients and Methods: Patients were treated with single agent ganetespib at 200 mg/m2 once weekly for 3 wk, on a 28-day cycle.  Therapy was continued until disease progression.  The primary end point was ORR using Reponse Evaluation Criteria in Solid Tumors version 1.1.  Results: Twenty-two patients were enrolled with a median age of 51(range, 38-70) years and a median Eastern Cooperative Oncol. Group performance status of 0 (range, 0-1).  Most patients had at least 2 previous lines of chemotherapy in the metastatic setting.  Most common toxicities, largely grade 1/2, were diarrhea, fatigue, nausea, and hypersensitivity reaction.  The ORR in this unselected population was 9%, with all responses coming from the subset of patients with HER2-pos. MBC (2/13; 15%).  One patient with TNBC had objective tumor regression in the lung metastases.  The clin. benefit rate (complete response + partial response + stable disease > 6 mo) was 9%, median progression-free survival was 7 wk (95% confidence interval [CI], 7-19), and median overall survival was 46 wk (95% CI, 27-not applicable).  Conclusion: The study did not meet the prespecified criteria for ORR in the first stage of the Simon 2-stage model in this heavily pretreated unselected population of MBC.  However, activity was obsd. in trastuzumab-refractory HER2-pos. and TNBC.  Ganetespib was well tolerated and responses in more targeted populations harboring specific HSP90-dependent oncoproteins justifies its further study, particularly as part of rational combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKRWFzPxBRzbVg90H21EOLACvtfcHk0lh-5SJUFxjcrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D&md5=15edad6cf71a9559eb42997563c57f53</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2013.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2013.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DLake%26aufirst%3DD.%26aulast%3DGilewski%26aufirst%3DT.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DGoldfarb%26aufirst%3DS.%26aulast%3DDrullinsky%26aufirst%3DP.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DWasserheit-Leiblich%26aufirst%3DC.%26aulast%3DFasano%26aufirst%3DJ.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DK.%26aulast%3DReddington%26aufirst%3DL.%26aulast%3DHaque%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DBauman%26aufirst%3DL.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520II%2520open-label%2520study%2520of%2520ganetespib%252C%2520a%2520novel%2520heat%2520shock%2520protein%252090%2520inhibitor%2520for%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D3%26spage%3D154%26epage%3D160%26doi%3D10.1016%2Fj.clbc.2013.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teofilivici, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karol, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L. S.</span></span> <span> </span><span class="NLM_article-title">A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">152</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-13-152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1186%2F1471-2407-13-152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=23530663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotVKisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=152&issue=1&author=J.+W.+Goldmanauthor=R.+N.+Rajuauthor=G.+A.+Gordonauthor=I.+El-Hariryauthor=F.+Teofiliviciauthor=V.+M.+Vukovicauthor=R.+Bradleyauthor=M.+D.+Karolauthor=Y.+Chenauthor=W.+Guoauthor=T.+Inoueauthor=L.+S.+Rosen&title=A+first+in+human%2C+safety%2C+pharmacokinetics%2C+and+clinical+activity+phase+I+study+of+once+weekly+administration+of+the+Hsp90+inhibitor+ganetespib+%28STA-9090%29+in+patients+with+solid+malignancies&doi=10.1186%2F1471-2407-13-152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies</span></div><div class="casAuthors">Goldman, Jonathan W.; Raju, Robert N.; Gordon, Gregory A.; El-Hariry, Iman; Teofilivici, Florentina; Vukovic, Vojo M.; Bradley, Robert; Karol, Michael D.; Chen, Yu; Guo, Wei; Inoue, Takayo; Rosen, Lee S.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">152</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: This phase I study investigated the max. tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies.  Methods: Patients were enrolled in cohorts of escalating ganetespib doses, given as 1 h IV infusion, once weekly for 3 wk, followed by a 1-wk rest until disease progression or unacceptable toxicity.  Endpoints included safety, pharmacokinetic and pharmacodynamic parameters and preliminary clin. activity.  Results: Fifty-three patients were treated at doses escalating from 7 to 259 mg/m2.  The most common adverse events were Grade 1 and 2 diarrhea, fatigue, nausea or vomiting.  Dose-limiting toxicities (DLT) obsd. were: one Grade 3 amylase elevation (150 mg/m2), one Grade 3 diarrhea and one Grade 3 and one Grade 4 asthenia (259 mg/m2).  The MTD was 216 mg/m2 and the recommended phase 2 dose was established at 200 mg/m2 given IV at Days 1, 8, and 15 every 4 wk.  There was a linear relationship between dose and exposure.  Plasma HSP70 protein levels remained elevated for over a week post treatment.  Disease control rate (objective response and stable disease at ≥16 wk) was 24.4%.  Conclusions: Ganetespib is well tolerated as a weekly infusion for 3 of every 4 wk cycle.  The recommended phase II dose is 200 mg/m2, and is assocd. with an acceptable tolerability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_c-SmyNHbmbVg90H21EOLACvtfcHk0lh-5SJUFxjcrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotVKisbc%253D&md5=55823d1bccdb38864b2528a787e3d16b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-152%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DRaju%26aufirst%3DR.%2BN.%26aulast%3DGordon%26aufirst%3DG.%2BA.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DTeofilivici%26aufirst%3DF.%26aulast%3DVukovic%26aufirst%3DV.%2BM.%26aulast%3DBradley%26aufirst%3DR.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26atitle%3DA%2520first%2520in%2520human%252C%2520safety%252C%2520pharmacokinetics%252C%2520and%2520clinical%2520activity%2520phase%2520I%2520study%2520of%2520once%2520weekly%2520administration%2520of%2520the%2520Hsp90%2520inhibitor%2520ganetespib%2520%2528STA-9090%2529%2520in%2520patients%2520with%2520solid%2520malignancies%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26issue%3D1%26spage%3D152%26doi%3D10.1186%2F1471-2407-13-152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagaya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seike, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiotsu, Y.</span></span> <span> </span><span class="NLM_article-title">New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2792</span>– <span class="NLM_lpage">2802</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-3112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1158%2F1078-0432.CCR-09-3112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=20406843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvF2hsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2792-2802&issue=10&author=T.+Nakashimaauthor=T.+Ishiiauthor=H.+Tagayaauthor=T.+Seikeauthor=H.+Nakagawaauthor=Y.+Kandaauthor=S.+Akinagaauthor=S.+Sogaauthor=Y.+Shiotsu&title=New+molecular+and+biological+mechanism+of+antitumor+activities+of+KW-2478%2C+a+novel+nonansamycin+heat+shock+protein+90+inhibitor%2C+in+multiple+myeloma+cells&doi=10.1158%2F1078-0432.CCR-09-3112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells</span></div><div class="casAuthors">Nakashima, Takayuki; Ishii, Toshihiko; Tagaya, Hisashi; Seike, Toshihiro; Nakagawa, Hiroshi; Kanda, Yutaka; Akinaga, Shiro; Soga, Shiro; Shiotsu, Yukimasa</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2792-2802</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The heat shock protein 90 (Hsp90) plays an important role in chaperoning oncogenic client proteins in multiple myeloma (MM) cells, and several Hsp90 inhibitors have shown antitumor activities both in vitro and in vivo.  However the precise mechanism of action of Hsp90 inhibitor in MM has not been fully elucidated.  Exptl. Design: The authors evaluated the antitumor activities of KW-2478, a nonansamycin Hsp90 inhibitor, in MM cells with various chromosomal translocations of Ig heavy chain (IgH) loci both in vitro and in vivo.  RESULTS: The authors' studies revealed that exposure of KW-2478 to MM cells resulted in growth inhibition and apoptosis, which were assocd. with degrdn. of well-known client proteins as well as a decrease in IgH translocation products (FGFR3, c-Maf, and cyclin D1), and FGFR3 was shown to be a new client protein of Hsp90 chaperon complex.  In addn., KW-2478 depleted the Hsp90 client Cdk9, a transcriptional kinase, and the phosphorylated 4E-BP1, a translational inhibitor.  Both inhibitory effects of KW-2478 on such transcriptional and translational pathways were shown to reduce c-Maf and cyclin D1 expression.  In NCI-H929 s.c. inoculated model, KW-2478 showed a significant suppression of tumor growth and induced the degrdn. of client proteins in tumors.  Furthermore, in a novel orthotopic MM model of i.v. inoculated OPM-2/green fluorescent protein, KW-2478 showed a significant redn. of both serum M protein and MM tumor burden in the bone marrow.  CONCLUSIONS: These results suggest that targeting such diverse pathways by KW-2478 could be a promising strategy for the treatment of MM with various cytogenetic abnormalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozKElc2AcPx7Vg90H21EOLACvtfcHk0liNYbeIsWJLQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvF2hsr8%253D&md5=dfe115d5696acc0a9ae62c94c24a42ec</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-3112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-3112%26sid%3Dliteratum%253Aachs%26aulast%3DNakashima%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DTagaya%26aufirst%3DH.%26aulast%3DSeike%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DSoga%26aufirst%3DS.%26aulast%3DShiotsu%26aufirst%3DY.%26atitle%3DNew%2520molecular%2520and%2520biological%2520mechanism%2520of%2520antitumor%2520activities%2520of%2520KW-2478%252C%2520a%2520novel%2520nonansamycin%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26issue%3D10%26spage%3D2792%26epage%3D2802%26doi%3D10.1158%2F1078-0432.CCR-09-3112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seike, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maharaj, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiotsu, Y.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e68</span>, <span class="refDoi"> DOI: 10.1038/bcj.2012.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fbcj.2012.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=22829970" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=e68&author=T.+Ishiiauthor=T.+Seikeauthor=T.+Nakashimaauthor=S.+Juligerauthor=L.+Maharajauthor=S.+Sogaauthor=S.+Akinagaauthor=J.+Cavenaghauthor=S.+Joelauthor=Y.+Shiotsu&title=Anti-tumor+activity+against+multiple+myeloma+by+combination+of+KW-2478%2C+an+Hsp90+inhibitor%2C+with+bortezomib&doi=10.1038%2Fbcj.2012.13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2012.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2012.13%26sid%3Dliteratum%253Aachs%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DSeike%26aufirst%3DT.%26aulast%3DNakashima%26aufirst%3DT.%26aulast%3DJuliger%26aufirst%3DS.%26aulast%3DMaharaj%26aufirst%3DL.%26aulast%3DSoga%26aufirst%3DS.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DJoel%26aufirst%3DS.%26aulast%3DShiotsu%26aufirst%3DY.%26atitle%3DAnti-tumor%2520activity%2520against%2520multiple%2520myeloma%2520by%2520combination%2520of%2520KW-2478%252C%2520an%2520Hsp90%2520inhibitor%252C%2520with%2520bortezomib%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2012%26volume%3D2%26spage%3De68%26doi%3D10.1038%2Fbcj.2012.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakervee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span> <span> </span><span class="NLM_article-title">Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fbjc.2015.422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=26695442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVelsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=7-13&author=K.+Yongauthor=J.+Cavetauthor=P.+Johnsonauthor=G.+Morganauthor=C.+Williamsauthor=D.+Nakashimaauthor=S.+Akinagaauthor=H.+Oakerveeauthor=J.+Cavenagh&title=Phase+I+study+of+KW-2478%2C+a+novel+Hsp90+inhibitor%2C+in+patients+with+B-cell+malignancies&doi=10.1038%2Fbjc.2015.422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies</span></div><div class="casAuthors">Yong, K.; Cavet, J.; Johnson, P.; Morgan, G.; Williams, C.; Nakashima, D.; Akinaga, S.; Oakervee, H.; Cavenagh, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-13</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: KW-2478 is a novel, non-ansamycin, non-purine heat-shock protein 90 (Hsp90) inhibitor.  Methods: In this phase I, multicentre study, KW-2478 was administered i.v. over 1 h at doses ranging from 14 to 176 mg m-2 once daily on days 1-5 of a 14-day cycle in a std. 3+3 design in 27 patients (22 with multiple myeloma and 5 with non-Hodgkin lymphoma).  Patients enrolled had relapsed/refractory disease previously treated with ≥2 regimens.  Results: There were no dose-limiting toxicities, thus the max.-tolerated dose was not reached.  KW-2478 was well tolerated and did not manifest significant retinal or ocular toxicity.  The most common treatment-related adverse events were diarrhoea (33.3%), fatigue (29.6%), headache (25.9%), hypertension (22.2%), nausea (14.8%), vomiting (7.4%), and dizziness (7.4%).  Plasma concns. peaked at the end of infusion and decayed in a biphasic manner with a terminal half-life of ∼6 h.  Target inhibition was inferred from the increase in Hsp70 levels in peripheral blood mononuclear cells at doses ≥71 mg m-2.  Twenty-four of 25 (96%) evaluable patients showed stable disease, with five being free of disease progression for ≥6 mo.  Conclusions: Preliminary clin. response data were encouraging and warrant further investigation of KW-2478 in combination regimens for relapsed/refractory B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEuon6lWQ0I7Vg90H21EOLACvtfcHk0liNYbeIsWJLQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVelsw%253D%253D&md5=b89fa1f0b51d458ec23154dc7c7fcafb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.422%26sid%3Dliteratum%253Aachs%26aulast%3DYong%26aufirst%3DK.%26aulast%3DCavet%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DMorgan%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DNakashima%26aufirst%3DD.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DOakervee%26aufirst%3DH.%26aulast%3DCavenagh%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520study%2520of%2520KW-2478%252C%2520a%2520novel%2520Hsp90%2520inhibitor%252C%2520in%2520patients%2520with%2520B-cell%2520malignancies%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D114%26spage%3D7%26epage%3D13%26doi%3D10.1038%2Fbjc.2015.422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakervee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baetiong-Caguioa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharibo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiraishi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, K.</span></span> <span> </span><span class="NLM_article-title">A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1038/bjc.2017.302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fbjc.2017.302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=28873084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKmu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=1295-1302&author=J.+Cavenaghauthor=H.+Oakerveeauthor=P.+Baetiong-Caguioaauthor=F.+Daviesauthor=M.+Ghariboauthor=N.+Rabinauthor=M.+Kurmanauthor=B.+Novakauthor=N.+Shiraishiauthor=D.+Nakashimaauthor=S.+Akinagaauthor=K.+Yong&title=A+phase+I%2FII+study+of+KW-2478%2C+an+Hsp90+inhibitor%2C+in+combination+with+bortezomib+in+patients+with+relapsed%2Frefractory+multiple+myeloma&doi=10.1038%2Fbjc.2017.302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma</span></div><div class="casAuthors">Cavenagh, J.; Oakervee, H.; Baetiong-Caguioa, P.; Davies, F.; Gharibo, M.; Rabin, N.; Kurman, M.; Novak, B.; Shiraishi, N.; Nakashima, D.; Akinaga, S.; Yong, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1295-1302</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: KW-2478 is a novel non-ansamycin Hsp90 inhibitor with modest single-agent activity in relapsed/refractory myeloma but which shows synergistic antimyeloma activity with bortezomib (BTZ) in preclin. studies.  This study detd. the safety, preliminary clin. activity, and pharmacokinetics of KW-2478, an Hsp90 inhibitor, in combination with BTZ in patients with relapsed/refractory multiple myeloma (MM).  Methods: Phase I dose escalation detd. the recommended phase II dose (RP2D) of KW-2478 plus BTZ, which was then used during phase II.  Results: The max. tolerated dose was not reached during phase I and the RP2D was KW-2478 175 mg m-2 plus BTZ 1.3 mg m-2 on days 1, 4, 8, and 11 every 3 wk.  In the efficacy evaluable phase I/II population treated at the RP2D (n=79), the objective response rate was 39.2% (95% confidence interval: 28.4-50.9%), clin. benefit rate 51.9% (40.4-63.3%), median progression-free survival 6.7 (5.9-not reached (NR)) months, and median duration of response 5.5 (4.9-NR) months.  In the phase I/II safety population (n=95), the most frequently obsd. treatment-related grade 3/4 adverse events were diarrhoea, fatigue, and neutropenia (each in 7.4% of patients), and nausea and thrombocytopenia (each in 5.3%).  Conclusions: KW-2478 plus BTZ was well tolerated with no apparent overlapping toxicity in patients with relapsed/refractory MM.  The antimyeloma activity of KW-2478 in combination with BTZ as scheduled in this trial appeared relatively modest; however, the good tolerability of the combination would support further exploration of alternate dosing schedules and combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJQI0ZKrISM7Vg90H21EOLACvtfcHk0lhrV5NV9DFoBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKmu7vJ&md5=4184f4253bfbc80b37507876d144f93d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.302%26sid%3Dliteratum%253Aachs%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DOakervee%26aufirst%3DH.%26aulast%3DBaetiong-Caguioa%26aufirst%3DP.%26aulast%3DDavies%26aufirst%3DF.%26aulast%3DGharibo%26aufirst%3DM.%26aulast%3DRabin%26aufirst%3DN.%26aulast%3DKurman%26aufirst%3DM.%26aulast%3DNovak%26aufirst%3DB.%26aulast%3DShiraishi%26aufirst%3DN.%26aulast%3DNakashima%26aufirst%3DD.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DYong%26aufirst%3DK.%26atitle%3DA%2520phase%2520I%252FII%2520study%2520of%2520KW-2478%252C%2520an%2520Hsp90%2520inhibitor%252C%2520in%2520combination%2520with%2520bortezomib%2520in%2520patients%2520with%2520relapsed%252Frefractory%2520multiple%2520myeloma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D117%26spage%3D1295%26epage%3D1302%26doi%3D10.1038%2Fbjc.2017.302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peace, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span> <span> </span><span class="NLM_article-title">The developability of heteroaromatic and heteroaliphatic rings – do some have a better pedigree as potential drug molecules than others?</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1062</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1039/c2md20111a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1039%2Fc2md20111a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1062-1069&issue=9&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=S.+Peaceauthor=S.+D.+Pickettauthor=C.+N.+Luscombe&title=The+developability+of+heteroaromatic+and+heteroaliphatic+rings+%E2%80%93+do+some+have+a+better+pedigree+as+potential+drug+molecules+than+others%3F&doi=10.1039%2Fc2md20111a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The developability of heteroaromatic and heteroaliphatic rings - do some have a better pedigree as potential drug molecules than others?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Peace, Simon; Pickett, Stephen D.; Luscombe, Christopher N.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1062-1069</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Aq. soly., protein binding and CYP450 inhibition data for compds. contg. a variety of heteroarom. and heteroaliph. rings were analyzed and compared to det. which ring types fared best and worst in these developability screens.  The results suggest that certain heterorings are generally more developable than others: how this information may be used and some caveats to be borne in mind are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCkxdTaUGig7Vg90H21EOLACvtfcHk0lhrV5NV9DFoBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE&md5=6aad4bc48b351d9d20683ee9af1a3354</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2Fc2md20111a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20111a%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DPeace%26aufirst%3DS.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26atitle%3DThe%2520developability%2520of%2520heteroaromatic%2520and%2520heteroaliphatic%2520rings%2520%25E2%2580%2593%2520do%2520some%2520have%2520a%2520better%2520pedigree%2520as%2520potential%2520drug%2520molecules%2520than%2520others%253F%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26issue%3D9%26spage%3D1062%26epage%3D1069%26doi%3D10.1039%2Fc2md20111a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Resorcinol-based Grp94-selective inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1013-1018&issue=10&author=A.+Khandelwalauthor=V.+M.+Crowleyauthor=B.+S.+J.+Blagg&title=Resorcinol-based+Grp94-selective+inhibitors&doi=10.1021%2Facsmedchemlett.7b00193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Resorcinol-Based Grp94-Selective Inhibitors</span></div><div class="casAuthors">Khandelwal, Anuj; Crowley, Vincent M.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1013-1018</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucose regulated protein 94 (Grp94) is the endoplasmic reticulum resident of the 90 kDa heat shock protein (Hsp90) family and represents a promising therapeutic target for the treatment of several diseases.  Grp94 is the most unique member of the 90 kDa heat shock protein family due to a five amino acid insertion into its primary sequence, which creates hydrophobic subpockets exclusive to Grp94 that can be utilized for selective inhibition.  The first resorcinol-based Grp94-selective inhibitor I to take advantage of the hydrophobic S2 subpocket has been developed and shown to manifest low nanomolar affinity and ∼10-fold selectivity for Grp94.  Furthermore, these Grp94-selective inhibitors manifest low micromolar GI50 values against multiple myeloma cells, supporting Grp94 as an emerging target for the treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok_wSMzlEsHLVg90H21EOLACvtfcHk0lhrV5NV9DFoBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs73K&md5=a398cf6e5adaacc4892aed8b2340b901</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00193%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DResorcinol-based%2520Grp94-selective%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D10%26spage%3D1013%26epage%3D1018%26doi%3D10.1021%2Facsmedchemlett.7b00193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catherine Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, M. R.</span></span> <span> </span><span class="NLM_article-title">Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6273</span>– <span class="NLM_lpage">6278</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.bmcl.2008.09.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=18929486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6273-6278&issue=23&author=P.-P.+Kungauthor=L.+Funkauthor=J.+Mengauthor=M.+Collinsauthor=J.+Z.+Zhouauthor=M.+Catherine+Johnsonauthor=A.+Ekkerauthor=J.+Wangauthor=P.+Mehtaauthor=M.-J.+Yinauthor=C.+Rodgersauthor=J.+F.+Daviesauthor=E.+Baymanauthor=T.+Smealauthor=K.+A.+Maegleyauthor=M.+R.+Gehring&title=Dihydroxylphenyl+amides+as+inhibitors+of+the+Hsp90+molecular+chaperone&doi=10.1016%2Fj.bmcl.2008.09.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone</span></div><div class="casAuthors">Kung, Pei-Pei; Funk, Lee; Meng, Jerry; Collins, Michael; Zhou, Joe Zhongxiang; Catherine Johnson, M.; Ekker, Anne; Wang, Jeff; Mehta, Pramod; Yin, Min-Jean; Rodgers, Caroline; Davies, Jay F., II; Bayman, Eileen; Smeal, Tod; Maegley, Karen A.; Gehring, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6273-6278</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Information from X-ray crystal structures were used to optimize the potency of a HTS hit in a Hsp90 competitive binding assay.  A class of novel and potent small mol. Hsp90 inhibitors were thereby identified.  Enantio-pure compds. I [n = 1, 2] were potent in PGA-based competitive binding assay and inhibited proliferation of various human cancer cell lines in vitro, with IC50 values averaging 20 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraBHD3PPbhDbVg90H21EOLACvtfcHk0lhz6rABX8JjUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtrzE&md5=36eb69d7ffb65443bc5328f74806fa0b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.081%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%2BZ.%26aulast%3DCatherine%2BJohnson%26aufirst%3DM.%26aulast%3DEkker%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DRodgers%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BF.%26aulast%3DBayman%26aufirst%3DE.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DGehring%26aufirst%3DM.%2BR.%26atitle%3DDihydroxylphenyl%2520amides%2520as%2520inhibitors%2520of%2520the%2520Hsp90%2520molecular%2520chaperone%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D23%26spage%3D6273%26epage%3D6278%26doi%3D10.1016%2Fj.bmcl.2008.09.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digits, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaptason, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neul, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elleraas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, M. R.</span></span> <span> </span><span class="NLM_article-title">Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (Hsp90) molecular chaperone</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1021/jm901209q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901209q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSgtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=499-503&issue=1&author=P.-P.+Kungauthor=B.+Huangauthor=G.+Zhangauthor=J.+Z.+Zhouauthor=J.+Wangauthor=J.+A.+Digitsauthor=J.+Skaptasonauthor=S.+Yamazakiauthor=D.+Neulauthor=M.+Zientekauthor=J.+Elleraasauthor=P.+Mehtaauthor=M.-J.+Yinauthor=M.+J.+Hickeyauthor=K.+S.+Gajiwalaauthor=C.+Rodgersauthor=J.+F.+Daviesauthor=M.+R.+Gehring&title=Dihydroxyphenylisoindoline+amides+as+orally+bioavailable+inhibitors+of+the+heat+shock+protein+90+%28Hsp90%29+molecular+chaperone&doi=10.1021%2Fjm901209q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroxyphenylisoindoline Amides as Orally Bioavailable Inhibitors of the Heat Shock Protein 90 (Hsp90) Molecular Chaperone</span></div><div class="casAuthors">Kung, Pei-Pei; Huang, Buwen; Zhang, Gang; Zhou, Joe Zhongxiang; Wang, Jeff; Digits, Jennifer A.; Skaptason, Judith; Yamazaki, Shinji; Neul, David; Zientek, Michael; Elleraas, Jeff; Mehta, Pramod; Yin, Min-Jean; Hickey, Michael J.; Gajiwala, Ketan S.; Rodgers, Caroline; Davies, Jay F.; Gehring, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">499-503</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of potency and metabolic stability of a novel class of dihyroxyphenylisoindoline amides as Hsp90 inhibitors are presented.  Optimization of a screening hit using structure-based design and modification of log D and chem. structural features led to the identification of a class of orally bioavailable non-quinone-contg. Hsp90 inhibitors.  This class is exemplified by 14 and 15, which possess improved cell potency and pharmacokinetic profiles compared with the original screening hit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEUFJeHqfCcbVg90H21EOLACvtfcHk0lhz6rABX8JjUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSgtb3I&md5=ddf40b545bfd06e4bf9f981c7a792eae</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm901209q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901209q%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DJ.%2BZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDigits%26aufirst%3DJ.%2BA.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DNeul%26aufirst%3DD.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DElleraas%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DHickey%26aufirst%3DM.%2BJ.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DRodgers%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BF.%26aulast%3DGehring%26aufirst%3DM.%2BR.%26atitle%3DDihydroxyphenylisoindoline%2520amides%2520as%2520orally%2520bioavailable%2520inhibitors%2520of%2520the%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520molecular%2520chaperone%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D1%26spage%3D499%26epage%3D503%26doi%3D10.1021%2Fjm901209q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J.</span></span> <span> </span><span class="NLM_article-title">Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5942</span>– <span class="NLM_lpage">5955</span>, <span class="refDoi"> DOI: 10.1021/jm100059d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100059d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVChsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5942-5955&author=C.+W.+Murrayauthor=M.+G.+Carrauthor=O.+Callaghanauthor=G.+Chessariauthor=M.+Congreveauthor=S.+Cowanauthor=J.+E.+Coyleauthor=R.+Downhamauthor=E.+Figueroaauthor=M.+Fredericksonauthor=B.+Grahamauthor=R.+McMenaminauthor=M.+A.+O%E2%80%99Brienauthor=S.+Patelauthor=T.+R.+Phillipsauthor=G.+Williamsauthor=A.+J.+Woodheadauthor=A.+J.+Woolford&title=Fragment-based+drug+discovery+applied+to+Hsp90.+Discovery+of+two+lead+series+with+high+ligand+efficiency&doi=10.1021%2Fjm100059d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency</span></div><div class="casAuthors">Murray, Christopher W.; Carr, Maria G.; Callaghan, Owen; Chessari, Gianni; Congreve, Miles; Cowan, Suzanna; Coyle, Joseph E.; Downham, Robert; Figueroa, Eva; Frederickson, Martyn; Graham, Brent; McMenamin, Rachel; O'Brien, M. Alistair; Patel, Sahil; Phillips, Theresa R.; Williams, Glyn; Woodhead, Andrew J.; Woolford, Alison J.-A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5942-5955</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the chaperone Hsp90 are potentially useful as chemotherapeutic agents in cancer.  This paper describes an application of fragment screening to Hsp90 using a combination of NMR and high throughput x-ray crystallog.  The screening identified an aminopyrimidine with affinity in the high micromolar range and subsequent structure-based design allowed its optimization into a low nanomolar series with good ligand efficiency.  A phenolic chemotype was also identified in fragment screening and was found to bind with affinity close to 1 mM.  This fragment was optimized using structure based design into a resorcinol lead which has subnanomolar affinity for Hsp90, excellent cell potency, and good ligand efficiency.  This fragment to lead campaign improved affinity for Hsp90 by over 1,000,000 fold with the addn. of only 6 heavy atoms.  The companion paper (DOI: 10.1021/jm100060b) describes how the resorcinol lead was optimized into a compd. that is now in clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqISC3cw2labbVg90H21EOLACvtfcHk0lhz6rABX8JjUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVChsb0%253D&md5=d1ad900aa5a45ba6ba3a5e9ccdcd96b3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm100059d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100059d%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCallaghan%26aufirst%3DO.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCowan%26aufirst%3DS.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%2BR.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DFragment-based%2520drug%2520discovery%2520applied%2520to%2520Hsp90.%2520Discovery%2520of%2520two%2520lead%2520series%2520with%2520high%2520ligand%2520efficiency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5942%26epage%3D5955%26doi%3D10.1021%2Fjm100059d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G. M.</span></span> <span> </span><span class="NLM_article-title">Total synthesis of resorcinol amide Hsp90 inhibitor AT13387</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11296</span>– <span class="NLM_lpage">11301</span>, <span class="refDoi"> DOI: 10.1021/jo302406w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo302406w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCgsbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=11296-11301&issue=24&author=B.+H.+Patelauthor=A.+G.+M.+Barrett&title=Total+synthesis+of+resorcinol+amide+Hsp90+inhibitor+AT13387&doi=10.1021%2Fjo302406w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of Resorcinol Amide Hsp90 Inhibitor AT13387</span></div><div class="casAuthors">Patel, Bhavesh H.; Barrett, Anthony G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11296-11301</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of C-5-substituted resorcinol amide AT13387 (I), a known Hsp90 inhibitor currently in clin. trials, is reported without the use of phenolic protection in an overall yield of 13.4%.  Biomimetic aromatization and Suzuki-Miyaura cross coupling approach were employed to synthesize the resorcinol and iso-indoline units, resp., which were efficiently coupled using Grignard-mediated amidation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB5oqQ4N5a47Vg90H21EOLACvtfcHk0lhUwvsbkQLuxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCgsbzN&md5=265c4db08cd8d2d0df61888dc542804f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjo302406w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo302406w%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DB.%2BH.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%2BM.%26atitle%3DTotal%2520synthesis%2520of%2520resorcinol%2520amide%2520Hsp90%2520inhibitor%2520AT13387%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2012%26volume%3D77%26issue%3D24%26spage%3D11296%26epage%3D11301%26doi%3D10.1021%2Fjo302406w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2525</span>– <span class="NLM_lpage">2529</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.bmcl.2014.03.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=24751441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmslahsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2525-2529&issue=11&author=J.+Renauthor=J.+Liauthor=Y.+Wangauthor=W.+Chenauthor=A.+Shenauthor=H.+Liuauthor=D.+Chenauthor=D.+Caoauthor=Y.+Liauthor=N.+Zhangauthor=Y.+Xuauthor=M.+Gengauthor=J.+Heauthor=B.+Xiongauthor=J.+Shen&title=Identification+of+a+new+series+of+potent+diphenol+HSP90+inhibitors+by+fragment+merging+and+structure-based+optimization&doi=10.1016%2Fj.bmcl.2014.03.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization</span></div><div class="casAuthors">Ren, Jing; Li, Jian; Wang, Yueqin; Chen, Wuyan; Shen, Aijun; Liu, Hongchun; Chen, Danqi; Cao, Danyan; Li, Yanlian; Zhang, Naixia; Xu, Yechun; Geng, Meiyu; He, Jianhua; Xiong, Bing; Shen, Jingkang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2525-2529</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Heat shock protein 90 (HSP90) is a mol. chaperone to fold and maintain the proper conformation of many signaling proteins, esp. some oncogenic proteins and mutated unstable proteins.  Inhibition of HSP90 was recognized as an effective approach to simultaneously suppress several aberrant signaling pathways, and therefore it was considered as a novel target for cancer therapy.  Here, by integrating several techniques including the fragment-based drug discovery method, fragment merging, computer aided inhibitor optimization, and structure-based drug design, the authors were able to identify a series of HSP90 inhibitors, e.g. I [R1 = H. HO2CCH2, NH2CH2CH2, MeCONHCH2CH2; r2 = H, Br, O2N, etc.; R3 = H, Br, Me, MeO].  Several compds. can inhibit HSP90 with IC50 about 20-40 nM, which is at least 200-fold more potent than initial fragments in the protein binding assay.  These new HSP90 inhibitors not only explore interactions with an under-studied subpocket, also offer new chemotypes for the development of novel HSP90 inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy4NL6r1yE8rVg90H21EOLACvtfcHk0lhUwvsbkQLuxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmslahsrY%253D&md5=057e15a1982cf723de8c7436accf4fff</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.100%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520a%2520new%2520series%2520of%2520potent%2520diphenol%2520HSP90%2520inhibitors%2520by%2520fragment%2520merging%2520and%2520structure-based%2520optimization%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D11%26spage%3D2525%26epage%3D2529%26doi%3D10.1016%2Fj.bmcl.2014.03.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Addie, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Room-temperature palladium-catalyzed coupling of heteroaryl amines with aryl or heteroaryl bromides</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span> (<span class="NLM_issue">02</span>),  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1055/s-0031-1290069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1055%2Fs-0031-1290069" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=285-289&issue=02&author=T.+A.+Mossauthor=M.+S.+Addieauthor=T.+Nowakauthor=M.+J.+Waring&title=Room-temperature+palladium-catalyzed+coupling+of+heteroaryl+amines+with+aryl+or+heteroaryl+bromides&doi=10.1055%2Fs-0031-1290069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1055%2Fs-0031-1290069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0031-1290069%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DAddie%26aufirst%3DM.%2BS.%26aulast%3DNowak%26aufirst%3DT.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DRoom-temperature%2520palladium-catalyzed%2520coupling%2520of%2520heteroaryl%2520amines%2520with%2520aryl%2520or%2520heteroaryl%2520bromides%26jtitle%3DSynlett%26date%3D2012%26volume%3D2012%26issue%3D02%26spage%3D285%26epage%3D289%26doi%3D10.1055%2Fs-0031-1290069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, J. P.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, S. R.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed couplings of heteroaryl amines with aryl halides using sodium phenolate as the stoichiometric base</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2007</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2331</span>– <span class="NLM_lpage">2336</span>, <span class="refDoi"> DOI: 10.1055/s-2007-985597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1055%2Fs-2007-985597" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2007&publication_year=2007&pages=2331-2336&issue=15&author=J.+P.+Schulteauthor=S.+R.+Tweedie&title=Palladium-catalyzed+couplings+of+heteroaryl+amines+with+aryl+halides+using+sodium+phenolate+as+the+stoichiometric+base&doi=10.1055%2Fs-2007-985597"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1055%2Fs-2007-985597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2007-985597%26sid%3Dliteratum%253Aachs%26aulast%3DSchulte%26aufirst%3DJ.%2BP.%26aulast%3DTweedie%26aufirst%3DS.%2BR.%26atitle%3DPalladium-catalyzed%2520couplings%2520of%2520heteroaryl%2520amines%2520with%2520aryl%2520halides%2520using%2520sodium%2520phenolate%2520as%2520the%2520stoichiometric%2520base%26jtitle%3DSynlett%26date%3D2007%26volume%3D2007%26issue%3D15%26spage%3D2331%26epage%3D2336%26doi%3D10.1055%2Fs-2007-985597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, Y. H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.ejmech.2017.11.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=29202402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=390-401&author=S.+Y.+Parkauthor=Y.+J.+Ohauthor=Y.+Lhoauthor=J.+H.+Jeongauthor=K.-H.+Liuauthor=J.+Songauthor=S.-H.+Kimauthor=E.+Haauthor=Y.+H.+Seo&title=Design%2C+synthesis%2C+and+biological+evaluation+of+a+series+of+resorcinol-based+N-benzyl+benzamide+derivatives+as+potent+Hsp90+inhibitors&doi=10.1016%2Fj.ejmech.2017.11.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors</span></div><div class="casAuthors">Park, Sun You; Oh, Yong Jin; Lho, Yunmee; Jeong, Ju Hui; Liu, Kwang-Hyeon; Song, Jaeyoung; Kim, Soong-Hyun; Ha, Eunyoung; Seo, Young Ho</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">390-401</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design, synthesis, and biol. evaluation of a series of resorcinol-based N-benzyl benzamide derivs. 2,4-(HO)6-5-R1C6H2C(O)R [R = benzylaminyl, N-methyl-N-(4-(propylcarbamoyl)benzyl)aminyl, N-methyl-3,4,5-trimethoxybenzylaminyl, etc.; R1 = Cl, i-Pr] as Hsp90 inhibitors has been reported.  In particular, compd. 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide shows a significant Hsp90α inhibitory activity with IC50 value of 5.3 nM and an excellent growth inhibition with GI50 value of 0.42 μM against non-small cell lung cancer cells, H1975.  Compd. 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide effectively reduces the expression levels of Hsp90 client proteins including Her2, EGFR, Met, Akt, and c-Raf.  Consequently, compd. 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide promotes substantial cleavages of PARP, Caspase 3, and Caspase 8, indicating that 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide induces cancer cell death via apoptotic pathway.  Moreover, cytochrome P 450 assay indicates that compd. 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide has weak inhibitory effect on the activities of five major P 450 isoforms (IC50 > 5 μM for 1A2, 2C9, 2C19, 2D6, and 3A), suggesting that clin. interactions between 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide and the substrate drugs of the five major P 450 isoforms are not expected.  Compd. 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide also inhibits the tumor growth in a mouse xenograft model bearing s.c. H1975 without noticeable abnormal behavior and body wt. changes.  The immunostaining and western immunoblot anal. of EGFR, Met, Akt in xenograft tissue sections of tumor further demonstrate a good agreement with the in vitro results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnyGeDPwxoarVg90H21EOLACvtfcHk0lh-E3YS_FiXpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FK&md5=b9568b778745c305d0dadb727c0d9671</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.054%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BY.%26aulast%3DOh%26aufirst%3DY.%2BJ.%26aulast%3DLho%26aufirst%3DY.%26aulast%3DJeong%26aufirst%3DJ.%2BH.%26aulast%3DLiu%26aufirst%3DK.-H.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DHa%26aufirst%3DE.%26aulast%3DSeo%26aufirst%3DY.%2BH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520resorcinol-based%2520N-benzyl%2520benzamide%2520derivatives%2520as%2520potent%2520Hsp90%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D390%26epage%3D401%26doi%3D10.1016%2Fj.ejmech.2017.11.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">21–22</span>),  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&issue=21%E2%80%9322&author=T.+J.+Ritchieauthor=S.+J.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability%2D%2Dare+too+many+aromatic+rings+a+liability+in+drug+design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0lh-E3YS_FiXpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability--are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26issue%3D21%25E2%2580%259322%26spage%3D1011%26epage%3D1020%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, T. C.</span></span> <span> </span><span class="NLM_article-title">Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1482</span>– <span class="NLM_lpage">1487</span>, <span class="refDoi"> DOI: 10.1128/AAC.41.7.1482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1128%2FAAC.41.7.1482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=9210670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADyaK2sXktlyrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=1482-1487&issue=7&author=T.+C.+White&title=Increased+mRNA+levels+of+ERG16%2C+CDR%2C+and+MDR1+correlate+with+increases+in+azole+resistance+in+Candida+albicans+isolates+from+a+patient+infected+with+human+immunodeficiency+virus&doi=10.1128%2FAAC.41.7.1482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus</span></div><div class="casAuthors">White, Theodore C.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1482-1487</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Resistance to antifungal drugs, specifically azoles such as fluconazole, in the opportunistic yeast Candida albicans has become an increasing problem in human immunodeficiency virus (HIV)-infected individuals.  The mol. mechanisms responsible for this resistance have only recently become apparent and can include alterations in the target enzyme of the azole drugs (lanosterol 14α demethylase [14DM]), or in various efflux pumps from both the ABC transporter and major facilitator gene families.  To det. which of these possible mechanisms was assocd. with the development of drug resistance in a particular case, mRNA levels have been studied in a series of 17 clin. isolates taken from a single HIV-infected patient over 2 yr, during which time the levels of fluconazole resistance of the strain increased over 200-fold.  Using Northern blot anal. of steady-state levels of total RNA from these isolates, we obsd. increased mRNA levels of ERG16 (the 14DM-encoding gene), CDR1 (an ABC transporter), and MDR1 (a major facilitator) in this series.  The timing of the increase in mRNA levels of each of these genes correlated with increases in fluconazole resistance of the isolates.  Increased mRNA levels were not obsd. for three other ABC transporters, two other genes in the ergosterol biosynthetic pathway, or the NADPH-cytochrome P 450 oxidoreductase gene that transfers electrons from NADPH to 14DM.  Increases in mRNA levels of ERG16 and CDR1 correlated with increased cross-resistance to ketoconazole and itraconazole but not to amphotericin B.  A compilation of the genetic alterations identified in this series suggests that resistance develops gradually and is the sum of several different changes, all of which contribute to the final resistant phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcePJcYuq0KrVg90H21EOLACvtfcHk0lh-E3YS_FiXpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlyrurw%253D&md5=4496d1afe63335deadeb234dae8b8a20</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.41.7.1482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.41.7.1482%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DT.%2BC.%26atitle%3DIncreased%2520mRNA%2520levels%2520of%2520ERG16%252C%2520CDR%252C%2520and%2520MDR1%2520correlate%2520with%2520increases%2520in%2520azole%2520resistance%2520in%2520Candida%2520albicans%2520isolates%2520from%2520a%2520patient%2520infected%2520with%2520human%2520immunodeficiency%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26issue%3D7%26spage%3D1482%26epage%3D1487%26doi%3D10.1128%2FAAC.41.7.1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Odds, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, N. A.</span></span> <span> </span><span class="NLM_article-title">Candida albicans genome sequence: a platform for genomics in the absence of genetics</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">230</span>, <span class="refDoi"> DOI: 10.1186/gb-2004-5-7-230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1186%2Fgb-2004-5-7-230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=15239821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A280%3ADC%252BD2czlsVChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=230&issue=7&author=F.+C.+Oddsauthor=A.+J.+Brownauthor=N.+A.+Gow&title=Candida+albicans+genome+sequence%3A+a+platform+for+genomics+in+the+absence+of+genetics&doi=10.1186%2Fgb-2004-5-7-230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Candida albicans genome sequence: a platform for genomics in the absence of genetics</span></div><div class="casAuthors">Odds Frank C; Brown Alistair J P; Gow Neil A R</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">230</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Publication of the complete diploid genome sequence of the yeast Candida albicans will accelerate research into the pathogenesis of Candida infections.  Comparative genomic analysis highlights genes that may contribute to C. albicans survival and its fitness as a human commensal and pathogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZ8wMZhrtbR7ZpSb_XWfMrfW6udTcc2eZVoslmXgk0O7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czlsVChtA%253D%253D&md5=9c6f15ae6ef6abcb772b13b4cbd4d033</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1186%2Fgb-2004-5-7-230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2004-5-7-230%26sid%3Dliteratum%253Aachs%26aulast%3DOdds%26aufirst%3DF.%2BC.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DGow%26aufirst%3DN.%2BA.%26atitle%3DCandida%2520albicans%2520genome%2520sequence%253A%2520a%2520platform%2520for%2520genomics%2520in%2520the%2520absence%2520of%2520genetics%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26issue%3D7%26spage%3D230%26doi%3D10.1186%2Fgb-2004-5-7-230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Granger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durack, D. T.</span></span> <span> </span><span class="NLM_article-title">Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1172/JCI112000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1172%2FJCI112000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=3928681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADyaL2MXltlyhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1985&pages=508-516&issue=2&author=D.+L.+Grangerauthor=J.+R.+Perfectauthor=D.+T.+Durack&title=Virulence+of+Cryptococcus+neoformans.+Regulation+of+capsule+synthesis+by+carbon+dioxide&doi=10.1172%2FJCI112000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Virulence of Cryptococcus neoformans.  Regulation of capsule synthesis by carbon dioxide</span></div><div class="casAuthors">Granger, Donald L.; Perfect, John R.; Durack, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">508-16</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">C. neoformans Is variably encapsulated in vitro, whereas in tissues it develops a large capsule.  It was obsd. that cells of a strain with thin capsules, when growing in a std. fungal culture medium, became heavily encapsulated when incubated in the serum-free cell culture medium, Dulbecco's modified Eagle's medium (DME).  Capsule size was quantitated phys. by measuring cell vol. and chem. by detg. the content of a capsular monosaccharide, glucuronate.  The CO2/HCO3- couple stimulated capsule development, resulting in visible enlargement by 3 h after exposure to high CO2/HCO3-.  The amt. of capsule per cell was directly proportional to the total millimolar CO2/HCO3- concn. between 24 and 2.4 mM at pH 7.35, but at const. PCO2 (40 torr) and varying [HCO3-], the cells were heavily encapsulated down to pH 6.8.  Concn. of CO2/HCO3- in the physiol. range increased elaboration of polysaccharide into the medium and slowed the cell generation time from 2 to 6 h.  Four other 1st-passage clin. isolates were all heavily encapsulated in DME with CO2/HCO3-, but variably encapsulated in DME without CO2/HCO3-.  Exposure of yeast to increased CO2/HCO3- caused a marked redn. in complement-mediated phagocytosis by mouse macrophages.  A stable clone was isolated which contained capsular polysaccharide, but lacked the CO2-inducible phenotype.  This clone was avirulent for steroid-treated rabbits.  Thus, the prevailing CO2 concn. in mammalian tissues may be one stimulus for capsular polysaccharide synthesis.  This could serve as an adaptive mechanism favoring parasite survival in the host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoShgYIceZrabVg90H21EOLACvtfcHk0li3cklnbmO-Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltlyhuro%253D&md5=6198ec56309728bd9d81a6fbb5e3045b</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1172%2FJCI112000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI112000%26sid%3Dliteratum%253Aachs%26aulast%3DGranger%26aufirst%3DD.%2BL.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DDurack%26aufirst%3DD.%2BT.%26atitle%3DVirulence%2520of%2520Cryptococcus%2520neoformans.%2520Regulation%2520of%2520capsule%2520synthesis%2520by%2520carbon%2520dioxide%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1985%26volume%3D76%26issue%3D2%26spage%3D508%26epage%3D516%26doi%3D10.1172%2FJCI112000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaFayette, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betancourt-Quiroz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunatilaka, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">e1001069</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1001069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1371%2Fjournal.ppat.1001069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=20865172" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=e1001069&issue=8&author=S.+L.+LaFayetteauthor=C.+Collinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=M.+Betancourt-Quirozauthor=A.+A.+Gunatilakaauthor=J.+R.+Perfectauthor=L.+E.+Cowen&title=PKC+signaling+regulates+drug+resistance+of+the+fungal+pathogen+Candida+albicans+via+circuitry+comprised+of+Mkc1%2C+calcineurin%2C+and+Hsp90&doi=10.1371%2Fjournal.ppat.1001069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1001069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1001069%26sid%3Dliteratum%253Aachs%26aulast%3DLaFayette%26aufirst%3DS.%2BL.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DBetancourt-Quiroz%26aufirst%3DM.%26aulast%3DGunatilaka%26aufirst%3DA.%2BA.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DPKC%2520signaling%2520regulates%2520drug%2520resistance%2520of%2520the%2520fungal%2520pathogen%2520Candida%2520albicans%2520via%2520circuitry%2520comprised%2520of%2520Mkc1%252C%2520calcineurin%252C%2520and%2520Hsp90%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26issue%3D8%26spage%3De1001069%26doi%3D10.1371%2Fjournal.ppat.1001069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. W.</span></span> <span> </span><span class="NLM_article-title">Analysis of protein-ligand interactions by fluorescence polarization</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1038/nprot.2011.305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fnprot.2011.305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=21372817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3MXislentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=365-387&issue=3&author=A.+M.+Rossiauthor=C.+W.+Taylor&title=Analysis+of+protein-ligand+interactions+by+fluorescence+polarization&doi=10.1038%2Fnprot.2011.305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of protein-ligand interactions by fluorescence polarization</span></div><div class="casAuthors">Rossi, Ana M.; Taylor, Colin W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-387</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Quantification of the assocns. between biomols. is required both to predict and understand the interactions that underpin all biol. activity.  Fluorescence polarization (FP) provides a nondisruptive means of measuring the assocn. of a fluorescent ligand with a larger mol.  We describe an FP assay in which binding of fluorescein-labeled inositol 1,4,5-trisphosphate (IP3) to N-terminal fragments of IP3 receptors can be characterized at different temps. and in competition with other ligands.  The assay allows the std. Gibbs free energy (ΔG°), enthalpy (ΔH°) and entropy (ΔS°) changes of ligand binding to be detd.  The method is applicable to any purified ligand-binding site for which an appropriate fluorescent ligand is available.  FP can be used to measure low-affinity interactions in real time without the use of radioactive materials, it is nondestructive and, with appropriate care, it can resolve ΔH° and ΔS°.  The first part of the protocol, protein prepn., may take several weeks, whereas the FP measurements, once they have been optimized, would normally take 1-6 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPmq_JwlOSg7Vg90H21EOLACvtfcHk0li3cklnbmO-Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXislentbg%253D&md5=b78e3bcd884a06cdeb8b090227963d33</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2011.305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2011.305%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%2BW.%26atitle%3DAnalysis%2520of%2520protein-ligand%2520interactions%2520by%2520fluorescence%2520polarization%26jtitle%3DNat.%2520Protoc.%26date%3D2011%26volume%3D6%26issue%3D3%26spage%3D365%26epage%3D387%26doi%3D10.1038%2Fnprot.2011.305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span> <span> </span><span class="NLM_article-title">Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1469</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(94)90520-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2F0006-2952%2894%2990520-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=8185657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADyaK2cXkt1Kju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1994&pages=1469-1479&issue=9&author=J.+B.+Houston&title=Utility+of+in+vitro+drug+metabolism+data+in+predicting+in+vivo+metabolic+clearance&doi=10.1016%2F0006-2952%2894%2990520-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance</span></div><div class="casAuthors">Houston, J. Brian</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1469-79</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A review with 54 refs.  The aim of the commentary is to present a strategy to achieve the prediction of in vivo clearance from in vitro data based on the current understanding of metabolite kinetics in vitro and in vivo.  Hepatic microsomes and hepatocyte suspension are the main in vitro system addressed.  The theor. basis of the strategy is outlined and its general applicability evaluated, using a data base of 25 drugs drawn from the literature.  Finally, the prospective value of the approach is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFHqQ8gCJ6lrVg90H21EOLACvtfcHk0li3cklnbmO-Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkt1Kju7c%253D&md5=a6d0abdbd2f0b238a6a01ba63ee67739</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2894%2990520-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252894%252990520-7%26sid%3Dliteratum%253Aachs%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26atitle%3DUtility%2520of%2520in%2520vitro%2520drug%2520metabolism%2520data%2520in%2520predicting%2520in%2520vivo%2520metabolic%2520clearance%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1994%26volume%3D47%26issue%3D9%26spage%3D1469%26epage%3D1479%26doi%3D10.1016%2F0006-2952%2894%2990520-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, F. H.</span>; <span class="NLM_string-name">Morgentin, R. R.</span>; <span class="NLM_string-name">Ple, P.</span></span> <span> </span><span class="NLM_article-title">Quinoline derivatives</span>. <span class="NLM_patent">WO2007099323</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=F.+H.+Jung&author=R.+R.+Morgentin&author=P.+Ple&title=Quinoline+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DF.%2BH.%26atitle%3DQuinoline%2520derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikolovska-Coleska, Z.</span>; <span class="NLM_string-name">Abulwerdi, F.</span>; <span class="NLM_string-name">Showalter, H.</span>; <span class="NLM_string-name">Miao, L.</span>; <span class="NLM_string-name">Stuckey, J.</span>; <span class="NLM_string-name">Mady, A.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors of MCL-1 and uses thereof</span>. <span class="NLM_patent">WO2015153959</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+Nikolovska-Coleska&author=F.+Abulwerdi&author=H.+Showalter&author=L.+Miao&author=J.+Stuckey&author=A.+Mady&title=Small+molecule+inhibitors+of+MCL-1+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNikolovska-Coleska%26aufirst%3DZ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520MCL-1%2520and%2520uses%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jefson, M. R.</span>; <span class="NLM_string-name">Lowe, J. A.</span>; <span class="NLM_string-name">Dey, F.</span>; <span class="NLM_string-name">Bergmann, A.</span>; <span class="NLM_string-name">Schoop, A.</span>; <span class="NLM_string-name">Fuller, N. O.</span></span> <span> </span><span class="NLM_article-title">Hetero-halo inhibitors of histone deacetylase</span>. <span class="NLM_patent">WO2017007756</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+R.+Jefson&author=J.+A.+Lowe&author=F.+Dey&author=A.+Bergmann&author=A.+Schoop&author=N.+O.+Fuller&title=Hetero-halo+inhibitors+of+histone+deacetylase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJefson%26aufirst%3DM.%2BR.%26atitle%3DHetero-halo%2520inhibitors%2520of%2520histone%2520deacetylase%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 18 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yunjin Lee, Emily Puumala, Nicole Robbins, <span class="NLM_string-name hlFld-ContribAuthor">Leah E. Cowen</span>. </span><span class="cited-content_cbyCitation_article-title">Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3390-3411. <a href="https://doi.org/10.1021/acs.chemrev.0c00199" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00199%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DAntifungal%252BDrug%252BResistance%25253A%252BMolecular%252BMechanisms%252Bin%252BCandida%252Balbicans%252Band%252BBeyond%26aulast%3DLee%26aufirst%3DYunjin%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D17032020%26date%3D22052020%26volume%3D121%26issue%3D6%26spage%3D3390%26epage%3D3411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Paul T. Marcyk, Emmanuelle V. LeBlanc, Douglas A. Kuntz, Alice Xue, Francisco Ortiz, Richard Trilles, Stephen Bengtson, Tristan M. G. Kenney, David S. Huang, Nicole Robbins, Noelle S. Williams, Damian J. Krysan, Gilbert G. Privé, Luke Whitesell, Leah E. Cowen, <span class="NLM_string-name hlFld-ContribAuthor">Lauren E. Brown</span>. </span><span class="cited-content_cbyCitation_article-title">Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 1139-1169. <a href="https://doi.org/10.1021/acs.jmedchem.0c01777" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01777%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFungal-Selective%252BResorcylate%252BAminopyrazole%252BHsp90%252BInhibitors%25253A%252BOptimization%252Bof%252BWhole-Cell%252BAnticryptococcal%252BActivity%252Band%252BInsights%252Binto%252Bthe%252BStructural%252BOrigins%252Bof%252BCryptococcal%252BSelectivity%26aulast%3DMarcyk%26aufirst%3DPaul%2BT.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D20102020%26date%3D14012021%26volume%3D64%26issue%3D2%26spage%3D1139%26epage%3D1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Danish Ali, Anoop Kumar Panday, <span class="NLM_string-name hlFld-ContribAuthor">Lokman H. Choudhury</span>. </span><span class="cited-content_cbyCitation_article-title">Hydrogen Peroxide-Mediated Rapid Room Temperature Metal-Free C(sp2)-H Thiocyanation of Amino Pyrazoles, Amino Uracils, and Enamines. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (21)
                                     , 13610-13620. <a href="https://doi.org/10.1021/acs.joc.0c01738" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01738</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01738%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DHydrogen%252BPeroxide-Mediated%252BRapid%252BRoom%252BTemperature%252BMetal-Free%252BC%252528sp2%252529-H%252BThiocyanation%252Bof%252BAmino%252BPyrazoles%25252C%252BAmino%252BUracils%25252C%252Band%252BEnamines%26aulast%3DAli%26aufirst%3DDanish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21072020%26date%3D15102020%26volume%3D85%26issue%3D21%26spage%3D13610%26epage%3D13620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wanqian  Li</span>, <span class="hlFld-ContribAuthor ">Manjari  Shrivastava</span>, <span class="hlFld-ContribAuthor ">Hui  Lu</span>, <span class="hlFld-ContribAuthor ">Yuanying  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Calcium-calcineurin signaling pathway in Candida albicans: A potential drug target. </span><span class="cited-content_cbyCitation_journal-name">Microbiological Research</span><span> <strong>2021,</strong> <em>249 </em>, 126786. <a href="https://doi.org/10.1016/j.micres.2021.126786" title="DOI URL">https://doi.org/10.1016/j.micres.2021.126786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.micres.2021.126786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.micres.2021.126786%26sid%3Dliteratum%253Aachs%26jtitle%3DMicrobiological%2520Research%26atitle%3DCalcium-calcineurin%252Bsignaling%252Bpathway%252Bin%252BCandida%252Balbicans%25253A%252BA%252Bpotential%252Bdrug%252Btarget%26aulast%3DLi%26aufirst%3DWanqian%26date%3D2021%26volume%3D249%26spage%3D126786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kali R.  Iyer</span>, <span class="hlFld-ContribAuthor ">Nicole M.  Revie</span>, <span class="hlFld-ContribAuthor ">Ci  Fu</span>, <span class="hlFld-ContribAuthor ">Nicole  Robbins</span>, <span class="hlFld-ContribAuthor ">Leah E.  Cowen</span>. </span><span class="cited-content_cbyCitation_article-title">Treatment strategies for cryptococcal infection: challenges, advances and future outlook. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Microbiology</span><span> <strong>2021,</strong> <em>19 </em>
                                    (7)
                                     , 454-466. <a href="https://doi.org/10.1038/s41579-021-00511-0" title="DOI URL">https://doi.org/10.1038/s41579-021-00511-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41579-021-00511-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41579-021-00511-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Microbiology%26atitle%3DTreatment%252Bstrategies%252Bfor%252Bcryptococcal%252Binfection%25253A%252Bchallenges%25252C%252Badvances%252Band%252Bfuture%252Boutlook%26aulast%3DIyer%26aufirst%3DKali%2BR.%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D7%26spage%3D454%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ellie Rose  Mattoon</span>, <span class="hlFld-ContribAuthor ">Arturo  Casadevall</span>, <span class="hlFld-ContribAuthor ">Radames JB.  Cordero</span>. </span><span class="cited-content_cbyCitation_article-title">Beat the heat: correlates, compounds, and mechanisms involved in fungal thermotolerance. </span><span class="cited-content_cbyCitation_journal-name">Fungal Biology Reviews</span><span> <strong>2021,</strong> <em>36 </em>, 60-75. <a href="https://doi.org/10.1016/j.fbr.2021.03.002" title="DOI URL">https://doi.org/10.1016/j.fbr.2021.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fbr.2021.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fbr.2021.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DFungal%2520Biology%2520Reviews%26atitle%3DBeat%252Bthe%252Bheat%25253A%252Bcorrelates%25252C%252Bcompounds%25252C%252Band%252Bmechanisms%252Binvolved%252Bin%252Bfungal%252Bthermotolerance%26aulast%3DMattoon%26aufirst%3DEllie%2BRose%26date%3D2021%26volume%3D36%26spage%3D60%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Yuan</span>, <span class="hlFld-ContribAuthor ">Jie  Tu</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>, <span class="hlFld-ContribAuthor ">Xi  Chen</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Microbiology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fmicb.2021.680382" title="DOI URL">https://doi.org/10.3389/fmicb.2021.680382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmicb.2021.680382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmicb.2021.680382%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Microbiology%26atitle%3DEffects%252Bof%252BHsp90%252BInhibitor%252BGanetespib%252Bon%252BInhibition%252Bof%252BAzole-Resistant%252BCandida%252Balbicans%26aulast%3DYuan%26aufirst%3DRui%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Lu</span>, <span class="hlFld-ContribAuthor ">Manjari  Shrivastava</span>, <span class="hlFld-ContribAuthor ">Malcolm  Whiteway</span>, <span class="hlFld-ContribAuthor ">Yuanying  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Candida albicans
              targets that potentially synergize with fluconazole. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Microbiology</span><span> <strong>2021,</strong> <em>47 </em>
                                    (3)
                                     , 323-337. <a href="https://doi.org/10.1080/1040841X.2021.1884641" title="DOI URL">https://doi.org/10.1080/1040841X.2021.1884641</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1040841X.2021.1884641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1040841X.2021.1884641%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Microbiology%26atitle%3DCandida%252Balbicans%252Btargets%252Bthat%252Bpotentially%252Bsynergize%252Bwith%252Bfluconazole%26aulast%3DLu%26aufirst%3DHui%26date%3D2021%26date%3D2021%26volume%3D47%26issue%3D3%26spage%3D323%26epage%3D337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Liu</span>, <span class="hlFld-ContribAuthor ">Jinyao  Chen</span>, <span class="hlFld-ContribAuthor ">Ming  Zhang</span>, <span class="hlFld-ContribAuthor ">Chuan  Tian</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Peng</span>, <span class="hlFld-ContribAuthor ">Gang  Li</span>, <span class="hlFld-ContribAuthor ">Wenqiang  Chang</span>, <span class="hlFld-ContribAuthor ">Hongxiang  Lou</span>. </span><span class="cited-content_cbyCitation_article-title">Azole-triphenylphosphonium conjugates combat antifungal resistance and alleviate the development of drug-resistance. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104771. <a href="https://doi.org/10.1016/j.bioorg.2021.104771" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104771</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104771%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DAzole-triphenylphosphonium%252Bconjugates%252Bcombat%252Bantifungal%252Bresistance%252Band%252Balleviate%252Bthe%252Bdevelopment%252Bof%252Bdrug-resistance%26aulast%3DWang%26aufirst%3DXin%26date%3D2021%26volume%3D110%26spage%3D104771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linda C.  Horianopoulos</span>, <span class="hlFld-ContribAuthor ">James W.  Kronstad</span>. </span><span class="cited-content_cbyCitation_article-title">Chaperone Networks in Fungal Pathogens of Humans. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fungi</span><span> <strong>2021,</strong> <em>7 </em>
                                    (3)
                                     , 209. <a href="https://doi.org/10.3390/jof7030209" title="DOI URL">https://doi.org/10.3390/jof7030209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jof7030209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjof7030209%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fungi%26atitle%3DChaperone%252BNetworks%252Bin%252BFungal%252BPathogens%252Bof%252BHumans%26aulast%3DHorianopoulos%26aufirst%3DLinda%2BC.%26date%3D2021%26date%3D2021%26volume%3D7%26issue%3D3%26spage%3D209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alison Felipe Alencar  Chaves</span>, <span class="hlFld-ContribAuthor ">Marina Valente  Navarro</span>, <span class="hlFld-ContribAuthor ">Yasmin Nascimento  de Barros</span>, <span class="hlFld-ContribAuthor ">Rafael Souza  Silva</span>, <span class="hlFld-ContribAuthor ">Patricia  Xander</span>, <span class="hlFld-ContribAuthor ">Wagner Luiz  Batista</span>. </span><span class="cited-content_cbyCitation_article-title">Updates in Paracoccidioides Biology and Genetic Advances in Fungus Manipulation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fungi</span><span> <strong>2021,</strong> <em>7 </em>
                                    (2)
                                     , 116. <a href="https://doi.org/10.3390/jof7020116" title="DOI URL">https://doi.org/10.3390/jof7020116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jof7020116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjof7020116%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fungi%26atitle%3DUpdates%252Bin%252BParacoccidioides%252BBiology%252Band%252BGenetic%252BAdvances%252Bin%252BFungus%252BManipulation%26aulast%3DChaves%26aufirst%3DAlison%2BFelipe%2BAlencar%26date%3D2021%26date%3D2021%26volume%3D7%26issue%3D2%26spage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deeva  Uthayakumar</span>, <span class="hlFld-ContribAuthor ">Jehoshua  Sharma</span>, <span class="hlFld-ContribAuthor ">Lauren  Wensing</span>, <span class="hlFld-ContribAuthor ">Rebecca S.  Shapiro</span>. </span><span class="cited-content_cbyCitation_article-title">CRISPR-Based Genetic Manipulation of Candida Species: Historical Perspectives and Current Approaches. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Genome Editing</span><span> <strong>2021,</strong> <em>2 </em><a href="https://doi.org/10.3389/fgeed.2020.606281" title="DOI URL">https://doi.org/10.3389/fgeed.2020.606281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fgeed.2020.606281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffgeed.2020.606281%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Genome%2520Editing%26atitle%3DCRISPR-Based%252BGenetic%252BManipulation%252Bof%252BCandida%252BSpecies%25253A%252BHistorical%252BPerspectives%252Band%252BCurrent%252BApproaches%26aulast%3DUthayakumar%26aufirst%3DDeeva%26date%3D2021%26date%3D2021%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Ramesh  Sistla</span>. </span><span class="cited-content_cbyCitation_article-title">A survey of applications of tetrahydropyrrolo-3,4-azoles and tetrahydropyrrolo-2,3-azoles in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 31-100. <a href="https://doi.org/10.1016/bs.aihch.2020.10.004" title="DOI URL">https://doi.org/10.1016/bs.aihch.2020.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2020.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2020.10.004%26sid%3Dliteratum%253Aachs%26atitle%3DA%252Bsurvey%252Bof%252Bapplications%252Bof%252Btetrahydropyrrolo-3%25252C4-azoles%252Band%252Btetrahydropyrrolo-2%25252C3-azoles%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2021%26spage%3D31%26epage%3D100%26pub%3DElsevier%26atitle%3DApplications%252Bof%252BHeterocycles%252Bin%252Bthe%252BDesign%252Bof%252BDrugs%252Band%252BAgricultural%252BProducts%26date%3D2021%26volume%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emmanuelle V.  LeBlanc</span>, <span class="hlFld-ContribAuthor ">Tanvi  Shekhar‐Guturja</span>, <span class="hlFld-ContribAuthor ">Luke  Whitesell</span>, <span class="hlFld-ContribAuthor ">Leah E.  Cowen</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorescence Polarization‐Based Measurement of Protein‐Ligand Interaction in Fungal Cell Lysates. </span><span class="cited-content_cbyCitation_journal-name">Current Protocols</span><span> <strong>2021,</strong> <em>1 </em>
                                    (1)
                                     <a href="https://doi.org/10.1002/cpz1.17" title="DOI URL">https://doi.org/10.1002/cpz1.17</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpz1.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpz1.17%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Protocols%26atitle%3DFluorescence%252BPolarization%2525E2%252580%252590Based%252BMeasurement%252Bof%252BProtein%2525E2%252580%252590Ligand%252BInteraction%252Bin%252BFungal%252BCell%252BLysates%26aulast%3DLeBlanc%26aufirst%3DEmmanuelle%2BV.%26date%3D2021%26date%3D2021%26volume%3D1%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emmanuelle V.  LeBlanc</span>, <span class="hlFld-ContribAuthor ">Elizabeth J.  Polvi</span>, <span class="hlFld-ContribAuthor ">Amanda O.  Veri</span>, <span class="hlFld-ContribAuthor ">Gilbert G.  Privé</span>, <span class="hlFld-ContribAuthor ">Leah E.  Cowen</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-guided approaches to targeting stress responses in human fungal pathogens. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2020,</strong> <em>295 </em>
                                    (42)
                                     , 14458-14472. <a href="https://doi.org/10.1074/jbc.REV120.013731" title="DOI URL">https://doi.org/10.1074/jbc.REV120.013731</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.REV120.013731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.REV120.013731%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DStructure-guided%252Bapproaches%252Bto%252Btargeting%252Bstress%252Bresponses%252Bin%252Bhuman%252Bfungal%252Bpathogens%26aulast%3DLeBlanc%26aufirst%3DEmmanuelle%2BV.%26date%3D2020%26volume%3D295%26issue%3D42%26spage%3D14458%26epage%3D14472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia  Skrzypczak</span>, <span class="hlFld-ContribAuthor ">Krystian  Pyta</span>, <span class="hlFld-ContribAuthor ">Piotr  Ruszkowski</span>, <span class="hlFld-ContribAuthor ">Maria  Gdaniec</span>, <span class="hlFld-ContribAuthor ">Franz  Bartl</span>, <span class="hlFld-ContribAuthor ">Piotr  Przybylski</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, structure and anticancer activity of new geldanamycin amine analogs containing C(17)- or C(20)- flexible and rigid arms as well as closed or open ansa-bridges. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>202 </em>, 112624. <a href="https://doi.org/10.1016/j.ejmech.2020.112624" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112624</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112624%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bstructure%252Band%252Banticancer%252Bactivity%252Bof%252Bnew%252Bgeldanamycin%252Bamine%252Banalogs%252Bcontaining%252BC%25252817%252529-%252Bor%252BC%25252820%252529-%252Bflexible%252Band%252Brigid%252Barms%252Bas%252Bwell%252Bas%252Bclosed%252Bor%252Bopen%252Bansa-bridges%26aulast%3DSkrzypczak%26aufirst%3DNatalia%26date%3D2020%26volume%3D202%26spage%3D112624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saif  Hossain</span>, <span class="hlFld-ContribAuthor ">Amanda O.  Veri</span>, <span class="hlFld-ContribAuthor ">Leah E.  Cowen</span>, . </span><span class="cited-content_cbyCitation_article-title">The Proteasome Governs Fungal Morphogenesis via Functional Connections with Hsp90 and cAMP-Protein Kinase A Signaling. </span><span class="cited-content_cbyCitation_journal-name">mBio</span><span> <strong>2020,</strong> <em>11 </em>
                                    (2)
                                     <a href="https://doi.org/10.1128/mBio.00290-20" title="DOI URL">https://doi.org/10.1128/mBio.00290-20</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/mBio.00290-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FmBio.00290-20%26sid%3Dliteratum%253Aachs%26jtitle%3DmBio%26atitle%3DThe%252BProteasome%252BGoverns%252BFungal%252BMorphogenesis%252Bvia%252BFunctional%252BConnections%252Bwith%252BHsp90%252Band%252BcAMP-Protein%252BKinase%252BA%252BSignaling%26aulast%3DHossain%26aufirst%3DSaif%26date%3D2020%26volume%3D11%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  de Castro Spadari</span>, <span class="hlFld-ContribAuthor ">Taissa  Vila</span>, <span class="hlFld-ContribAuthor ">Vinícius  de Morais Barroso</span>, <span class="hlFld-ContribAuthor ">Kelly  Ishida</span>. </span><span class="cited-content_cbyCitation_article-title">New Targets for the Development of Antifungal Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-809633-8.21026-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-809633-8.21026-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809633-8.21026-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809633-8.21026-1%26sid%3Dliteratum%253Aachs%26atitle%3DNew%252BTargets%252Bfor%252Bthe%252BDevelopment%252Bof%252BAntifungal%252BAgents%26aulast%3Dde%2BCastro%2BSpadari%26aufirst%3DCristina%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BLife%252BSciences%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of aminopyrazole resorcylate-type inhibitor chemotype <b>8</b> based on precedented fungal-selective natural-product-derived inhibitors (A) and truncated resorcylates under clinical evaluation in oncology (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. First-Generation Synthetic Route to Aminopyrazole/Isoindoline Resorcylate Amides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) POCl<sub>3</sub>, DMF, 100 °C; (b) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C to rt; (c) MOMCl, DIPEA, DMF; (d) NaOCl<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, 2-methyl-2-butene, THF/<sup><i>t</i></sup>BuOH/H<sub>2</sub>O; (e) isoindoline·HCl, HATU, Et<sub>3</sub>N, THF/CH<sub>2</sub>Cl<sub>2</sub>; (f) <sup><i>t</i></sup>BuXphos Pd G1 (10 mol %), <sup><i>t</i></sup>BuXPhos (10 mol %), NaO<sup><i>t</i></sup>Bu, <sup><i>t</i></sup>BuOH, or Pd<sub>2</sub>(dba)<sub>3</sub> (4 mol %), Xantphos (8 mol %), NaOPh, dioxane, 60–120 °C, or Pd<sub>2</sub>(dba)<sub>3</sub> (10 mol %), Xantphos (10 mol %), NaOPh, dioxane, 170 °C, microwave; (g) HCl, methanol, 50 °C.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Early Exploration of Amide SAR Using First-Generation Synthetic Route<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) HNR<sup>4</sup>R<sup>5</sup>, HATU, Et<sub>3</sub>N, THF/CH<sub>2</sub>Cl<sub>2</sub>; (b) <b>10a</b>, Pd<sub>2</sub>(dba)<sub>3</sub> (4 mol %), Xantphos (10 mol %), NaOPh, dioxane, 170 °C, microwave; (c) HCl, methanol, 50 °C.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Second-Generation Synthetic Route to Aminopyrazole Resorcylate Amides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C; (b) <b>10</b>, Pd<sub>2</sub>(dba)<sub>3</sub> (4 mol %), Xantphos (10 mol %), NaOPh; (c) KOH, EtOH, 95 °C; (d) HNR<sup>4</sup>R<sup>5</sup>, HATU, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>/THF, rt or HNR<sup>4</sup>R<sup>5</sup>, PS-CDI, HOBt·<i>x</i>H<sub>2</sub>O, Et<sub>3</sub>N, THF/CH<sub>2</sub>Cl<sub>2</sub>; (e) HCl, methanol, 50 °C.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Summary of iterative progression to fungal selective inhibitors <b>106</b>–<b>132</b> with divergent patterns of species selectivity dependent on position of substitution on the aminopyrazole phenyl ring (red).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Scatter plots depict fungal potency (<i>x</i>-axis) vs fungal selectivity (<i>y</i>-axis) relationships for all aminopyrazoles when screened using human cell lysate and lysate of either <i>C. neoformans</i> (A) or <i>C. albicans</i> (B). All potencies are reported as the inverse log<sub>10</sub> of compound EC<sub>50</sub> (pEC<sub>50</sub> as measured by FP assay). The scatter plot in panel C compares compound selectivity patterns between the two fungi. Key fungal-selective compounds for each species (<b>112</b>–<b>114</b> and <b>130</b>–<b>132</b>) are highlighted in color to underscore their divergence in potency and selectivity. Each point represents the mean of duplicate determinations in a single experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Biological activity of fungal-selective inhibitors: (A) growth inhibition by fungal-selective aminopyrazoles of <i>C. neoformans</i> reference strain H99 cultured in RPMI 1640 medium at 37 °C; (B) growth inhibition by fungal-selective aminopyrazoles of a <i>C. albicans</i> clinical isolate (CaCi2) with or without a background concentration of 8 μg/mL fluconazole. The effect of 48 h exposure to inhibitors over a 2-fold dilution series of concentrations is displayed in heat-map format. Color scale bar: no growth inhibition (green) to complete inhibition (black). Each colored box represents the mean of technical duplicates. The experiment was repeated as an independent biological replicate to confirm results. Following exposure to compounds, aliquots of the cultures in each well were spotted onto compound-free YPD agar and plates were incubated at 30 °C for an additional 24 h before imaging to assess fungicidal activity (panel B, right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/medium/jm9b00826_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Microsomal stability (mouse liver microsomes) of a panel of fungal-selective inhibitors. Assays were performed by Charles River Laboratories (Worcester, MA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00826/20200306/images/large/jm9b00826_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00826&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i277">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83487" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83487" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 66 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denning, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitz, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netea, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, T. C.</span></span> <span> </span><span class="NLM_article-title">Hidden killers: human fungal infections</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">165</span>),  <span class="NLM_fpage">165rv13</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3004404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1126%2Fscitranslmed.3004404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=23253612" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=165rv13&issue=165&author=G.+D.+Brownauthor=D.+W.+Denningauthor=N.+A.+Gowauthor=S.+M.+Levitzauthor=M.+G.+Neteaauthor=T.+C.+White&title=Hidden+killers%3A+human+fungal+infections&doi=10.1126%2Fscitranslmed.3004404"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004404%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DG.%2BD.%26aulast%3DDenning%26aufirst%3DD.%2BW.%26aulast%3DGow%26aufirst%3DN.%2BA.%26aulast%3DLevitz%26aufirst%3DS.%2BM.%26aulast%3DNetea%26aufirst%3DM.%2BG.%26aulast%3DWhite%26aufirst%3DT.%2BC.%26atitle%3DHidden%2520killers%253A%2520human%2520fungal%2520infections%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26issue%3D165%26spage%3D165rv13%26doi%3D10.1126%2Fscitranslmed.3004404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span>; <span class="NLM_string-name">Wright, G. D.</span>; <span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Antifungal drugs: the current armamentarium and development of new agents</span>. In  <i>The Fungal Kingdom</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, J.</span>, <span class="NLM_string-name">Howlett, B.</span>, <span class="NLM_string-name">Crous, P.</span>, <span class="NLM_string-name">Stukenbrock, E.</span>, <span class="NLM_string-name">James, T.</span>, <span class="NLM_string-name">Gow, N.</span></span>, Eds.; <span class="NLM_publisher-name">ASM Press</span>: <span class="NLM_publisher-loc">Washington DC</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">4</span>, pp  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">922</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1128%2F9781555819583.ch44" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=903-922&author=N.+Robbins&author=G.+D.+Wright&author=L.+E.+Cowenauthor=J.+Heitman&author=B.+Howlett&author=P.+Crous&author=E.+Stukenbrock&author=T.+James&author=N.+Gow&title=The+Fungal+Kingdom"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1128%2F9781555819583.ch44&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1128%252F9781555819583.ch44%26sid%3Dliteratum%253Aachs%26aulast%3DRobbins%26aufirst%3DN.%26atitle%3DAntifungal%2520drugs%253A%2520the%2520current%2520armamentarium%2520and%2520development%2520of%2520new%2520agents%26btitle%3DThe%2520Fungal%2520Kingdom%26aulast%3DHeitman%26aufirst%3DJ.%26pub%3DASM%2520Press%26date%3D2017%26volume%3D4%26spage%3D903%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mora-Montes, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erwig, L. P.</span></span> <span> </span><span class="NLM_article-title">Contribution of Candida albicans cell wall components to recognition by and escape from murine macrophages</span>. <i>Infect. Immun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1650</span>– <span class="NLM_lpage">1658</span>, <span class="refDoi"> DOI: 10.1128/IAI.00001-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1128%2FIAI.00001-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=20123707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt12gtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=1650-1658&issue=4&author=C.+G.+McKenzieauthor=U.+Koserauthor=L.+E.+Lewisauthor=J.+M.+Bainauthor=H.+M.+Mora-Montesauthor=R.+N.+Barkerauthor=N.+A.+Gowauthor=L.+P.+Erwig&title=Contribution+of+Candida+albicans+cell+wall+components+to+recognition+by+and+escape+from+murine+macrophages&doi=10.1128%2FIAI.00001-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of Candida albicans cell wall components to recognition by and escape from murine macrophages</span></div><div class="casAuthors">McKenzie, C. G. J.; Koser, U.; Lewis, L. E.; Bain, J. M.; Mora-Montes, H. M.; Barker, R. N.; Gow, N. A. R.; Erwig, L. P.</div><div class="citationInfo"><span class="NLM_cas:title">Infection and Immunity</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1650-1658</span>CODEN:
                <span class="NLM_cas:coden">INFIBR</span>;
        ISSN:<span class="NLM_cas:issn">0019-9567</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The pathogenicity of the opportunistic human fungal pathogen Candida albicans depends on its ability to escape destruction by the host immune system.  Using mutant strains that are defective in cell surface glycosylation, cell wall protein synthesis, and yeast-hypha morphogenesis, the authors have investigated three important aspects of C. albicans innate immune interactions: phagocytosis by primary macrophages and macrophage cell lines, hyphal formation within macrophage phagosomes, and the ability to escape from and kill macrophages.  The authors show that cell wall glycosylation is critically important for the recognition and ingestion of C. albicans by macrophages.  Phagocytosis was significantly reduced for mutants deficient in phosphomannan biosynthesis (mmn4Δ, pmr1Δ, and mnt3 mnt5Δ), whereas O- and N-linked mannan defects (mnt1Δ mnt2Δ and mns1Δ) were assocd. with increased ingestion, compared to the parent wild-type strains and genetically complemented controls.  In contrast, macrophage uptake of mutants deficient in cell wall proteins such as adhesins (ece1Δ, hwp1Δ, and als3Δ) and yeast-locked mutants (clb2Δ, hgc1Δ, cph1Δ, efg1Δ, and efg1Δ cph1Δ), was similar to that obsd. for wild-type C. albicans.  Killing of macrophages was abrogated in hypha-deficient strains, significantly reduced in all glycosylation mutants, and comparable to wild type in cell wall protein mutants.  The diminished ability of glycosylation mutants to kill macrophages was not a consequence of impaired hyphal formation within macrophage phagosomes.  Therefore, cell wall compn. and the ability to undergo yeast-hypha morphogenesis are crit. determinants of the macrophage's ability to ingest and process C. albicans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5E710wN4SdbVg90H21EOLACvtfcHk0lhYfvj1IiskWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt12gtLc%253D&md5=c0fd80f2331d012cdeec203301f2a588</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FIAI.00001-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FIAI.00001-10%26sid%3Dliteratum%253Aachs%26aulast%3DMcKenzie%26aufirst%3DC.%2BG.%26aulast%3DKoser%26aufirst%3DU.%26aulast%3DLewis%26aufirst%3DL.%2BE.%26aulast%3DBain%26aufirst%3DJ.%2BM.%26aulast%3DMora-Montes%26aufirst%3DH.%2BM.%26aulast%3DBarker%26aufirst%3DR.%2BN.%26aulast%3DGow%26aufirst%3DN.%2BA.%26aulast%3DErwig%26aufirst%3DL.%2BP.%26atitle%3DContribution%2520of%2520Candida%2520albicans%2520cell%2520wall%2520components%2520to%2520recognition%2520by%2520and%2520escape%2520from%2520murine%2520macrophages%26jtitle%3DInfect.%2520Immun.%26date%3D2010%26volume%3D78%26issue%3D4%26spage%3D1650%26epage%3D1658%26doi%3D10.1128%2FIAI.00001-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mylonakis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2818</span>– <span class="NLM_lpage">2823</span>, <span class="refDoi"> DOI: 10.1073/pnas.0813394106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1073%2Fpnas.0813394106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=19196973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislaht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=2818-2823&issue=8&author=L.+E.+Cowenauthor=S.+D.+Singhauthor=J.+R.+Kohlerauthor=C.+Collinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=H.+Azizauthor=E.+Mylonakisauthor=J.+R.+Perfectauthor=L.+Whitesellauthor=S.+Lindquist&title=Harnessing+Hsp90+function+as+a+powerful%2C+broadly+effective+therapeutic+strategy+for+fungal+infectious+disease&doi=10.1073%2Fpnas.0813394106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease</span></div><div class="casAuthors">Cowen, Leah E.; Singh, Sheena D.; Kohler, Julia R.; Collins, Cathy; Zaas, Aimee; Schell, Wiley A.; Aziz, Hamza; Mylonakis, Eleftherios; Perfect, John R.; Whitesell, Luke; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2818-2823</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Invasive fungal infections are a leading cause of mortality among immunocompromised individuals.  Treatment is notoriously difficult with the limited armamentarium of antifungal drugs, whose efficacy is compromised by host toxicity, a limited activity spectrum, or the emergence of drug resistance.  We previously established that the mol. chaperone Hsp90 enables the emergence and maintenance of fungal drug resistance.  For the most prevalent fungal pathogen of humans, Candida albicans, Hsp90 mediates resistance to azoles, which inhibit ergosterol biosynthesis and are the most widely deployed antifungals in the clinic.  For the emerging opportunistic pathogen Aspergillus terreus, Hsp90 is required for basal resistance to echinocandins, which inhibit β(1, 3)-glucan synthesis and are the only new class of antifungals to reach the clinic in decades.  Here, we explore the therapeutic potential of Hsp90 inhibitors in fungal disease using a tractable host-model system, larvae of the greater wax moth Galleria mellonella, and a murine model of disseminated disease.  Combination therapy with Hsp90 inhibitors that are well tolerated in humans and an azole rescued larvae from lethal C. albicans infections.  Combination therapy with an Hsp90 inhibitor and an echinocandin rescued larvae from infections with the most lethal mold, Aspergillus fumigatus.  In a murine model of disseminated candidiasis, genetic compromise of C. albicans HSP90 expression enhanced the therapeutic efficacy of an azole.  Thus, harnessing Hsp90 provides a much-needed strategy for improving the treatment of fungal disease because it enhances the efficacy of existing antifungals, blocks the emergence of drug resistance, and exerts broad-spectrum activity against diverse fungal pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtMf02gFiLZLVg90H21EOLACvtfcHk0lhYfvj1IiskWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislaht7s%253D&md5=a0bf89b9285831333d619bb9edc8f4ef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0813394106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0813394106%26sid%3Dliteratum%253Aachs%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DSingh%26aufirst%3DS.%2BD.%26aulast%3DKohler%26aufirst%3DJ.%2BR.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DAziz%26aufirst%3DH.%26aulast%3DMylonakis%26aufirst%3DE.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHarnessing%2520Hsp90%2520function%2520as%2520a%2520powerful%252C%2520broadly%2520effective%2520therapeutic%2520strategy%2520for%2520fungal%2520infectious%2520disease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D8%26spage%3D2818%26epage%3D2823%26doi%3D10.1073%2Fpnas.0813394106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>309</i></span> (<span class="NLM_issue">5744</span>),  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2189</span>, <span class="refDoi"> DOI: 10.1126/science.1118370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1126%2Fscience.1118370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=16195452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeksbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2005&pages=2185-2189&issue=5744&author=L.+E.+Cowenauthor=S.+Lindquist&title=Hsp90+potentiates+the+rapid+evolution+of+new+traits%3A+drug+resistance+in+diverse+fungi&doi=10.1126%2Fscience.1118370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi</span></div><div class="casAuthors">Cowen, Leah E.; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">5744</span>),
    <span class="NLM_cas:pages">2185-2189</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Hsp90 is a mol. chaperone for many signal transducers and may influence evolution by releasing previously silent genetic variation in response to environmental change.  In fungi sepd. by ∼800 million years of evolution, Hsp90 potentiated the evolution of drug resistance in a different way, by enabling new mutations to have immediate phenotypic consequences.  Resistance was abrogated by Hsp90 inhibitors and by febrile temps., suggesting new therapeutic strategies and a clin. benefit of fever.  During selection in a human host, drug resistance that was initially Hsp90-dependent evolved toward independence.  Thus, Hsp90 can act in diverse ways to couple environmental contingency to the emergence and fixation of new traits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiYEERY_9yw7Vg90H21EOLACvtfcHk0lhs4jH-lB5O0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeksbbI&md5=153bda853d501270402f5e18ab14b5d8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1118370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1118370%26sid%3Dliteratum%253Aachs%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHsp90%2520potentiates%2520the%2520rapid%2520evolution%2520of%2520new%2520traits%253A%2520drug%2520resistance%2520in%2520diverse%2520fungi%26jtitle%3DScience%26date%3D2005%26volume%3D309%26issue%3D5744%26spage%3D2185%26epage%3D2189%26doi%3D10.1126%2Fscience.1118370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">e1000532</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1000532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1371%2Fjournal.ppat.1000532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=19649312" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=e1000532&issue=7&author=S.+D.+Singhauthor=N.+Robbinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=J.+R.+Perfectauthor=L.+E.+Cowen&title=Hsp90+governs+echinocandin+resistance+in+the+pathogenic+yeast+Candida+albicans+via+calcineurin&doi=10.1371%2Fjournal.ppat.1000532"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000532%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%2BD.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DHsp90%2520governs%2520echinocandin%2520resistance%2520in%2520the%2520pathogenic%2520yeast%2520Candida%2520albicans%2520via%2520calcineurin%26jtitle%3DPLoS%2520Pathog.%26date%3D2009%26volume%3D5%26issue%3D7%26spage%3De1000532%26doi%3D10.1371%2Fjournal.ppat.1000532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatu, U.</span></span> <span> </span><span class="NLM_article-title">Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">e0005836</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0005836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1371%2Fjournal.pntd.0005836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=28783748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCltbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=e0005836&issue=8&author=S.+Chatterjeeauthor=U.+Tatu&title=Heat+shock+protein+90+localizes+to+the+surface+and+augments+virulence+factors+of+Cryptococcus+neoformans&doi=10.1371%2Fjournal.pntd.0005836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans</span></div><div class="casAuthors">Chatterjee, Sharanya; Tatu, Utpal</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0005836/1-e0005836/20</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Thermotolerance is an essential attribute for pathogenesis of Cryptococcus as exemplified by the fact that only two species in the genus, which can grow at 37°C, are human pathogens.  Species which have other virulence factors including capsule formation and melanisation, but lack the ability to propagate at 37°C are not pathogenic.  In another related fungal pathogen, Candida albicans, heat shock protein 90 has been implicated to be a central player in commanding pathogenicity by governing yeast to hyphal transition and drug resistance.  Exploring Hsp90 biol. in Cryptococcus in context of thermotolerance may thus highlight important regulatory principles of virulence and open new therapeutic avenues.  Methodol./Principal findings Hsp90 is involved in regulating thermotolerance in Cryptococcus as indicated by growth hypersensitivity at 37°C upon mild compromise of Hsp90 function relative to 25°C.  Biochem. studies revealed a more potent inhibition of ATPase activity by pharmacol. inhibitor 17-AAG at 37°C as compared to 25°C.  Catalytic efficiency of the protein at 37°C was found to be 6.39 × 10-5μM-1.  Furthermore, indirect immunofluorescence anal. using a specific antibody revealed cell surface localization of Hsp90 via ER Golgi classical secretory pathway.  Hsp90 was found to be induced under capsule inducing conditions and Hsp90 inhibition led to decrease in capsular vol.  Finally compromising Hsp90 function improved anidulafungin tolerance in Cryptococcus.  Conclusions/Significance Our findings highlight that Hsp90 regulates pathogenicity of the fungus by myriad ways.  Firstly, it is involved in mediating thermotolerance which implies targeting Hsp90 can abrogate thermotolerance and hence growth of the fungus.  Secondly, this study provides the first report of biochem. properties of Hsp90 of a pathogenic fungus.  Finally, since Hsp90 is localised at the cell wall, targeting cell surface Hsp90 can represent a novel strategy to combat this lethal infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox--VK--z5SLVg90H21EOLACvtfcHk0lhs4jH-lB5O0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCltbjF&md5=d268755893a680cd9ef4f3e35e88690c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005836%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DTatu%26aufirst%3DU.%26atitle%3DHeat%2520shock%2520protein%252090%2520localizes%2520to%2520the%2520surface%2520and%2520augments%2520virulence%2520factors%2520of%2520Cryptococcus%2520neoformans%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26issue%3D8%26spage%3De0005836%26doi%3D10.1371%2Fjournal.pntd.0005836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Aguiar Cordeiro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Evangelista, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serpa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Farias Marques, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Melo, C. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva Franco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Alencar, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Pinheiro Gomes
Bandeira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brilhante, R. S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidrim, J. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, M. F. G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of Cryptococcus neoformans/Cryptococcus gattii species complex</span>. <i>Microbiology (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1099/mic.0.000222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1099%2Fmic.0.000222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=26645478" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2016&pages=309-317&issue=2&author=R.+de%0AAguiar+Cordeiroauthor=A.+J.+de+Jesus+Evangelistaauthor=R.+Serpaauthor=F.+J.+de+Farias+Marquesauthor=C.+V.+S.+de+Meloauthor=J.+S.+de+Oliveiraauthor=J.+da+Silva+Francoauthor=L.+P.+de+Alencarauthor=T.+de+Jesus+Pinheiro+Gomes%0ABandeiraauthor=R.+S.+N.+Brilhanteauthor=J.+J.+C.+Sidrimauthor=M.+F.+G.+Rocha&title=Inhibition+of+heat-shock+protein+90+enhances+the+susceptibility+to+antifungals+and+reduces+the+virulence+of+Cryptococcus+neoformans%2FCryptococcus+gattii+species+complex&doi=10.1099%2Fmic.0.000222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1099%2Fmic.0.000222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fmic.0.000222%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BAguiar%2BCordeiro%26aufirst%3DR.%26aulast%3Dde%2BJesus%2BEvangelista%26aufirst%3DA.%2BJ.%26aulast%3DSerpa%26aufirst%3DR.%26aulast%3Dde%2BFarias%2BMarques%26aufirst%3DF.%2BJ.%26aulast%3Dde%2BMelo%26aufirst%3DC.%2BV.%2BS.%26aulast%3Dde%2BOliveira%26aufirst%3DJ.%2BS.%26aulast%3Dda%2BSilva%2BFranco%26aufirst%3DJ.%26aulast%3Dde%2BAlencar%26aufirst%3DL.%2BP.%26aulast%3Dde%2BJesus%2BPinheiro%2BGomes%2BBandeira%26aufirst%3DT.%26aulast%3DBrilhante%26aufirst%3DR.%2BS.%2BN.%26aulast%3DSidrim%26aufirst%3DJ.%2BJ.%2BC.%26aulast%3DRocha%26aufirst%3DM.%2BF.%2BG.%26atitle%3DInhibition%2520of%2520heat-shock%2520protein%252090%2520enhances%2520the%2520susceptibility%2520to%2520antifungals%2520and%2520reduces%2520the%2520virulence%2520of%2520Cryptococcus%2520neoformans%252FCryptococcus%2520gattii%2520species%2520complex%26jtitle%3DMicrobiology%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2016%26volume%3D162%26issue%3D2%26spage%3D309%26epage%3D317%26doi%3D10.1099%2Fmic.0.000222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Annessa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compostella, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, G.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulators of HSP90 and HSP70: dynamics meets function through structure-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00825</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlykurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=60-87&issue=1&author=M.+Ferraroauthor=I.+D%E2%80%99Annessaauthor=E.+Moroniauthor=G.+Morraauthor=A.+Paladinoauthor=S.+Rinaldiauthor=F.+Compostellaauthor=G.+Colombo&title=Allosteric+modulators+of+HSP90+and+HSP70%3A+dynamics+meets+function+through+structure-based+drug+design&doi=10.1021%2Facs.jmedchem.8b00825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design</span></div><div class="casAuthors">Ferraro, Mariarosaria; DAnnessa, Ilda; Moroni, Elisabetta; Morra, Giulia; Paladino, Antonella; Rinaldi, Silvia; Compostella, Federica; Colombo, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-87</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Mol. chaperones HSP90 and HSP70 are essential regulators of the folding and activation of a disparate ensemble of client proteins.  They function through ATP hydrolysis and the assembly of multiprotein complexes with co-chaperones and clients.  While their therapeutic relevance is recognized, important details underlying the links between ATP-dependent conformational dynamics and clients/co-chaperones recruitment remain elusive.  Allosteric modulators represent fundamental tools to obtain mol. insights into functional regulation.  By selectively perturbing different aspect of HSP90/HSP70 activities, allosteric drugs can tune rather than completely inhibit signaling cascades, providing information on the relationships between structure-dynamics and function.  Herein, the authors review advances in the design of HSP90 and HSP70 allosteric modulators.  The authors consider inhibitors and activators in different biochem. and disease models.  The authors discuss these compds. as probes to decipher the complexity of the chaperone machinery that at the same time represent starting leads for the development of drugs against cancer and neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl2ddWfMChFbVg90H21EOLACvtfcHk0litKoUQ8LAOxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlykurvF&md5=0e8378f0f6d03fb976e82088bca82f21</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00825%26sid%3Dliteratum%253Aachs%26aulast%3DFerraro%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Annessa%26aufirst%3DI.%26aulast%3DMoroni%26aufirst%3DE.%26aulast%3DMorra%26aufirst%3DG.%26aulast%3DPaladino%26aufirst%3DA.%26aulast%3DRinaldi%26aufirst%3DS.%26aulast%3DCompostella%26aufirst%3DF.%26aulast%3DColombo%26aufirst%3DG.%26atitle%3DAllosteric%2520modulators%2520of%2520HSP90%2520and%2520HSP70%253A%2520dynamics%2520meets%2520function%2520through%2520structure-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D1%26spage%3D60%26epage%3D87%26doi%3D10.1021%2Facs.jmedchem.8b00825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taipale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosz, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">HSP90 at the hub of protein homeostasis: emerging mechanistic insights</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1038/nrm2918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fnrm2918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=20531426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFSmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=515-528&author=M.+Taipaleauthor=D.+F.+Jaroszauthor=S.+Lindquist&title=HSP90+at+the+hub+of+protein+homeostasis%3A+emerging+mechanistic+insights&doi=10.1038%2Fnrm2918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 at the hub of protein homeostasis: emerging mechanistic insights</span></div><div class="casAuthors">Taipale, Mikko; Jarosz, Daniel F.; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">515-528</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Heat-shock protein 90 (HSP90) is a highly conserved mol. chaperone that facilitates the maturation of a wide range of proteins (known as clients).  Clients are enriched in signal transducers, including kinases and transcription factors.  Therefore, HSP90 regulates diverse cellular functions and exerts marked effects on normal biol., disease, and evolutionary processes.  Recent structural and functional analyses have provided new insights on the transcriptional and biochem. regulation of HSP90 and the structural dynamics it uses to act on a diverse client repertoire.  A comprehensive understanding of how HSP90 functions promises not only to provide new avenues for therapeutic intervention, but to shed light on fundamental biol. questions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuMRSaY8uzGbVg90H21EOLACvtfcHk0litKoUQ8LAOxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFSmt7c%253D&md5=492dca92cea32384d2ab4145230f53dd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrm2918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2918%26sid%3Dliteratum%253Aachs%26aulast%3DTaipale%26aufirst%3DM.%26aulast%3DJarosz%26aufirst%3DD.%2BF.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHSP90%2520at%2520the%2520hub%2520of%2520protein%2520homeostasis%253A%2520emerging%2520mechanistic%2520insights%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2010%26volume%3D11%26spage%3D515%26epage%3D528%26doi%3D10.1038%2Fnrm2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar-Guturja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nation, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trilles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizarro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">402</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-08248-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fs41467-018-08248-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=30679438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFersrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=402&issue=1&author=L.+Whitesellauthor=N.+Robbinsauthor=D.+S.+Huangauthor=C.+A.+McLellanauthor=T.+Shekhar-Guturjaauthor=E.+V.+LeBlancauthor=C.+S.+Nationauthor=R.+Huiauthor=A.+Hutchinsonauthor=C.+Collinsauthor=S.+Chatterjeeauthor=R.+Trillesauthor=J.+L.+Xieauthor=D.+J.+Krysanauthor=S.+Lindquistauthor=J.+A.+Porcoauthor=U.+Tatuauthor=L.+E.+Brownauthor=J.+Pizarroauthor=L.+E.+Cowen&title=Structural+basis+for+species-selective+targeting+of+Hsp90+in+a+pathogenic+fungus&doi=10.1038%2Fs41467-018-08248-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus</span></div><div class="casAuthors">Whitesell, Luke; Robbins, Nicole; Huang, David S.; McLellan, Catherine A.; Shekhar-Guturja, Tanvi; LeBlanc, Emmanuelle V.; Nation, Catherine S.; Hui, Raymond; Hutchinson, Ashley; Collins, Cathy; Chatterjee, Sharanya; Trilles, Richard; Xie, Jinglin L.; Krysan, Damian J.; Lindquist, Susan; Porco, John A., Jr.; Tatu, Utpal; Brown, Lauren E.; Pizarro, Juan; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">402</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">New strategies are needed to counter the escalating threat posed by drug-resistant fungi.  The mol. chaperone Hsp90 affords a promising target because it supports survival, virulence and drug-resistance across diverse pathogens.  Inhibitors of human Hsp90 under development as anticancer therapeutics, however, exert host toxicities that preclude their use as antifungals.  Seeking a route to species-selectivity, we investigate the nucleotide-binding domain (NBD) of Hsp90 from the most common human fungal pathogen, Candida albicans.  Here we report structures for this NBD alone, in complex with ADP or in complex with known Hsp90 inhibitors.  Encouraged by the conformational flexibility revealed by these structures, we synthesize an inhibitor with >25-fold binding-selectivity for fungal Hsp90 NBD.  Comparing co-crystals occupied by this probe vs. anticancer Hsp90 inhibitors revealed major, previously unreported conformational rearrangements.  These insights and our probe's species-selectivity in culture support the feasibility of targeting Hsp90 as a promising antifungal strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc0j6rgX3IDrVg90H21EOLACvtfcHk0lhl7RDE90ohKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFersrg%253D&md5=ee973dc62c7912479f26d2ad26f024bc</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08248-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08248-w%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DD.%2BS.%26aulast%3DMcLellan%26aufirst%3DC.%2BA.%26aulast%3DShekhar-Guturja%26aufirst%3DT.%26aulast%3DLeBlanc%26aufirst%3DE.%2BV.%26aulast%3DNation%26aufirst%3DC.%2BS.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DHutchinson%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DTrilles%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DJ.%2BL.%26aulast%3DKrysan%26aufirst%3DD.%2BJ.%26aulast%3DLindquist%26aufirst%3DS.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DTatu%26aufirst%3DU.%26aulast%3DBrown%26aufirst%3DL.%2BE.%26aulast%3DPizarro%26aufirst%3DJ.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DStructural%2520basis%2520for%2520species-selective%2520targeting%2520of%2520Hsp90%2520in%2520a%2520pathogenic%2520fungus%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D402%26doi%3D10.1038%2Fs41467-018-08248-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rehn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zierer, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tippel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchner, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric regulation points control the conformational dynamics of the molecular chaperone Hsp90</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>428</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">4559</span>– <span class="NLM_lpage">4571</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2016.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.jmb.2016.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=27663270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFKmurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2016&pages=4559-4571&issue=22&author=A.+Rehnauthor=E.+Moroniauthor=B.+K.+Ziererauthor=F.+Tippelauthor=G.+Morraauthor=C.+Johnauthor=K.+Richterauthor=G.+Colomboauthor=J.+Buchner&title=Allosteric+regulation+points+control+the+conformational+dynamics+of+the+molecular+chaperone+Hsp90&doi=10.1016%2Fj.jmb.2016.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric regulation points control the conformational dynamics of the molecular chaperone Hsp90</span></div><div class="casAuthors">Rehn, Alexandra; Moroni, Elisabetta; Zierer, Bettina K.; Tippel, Franziska; Morra, Giulia; John, Christine; Richter, Klaus; Colombo, Giorgio; Buchner, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4559-4571</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Heat-shock protein 90 (Hsp90) is an ATP-dependent mol. chaperone responsible for the activation, maturation, and trafficking of several hundred client proteins in the cell.  It is well known that (but not understood how) residues far away from Hsp90's nucleotide binding pocket can regulate its ATPase activity, a phenomenon called allosteric regulation.  Here, the computational design of allosteric mutations was combined with in vitro and in vivo expts. to unravel nucleotide-responsive hot spots in the regulation of Hsp90.  With this approach, the authors identified both activating and inhibiting regulation points and showed that changes in those amino acids affect the conformational dynamics and ATPase activity of Hsp90 in vitro.  These observations that activating mutations loosen and inhibiting mutations rigidify the protein explain for the 1st time how Hsp90 changes in response to allosteric mutations.  Addnl., mutations of these allosteric regulation points can be controlled by the interplay with Hsp90 co-chaperones, thus providing cells with an efficient mechanism of modifying Hsp90's intrinsic properties via different layers of regulation.  Altogether, these results show that a framework for transmitting conformational information exists in the Hsp90 structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6oPpgyNANF7Vg90H21EOLACvtfcHk0lhl7RDE90ohKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFKmurrF&md5=131cd1d14b7204c1071f7291e557edf1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2016.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2016.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DRehn%26aufirst%3DA.%26aulast%3DMoroni%26aufirst%3DE.%26aulast%3DZierer%26aufirst%3DB.%2BK.%26aulast%3DTippel%26aufirst%3DF.%26aulast%3DMorra%26aufirst%3DG.%26aulast%3DJohn%26aufirst%3DC.%26aulast%3DRichter%26aufirst%3DK.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DBuchner%26aufirst%3DJ.%26atitle%3DAllosteric%2520regulation%2520points%2520control%2520the%2520conformational%2520dynamics%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2016%26volume%3D428%26issue%3D22%26spage%3D4559%26epage%3D4571%26doi%3D10.1016%2Fj.jmb.2016.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gewirth, D. T.</span></span> <span> </span><span class="NLM_article-title">Paralog specific Hsp90 inhibitors - a brief history and a bright future</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">2779</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160413141154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.2174%2F1568026616666160413141154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=27072700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2779-2791&issue=25&author=D.+T.+Gewirth&title=Paralog+specific+Hsp90+inhibitors+-+a+brief+history+and+a+bright+future&doi=10.2174%2F1568026616666160413141154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future</span></div><div class="casAuthors">Gewirth, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2779-2791</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background. The high sequence and structural homol. among the hsp90 paralogs - Hsp90α, Hsp90β, Grp94, and Trap-1 - has made the development of paralog-specific inhibitors a challenging proposition.  Objective. This review surveys the state of developments in structural anal., compd. screening, and structure-based design that have been brought to bear on this problem.  Results. First generation compds. that selectively bind to Hsp90, Grp94, or Trap-1 have been identified.  Conclusion. With the proof of principle firmly established, the prospects for further progress are bright.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdyZyrXOyou7Vg90H21EOLACvtfcHk0lhl7RDE90ohKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrzN&md5=208025ff36aa6e2d92d3ee107b20ab5f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160413141154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160413141154%26sid%3Dliteratum%253Aachs%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26atitle%3DParalog%2520specific%2520Hsp90%2520inhibitors%2520-%2520a%2520brief%2520history%2520and%2520a%2520bright%2520future%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26issue%3D25%26spage%3D2779%26epage%3D2791%26doi%3D10.2174%2F1568026616666160413141154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, B. H.</span></span> <span> </span><span class="NLM_article-title">Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">4358</span>– <span class="NLM_lpage">4367</span>, <span class="refDoi"> DOI: 10.1021/ja511893n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja511893n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2htrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=4358-4367&issue=13&author=C.+Leeauthor=H.+K.+Parkauthor=H.+Jeongauthor=J.+Limauthor=A.+J.+Leeauthor=K.+Y.+Cheonauthor=C.+S.+Kimauthor=A.+P.+Thomasauthor=B.+Baeauthor=N.+D.+Kimauthor=S.+H.+Kimauthor=P.+G.+Suhauthor=J.+H.+Ryuauthor=B.+H.+Kang&title=Development+of+a+mitochondria-targeted+Hsp90+inhibitor+based+on+the+crystal+structures+of+human+TRAP1&doi=10.1021%2Fja511893n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Mitochondria-Targeted Hsp90 Inhibitor Based on the Crystal Structures of Human TRAP1</span></div><div class="casAuthors">Lee, Changwook; Park, Hye-Kyung; Jeong, Hanbin; Lim, Jaehwa; Lee, An-Jung; Cheon, Keun Young; Kim, Chul-Su; Thomas, Ajesh P.; Bae, Boram; Kim, Nam Doo; Kim, Seong Heon; Suh, Pann-Ghill; Ryu, Ja-Hyoung; Kang, Byoung Heon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4358-4367</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mitochondrial pool of Hsp90 and its mitochondrial paralog, TRAP1, suppresses cell death and reprograms energy metab. in cancer cells; therefore, Hsp90 and TRAP1 have been suggested as target proteins for anticancer drug development.  Here, the authors report that the actual target protein in cancer cell mitochondria is TRAP1, and current Hsp90 inhibitors cannot effectively inactivate TRAP1 because of their insufficient accumulation in the mitochondria.  To develop mitochondrial TRAP1 inhibitors, the authors detd. the crystal structures of human TRAP1 complexed with Hsp90 inhibitors.  The iso-Pr amine of the Hsp90 inhibitor PU-H71 was replaced with the mitochondria-targeting moiety triphenylphosphonium to produce SMTIN-P01.  SMTIN-P01 showed a different mode of action from the nontargeted PU-H71, as well as much improved cytotoxicity to cancer cells.  In addn., the authors detd. the structure of a TRAP1-adenylyl-imidodiphosphate (AMP-PNP) complex.  On the basis of comparative anal. of TRAP1 structures, the authors propose a mol. mechanism of ATP hydrolysis that is crucial for chaperone function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN-VB5CkPi2LVg90H21EOLACvtfcHk0lhl7RDE90ohKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2htrs%253D&md5=c1142149eaa5f4157377ce64662fcfc1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fja511893n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja511893n%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DH.%2BK.%26aulast%3DJeong%26aufirst%3DH.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DA.%2BJ.%26aulast%3DCheon%26aufirst%3DK.%2BY.%26aulast%3DKim%26aufirst%3DC.%2BS.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DBae%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSuh%26aufirst%3DP.%2BG.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DKang%26aufirst%3DB.%2BH.%26atitle%3DDevelopment%2520of%2520a%2520mitochondria-targeted%2520Hsp90%2520inhibitor%2520based%2520on%2520the%2520crystal%2520structures%2520of%2520human%2520TRAP1%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26issue%3D13%26spage%3D4358%26epage%3D4367%26doi%3D10.1021%2Fja511893n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stothert, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, D. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerfeldt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizziah, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Development of glucose regulated protein 94-selective inhibitors based on the BnIm and radamide scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3471</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFGrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3471-3488&issue=7&author=V.+M.+Crowleyauthor=A.+Khandelwalauthor=S.+Mishraauthor=A.+R.+Stothertauthor=D.+J.+E.+Huardauthor=J.+Zhaoauthor=A.+Muthauthor=A.+S.+Duerfeldtauthor=J.+L.+Kizziahauthor=R.+L.+Liebermanauthor=C.+A.+Dickeyauthor=B.+S.+J.+Blagg&title=Development+of+glucose+regulated+protein+94-selective+inhibitors+based+on+the+BnIm+and+radamide+scaffold&doi=10.1021%2Facs.jmedchem.6b00085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold</span></div><div class="casAuthors">Crowley, Vincent M.; Khandelwal, Anuj; Mishra, Sanket; Stothert, Andrew R.; Huard, Dustin J. E.; Zhao, Jinbo; Muth, Aaron; Duerfeldt, Adam S.; Kizziah, James L.; Lieberman, Raquel L.; Dickey, Chad A.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3471-3488</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(Arylmethyl)imidazolylethyl chlorodihydroxybenzoates I (R = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-IC6H4, 4-MeC6H4, 4-EtC6H4, 4-i-PrC6H4, 4-NCC6H4, 4-HC≡CC6H4, 4-F3CC6H4, 4-PhC6H4, 4-MeOC6H4, 3,4-Cl2C6H3, 1-naphthyl, 2-naphthyl, 5-quinolinyl, 3-FC6H4, 3-ClC6H4, 3-BrC6H4, 3-IC6H4, 3-MeOC6H4, 3-MeC6H4, 3-PhC6H4, 2-FC6H4, 2-ClC6H4, 2-BrC6H4, 2-MeC6H4, 2-H2NC6H4, 2-MeOC6H4, 2-EtC6H4, 2-EtOC6H4, 2-i-PrOC6H4, 2-n-PrOC6H4, 2-F3CC6H4, 2-MeO-4-MeC6H3, 3-furanyl, 2-furanyl, 5-Me-2-furanyl, 5-Cl-2-furanyl, 3,5-dimethyl-2-furanyl, 2-thienyl, 3-thienyl, 5-Me-2-thienyl, 5-Cl-2-thienyl, 4-Cl-2-thienyl, 3-Cl-2-thienyl, 5-isoxazolyl, 2-thiazolyl, 3-vinyl-2-thienyl, 3-vinyl-2-furanyl, 3-Et-2-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 5-pyrimidinyl) were prepd. as selective inhibitors of glucose regulated protein 94 (Grp94), the endoplasmic reticulum-resident isoform of the heat shock protein 90 (Hsp90), for potential use in the treatment of glaucoma and cancer; the effect of the aryl substituents on Grp94 binding and selectivity was detd.  I were prepd. by the cyclocondensation of a bissilylated chloro(oxopropyl)dihydroxybenzoate with glyoxal and arylmethylamines RCH2NH2 (R = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-IC6H4, 4-MeC6H4, 4-EtC6H4, 4-i-PrC6H4, 4-NCC6H4, 4-HC≡CC6H4, 4-F3CC6H4, 4-PhC6H4, 4-MeOC6H4, 3,4-Cl2C6H3, 1-naphthyl, 2-naphthyl, 5-quinolinyl, 3-FC6H4, 3-ClC6H4, 3-BrC6H4, 3-IC6H4, 3-MeOC6H4, 3-MeC6H4, 3-PhC6H4, 2-FC6H4, 2-ClC6H4, 2-BrC6H4, 2-MeC6H4, 2-H2NC6H4, 2-MeOC6H4, 2-EtC6H4, 2-EtOC6H4, 2-i-PrOC6H4, 2-n-PrOC6H4, 2-F3CC6H4, 2-MeO-4-MeC6H3, 3-furanyl, 2-furanyl, 5-Me-2-furanyl, 5-Cl-2-furanyl, 3,5-dimethyl-2-furanyl, 2-thienyl, 3-thienyl, 5-Me-2-thienyl, 5-Cl-2-thienyl, 4-Cl-2-thienyl, 3-Cl-2-thienyl, 5-isoxazolyl, 2-thiazolyl, 3-vinyl-2-thienyl, 3-vinyl-2-furanyl, 3-Et-2-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 5-pyrimidinyl) followed by desilylation.  I (R = 2-MeO-4-MeC6H3CH2, 5-chloro-2-furanylmethyl) were tested as inhibitors of cell migration in a cancer metastasis model and for their enhancement of the degrdn. of mutants of the protein myocilin in a glaucoma model.  The structures of the lead compd. radamide bound to Hsp82 and Grp94 and of I (R = 5-chloro-2-furanyl) bound to the N-terminal domain of Hsp94 lacking its acidic linker were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3v_0NEYj1Z7Vg90H21EOLACvtfcHk0ljyaH6cxqcRgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFGrs7k%253D&md5=c73bbf30c243e281aae197689162c9e1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00085%26sid%3Dliteratum%253Aachs%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DStothert%26aufirst%3DA.%2BR.%26aulast%3DHuard%26aufirst%3DD.%2BJ.%2BE.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DKizziah%26aufirst%3DJ.%2BL.%26aulast%3DLieberman%26aufirst%3DR.%2BL.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520glucose%2520regulated%2520protein%252094-selective%2520inhibitors%2520based%2520on%2520the%2520BnIm%2520and%2520radamide%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D7%26spage%3D3471%26epage%3D3488%26doi%3D10.1021%2Facs.jmedchem.6b00085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidler, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Que, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taldone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephani, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gewirth, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span> <span> </span><span class="NLM_article-title">Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fnchembio.1335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=23995768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGltb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=677-684&author=P.+D.+Patelauthor=P.+Yanauthor=P.+M.+Seidlerauthor=H.+J.+Patelauthor=W.+Sunauthor=C.+Yangauthor=N.+S.+Queauthor=T.+Taldoneauthor=P.+Finottiauthor=R.+A.+Stephaniauthor=D.+T.+Gewirthauthor=G.+Chiosis&title=Paralog-selective+Hsp90+inhibitors+define+tumor-specific+regulation+of+HER2&doi=10.1038%2Fnchembio.1335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2</span></div><div class="casAuthors">Patel, Pallav D.; Yan, Pengrong; Seidler, Paul M.; Patel, Hardik J.; Sun, Weilin; Yang, Chenghua; Que, Nanette S.; Taldone, Tony; Finotti, Paola; Stephani, Ralph A.; Gewirth, Daniel T.; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">677-684</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy, the contribution of each paralog to the cancer phenotype is poorly understood.  This is in large part because reagents to study paralog-specific functions in cancer cells have been unavailable.  Here the authors combine compd. library screening with structural and computational analyses to identify purine-based chem. tools that are specific for Hsp90 paralogs.  The authors show that Grp94 selectivity is due to the insertion of these compds. into a new allosteric pocket.  The authors use these tools to demonstrate that cancer cells use individual Hsp90 paralogs to regulate a client protein in a tumor-specific manner and in response to proteome alterations.  Finally, the authors provide new mechanistic evidence explaining why selective Grp94 inhibition is particularly efficacious in certain breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAIwIoA9btZLVg90H21EOLACvtfcHk0ljyaH6cxqcRgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGltb7J&md5=8bdfb2c60b4171bbdd6046e455e413bb</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1335%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%2BD.%26aulast%3DYan%26aufirst%3DP.%26aulast%3DSeidler%26aufirst%3DP.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BJ.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DQue%26aufirst%3DN.%2BS.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DFinotti%26aufirst%3DP.%26aulast%3DStephani%26aufirst%3DR.%2BA.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DParalog-selective%2520Hsp90%2520inhibitors%2520define%2520tumor-specific%2520regulation%2520of%2520HER2%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D677%26epage%3D684%26doi%3D10.1038%2Fnchembio.1335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duerfeldt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eletto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrovsky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinogle, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicchitta, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S.</span></span> <span> </span><span class="NLM_article-title">Development of a Grp94 inhibitor</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">9796</span>– <span class="NLM_lpage">9804</span>, <span class="refDoi"> DOI: 10.1021/ja303477g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja303477g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC38XnslGqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=9796-9804&author=A.+S.+Duerfeldtauthor=L.+B.+Petersonauthor=J.+C.+Maynardauthor=C.+L.+Ngauthor=D.+Elettoauthor=O.+Ostrovskyauthor=H.+E.+Shinogleauthor=D.+S.+Mooreauthor=Y.+Argonauthor=C.+V.+Nicchittaauthor=B.+S.+Blagg&title=Development+of+a+Grp94+inhibitor&doi=10.1021%2Fja303477g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Grp94 inhibitor</span></div><div class="casAuthors">Duerfeldt, Adam S.; Peterson, Laura B.; Maynard, Jason C.; Ng, Chun Leung; Eletto, Davide; Ostrovsky, Olga; Shinogle, Heather E.; Moore, David S.; Argon, Yair; Nicchitta, Christopher V.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9796-9804</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) represents a promising therapeutic target for the treatment of cancer and other diseases.  Unfortunately, results from clin. trials have been disappointing as off-target effects and toxicities have been obsd.  These detriments may be a consequence of pan-Hsp90 inhibition, as all clin. evaluated Hsp90 inhibitors simultaneously disrupt all four human Hsp90 isoforms.  Using a structure-based approach, we designed an inhibitor of Grp94, the ER-resident Hsp90.  The effect manifested by compd. (I) on several Grp94 and Hsp90α/β (cytosolic isoforms) clients were investigated.  Compd. I prevented intracellular trafficking of the Toll receptor, inhibited the secretion of IGF-II, affected the conformation of Grp94, and suppressed Drosophila larval growth, all Grp94-dependent processes.  In contrast, compd. I had no effect on cell viability or cytosolic Hsp90α/β client proteins at similar concns.  The design, synthesis, and evaluation of I are described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoayCAvZU_mzrVg90H21EOLACvtfcHk0ljQ1USyFp-g0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnslGqsLw%253D&md5=00c0b3f15f2cfd04658225c8a6fb708d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fja303477g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja303477g%26sid%3Dliteratum%253Aachs%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DMaynard%26aufirst%3DJ.%2BC.%26aulast%3DNg%26aufirst%3DC.%2BL.%26aulast%3DEletto%26aufirst%3DD.%26aulast%3DOstrovsky%26aufirst%3DO.%26aulast%3DShinogle%26aufirst%3DH.%2BE.%26aulast%3DMoore%26aufirst%3DD.%2BS.%26aulast%3DArgon%26aufirst%3DY.%26aulast%3DNicchitta%26aufirst%3DC.%2BV.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%26atitle%3DDevelopment%2520of%2520a%2520Grp94%2520inhibitor%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D9796%26epage%3D9804%26doi%3D10.1021%2Fja303477g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stothert, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordhues, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, D. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passaglia, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, C. A.</span></span> <span> </span><span class="NLM_article-title">Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">17951</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-18344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fs41598-017-18344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=29263415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A280%3ADC%252BC1MzjslWisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=17951&issue=1&author=A.+R.+Stothertauthor=A.+Suntharalingamauthor=X.+Tangauthor=V.+M.+Crowleyauthor=S.+J.+Mishraauthor=J.+M.+Websterauthor=B.+A.+Nordhuesauthor=D.+J.+E.+Huardauthor=C.+L.+Passagliaauthor=R.+L.+Liebermanauthor=B.+S.+J.+Blaggauthor=L.+J.+Blairauthor=J.+Korenauthor=C.+A.+Dickey&title=Isoform-selective+Hsp90+inhibition+rescues+model+of+hereditary+open-angle+glaucoma&doi=10.1038%2Fs41598-017-18344-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma</span></div><div class="casAuthors">Stothert Andrew R; Suntharalingam Amirthaa; Tang Xiaolan; Webster Jack M; Nordhues Bryce A; Blair Laura J; Koren John 3rd; Dickey Chad A; Tang Xiaolan; Passaglia Christopher L; Crowley Vincent M; Mishra Sanket J; Blagg Brian S J; Huard Dustin J E; Lieberman Raquel L</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17951</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The heat shock protein 90 (Hsp90) family of molecular chaperones regulates protein homeostasis, folding, and degradation.  The ER-resident Hsp90 isoform, glucose-regulated protein 94 (Grp94), promotes the aggregation of mutant forms of myocilin, a protein associated with primary open-angle glaucoma.  While inhibition of Grp94 promotes the degradation of mutant myocilin in vitro, to date no Grp94-selective inhibitors have been investigated in vivo.  Here, a Grp94-selective inhibitor facilitated mutant myocilin degradation and rescued phenotypes in a transgenic mouse model of hereditary primary open-angle glaucoma.  Ocular toxicities previously associated with pan-Hsp90 inhibitors were not evident with our Grp94-selective inhibitor, 4-Br-BnIm.  Our study suggests that selective inhibition of a distinct Hsp90 family member holds translational promise for ocular and other diseases associated with cell stress and protein misfolding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREMjSSm_naSNhSDZx9hyjKfW6udTcc2eZnJ8RAWq4Kmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzjslWisQ%253D%253D&md5=2d2b50528853d6b6d6a5704655da3c56</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-18344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-18344-4%26sid%3Dliteratum%253Aachs%26aulast%3DStothert%26aufirst%3DA.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DWebster%26aufirst%3DJ.%2BM.%26aulast%3DNordhues%26aufirst%3DB.%2BA.%26aulast%3DHuard%26aufirst%3DD.%2BJ.%2BE.%26aulast%3DPassaglia%26aufirst%3DC.%2BL.%26aulast%3DLieberman%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26aulast%3DBlair%26aufirst%3DL.%2BJ.%26aulast%3DKoren%26aufirst%3DJ.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26atitle%3DIsoform-selective%2520Hsp90%2520inhibition%2520rescues%2520model%2520of%2520hereditary%2520open-angle%2520glaucoma%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26issue%3D1%26spage%3D17951%26doi%3D10.1038%2Fs41598-017-18344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Development of radamide analogs as Grp94 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4083</span>– <span class="NLM_lpage">4098</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.05.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.bmc.2014.05.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=25027801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGru7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4083-4098&issue=15&author=A.+Muthauthor=V.+Crowleyauthor=A.+Khandelwalauthor=S.+Mishraauthor=J.+Zhaoauthor=J.+Hallauthor=B.+S.+J.+Blagg&title=Development+of+radamide+analogs+as+Grp94+inhibitors&doi=10.1016%2Fj.bmc.2014.05.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Development of radamide analogs as Grp94 inhibitors</span></div><div class="casAuthors">Muth, Aaron; Crowley, Vincent; Khandelwal, Anuj; Mishra, Sanket; Zhao, Jinbo; Hall, Jessica; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4083-4098</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hsp90 isoform-selective inhibition is highly desired as it can potentially avoid the toxic side-effects of pan-inhibition.  The current study developed selective inhibitors of one such isoform, Grp94, predicated on the chimeric and pan-Hsp90 inhibitor, radamide (RDA).  Replacement of the quinone moiety of RDA with a Ph ring (2) was found to be better suited for Grp94 inhibition as it can fully interact with a unique hydrophobic pocket present in Grp94.  An extensive SAR for this scaffold showed that substitutions at the 2- and 4-positions (8 and 27, resp.) manifested excellent Grp94 affinity and selectivity.  Introduction of heteroatoms into the ring also proved beneficial, with a 2-pyridine deriv. (38) exhibiting the highest Grp94 affinity (Kd = 820 nM).  Subsequent cell-based assays showed that these Grp94 inhibitors inhibit migration of the metastatic breast cancer cell line, MDA-MB-231, as well as exhibit an anti-proliferative affect against the multiple myeloma cell line, RPMI 8226.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxdbHibsHh3rVg90H21EOLACvtfcHk0ljQ1USyFp-g0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGru7bK&md5=6025c533f1c107eb5c54a559c679c8d2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.05.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.05.075%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DCrowley%26aufirst%3DV.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DJ.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520radamide%2520analogs%2520as%2520Grp94%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26issue%3D15%26spage%3D4083%26epage%3D4098%26doi%3D10.1016%2Fj.bmc.2014.05.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzbeierlein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">425</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-02013-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fs41467-017-02013-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=29382832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=425&issue=1&author=A.+Khandelwalauthor=C.+N.+Kentauthor=M.+Balchauthor=S.+Pengauthor=S.+J.+Mishraauthor=J.+Dengauthor=V.+W.+Dayauthor=W.+Liuauthor=C.+Subramanianauthor=M.+Cohenauthor=J.+M.+Holzbeierleinauthor=R.+Mattsauthor=B.+S.+J.+Blagg&title=Structure-guided+design+of+an+Hsp90%CE%B2+N-terminal+isoform-selective+inhibitor&doi=10.1038%2Fs41467-017-02013-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor</span></div><div class="casAuthors">Khandelwal Anuj; Mishra Sanket J; Kent Caitlin N; Blagg Brian S J; Balch Maurie; Peng Shuxia; Deng Junpeng; Matts Robert; Day Victor W; Liu Weiya; Holzbeierlein Jeffery M; Subramanian Chitra; Cohen Mark</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">425</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 90 kDa heat shock protein (Hsp90) is a molecular chaperone responsible for folding proteins that are directly associated with cancer progression.  Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways.  Seventeen small-molecule inhibitors of Hsp90 have entered clinical trials, all of which bind the Hsp90 N-terminus and exhibit pan-inhibitory activity against all four Hsp90 isoforms. pan-Inhibition of Hsp90 appears to be detrimental as toxicities have been reported alongside induction of the pro-survival heat shock response.  The development of Hsp90 isoform-selective inhibitors represents an alternative approach towards the treatment of cancer that may limit some of the detriments.  Described herein is a structure-based approach to design isoform-selective inhibitors of Hsp90β, which induces the degradation of select Hsp90 clients without concomitant induction of Hsp90 levels.  Together, these initial studies support the development of Hsp90β-selective inhibitors as a method to overcome the detriments associated with pan-inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmyRre9-yoQBpyrDyM_m9cfW6udTcc2eaC-YN3ECT1ebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D&md5=cfa47e314c9bdbc1c38802108330cba7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02013-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02013-1%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DKent%26aufirst%3DC.%2BN.%26aulast%3DBalch%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DDay%26aufirst%3DV.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSubramanian%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DMatts%26aufirst%3DR.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DStructure-guided%2520design%2520of%2520an%2520Hsp90%25CE%25B2%2520N-terminal%2520isoform-selective%2520inhibitor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1%26spage%3D425%26doi%3D10.1038%2Fs41467-017-02013-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitotsumachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekura, K.</span></span> <span> </span><span class="NLM_article-title">TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1158%2F1535-7163.MCT-14-0219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=25416789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=14-22&issue=1&author=S.+Ohkuboauthor=Y.+Kodamaauthor=H.+Muraokaauthor=H.+Hitotsumachiauthor=C.+Yoshimuraauthor=M.+Kitadeauthor=A.+Hashimotoauthor=K.+Itoauthor=A.+Gomoriauthor=K.+Takahashiauthor=Y.+Shibataauthor=A.+Kanohauthor=K.+Yonekura&title=TAS-116%2C+a+highly+selective+inhibitor+of+heat+shock+protein+90%CE%B1+and+%CE%B2%2C+demonstrates+potent+antitumor+activity+and+minimal+ocular+toxicity+in+preclinical+models&doi=10.1158%2F1535-7163.MCT-14-0219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span></div><div class="casAuthors">Ohkubo, Shuichi; Kodama, Yasuo; Muraoka, Hiromi; Hitotsumachi, Hiroko; Yoshimura, Chihoko; Kitade, Makoto; Hashimoto, Akihiro; Ito, Kenjiro; Gomori, Akira; Takahashi, Koichi; Shibata, Yoshihiro; Kanoh, Akira; Yonekura, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-22</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mol. chaperone HSP90 plays a crucial role in cancer cell growth and survival by stabilizing cancer-related proteins.  A no. of HSP90 inhibitors have been developed clin. for cancer therapy; however, potential off-target and/or HSP90-related toxicities have proved problematic.  The 4-(1H-pyrazolo[3,4-b]pyridine-1-yl)benzamide TAS-116 is a selective inhibitor of cytosolic HSP90α and β that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1.  Oral administration of TAS-116 led to tumor shrinkage in human tumor xenograft mouse models accompanied by depletion of multiple HSP90 clients, demonstrating that the inhibition of HSP90α and β alone was sufficient to exert antitumor activity in certain tumor models.  One of the most notable HSP90-related adverse events universally obsd. to differing degrees in the clin. setting is visual disturbance.  A two-week administration of the isoxazole resorcinol NVP-AUY922, an HSP90 inhibitor, caused marked degeneration and disarrangement of the outer nuclear layer of the retina and induced photoreceptor cell death in rats.  In contrast, TAS-116 did not produce detectable photoreceptor injury in rats, probably due to its lower distribution in retinal tissue.  Importantly, in a rat model, the antitumor activity of TAS-116 was accompanied by a higher distribution of the compd. in s.c. xenografted NCI-H1975 non-small cell lung carcinoma tumors than in retina.  Moreover, TAS-116 showed activity against orthotopically transplanted NCI-H1975 lung tumors.  Together, these data suggest that TAS-116 has a potential to maximize antitumor activity while minimizing adverse effects such as visual disturbances that are obsd. with other compds. of this class.  Mol Cancer Ther; 14(1); 14-22. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB25Txc_IcKbVg90H21EOLACvtfcHk0lhHCKG6hy7ndw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D&md5=3ffdc26a7f0178d4e44413e22c003f77</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0219%26sid%3Dliteratum%253Aachs%26aulast%3DOhkubo%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DHitotsumachi%26aufirst%3DH.%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DKitade%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DGomori%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DKanoh%26aufirst%3DA.%26aulast%3DYonekura%26aufirst%3DK.%26atitle%3DTAS-116%252C%2520a%2520highly%2520selective%2520inhibitor%2520of%2520heat%2520shock%2520protein%252090%25CE%25B1%2520and%2520%25CE%25B2%252C%2520demonstrates%2520potent%2520antitumor%2520activity%2520and%2520minimal%2520ocular%2520toxicity%2520in%2520preclinical%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26issue%3D1%26spage%3D14%26epage%3D22%26doi%3D10.1158%2F1535-7163.MCT-14-0219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woody, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcacio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nezami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, D.</span></span> <span> </span><span class="NLM_article-title">Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3382</span>– <span class="NLM_lpage">3400</span>, <span class="refDoi"> DOI: 10.1021/jm500042s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500042s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3382-3400&issue=8&author=J.+T.+Ernstauthor=T.+Neubertauthor=M.+Liuauthor=S.+Sperryauthor=H.+Zuccolaauthor=A.+Turnbullauthor=B.+Fleckauthor=W.+Kargoauthor=L.+Woodyauthor=P.+Chiangauthor=D.+Tranauthor=W.+Chenauthor=P.+Snyderauthor=T.+Alcacioauthor=A.+Nezamiauthor=J.+Reynoldsauthor=K.+Alviauthor=L.+Gouletauthor=D.+Stamos&title=Identification+of+novel+HSP90%CE%B1%2F%CE%B2+isoform+selective+inhibitors+using+structure-based+drug+design.+Demonstration+of+potential+utility+in+treating+CNS+disorders+such+as+Huntington%E2%80%99s+Disease&doi=10.1021%2Fjm500042s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease</span></div><div class="casAuthors">Ernst, Justin T.; Neubert, Timothy; Liu, Michael; Sperry, Samuel; Zuccola, Harmon; Turnbull, Amy; Fleck, Beth; Kargo, William; Woody, Lisa; Chiang, Peggy; Tran, Dao; Chen, Weichao; Snyder, Phillip; Alcacio, Timothy; Nezami, Azin; Reynolds, James; Alvi, Khisal; Goulet, Lance; Stamos, Dean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3382-3400</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based drug design strategy was used to optimize a novel benzolactam series of HSP90α/β inhibitors to achieve >1000-fold selectivity vs. the HSP90 endoplasmic reticulum and mitochondrial isoforms (GRP94 and TRAP1, resp.).  Selective HSP90α/β inhibitors were found to be equipotent to pan-HSP90 inhibitors in promoting the clearance of mutant huntington protein (mHtt) in vitro, however with less cellular toxicity.  Improved tolerability profiles may enable the use of HSP90α/β selective inhibitors in treating chronic neurodegenerative indications such as Huntington's disease (HD).  A potent, selective, orally available HSP90α/β inhibitor, 8-Cyclopentyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one, was identified that crosses the blood-brain barrier and demonstrated proof of concept by successfully reducing brain Htt levels following oral dosing in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKpHcuphxPXbVg90H21EOLACvtfcHk0lhHCKG6hy7ndw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGlsLY%253D&md5=0d55fb738fc0f0615b5336b8dc17056a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm500042s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500042s%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DNeubert%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DZuccola%26aufirst%3DH.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DFleck%26aufirst%3DB.%26aulast%3DKargo%26aufirst%3DW.%26aulast%3DWoody%26aufirst%3DL.%26aulast%3DChiang%26aufirst%3DP.%26aulast%3DTran%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSnyder%26aufirst%3DP.%26aulast%3DAlcacio%26aufirst%3DT.%26aulast%3DNezami%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DJ.%26aulast%3DAlvi%26aufirst%3DK.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DStamos%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520novel%2520HSP90%25CE%25B1%252F%25CE%25B2%2520isoform%2520selective%2520inhibitors%2520using%2520structure-based%2520drug%2520design.%2520Demonstration%2520of%2520potential%2520utility%2520in%2520treating%2520CNS%2520disorders%2520such%2520as%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D8%26spage%3D3382%26epage%3D3400%26doi%3D10.1021%2Fjm500042s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vought, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, D.</span></span> <span> </span><span class="NLM_article-title">Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity—Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.bmcl.2013.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=24332488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOlt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=204-208&issue=1&author=J.+T.+Ernstauthor=M.+Liuauthor=H.+Zuccolaauthor=T.+Neubertauthor=K.+Beaumontauthor=A.+Turnbullauthor=A.+Kallelauthor=B.+Voughtauthor=D.+Stamos&title=Correlation+between+chemotype-dependent+binding+conformations+of+HSP90%CE%B1%2F%CE%B2+and+isoform+selectivity%E2%80%94Implications+for+the+structure-based+design+of+HSP90%CE%B1%2F%CE%B2+selective+inhibitors+for+treating+neurodegenerative+diseases&doi=10.1016%2Fj.bmcl.2013.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases</span></div><div class="casAuthors">Ernst, Justin T.; Liu, Michael; Zuccola, Harmon; Neubert, Timothy; Beaumont, Kevin; Turnbull, Amy; Kallel, Adam; Vought, Bryan; Stamos, Dean</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">204-208</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HSP90 continues to be a target of interest for neurodegeneration indications.  Selective knockdown of the HSP90 cytosolic isoforms α and β is sufficient to reduce mutant huntingtin protein levels in vitro.  Chemotype-dependent binding conformations of HSP90α/β appear to strongly influence isoform selectivity.  The rational design of HSP90α/β inhibitors selective vs. the mitochondrial (TRAP1) and endoplasmic reticulum (GRP94) isoforms offers a potential mitigating strategy for mechanism-based toxicities.  Better tolerated HSP90 inhibitors would be attractive for targeting chronic neurodegenerative diseases such as Huntington's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq64ZOr5JsRerVg90H21EOLACvtfcHk0li_A2nUDZGIzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOlt7jO&md5=6799a46090ee297d70700f7c42b79f80</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZuccola%26aufirst%3DH.%26aulast%3DNeubert%26aufirst%3DT.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DKallel%26aufirst%3DA.%26aulast%3DVought%26aufirst%3DB.%26aulast%3DStamos%26aufirst%3DD.%26atitle%3DCorrelation%2520between%2520chemotype-dependent%2520binding%2520conformations%2520of%2520HSP90%25CE%25B1%252F%25CE%25B2%2520and%2520isoform%2520selectivity%25E2%2580%2594Implications%2520for%2520the%2520structure-based%2520design%2520of%2520HSP90%25CE%25B1%252F%25CE%25B2%2520selective%2520inhibitors%2520for%2520treating%2520neurodegenerative%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D1%26spage%3D204%26epage%3D208%26doi%3D10.1016%2Fj.bmcl.2013.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angove, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewartha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5956</span>– <span class="NLM_lpage">5969</span>, <span class="refDoi"> DOI: 10.1021/jm100060b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100060b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5956-5969&author=A.+J.+Woodheadauthor=H.+Angoveauthor=M.+G.+Carrauthor=G.+Chessariauthor=M.+Congreveauthor=J.+E.+Coyleauthor=J.+Cosmeauthor=B.+Grahamauthor=P.+J.+Dayauthor=R.+Downhamauthor=L.+Fazalauthor=R.+Feltellauthor=E.+Figueroaauthor=M.+Fredericksonauthor=J.+Lewisauthor=R.+McMenaminauthor=C.+W.+Murrayauthor=M.+A.+O%E2%80%99Brienauthor=L.+Parraauthor=S.+Patelauthor=T.+Phillipsauthor=D.+C.+Reesauthor=S.+Richauthor=D.+M.+Smithauthor=G.+Trewarthaauthor=M.+Vinkovicauthor=B.+Williamsauthor=A.+J.+Woolford&title=Discovery+of+%282%2C4-dihydroxy-5-isopropylphenyl%29-%5B5-%284-methylpiperazin-1-ylmethyl%29-1%2C3-dihydrois+oindol-2-yl%5Dmethanone+%28AT13387%29%2C+a+novel+inhibitor+of+the+molecular+chaperone+Hsp90+by+fragment+based+drug+design&doi=10.1021%2Fjm100060b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design</span></div><div class="casAuthors">Woodhead, Andrew J.; Angove, Hayley; Carr, Maria G.; Chessari, Gianni; Congreve, Miles; Coyle, Joseph E.; Cosme, Jose; Graham, Brent; Day, Philip J.; Downham, Robert; Fazal, Lynsey; Feltell, Ruth; Figueroa, Eva; Frederickson, Martyn; Lewis, Jonathan; McMenamin, Rachel; Murray, Christopher W.; O'Brien, M. Alistair; Parra, Lina; Patel, Sahil; Phillips, Theresa; Rees, David C.; Rich, Sharna; Smith, Donna-Michelle; Trewartha, Gary; Vinkovic, Mladen; Williams, Brian; Woolford, Alison J.-A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5956-5969</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the mol. chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clin. development as potential treatments for cancer.  In a preceding publication (DOI: 10.1021/jm100059d) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range.  This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead mol. 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclin. development and is currently being tested in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEEtcgAmkVk7Vg90H21EOLACvtfcHk0li_A2nUDZGIzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D&md5=a2d2ac6dd9e9ba4cb89f83c32727a1d8</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm100060b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100060b%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DParra%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520%25282%252C4-dihydroxy-5-isopropylphenyl%2529-%255B5-%25284-methylpiperazin-1-ylmethyl%2529-1%252C3-dihydrois%2520oindol-2-yl%255Dmethanone%2520%2528AT13387%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%2520by%2520fragment%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5956%26epage%3D5969%26doi%3D10.1021%2Fjm100060b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speranza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polley, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinders, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antony, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span> <span> </span><span class="NLM_article-title">Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0255-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1007%2Fs10637-015-0255-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=26082332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVektLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=921-930&issue=4&author=K.+Doauthor=G.+Speranzaauthor=L.-C.+Changauthor=E.+C.+Polleyauthor=R.+Bishopauthor=W.+Zhuauthor=J.+B.+Trepelauthor=S.+Leeauthor=M.-J.+Leeauthor=R.+J.+Kindersauthor=L.+Phillipsauthor=J.+Collinsauthor=J.+Lyonsauthor=W.+Jeongauthor=R.+Antonyauthor=A.+P.+Chenauthor=L.+Neckersauthor=J.+H.+Doroshowauthor=S.+Kummar&title=Phase+I+study+of+the+heat+shock+protein+90+%28Hsp90%29+inhibitor+onalespib+%28AT13387%29+administered+on+a+daily+for+2+consecutive+days+per+week+dosing+schedule+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-015-0255-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Do, Khanh; Speranza, Giovanna; Chang, Lun-Ching; Polley, Eric C.; Bishop, Rachel; Zhu, Weimin; Trepel, Jane B.; Lee, Sunmin; Lee, Min-Jung; Kinders, Robert J.; Phillips, Larry; Collins, Jerry; Lyons, John; Jeong, Woondong; Antony, Ramya; Chen, Alice P.; Neckers, Len; Doroshow, James H.; Kummar, Shivaani</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">921-930</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Inhibition of heat shock 90 (Hsp90) mol. chaperones allows targeting of multiple proteins involved in tumorigenesis.  We investigated the safety, recommended phase 2 dose (RP2D), and pharmacokinetic and pharmacodynamic profile of onalespib (AT13387), a potent synthetic Hsp90 inhibitor, administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/wk) in a phase I trial.  This study followed an accelerated titrn. design with a starting dose of 20 mg/m2/dose and a std. 3 + 3 dose escalation design for dose level 4 (120 mg/m2/dose) and above.  Addnl. patients were enrolled at the RP2D with mandatory paired tumor biopsies to assess modulation of 210 client proteins using reverse phase protein array anal.  Thirty-one patients were treated; RP2D was established at 160 mg/m2/dose on the QDx2/wk schedule.  Common toxicities were gastrointestinal, hepatic, and hematol.  Pharmacokinetic profile was linear and plasma levels increased proportionally with dose (T1/2 ∼8 h).  No responses were obsd.; eight patients had stable disease for > 2 cycles with one patient remaining on study for 6 cycles.  Target engagement was demonstrated by transcriptional upregulation of Hsp70 and Hsp27 in PBMCs.  Statistically significant modulation of client proteins was not achieved in the 9 paired tumor biopsies evaluated; however, hierarchical clustering revealed two subgroups of patients with differential patterns of protein expression.  Further combination studies are needed in order to target prospective driver oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCXt8s5_XMBLVg90H21EOLACvtfcHk0lgdxPvGPKfCoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVektLfJ&md5=624adbaad8dad65d69ea9318a96e984e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0255-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0255-1%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DK.%26aulast%3DSperanza%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DL.-C.%26aulast%3DPolley%26aufirst%3DE.%2BC.%26aulast%3DBishop%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.-J.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DPhillips%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DJeong%26aufirst%3DW.%26aulast%3DAntony%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%2BP.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DKummar%26aufirst%3DS.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitor%2520onalespib%2520%2528AT13387%2529%2520administered%2520on%2520a%2520daily%2520for%25202%2520consecutive%2520days%2520per%2520week%2520dosing%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26issue%3D4%26spage%3D921%26epage%3D930%26doi%3D10.1007%2Fs10637-015-0255-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agulnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedel, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oganesian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keer, H.</span></span> <span> </span><span class="NLM_article-title">Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2016.03.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.ejca.2016.03.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=27156227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslKqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=94-101&author=A.+J.+Wagnerauthor=M.+Agulnikauthor=M.+C.+Heinrichauthor=D.+Mahadevanauthor=R.+F.+Riedelauthor=M.+von+Mehrenauthor=J.+Trentauthor=G.+D.+Demetriauthor=C.+L.+Corlessauthor=M.+Yuleauthor=J.+F.+Lyonsauthor=A.+Oganesianauthor=H.+Keer&title=Dose-escalation+study+of+a+second-generation+non-ansamycin+HSP90+inhibitor%2C+onalespib+%28AT13387%29%2C+in+combination+with+imatinib+in+patients+with+metastatic+gastrointestinal+stromal+tumour&doi=10.1016%2Fj.ejca.2016.03.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour</span></div><div class="casAuthors">Wagner, Andrew J.; Agulnik, Mark; Heinrich, Michael C.; Mahadevan, Daruka; Riedel, Richard F.; von Mehren, Margaret; Trent, Jonathan; Demetri, George D.; Corless, Christopher L.; Yule, Murray; Lyons, John F.; Oganesian, Aram; Keer, Harold</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94-101</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) treated with the tyrosine kinase inhibitor (TKI) imatinib can become resistant when addnl. mutations in the receptor tyrosine kinases KIT or PDGFRA block imatinib activity.  Mutated KIT requires the mol. chaperone heat-shock protein 90 (HSP90) to maintain stability and activity.  Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor.  We hypothesised that the combination of onalespib and imatinib may be safe and effective in managing TKI-resistant GIST.In this dose-escalation study, we evaluated the safety and efficacy of combination once-weekly i.v. onalespib for 3 wk and daily oral imatinib in 28-d cycles.  Twenty-six patients with TKI-resistant GIST were enrolled into four sequential dose cohorts of onalespib (dose range, 150-220 mg/m2) and imatinib 400 mg.  The relationship between tumor mutational status (KIT/PDGFRA) and efficacy of treatment was explored.Common onalespib-related adverse events were diarrhea (58%), nausea (50%), injection site events (46%), vomiting (39%), fatigue (27%), and muscle spasms (23%).  Overall, 81% of patients reported more than one onalespib-related gastrointestinal disorder.  Nine patients (35%) had a best response of stable disease, including two patients who had KIT mutations known to be assocd. with resistance to imatinib and sunitinib.  Disease control at 4 mo was achieved in five patients (19%), and median progression-free survival was 112 d (95% confidence interval 43-165).  One patient with PDGFRA-mutant GIST had a partial response for more than 376 d.The combination of onalespib plus imatinib was well tolerated but exhibited limited antitumor activity as dosed in this TKI-resistant GIST patient population.Trial registration ID: clinicaltrials.gov: NCT01294202.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0EPUydR0h8bVg90H21EOLACvtfcHk0lgdxPvGPKfCoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslKqs7s%253D&md5=53b38c85eb3a83c174f28347d985ecf9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2016.03.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2016.03.076%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DAgulnik%26aufirst%3DM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DRiedel%26aufirst%3DR.%2BF.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DTrent%26aufirst%3DJ.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DOganesian%26aufirst%3DA.%26aulast%3DKeer%26aufirst%3DH.%26atitle%3DDose-escalation%2520study%2520of%2520a%2520second-generation%2520non-ansamycin%2520HSP90%2520inhibitor%252C%2520onalespib%2520%2528AT13387%2529%252C%2520in%2520combination%2520with%2520imatinib%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumour%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D61%26spage%3D94%26epage%3D101%26doi%3D10.1016%2Fj.ejca.2016.03.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welker, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesanakurti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulman, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurcan, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puduvalli, V. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy of onalespib, a long-acting second-generation HSP90 inhibitor, as a single agent and in combination with temozolomide against malignant gliomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6215</span>– <span class="NLM_lpage">6226</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-3151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1158%2F1078-0432.CCR-16-3151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=28679777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6215-6226&issue=20&author=A.+Canellaauthor=A.+M.+Welkerauthor=J.+Y.+Yooauthor=J.+Xuauthor=F.+S.+Abasauthor=D.+Kesanakurtiauthor=P.+Nagarajanauthor=C.+E.+Beattieauthor=E.+P.+Sulmanauthor=J.+Liuauthor=J.+Guminauthor=F.+F.+Langauthor=M.+N.+Gurcanauthor=B.+Kaurauthor=D.+Sampathauthor=V.+K.+Puduvalli&title=Efficacy+of+onalespib%2C+a+long-acting+second-generation+HSP90+inhibitor%2C+as+a+single+agent+and+in+combination+with+temozolomide+against+malignant+gliomas&doi=10.1158%2F1078-0432.CCR-16-3151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas</span></div><div class="casAuthors">Canella, Alessandro; Welker, Alessandra M.; Yoo, Ji Young; Xu, Jihong; Abas, Fazly S.; Kesanakurti, Divya; Nagarajan, Prabakaran; Beattie, Christine E.; Sulman, Erik P.; Liu, Joseph; Gumin, Joy; Lang, Frederick F.; Gurcan, Metin N.; Kaur, Balveen; Sampath, Deepa; Puduvalli, Vinay K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6215-6226</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: HSP90, a highly conserved mol. chaperone that regulates the function of several oncogenic client proteins, is altered in glioblastoma.  However, HSP90 inhibitors currently in clin. trials are short-acting, have unacceptable toxicities, or are unable to cross the blood-brain barrier (BBB).  We examd. the efficacy of onalespib, a potent, long-acting novel HSP90 inhibitor as a single agent and in combination with temozolomide (TMZ) against gliomas in vitro and in vivo.  Exptl. Design: The effect of onalespib on HSP90, its client proteins, and on the biol. of glioma cell lines and patient-derived glioma-initiating cells (GSC) was detd.  Brain and plasma pharmacokinetics of onalespib and its ability to inhibit HSP90 in vivo were assessed in non-tumor-bearing mice.  Its efficacy as a single agent or in combination with TMZ was assessed in vitro and in vivo using zebrafish and patient-derived GSC xenograft mouse glioma models.  Results: Onalespib-mediated HSP90 inhibition depleted several survival-promoting client proteins such as EGFR, EGFRvIII, and AKT, disrupted their downstream signaling, and decreased the proliferation, migration, angiogenesis, and survival of glioma cell lines and GSCs.  Onalespib effectively crossed the BBB to inhibit HSP90 in vivo and extended survival as a single agent in zebrafish xenografts and in combination with TMZ in both zebrafish and GSC mouse xenografts.  Conclusions: Our results demonstrate the long-acting effects of onalespib against gliomas in vitro and in vivo, which combined with its ability to cross the BBB support its development as a potential therapeutic agent in combination with TMZ against gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqiyFYlY0U3bVg90H21EOLACvtfcHk0lgdxPvGPKfCoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrfO&md5=ad3c936d44737c257889bbd4602c4dc3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-3151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-3151%26sid%3Dliteratum%253Aachs%26aulast%3DCanella%26aufirst%3DA.%26aulast%3DWelker%26aufirst%3DA.%2BM.%26aulast%3DYoo%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DAbas%26aufirst%3DF.%2BS.%26aulast%3DKesanakurti%26aufirst%3DD.%26aulast%3DNagarajan%26aufirst%3DP.%26aulast%3DBeattie%26aufirst%3DC.%2BE.%26aulast%3DSulman%26aufirst%3DE.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGumin%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DF.%2BF.%26aulast%3DGurcan%26aufirst%3DM.%2BN.%26aulast%3DKaur%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DPuduvalli%26aufirst%3DV.%2BK.%26atitle%3DEfficacy%2520of%2520onalespib%252C%2520a%2520long-acting%2520second-generation%2520HSP90%2520inhibitor%252C%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520with%2520temozolomide%2520against%2520malignant%2520gliomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26issue%3D20%26spage%3D6215%26epage%3D6226%26doi%3D10.1158%2F1078-0432.CCR-16-3151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stühmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zöllinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knop, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortüm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzicker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chène, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Echeverría, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wajant, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargou, R. C.</span></span> <span> </span><span class="NLM_article-title">Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1604</span>– <span class="NLM_lpage">1612</span>, <span class="refDoi"> DOI: 10.1038/leu.2008.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fleu.2008.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=18480838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslSntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=1604-1612&author=T.+St%C3%BChmerauthor=A.+Z%C3%B6llingerauthor=D.+Siegmundauthor=M.+Chatterjeeauthor=E.+Grellaauthor=S.+Knopauthor=M.+Kort%C3%BCmauthor=C.+Unzickerauthor=M.+R.+Jensenauthor=C.+Quadtauthor=P.+Ch%C3%A8neauthor=J.+Schoepferauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=H.+Einseleauthor=H.+Wajantauthor=R.+C.+Bargou&title=Signalling+profile+and+antitumour+activity+of+the+novel+Hsp90+inhibitor+NVP-AUY922+in+multiple+myeloma&doi=10.1038%2Fleu.2008.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma</span></div><div class="casAuthors">Stuehmer, T.; Zoellinger, A.; Siegmund, D.; Chatterjee, M.; Grella, E.; Knop, S.; Kortuem, M.; Unzicker, C.; Jensen, M. R.; Quadt, C.; Chene, P.; Schoepfer, J.; Garcia-Echeverria, C.; Einsele, H.; Wajant, H.; Bargou, R. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1604-1612</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We as well as others have recently shown that Hsp90 is overexpressed in multiple myeloma (MM) and critically contributes to tumor cell survival.  Pharmacol. blockade of Hsp90 has consistently been found to induce MM cell death.  However, most data have been obtained with MM cell lines whereas knowledge about the mol. effects of pharmacol. Hsp90 blockade in primary tumor cells is limited.  Furthermore, these investigations have so far focused on geldanamycin derivs.  We analyzed the biochem. effects of a novel diarylisoxazole-based Hsp90 inhibitor (NVP-AUY922) on signalling pathways and cell death in a large set of primary MM tumor samples and in MM cell lines.  Treated cells displayed the mol. signature and pharmacodynamic properties for abrogation of Hsp90 function, such as downregulation of multiple survival pathways and strong upregulation of Hsp70.  NVP-AUY922 treatment efficiently induced MM cell apoptosis and revealed both sensitive and resistant subgroups.  Sensitivity was not correlated with TP53 mutation or Hsp70 induction levels and stromal cells from the bone marrow microenvironment were unable to abrogate NVP-AUY922-induced apoptosis of MM cells.  Thus, NVP-AUY922 may be a promising drug for treatment of MM and clin. studies are warranted.  Leukemia (2008) 22, 1604-1612; doi:10.1038/leu.2008.111; published online 15 May 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY5_BOjQZtgLVg90H21EOLACvtfcHk0liWM-KXJ7FXYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslSntL8%253D&md5=5a83e6c4e8d05b3ad9fddd3b0d55a63f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.111%26sid%3Dliteratum%253Aachs%26aulast%3DSt%25C3%25BChmer%26aufirst%3DT.%26aulast%3DZ%25C3%25B6llinger%26aufirst%3DA.%26aulast%3DSiegmund%26aufirst%3DD.%26aulast%3DChatterjee%26aufirst%3DM.%26aulast%3DGrella%26aufirst%3DE.%26aulast%3DKnop%26aufirst%3DS.%26aulast%3DKort%25C3%25BCm%26aufirst%3DM.%26aulast%3DUnzicker%26aufirst%3DC.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DWajant%26aufirst%3DH.%26aulast%3DBargou%26aufirst%3DR.%2BC.%26atitle%3DSignalling%2520profile%2520and%2520antitumour%2520activity%2520of%2520the%2520novel%2520Hsp90%2520inhibitor%2520NVP-AUY922%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D1604%26epage%3D1612%26doi%3D10.1038%2Fleu.2008.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radimerski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chène, P.</span></span> <span> </span><span class="NLM_article-title">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">R33</span>, <span class="refDoi"> DOI: 10.1186/bcr1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1186%2Fbcr1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=18430202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=R33&issue=2&author=M.+R.+Jensenauthor=J.+Schoepferauthor=T.+Radimerskiauthor=A.+Masseyauthor=C.+T.+Guyauthor=J.+Brueggenauthor=C.+Quadtauthor=A.+Bucklerauthor=R.+Cozensauthor=M.+J.+Drysdaleauthor=C.+Garcia-Echeverriaauthor=P.+Ch%C3%A8ne&title=NVP-AUY922%3A+a+small+molecule+HSP90+inhibitor+with+potent+antitumor+activity+in+preclinical+breast+cancer+models&doi=10.1186%2Fbcr1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span></div><div class="casAuthors">Jensen Michael Rugaard; Schoepfer Joseph; Radimerski Thomas; Massey Andrew; Guy Chantale T; Brueggen Josef; Quadt Cornelia; Buckler Alan; Cozens Robert; Drysdale Martin J; Garcia-Echeverria Carlos; Chene Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">R33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Heat shock protein 90 (HSP90) is a key component of a multichaperone complex involved in the post-translational folding of a large number of client proteins, many of which play essential roles in tumorigenesis.  HSP90 has emerged in recent years as a promising new target for anticancer therapies.  METHODS:  The concentrations of the HSP90 inhibitor NVP-AUY922 required to reduce cell numbers by 50% (GI50 values) were established in a panel of breast cancer cell lines and patient-derived human breast tumors.  To investigate the properties of the compound in vivo, the pharmacokinetic profile, antitumor effect, and dose regimen were established in a BT-474 breast cancer xenograft model.  The effect on HSP90-p23 complexes, client protein degradation, and heat shock response was investigated in cell culture and breast cancer xenografts by immunohistochemistry, Western blot analysis, and immunoprecipitation.  RESULTS:  We show that the novel small molecule HSP90 inhibitor NVP-AUY922 potently inhibits the proliferation of human breast cancer cell lines with GI50 values in the range of 3 to 126 nM.  NVP-AUY922 induced proliferative inhibition concurrent with HSP70 upregulation and client protein depletion--hallmarks of HSP90 inhibition.  Intravenous acute administration of NVP-AUY922 to athymic mice (30 mg/kg) bearing subcutaneous BT-474 breast tumors resulted in drug levels in excess of 1,000 times the cellular GI50 value for about 2 days.  Significant growth inhibition and good tolerability were observed when the compound was administered once per week.  Therapeutic effects were concordant with changes in pharmacodynamic markers, including HSP90-p23 dissociation, decreases in ERBB2 and P-AKT, and increased HSP70 protein levels.  CONCLUSION:  NVP-AUY922 is a potent small molecule HSP90 inhibitor showing significant activity against breast cancer cells in cellular and in vivo settings.  On the basis of its mechanism of action, preclinical activity profile, tolerability, and pharmaceutical properties, the compound recently has entered clinical phase I breast cancer trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRY3cZ5prrYd1QT_1O5WBYfW6udTcc2eaQr7ARJZ9IB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D&md5=2779e042ee1da49407fc813cca82305e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2Fbcr1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr1996%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DGuy%26aufirst%3DC.%2BT.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBuckler%26aufirst%3DA.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26atitle%3DNVP-AUY922%253A%2520a%2520small%2520molecule%2520HSP90%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520breast%2520cancer%2520models%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2008%26volume%3D10%26issue%3D2%26spage%3DR33%26doi%3D10.1186%2Fbcr1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onozawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuse, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, A.</span></span> <span> </span><span class="NLM_article-title">Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1007/s00280-014-2521-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1007%2Fs00280-014-2521-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=25059319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=629-636&issue=3&author=T.+Doiauthor=Y.+Onozawaauthor=N.+Fuseauthor=T.+Yoshinoauthor=K.+Yamazakiauthor=J.+Watanabeauthor=M.+Akimovauthor=M.+Robsonauthor=N.+Bokuauthor=A.+Ohtsu&title=Phase+I+dose-escalation+study+of+the+HSP90+inhibitor+AUY922+in+Japanese+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-014-2521-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span></div><div class="casAuthors">Doi, Toshihiko; Onozawa, Yusuke; Fuse, Nozomu; Yoshino, Takayuki; Yamazaki, Kentaro; Watanabe, Junichiro; Akimov, Mikhail; Robson, Matthew; Boku, Narikazu; Ohtsu, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-636</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: AUY922 is a potent non-geldanamycin inhibitor of heat-shock protein 90.  This study was carried out in Japanese patients to det. the max. tolerated dose (MTD), and to characterize safety, tolerability and pharmacokinetics of single-agent AUY922.  Methods: Japanese patients with advanced solid tumors whose disease had progressed on at least one line of std. therapy, or for whom no std. therapy existed, were treated with AUY922 (i.v., once-weekly, 28-day cycle, starting dose 8 mg/m2).  Results: Thirty-one patients were treated.  Two DLTs were reported in one patient of the 54 mg/m2 cohort; fatigue and decreased appetite (both Grade 3, resolving to Grade 1 within 8 days).  No MTD was detd., and the dose recommended for Phase II studies was detd. to be 70 mg/m2 once-weekly.  Most common drug-related toxicities were diarrhea, night blindness and nausea.  Grade 1 and 2 visual toxicities at high AUY922 doses ≥22 mg/m2 were obsd.  Ten patients (32 %) achieved a best overall response of stable disease, and one patient (3 %) achieved a confirmed partial response.  Conclusion: Overall, AUY922 exhibited acceptable toxicities and demonstrated potential clin. activity in Japanese patients, with similar safety and pharmacokinetic profiles to those reported in a preceding global Phase I study in Western patients (CAUY922A2101).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpBWf7yeQ6rVg90H21EOLACvtfcHk0liWM-KXJ7FXYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI&md5=b45329cadb86c932a68ced6951b796db</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs00280-014-2521-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-014-2521-x%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DOnozawa%26aufirst%3DY.%26aulast%3DFuse%26aufirst%3DN.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DBoku%26aufirst%3DN.%26aulast%3DOhtsu%26aufirst%3DA.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520AUY922%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2014%26volume%3D74%26issue%3D3%26spage%3D629%26epage%3D636%26doi%3D10.1007%2Fs00280-014-2521-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargou, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alegre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bladé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ibarra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. P.</span></span> <span> </span><span class="NLM_article-title">Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2192</span>, <span class="refDoi"> DOI: 10.1002/cncr.29339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1002%2Fcncr.29339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=25809731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKntL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=2185-2192&issue=13&author=R.+Seggewiss-Bernhardtauthor=R.+C.+Bargouauthor=Y.+T.+Gohauthor=A.+K.+Stewartauthor=A.+Spencerauthor=A.+Alegreauthor=J.+Blad%C3%A9author=O.+G.+Ottmannauthor=C.+Fernandez-Ibarraauthor=H.+Luauthor=S.+Painauthor=M.+Akimovauthor=S.+P.+Iyer&title=Phase+1%2F1B+trial+of+the+heat+shock+protein+90+inhibitor+NVP-AUY922+as+monotherapy+or+in+combination+with+bortezomib+in+patients+with+relapsed+or+refractory+multiple+myeloma&doi=10.1002%2Fcncr.29339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma</span></div><div class="casAuthors">Seggewiss-Bernhardt, Ruth; Bargou, Ralf C.; Goh, Yeow Tee; Stewart, A. Keith; Spencer, Andrew; Alegre, Adrian; Blade, Joan; Ottmann, Oliver G.; Fernandez-Ibarra, Cristina; Lu, Hong; Pain, Scott; Akimov, Mikhail; Iyer, Swaminathan Padmanabhan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2185-2192</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : NVP-AUY922 (AUY; Luminespib) with or without bortezomib showed preclin. activity against multiple myeloma (MM) cells.  This phase 1/1B study assessed NVP-AUY922 alone and with bortezomib in patients with relapsed or refractory MM.  METHODS : Dose escalation was guided by an adaptive Bayesian logistic regression model.  In phase 1, patients who progressed after 2 to 4 prior therapies received NVP-AUY922 i.v. once weekly.  In phase 1B, patients who progressed after 2 or fewer prior therapies received NVP-AUY922 plus bortezomib.  The primary objective was to det. the max. tolerated dose (MTD) of NVP-AUY922.  RESULTS : Twenty-four patients received NVP-AUY922 monotherapy at doses of 8 to 70 mg/m2.  One dose-limiting toxicity (DLT) was obsd. (grade 3 blurred vision at 70 mg/m2); no MTD was reached.  The recommended phase 2 dose was 70 mg/m2.  The most frequent drug-related adverse events (AEs) were diarrhea, nausea, and ocular toxicities.  Grade 3/4 AEs were uncommon (<10%).  Eight patients discontinued treatment because of AEs; 5 had ocular toxicities (≥45 mg/m2).  The best response was stable disease in 66.7% of the patients.  There were no partial or complete responses.  Five patients received NVP-AUY922 (which was started at 50 mg/m2) plus bortezomib (1.3 mg/m2).  Three of these patients experienced DLT.  No further dose escalation was performed; the MTD for NVP-AUY922 plus bortezomib was not established.  CONCLUSIONS : This study showed disease stabilization with NVP-AUY922 in patients with relapsed or refractory MM.  The MTD for NVP-AUY922 was not reached, but reversible ocular toxicity has been reported at high dose levels.  Bortezomib at the std. recommended dose plus NVP-AUY922 was not tolerated.  Cancer 2015;121:2185-2192. © 2015 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV8J1qkTHQbbVg90H21EOLACvtfcHk0lhTQeqYr0OfgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKntL3L&md5=5ecc6c0563033e7449a8bda4490354ce</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29339%26sid%3Dliteratum%253Aachs%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DBargou%26aufirst%3DR.%2BC.%26aulast%3DGoh%26aufirst%3DY.%2BT.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DSpencer%26aufirst%3DA.%26aulast%3DAlegre%26aufirst%3DA.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DFernandez-Ibarra%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPain%26aufirst%3DS.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26atitle%3DPhase%25201%252F1B%2520trial%2520of%2520the%2520heat%2520shock%2520protein%252090%2520inhibitor%2520NVP-AUY922%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520bortezomib%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26issue%3D13%26spage%3D2185%26epage%3D2192%26doi%3D10.1002%2Fcncr.29339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renouf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzyzanowska, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmuck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. J.</span></span> <span> </span><span class="NLM_article-title">A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1007/s00280-016-3102-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1007%2Fs00280-016-3102-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=27422303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ejtLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2016&pages=541-545&issue=3&author=D.+J.+Renoufauthor=D.+Hedleyauthor=M.+K.+Krzyzanowskaauthor=M.+Schmuckauthor=L.+Wangauthor=M.+J.+Moore&title=A+phase+II+study+of+the+HSP90+inhibitor+AUY922+in+chemotherapy+refractory+advanced+pancreatic+cancer&doi=10.1007%2Fs00280-016-3102-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer</span></div><div class="casAuthors">Renouf, D. J.; Hedley, D.; Krzyzanowska, M. K.; Schmuck, M.; Wang, L.; Moore, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">541-545</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Objectives: AUY922 is a novel heat shock protein inhibitor with preclin. activity in pancreatic cancer.  This phase II study evaluated the efficacy of AUY922 in patients with advanced pancreatic cancer previously treated with chemotherapy.  Methods: In this single-arm, Simon two-stage phase II trial, patients with metastatic or locally advanced pancreatic ductal adenocarcinoma who had progressed on at least one line of chemotherapy and were of good performances status (ECOG 0 or 1) were treated with AUY922 at a dose of 70 mg/m2 IV weekly.  The primary endpoint was disease control rate (objective response and stable disease ≥16 wk).  Results: Twelve patients were accrued, all of whom received treatment.  At least possibly related ≥grade 3 adverse events included fatigue (8 %) and AST elevation (8 %).  Ten patients were evaluable for response with 1 (10 %) having stable disease and 9 (90 %) progressive disease.  The median progression-free survival was 1.6 mo, and the median overall survival was 2.9 mo.  Conclusions: AUY922 was not assocd. with significant efficacy in previously treated patients with advanced pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCYdfJvebVGLVg90H21EOLACvtfcHk0lhTQeqYr0OfgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ejtLrJ&md5=e34132dfb40cc97ab41c169c59612e8a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3102-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3102-y%26sid%3Dliteratum%253Aachs%26aulast%3DRenouf%26aufirst%3DD.%2BJ.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DKrzyzanowska%26aufirst%3DM.%2BK.%26aulast%3DSchmuck%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DM.%2BJ.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520AUY922%2520in%2520chemotherapy%2520refractory%2520advanced%2520pancreatic%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D78%26issue%3D3%26spage%3D541%26epage%3D545%26doi%3D10.1007%2Fs00280-016-3102-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earwood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors</span>. <i>Cancer Invest.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1080/07357907.2016.1193746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1080%2F07357907.2016.1193746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=27379708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCrsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=265-270&issue=6&author=J.+C.+Bendellauthor=T.+M.+Bauerauthor=R.+Lamarauthor=M.+Josephauthor=W.+Penleyauthor=D.+S.+Thompsonauthor=D.+R.+Spigelauthor=R.+Oweraauthor=C.+M.+Laneauthor=C.+Earwoodauthor=H.+A.+Burris&title=A+phase+2+study+of+the+Hsp90+inhibitor+AUY922+as+treatment+for+patients+with+refractory+gastrointestinal+stromal+tumors&doi=10.1080%2F07357907.2016.1193746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Bendell, Johanna C.; Bauer, Todd M.; Lamar, Ruth; Joseph, Mathew; Penley, William; Thompson, Dana S.; Spigel, David R.; Owera, Rami; Lane, Cassie M.; Earwood, Chris; Burris, Howard A., III</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Investigation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">265-270</span>CODEN:
                <span class="NLM_cas:coden">CINVD7</span>;
        ISSN:<span class="NLM_cas:issn">0735-7907</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Background: AUY922 is an inhibitor of heat shock protein 90 (Hsp90).  Hsp90 inhibitors induce kit degrdn. in preclin. gastrointestinal stromal tumor (GIST) models.  This trial was designed to det. the progression-free survival (PFS) of patients with GIST refractory to or intolerant of imatinib and sunitinib.  Methods: Eligible patients received AUY922 70 mg/mg2 by i.v. (IV) infusion on days 1, 8, and 15 of 21-day cycles.  Treatment continued until progression or unacceptable toxicity.  Results: Between Dec. 2011 and Jan. 2015, 25 patients were enrolled (median age, 63 years; 56% male) and received a median of 2 cycles (range: 1-12) of AUY922 treatment.  Thirty-four patients were planned, but enrollment was stopped early due to slow accrual.  Median PFS was 3.9 mo (95% CI: 2.5, 5.3) and median OS was 8.5 mo (95% CI: 5.2, 16.7).  Radiog. response was evaluated in 21 patients; one patient achieved PR (4%) with another 15 having best response of stable disease (60%).  The most common treatment-related adverse event was diarrhea (60% all grades).  Reversible ocular toxicities that resulted in drug hold (24%) or redn. (8%) were also obsd.  Conclusion: AUY922 produced a median PFS which compares favorably to historical controls of placebo (6 wk) for patients refractory to treatment with imatinib.  While diarrhea and ocular toxicities were common, the majority of patients received treatment until disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmYmW82WPEprVg90H21EOLACvtfcHk0lhTQeqYr0OfgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCrsr%252FE&md5=5dfc57d92a51bc78c5765387cac0393c</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1080%2F07357907.2016.1193746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07357907.2016.1193746%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DLamar%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DM.%26aulast%3DPenley%26aufirst%3DW.%26aulast%3DThompson%26aufirst%3DD.%2BS.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DOwera%26aufirst%3DR.%26aulast%3DLane%26aufirst%3DC.%2BM.%26aulast%3DEarwood%26aufirst%3DC.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DA%2520phase%25202%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520as%2520treatment%2520for%2520patients%2520with%2520refractory%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Invest.%26date%3D2016%26volume%3D34%26issue%3D6%26spage%3D265%26epage%3D270%26doi%3D10.1080%2F07357907.2016.1193746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bear, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, C.</span></span> <span> </span><span class="NLM_article-title">The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1016/j.exphem.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.exphem.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=18657349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1266-1277&issue=10&author=T.-Y.+Linauthor=M.+Bearauthor=Z.+Duauthor=K.+P.+Foleyauthor=W.+Yingauthor=J.+Barsoumauthor=C.+London&title=The+novel+HSP90+inhibitor+STA-9090+exhibits+activity+against+Kit-dependent+and+-independent+malignant+mast+cell+tumors&doi=10.1016%2Fj.exphem.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors</span></div><div class="casAuthors">Lin, Tzu-Yin; Bear, Misty; Du, Zhenjian; Foley, Kevin P.; Ying, Weiwen; Barsoum, James; London, Cheryl</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1266-1277</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers.  While Kit inhibitors have activity in the clin. setting, they possess variable efficacy against particular forms of mutant Kit and drug resistance often develops over time.  Inhibitors of heat shock protein 90 (HSP90), a chaperone for which Kit is a client protein, have demonstrated activity against human cancers and evidence suggests they downregulate several mutated and imatinib-resistant forms of Kit.  The purpose of this study was to evaluate a novel HSP90 inhibitor, STA-9090, against wild-type (WT) and mutant Kit in canine bone marrow-derived cultured mast cells (BMCMCs), malignant mast cell lines, and fresh malignant mast cells.  BMCMCs, cell lines, and fresh malignant mast cells were treated with STA-9090, 17-AAG, and SU11654 and evaluated for loss in cell viability, cell death, alterations in HSP90 and Kit expression/signaling, and Kit mutation.  STA-9090 activity was tested in a canine mastocytoma xenograft model.  Treatment of BMCMCs, cell lines, and fresh malignant cells with STA-9090 induced growth inhibition, apoptosis that was caspase-3/7-dependent, and downregulation of phospho/total Kit and Akt, but not extracellular signal-regulated kinase (ERK) or phosphoinositide-3 kinase (PI-3K).  Loss of Kit cell-surface expression was also obsd.  Furthermore, STA-9090 exhibited superior activity to 17-AAG and SU11654, and was effective against malignant mast cells expressing either WT or mutant Kit.  Lastly, STA-9090 inhibited tumor growth in a canine mastocytoma mouse xenograft model.  STA-9090 exhibits broad activity against mast cells expressing WT or mutant Kit, suggesting it may be an effective agent in the clin. setting against mast cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzWCSaAah6lrVg90H21EOLACvtfcHk0lhnoW0qmU8qRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK&md5=0ded2a0f878a699b895088651fc47913</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.-Y.%26aulast%3DBear%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DYing%26aufirst%3DW.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DLondon%26aufirst%3DC.%26atitle%3DThe%2520novel%2520HSP90%2520inhibitor%2520STA-9090%2520exhibits%2520activity%2520against%2520Kit-dependent%2520and%2520-independent%2520malignant%2520mast%2520cell%2520tumors%26jtitle%3DExp.%2520Hematol.%26date%3D2008%26volume%3D36%26issue%3D10%26spage%3D1266%26epage%3D1277%26doi%3D10.1016%2Fj.exphem.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackman, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acquaviva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, K.</span></span> <span> </span><span class="NLM_article-title">Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1158%2F1535-7163.MCT-11-0755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=22144665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=475-484&issue=2&author=W.+W.+Yingauthor=Z.+J.+Duauthor=L.+J.+Sunauthor=K.+P.+Foleyauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=D.+Zhouauthor=T.+Inoueauthor=N.+Tatsutaauthor=J.+Sangauthor=S.+X.+Yeauthor=J.+Acquavivaauthor=L.+S.+Ogawaauthor=Y.+Wadaauthor=J.+Barsoumauthor=K.+Koya&title=Ganetespib%2C+a+unique+triazolone-containing+Hsp90+inhibitor%2C+exhibits+potent+antitumor+activity+and+a+superior+safety+profile+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-11-0755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy</span></div><div class="casAuthors">Ying, Weiwen; Du, Zhenjian; Sun, Lijun; Foley, Kevin P.; Proia, David A.; Blackman, Ronald K.; Zhou, Dan; Inoue, Takayo; Tatsuta, Noriaki; Sang, Jim; Ye, Shuxia; Acquaviva, Jamie; Ogawa, Luisa Shin; Wada, Yumiko; Barsoum, James; Koya, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of the mol. chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics.  Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clin. trials for a no. of human cancers.  In the present study, we showed that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematol. tumor cell lines, including those that express mutated kinases that confer resistance to small-mol. tyrosine kinase inhibitors.  Ganetespib treatment rapidly induced the degrdn. of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times.  In vivo, ganetespib showed potent antitumor efficacy in solid and hematol. xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions.  Notably, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib was efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis.  Importantly, ganetespib showed no evidence of cardiac or liver toxicity.  Taken together, this preclin. activity profile indicates that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.  Mol Cancer Ther; 11(2); 475-84.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhzG1TPr4lbVg90H21EOLACvtfcHk0lhnoW0qmU8qRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D&md5=269d41b30e5add9b9503cb43a98b0157</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0755%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%2BW.%26aulast%3DDu%26aufirst%3DZ.%2BJ.%26aulast%3DSun%26aufirst%3DL.%2BJ.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DS.%2BX.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26atitle%3DGanetespib%252C%2520a%2520unique%2520triazolone-containing%2520Hsp90%2520inhibitor%252C%2520exhibits%2520potent%2520antitumor%2520activity%2520and%2520a%2520superior%2520safety%2520profile%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D2%26spage%3D475%26epage%3D484%26doi%3D10.1158%2F1535-7163.MCT-11-0755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billups, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurmasheva, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span> <span> </span><span class="NLM_article-title">Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">E42</span>– <span class="NLM_lpage">E45</span>, <span class="refDoi"> DOI: 10.1002/pbc.24451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1002%2Fpbc.24451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=23303741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWhu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2013&pages=E42-E45&issue=7&author=R.+B.+Lockauthor=H.+Carolauthor=J.+M.+Marisauthor=M.+H.+Kangauthor=C.+P.+Reynoldsauthor=E.+A.+Kolbauthor=R.+Gorlickauthor=S.+T.+Keirauthor=C.+A.+Billupsauthor=R.+T.+Kurmashevaauthor=P.+J.+Houghtonauthor=M.+A.+Smith&title=Initial+testing+%28stage+1%29+of+ganetespib%2C+an+Hsp90+inhibitor%2C+by+the+pediatric+preclinical+testing+program&doi=10.1002%2Fpbc.24451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program</span></div><div class="casAuthors">Lock, Richard B.; Carol, Hernan; Maris, John M.; Kang, Min H.; Reynolds, C. Patrick; Kolb, E. Anders; Gorlick, Richard; Keir, Stephen T.; Billups, Catherine A.; Kurmasheva, Raushan T.; Houghton, Peter J.; Smith, Malcolm A.</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Blood & Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">E42-E45, 4</span>CODEN:
                <span class="NLM_cas:coden">PBCEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1545-5017</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Ganetespib, an Hsp90 inhibitor, was tested against the PPTP in vitro cell line panel and selected xenografts in vivo, including JAK2- and BRAF-mutated models.  Ganetespib demonstrated potent in vitro cytotoxic activity (median rIC50 8.8 nM, range 4.4- 27.1 nM).  In vivo, ganetespib induced significant differences in EFS distribution for 4 of 11 xenografts.  Intermediate activity (EFS T/C > 2) was noted only for the MV4;11 xenograft, and there were no objective responses.  Administered as single agents, Hsp90 inhibitors examd. by the PPTP have shown limited evidence for a therapeutic window against both solid tumor and leukemia pediatric preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxyDM0rHGFS7Vg90H21EOLACvtfcHk0lhnoW0qmU8qRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWhu7bJ&md5=20c807fb3c0f989ef4825d486764032f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fpbc.24451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.24451%26sid%3Dliteratum%253Aachs%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DKang%26aufirst%3DM.%2BH.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DBillups%26aufirst%3DC.%2BA.%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DInitial%2520testing%2520%2528stage%25201%2529%2520of%2520ganetespib%252C%2520an%2520Hsp90%2520inhibitor%252C%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2013%26volume%3D60%26issue%3D7%26spage%3DE42%26epage%3DE45%26doi%3D10.1002%2Fpbc.24451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplinsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteva, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.1186/s13058-017-0879-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1186%2Fs13058-017-0879-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=28764748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGju7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=89&issue=1&author=K.+Jhaveriauthor=R.+Wangauthor=E.+Teplinskyauthor=S.+Chandarlapatyauthor=D.+Solitauthor=K.+Cadooauthor=J.+Speyerauthor=G.+D%E2%80%99Andreaauthor=S.+Adamsauthor=S.+Patilauthor=S.+Haqueauthor=T.+O%E2%80%99Neillauthor=K.+Friedmanauthor=F.+J.+Estevaauthor=C.+Hudisauthor=S.+Modi&title=A+phase+I+trial+of+ganetespib+in+combination+with+paclitaxel+and+trastuzumab+in+patients+with+human+epidermal+growth+factor+receptor-2+%28HER2%29-positive+metastatic+breast+cancer&doi=10.1186%2Fs13058-017-0879-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer</span></div><div class="casAuthors">Jhaveri, Komal; Wang, Rui; Teplinsky, Eleonora; Chandarlapaty, Sarat; Solit, David; Cadoo, Karen; Speyer, James; D'Andrea, Gabriella; Adams, Sylvia; Patil, Sujata; Haque, Sofia; O'Neill, Tara; Friedman, Kent; Esteva, Francisco J.; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89/1-89/8</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Targeted therapies in HER2-pos. metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance.  HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance.  Preclin. data suggest that HSP90 inhibition is synergistic with taxanes with the potential for significant clin. activity.  We therefore tested ganetespib, a HSP90 inhibitor, in combination with paclitaxel and trastuzumab in patients with trastuzumab-refractory HER2-pos. metastatic breast cancer.  Methods: In this phase I dose-escalation study, patients with trastuzumab-resistant HER2-pos. metastatic breast cancer received weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m2) on days 1, 8, 15, and 22 of a 28-day cycle with escalating doses of ganetespib (100 mg/m2, 150 mg/m2, and a third cohort of 125 mg/m2 if needed) on days 1, 8, and 15.  Therapy was continued until disease progression or toxicity.  The primary objective was to establish the safety and max. tolerated dose and/or recommended phase II dose (RP2D) of this therapy.  The secondary objectives included evaluation of the effects of ganetespib on the pharmacokinetics of paclitaxel, and to make a preliminary assessment of the efficacy of the combination therapy.  Results: Dose escalation was completed for the two main cohorts without any obsd. dose-limiting toxicities.  Nine patients received treatment.  The median prior lines of anti-HER2 therapy numbered three (range 2-4), including prior pertuzumab in 9/9 patients and ado-trastuzumab emtansine (T-DM1) in 8/9 patients.  The most common grade 1/2 adverse events (AEs) were diarrhea, fatigue, anemia, and rash.  There were no grade 4 AEs related to ganetespib.  The overall response rate was 22% (2/9 patients had partial response) and stable disease was seen in 56% (5/9 patients).  The clin. benefit rate was 44% (4/9 patients).  The median progression-free survival was 20 wk (range 8-55).  Conclusion: The RP2D of ganetespib is 150 mg/m2 in combination with weekly paclitaxel plus trastuzumab.  The combination was safe and well tolerated.  Despite prior taxanes, pertuzumab, and T-DM1, clin. activity of this triplet regimen in this heavily pretreated cohort is promising and warrants further study in HER2-pos. metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUSvrm6d3_trVg90H21EOLACvtfcHk0lgYP-pbknz8kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGju7zO&md5=7e725dae322c9d5b8cf3967665da5c82</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1186%2Fs13058-017-0879-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-017-0879-5%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DTeplinsky%26aufirst%3DE.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DCadoo%26aufirst%3DK.%26aulast%3DSpeyer%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DHaque%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DT.%26aulast%3DFriedman%26aufirst%3DK.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520ganetespib%2520in%2520combination%2520with%2520paclitaxel%2520and%2520trastuzumab%2520in%2520patients%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER2%2529-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2017%26volume%3D19%26issue%3D1%26spage%3D89%26doi%3D10.1186%2Fs13058-017-0879-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilbrun, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishampayan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzinic, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0307-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1007%2Fs10637-015-0307-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=26581400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWlsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=112-118&issue=1&author=M.+K.+Thakurauthor=L.+K.+Heilbrunauthor=S.+Shengauthor=M.+Steinauthor=G.+Liuauthor=E.+S.+Antonarakisauthor=U.+Vaishampayanauthor=S.+H.+Dzinicauthor=X.+Liauthor=S.+Freemanauthor=D.+Smithauthor=E.+I.+Heath&title=A+phase+II+trial+of+ganetespib%2C+a+heat+shock+protein+90+Hsp90%29+inhibitor%2C+in+patients+with+docetaxel-pretreated+metastatic+castrate-resistant+prostate+cancer+%28CRPC%29-a+prostate+cancer+clinical+trials+consortium+%28PCCTC%29+study&doi=10.1007%2Fs10637-015-0307-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study</span></div><div class="casAuthors">Thakur, Manish K.; Heilbrun, Lance K.; Sheng, Shijie; Stein, Mark; Liu, Glenn; Antonarakis, Emmanuel S.; Vaishampayan, Ulka; Dzinic, Sijana H.; Li, Xiaohua; Freeman, Stacy; Smith, Daryn; Heath, Elisabeth I.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-118</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Introduction Heat shock protein 90 (Hsp90) has been studied as a therapeutic target in many cancers.  In preclin. trials, the Hsp90 ATPase inhibitor ganetespib demonstrated potent inhibition of solid tumor growth, with superior potency than prior Hsp90 inhibitors.  Given the promising preclin. outcome and favorable pharmacol. properties of ganetespib, we conducted a phase II trial of single-agent ganetespib in patients with metastatic, castrate-resistant prostate cancer (mCRPC).  The primary objective of the study was to det. the 6-mo progression-free survival (PFS) rate.  Methods Patients with mCRPC who had been previously treated with docetaxel were enrolled after meeting eligibility criteria.  All patients received ganetespib at 200 mg/m2 on days 1, 8, and 15 of every 28 days (one cycle).  Subjects who tolerated therapy were continued on ganetespib until disease progression.  Considering that Hsp90 acetylation may confer insensitivity to Hsp90 inhibitors and maspin inhibits protein deacetylation, maspin-assocd. mol. markers were evaluated.  Results Eighteen patients were recruited into the trial; most were Caucasian, had performance status 1, had received prior docetaxel, and were heavily pretreated.  Of the 17 patients who were treated, none attained 6-mo PFS.  Only 2 patients achieved PFS > 4 mo.  The median PFS was 1.9 mo.  As per the study design, the trial was terminated after the interim anal.  The most frequent types of Grade 3 toxicity were dehydration, diarrhea, and fatigue.  Mol. markers provided little addnl. insight regarding drug activity.  Conclusions Ganetespib demonstrated minimal clin. activity in men with mCRPC.  The true 6-mo PFS rate was, at most, 0.20.  Possible reasons for this include selection of a heavily pretreated patient population and lack of agent potency in patients with mCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEc_FjjTbGprVg90H21EOLACvtfcHk0li4_reeiQmXDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWlsLjN&md5=08f9e46b0d9880d2caa2395be001ce8e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0307-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0307-6%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DM.%2BK.%26aulast%3DHeilbrun%26aufirst%3DL.%2BK.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DStein%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DVaishampayan%26aufirst%3DU.%26aulast%3DDzinic%26aufirst%3DS.%2BH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520ganetespib%252C%2520a%2520heat%2520shock%2520protein%252090%2520Hsp90%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520docetaxel-pretreated%2520metastatic%2520castrate-resistant%2520prostate%2520cancer%2520%2528CRPC%2529-a%2520prostate%2520cancer%2520clinical%2520trials%2520consortium%2520%2528PCCTC%2529%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2016%26volume%3D34%26issue%3D1%26spage%3D112%26epage%3D118%26doi%3D10.1007%2Fs10637-015-0307-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadlow, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaszkowsky, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolpin, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCleary, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karol, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, A. X.</span></span> <span> </span><span class="NLM_article-title">A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0164-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1007%2Fs10637-014-0164-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=25248753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=128-137&issue=1&author=L.+Goyalauthor=R.+C.+Wadlowauthor=L.+S.+Blaszkowskyauthor=B.+M.+Wolpinauthor=T.+A.+Abramsauthor=N.+J.+McClearyauthor=S.+Sheehanauthor=E.+Sundaramauthor=M.+D.+Karolauthor=J.+Chenauthor=A.+X.+Zhu&title=A+phase+I+and+pharmacokinetic+study+of+ganetespib+%28STA-9090%29+in+advanced+hepatocellular+carcinoma&doi=10.1007%2Fs10637-014-0164-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma</span></div><div class="casAuthors">Goyal, Lipika; Wadlow, Raymond C.; Blaszkowsky, Lawrence S.; Wolpin, Brian M.; Abrams, Thomas A.; McCleary, Nadine Jackson; Sheehan, Susan; Sundaram, Eamala; Karol, Michael D.; Chen, John; Zhu, Andrew X.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-137</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other Hsp90 client proteins involved in hepatocarcinogenesis, thereby making it an attractive therapy for HCC.  This Phase I study was performed to establish the safety, tolerability, recommended Phase 2 dose (RP2D), and preliminary clin. activity of ganetespib in previously treated patients with advanced HCC.  Methods: Patients with advanced HCC, Child-Pugh A cirrhosis, progression on or intolerance to sorafenib, and ECOG PS ≤ 1 were enrolled in a std. 3x3 dose escalation study at doses of 100 mg/m2, 150 mg/m2, and 200 mg/m2 IV given on days 1, 8, and 15 of each 28-day cycle.  Objective response by RECIST version 1.1 criteria was evaluated by CT/MRI every 8 wk.  Results: Fourteen patients were enrolled in this trial and received at least one dose of the study drug.  Of the 14 patients: median age, 57 years old; male 71 %; Asian 36 %; HCC etiol. (HBV 36 %, HCV 43 %, Hemachromatosis 7 %, unknown 21 %); Child Pugh Class (A 93 %, B 7 %); median no. of prior treatments 2; median baseline AFP 70.1 ng/mL.  The RP2D was detd. to be 200 mg/m2.  The most commonly seen AEs were diarrhea (93 %), fatigue (71 %), AST elevation (64 %), and hyperglycemia (64 %).  The most common Gr 3/4 AEs were hyperglycemia (21 %) and lipasemia (21 %).  One (7 %) patient had a fatal AE, septic shock, within 30 days of receiving the study drug.  One dose-limiting toxicity, grade 3 lipasemia, was obsd. at the 100 mg/m2 dose.  Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m2), 0.76 h, and 191 L (100.4 L/m2), resp.  No objective responses were seen; one patient (7 %) had stable disease at 16 wk.  Median time to progression was 1.8 mo, and median overall survival was 7.2 mo.  Conclusion: Ganetespib had a manageable safety profile in patients with advanced HCC who had progressed on at least one line of systemic therapy.  The pharmacokinetic profile showed that ganetespib exposure in patients with mild hepatic dysfunction is similar to that seen in patients with normal liver function.  Ganetespib showed limited clin. benefit in patients with advanced HCC in this phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr57teDffjuSrVg90H21EOLACvtfcHk0ljaGKxlfz4zMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSru7c%253D&md5=c55ec15b28353dea4e1aca73525f7e9b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0164-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0164-8%26sid%3Dliteratum%253Aachs%26aulast%3DGoyal%26aufirst%3DL.%26aulast%3DWadlow%26aufirst%3DR.%2BC.%26aulast%3DBlaszkowsky%26aufirst%3DL.%2BS.%26aulast%3DWolpin%26aufirst%3DB.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BA.%26aulast%3DMcCleary%26aufirst%3DN.%2BJ.%26aulast%3DSheehan%26aufirst%3DS.%26aulast%3DSundaram%26aufirst%3DE.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520ganetespib%2520%2528STA-9090%2529%2520in%2520advanced%2520hepatocellular%2520carcinoma%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26issue%3D1%26spage%3D128%26epage%3D137%26doi%3D10.1007%2Fs10637-014-0164-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Socinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koczywas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonomi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belani, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huberman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teofilovici, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3068</span>– <span class="NLM_lpage">3077</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1158%2F1078-0432.CCR-12-3381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=23553849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3068-3077&issue=11&author=M.+A.+Socinskiauthor=J.+Goldmanauthor=I.+El-Hariryauthor=M.+Koczywasauthor=V.+Vukovicauthor=L.+Hornauthor=E.+Pascholdauthor=R.+Salgiaauthor=H.+Westauthor=L.+V.+Sequistauthor=P.+Bonomiauthor=J.+Brahmerauthor=L.-C.+Chenauthor=A.+Sandlerauthor=C.+P.+Belaniauthor=T.+Webbauthor=H.+Harperauthor=M.+Hubermanauthor=S.+Ramalingamauthor=K.-K.+Wongauthor=F.+Teofiloviciauthor=W.+Guoauthor=G.+I.+Shapiro&title=A+multicenter+phase+II+study+of+ganetespib+monotherapy+in+patients+with+genotypically+defined+advanced+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-12-3381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Socinski, Mark A.; Goldman, Jonathan; El-Hariry, Iman; Koczywas, Marianna; Vukovic, Vojo; Horn, Leora; Paschold, Eugene; Salgia, Ravi; West, Howard; Sequist, Lecia V.; Bonomi, Philip; Brahmer, Julie; Chen, Lin-Chi; Sandler, Alan; Belani, Chandra P.; Webb, Timothy; Harper, Harry; Huberman, Mark; Ramalingam, Suresh; Wong, Kwok-Kin; Teofilovici, Florentina; Guo, Wei; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3068-3077</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone protein crit. to tumor growth and proliferation.  In this phase II study, we evaluated the activity and tolerability of ganetespib in previously treated patients with non-small cell lung cancer (NSCLC).  Exptl. Design: Patients were enrolled into cohort A (mutant EGFR), B (mutant KRAS), or C (no EGFR or KRAS mutations).  Patients were treated with 200 mg/m2 ganetespib by i.v. infusion once weekly for 3 wk followed by 1 wk of rest, until disease progression.  The primary endpoint was progression-free survival (PFS) at 16 wk.  Secondary endpoints included objective response (ORR), duration of treatment, tolerability, median PFS, overall survival (OS), and correlative studies.  Results: Ninety-nine patients with a median of 2 prior systemic therapies were enrolled; 98 were assigned to cohort A (n = 15), B (n = 17), or C (n = 66), with PFS rates at 16 wk of 13.3%, 5.9%, and 19.7%, resp.  Four patients (4%) achieved partial response (PR); all had disease that harbored anaplastic lymphoma kinase (ALK) gene rearrangement, retrospectively detected by FISH (n = 1) or PCR-based assays (n = 3), in crizotinib-naive patients enrolled to cohort C. Eight patients (8.1%) experienced treatment-related serious adverse events (AE); 2 of these (cardiac arrest and renal failure) resulted in death.  The most common AEs were diarrhea, fatigue, nausea, and anorexia.  Conclusions: Ganetespib monotherapy showed a manageable side effect profile as well as clin. activity in heavily pretreated patients with advanced NSCLCs, particularly in patients with tumors harboring ALK gene rearrangement.  Clin Cancer Res; 19(11); 3068-77. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFukeZlyNCmbVg90H21EOLACvtfcHk0ljaGKxlfz4zMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D&md5=7fe5177633a6f003a7412431e6fb492d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3381%26sid%3Dliteratum%253Aachs%26aulast%3DSocinski%26aufirst%3DM.%2BA.%26aulast%3DGoldman%26aufirst%3DJ.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DKoczywas%26aufirst%3DM.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DPaschold%26aufirst%3DE.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBonomi%26aufirst%3DP.%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.-C.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DWebb%26aufirst%3DT.%26aulast%3DHarper%26aufirst%3DH.%26aulast%3DHuberman%26aufirst%3DM.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DA%2520multicenter%2520phase%2520II%2520study%2520of%2520ganetespib%2520monotherapy%2520in%2520patients%2520with%2520genotypically%2520defined%2520advanced%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D11%26spage%3D3068%26epage%3D3077%26doi%3D10.1158%2F1078-0432.CCR-12-3381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lake, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilewski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drullinsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserheit-Leiblich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynahan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span> <span> </span><span class="NLM_article-title">A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2013.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.clbc.2013.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=24512858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=154-160&issue=3&author=K.+Jhaveriauthor=S.+Chandarlapatyauthor=D.+Lakeauthor=T.+Gilewskiauthor=M.+Robsonauthor=S.+Goldfarbauthor=P.+Drullinskyauthor=S.+Sugarmanauthor=C.+Wasserheit-Leiblichauthor=J.+Fasanoauthor=M.+E.+Moynahanauthor=G.+D%E2%80%99Andreaauthor=K.+Limauthor=L.+Reddingtonauthor=S.+Haqueauthor=S.+Patilauthor=L.+Baumanauthor=V.+Vukovicauthor=I.+El-Hariryauthor=C.+Hudisauthor=S.+Modi&title=A+phase+II+open-label+study+of+ganetespib%2C+a+novel+heat+shock+protein+90+inhibitor+for+patients+with+metastatic+breast+cancer&doi=10.1016%2Fj.clbc.2013.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer</span></div><div class="casAuthors">Jhaveri, Komal; Chandarlapaty, Sarat; Lake, Diana; Gilewski, Teresa; Robson, Mark; Goldfarb, Shari; Drullinsky, Pamela; Sugarman, Steven; Wasserheit-Leiblich, Carolyn; Fasano, Julie; Moynahan, Mary Ellen; D'Andrea, Gabriella; Lim, Kristina; Reddington, Laura; Haque, Sofia; Patil, Sujata; Bauman, Lynne; Vukovic, Vojo; El-Hariry, Iman; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">154-160</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background:Ganetespib is a small mol., nongeldanamycin HSP90 inhibitor with potent inhibitory effects on HSP90-dependent oncoproteins of relevance to breast cancer pathogenesis.  We therefore tested ganetespib in an unselected cohort of patients with MBC.  Patients and Methods: Patients were treated with single agent ganetespib at 200 mg/m2 once weekly for 3 wk, on a 28-day cycle.  Therapy was continued until disease progression.  The primary end point was ORR using Reponse Evaluation Criteria in Solid Tumors version 1.1.  Results: Twenty-two patients were enrolled with a median age of 51(range, 38-70) years and a median Eastern Cooperative Oncol. Group performance status of 0 (range, 0-1).  Most patients had at least 2 previous lines of chemotherapy in the metastatic setting.  Most common toxicities, largely grade 1/2, were diarrhea, fatigue, nausea, and hypersensitivity reaction.  The ORR in this unselected population was 9%, with all responses coming from the subset of patients with HER2-pos. MBC (2/13; 15%).  One patient with TNBC had objective tumor regression in the lung metastases.  The clin. benefit rate (complete response + partial response + stable disease > 6 mo) was 9%, median progression-free survival was 7 wk (95% confidence interval [CI], 7-19), and median overall survival was 46 wk (95% CI, 27-not applicable).  Conclusion: The study did not meet the prespecified criteria for ORR in the first stage of the Simon 2-stage model in this heavily pretreated unselected population of MBC.  However, activity was obsd. in trastuzumab-refractory HER2-pos. and TNBC.  Ganetespib was well tolerated and responses in more targeted populations harboring specific HSP90-dependent oncoproteins justifies its further study, particularly as part of rational combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKRWFzPxBRzbVg90H21EOLACvtfcHk0ljARNliNLTeiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D&md5=15edad6cf71a9559eb42997563c57f53</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2013.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2013.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DLake%26aufirst%3DD.%26aulast%3DGilewski%26aufirst%3DT.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DGoldfarb%26aufirst%3DS.%26aulast%3DDrullinsky%26aufirst%3DP.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DWasserheit-Leiblich%26aufirst%3DC.%26aulast%3DFasano%26aufirst%3DJ.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DK.%26aulast%3DReddington%26aufirst%3DL.%26aulast%3DHaque%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DBauman%26aufirst%3DL.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520II%2520open-label%2520study%2520of%2520ganetespib%252C%2520a%2520novel%2520heat%2520shock%2520protein%252090%2520inhibitor%2520for%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26issue%3D3%26spage%3D154%26epage%3D160%26doi%3D10.1016%2Fj.clbc.2013.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teofilivici, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karol, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L. S.</span></span> <span> </span><span class="NLM_article-title">A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">152</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-13-152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1186%2F1471-2407-13-152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=23530663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotVKisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=152&issue=1&author=J.+W.+Goldmanauthor=R.+N.+Rajuauthor=G.+A.+Gordonauthor=I.+El-Hariryauthor=F.+Teofiliviciauthor=V.+M.+Vukovicauthor=R.+Bradleyauthor=M.+D.+Karolauthor=Y.+Chenauthor=W.+Guoauthor=T.+Inoueauthor=L.+S.+Rosen&title=A+first+in+human%2C+safety%2C+pharmacokinetics%2C+and+clinical+activity+phase+I+study+of+once+weekly+administration+of+the+Hsp90+inhibitor+ganetespib+%28STA-9090%29+in+patients+with+solid+malignancies&doi=10.1186%2F1471-2407-13-152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies</span></div><div class="casAuthors">Goldman, Jonathan W.; Raju, Robert N.; Gordon, Gregory A.; El-Hariry, Iman; Teofilivici, Florentina; Vukovic, Vojo M.; Bradley, Robert; Karol, Michael D.; Chen, Yu; Guo, Wei; Inoue, Takayo; Rosen, Lee S.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">152</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: This phase I study investigated the max. tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies.  Methods: Patients were enrolled in cohorts of escalating ganetespib doses, given as 1 h IV infusion, once weekly for 3 wk, followed by a 1-wk rest until disease progression or unacceptable toxicity.  Endpoints included safety, pharmacokinetic and pharmacodynamic parameters and preliminary clin. activity.  Results: Fifty-three patients were treated at doses escalating from 7 to 259 mg/m2.  The most common adverse events were Grade 1 and 2 diarrhea, fatigue, nausea or vomiting.  Dose-limiting toxicities (DLT) obsd. were: one Grade 3 amylase elevation (150 mg/m2), one Grade 3 diarrhea and one Grade 3 and one Grade 4 asthenia (259 mg/m2).  The MTD was 216 mg/m2 and the recommended phase 2 dose was established at 200 mg/m2 given IV at Days 1, 8, and 15 every 4 wk.  There was a linear relationship between dose and exposure.  Plasma HSP70 protein levels remained elevated for over a week post treatment.  Disease control rate (objective response and stable disease at ≥16 wk) was 24.4%.  Conclusions: Ganetespib is well tolerated as a weekly infusion for 3 of every 4 wk cycle.  The recommended phase II dose is 200 mg/m2, and is assocd. with an acceptable tolerability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_c-SmyNHbmbVg90H21EOLACvtfcHk0ljARNliNLTeiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotVKisbc%253D&md5=55823d1bccdb38864b2528a787e3d16b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-152%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DRaju%26aufirst%3DR.%2BN.%26aulast%3DGordon%26aufirst%3DG.%2BA.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DTeofilivici%26aufirst%3DF.%26aulast%3DVukovic%26aufirst%3DV.%2BM.%26aulast%3DBradley%26aufirst%3DR.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26atitle%3DA%2520first%2520in%2520human%252C%2520safety%252C%2520pharmacokinetics%252C%2520and%2520clinical%2520activity%2520phase%2520I%2520study%2520of%2520once%2520weekly%2520administration%2520of%2520the%2520Hsp90%2520inhibitor%2520ganetespib%2520%2528STA-9090%2529%2520in%2520patients%2520with%2520solid%2520malignancies%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26issue%3D1%26spage%3D152%26doi%3D10.1186%2F1471-2407-13-152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagaya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seike, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiotsu, Y.</span></span> <span> </span><span class="NLM_article-title">New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2792</span>– <span class="NLM_lpage">2802</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-3112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1158%2F1078-0432.CCR-09-3112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=20406843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvF2hsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2792-2802&issue=10&author=T.+Nakashimaauthor=T.+Ishiiauthor=H.+Tagayaauthor=T.+Seikeauthor=H.+Nakagawaauthor=Y.+Kandaauthor=S.+Akinagaauthor=S.+Sogaauthor=Y.+Shiotsu&title=New+molecular+and+biological+mechanism+of+antitumor+activities+of+KW-2478%2C+a+novel+nonansamycin+heat+shock+protein+90+inhibitor%2C+in+multiple+myeloma+cells&doi=10.1158%2F1078-0432.CCR-09-3112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells</span></div><div class="casAuthors">Nakashima, Takayuki; Ishii, Toshihiko; Tagaya, Hisashi; Seike, Toshihiro; Nakagawa, Hiroshi; Kanda, Yutaka; Akinaga, Shiro; Soga, Shiro; Shiotsu, Yukimasa</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2792-2802</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The heat shock protein 90 (Hsp90) plays an important role in chaperoning oncogenic client proteins in multiple myeloma (MM) cells, and several Hsp90 inhibitors have shown antitumor activities both in vitro and in vivo.  However the precise mechanism of action of Hsp90 inhibitor in MM has not been fully elucidated.  Exptl. Design: The authors evaluated the antitumor activities of KW-2478, a nonansamycin Hsp90 inhibitor, in MM cells with various chromosomal translocations of Ig heavy chain (IgH) loci both in vitro and in vivo.  RESULTS: The authors' studies revealed that exposure of KW-2478 to MM cells resulted in growth inhibition and apoptosis, which were assocd. with degrdn. of well-known client proteins as well as a decrease in IgH translocation products (FGFR3, c-Maf, and cyclin D1), and FGFR3 was shown to be a new client protein of Hsp90 chaperon complex.  In addn., KW-2478 depleted the Hsp90 client Cdk9, a transcriptional kinase, and the phosphorylated 4E-BP1, a translational inhibitor.  Both inhibitory effects of KW-2478 on such transcriptional and translational pathways were shown to reduce c-Maf and cyclin D1 expression.  In NCI-H929 s.c. inoculated model, KW-2478 showed a significant suppression of tumor growth and induced the degrdn. of client proteins in tumors.  Furthermore, in a novel orthotopic MM model of i.v. inoculated OPM-2/green fluorescent protein, KW-2478 showed a significant redn. of both serum M protein and MM tumor burden in the bone marrow.  CONCLUSIONS: These results suggest that targeting such diverse pathways by KW-2478 could be a promising strategy for the treatment of MM with various cytogenetic abnormalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozKElc2AcPx7Vg90H21EOLACvtfcHk0ljARNliNLTeiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvF2hsr8%253D&md5=dfe115d5696acc0a9ae62c94c24a42ec</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-3112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-3112%26sid%3Dliteratum%253Aachs%26aulast%3DNakashima%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DTagaya%26aufirst%3DH.%26aulast%3DSeike%26aufirst%3DT.%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DSoga%26aufirst%3DS.%26aulast%3DShiotsu%26aufirst%3DY.%26atitle%3DNew%2520molecular%2520and%2520biological%2520mechanism%2520of%2520antitumor%2520activities%2520of%2520KW-2478%252C%2520a%2520novel%2520nonansamycin%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26issue%3D10%26spage%3D2792%26epage%3D2802%26doi%3D10.1158%2F1078-0432.CCR-09-3112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seike, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juliger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maharaj, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiotsu, Y.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e68</span>, <span class="refDoi"> DOI: 10.1038/bcj.2012.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fbcj.2012.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=22829970" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=e68&author=T.+Ishiiauthor=T.+Seikeauthor=T.+Nakashimaauthor=S.+Juligerauthor=L.+Maharajauthor=S.+Sogaauthor=S.+Akinagaauthor=J.+Cavenaghauthor=S.+Joelauthor=Y.+Shiotsu&title=Anti-tumor+activity+against+multiple+myeloma+by+combination+of+KW-2478%2C+an+Hsp90+inhibitor%2C+with+bortezomib&doi=10.1038%2Fbcj.2012.13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2012.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2012.13%26sid%3Dliteratum%253Aachs%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DSeike%26aufirst%3DT.%26aulast%3DNakashima%26aufirst%3DT.%26aulast%3DJuliger%26aufirst%3DS.%26aulast%3DMaharaj%26aufirst%3DL.%26aulast%3DSoga%26aufirst%3DS.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DJoel%26aufirst%3DS.%26aulast%3DShiotsu%26aufirst%3DY.%26atitle%3DAnti-tumor%2520activity%2520against%2520multiple%2520myeloma%2520by%2520combination%2520of%2520KW-2478%252C%2520an%2520Hsp90%2520inhibitor%252C%2520with%2520bortezomib%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2012%26volume%3D2%26spage%3De68%26doi%3D10.1038%2Fbcj.2012.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakervee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span> <span> </span><span class="NLM_article-title">Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fbjc.2015.422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=26695442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVelsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2016&pages=7-13&author=K.+Yongauthor=J.+Cavetauthor=P.+Johnsonauthor=G.+Morganauthor=C.+Williamsauthor=D.+Nakashimaauthor=S.+Akinagaauthor=H.+Oakerveeauthor=J.+Cavenagh&title=Phase+I+study+of+KW-2478%2C+a+novel+Hsp90+inhibitor%2C+in+patients+with+B-cell+malignancies&doi=10.1038%2Fbjc.2015.422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies</span></div><div class="casAuthors">Yong, K.; Cavet, J.; Johnson, P.; Morgan, G.; Williams, C.; Nakashima, D.; Akinaga, S.; Oakervee, H.; Cavenagh, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-13</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: KW-2478 is a novel, non-ansamycin, non-purine heat-shock protein 90 (Hsp90) inhibitor.  Methods: In this phase I, multicentre study, KW-2478 was administered i.v. over 1 h at doses ranging from 14 to 176 mg m-2 once daily on days 1-5 of a 14-day cycle in a std. 3+3 design in 27 patients (22 with multiple myeloma and 5 with non-Hodgkin lymphoma).  Patients enrolled had relapsed/refractory disease previously treated with ≥2 regimens.  Results: There were no dose-limiting toxicities, thus the max.-tolerated dose was not reached.  KW-2478 was well tolerated and did not manifest significant retinal or ocular toxicity.  The most common treatment-related adverse events were diarrhoea (33.3%), fatigue (29.6%), headache (25.9%), hypertension (22.2%), nausea (14.8%), vomiting (7.4%), and dizziness (7.4%).  Plasma concns. peaked at the end of infusion and decayed in a biphasic manner with a terminal half-life of ∼6 h.  Target inhibition was inferred from the increase in Hsp70 levels in peripheral blood mononuclear cells at doses ≥71 mg m-2.  Twenty-four of 25 (96%) evaluable patients showed stable disease, with five being free of disease progression for ≥6 mo.  Conclusions: Preliminary clin. response data were encouraging and warrant further investigation of KW-2478 in combination regimens for relapsed/refractory B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEuon6lWQ0I7Vg90H21EOLACvtfcHk0liYQyULvYIA5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVelsw%253D%253D&md5=b89fa1f0b51d458ec23154dc7c7fcafb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.422%26sid%3Dliteratum%253Aachs%26aulast%3DYong%26aufirst%3DK.%26aulast%3DCavet%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DMorgan%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DNakashima%26aufirst%3DD.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DOakervee%26aufirst%3DH.%26aulast%3DCavenagh%26aufirst%3DJ.%26atitle%3DPhase%2520I%2520study%2520of%2520KW-2478%252C%2520a%2520novel%2520Hsp90%2520inhibitor%252C%2520in%2520patients%2520with%2520B-cell%2520malignancies%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2016%26volume%3D114%26spage%3D7%26epage%3D13%26doi%3D10.1038%2Fbjc.2015.422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cavenagh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakervee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baetiong-Caguioa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharibo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiraishi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, K.</span></span> <span> </span><span class="NLM_article-title">A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1038/bjc.2017.302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fbjc.2017.302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=28873084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKmu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=1295-1302&author=J.+Cavenaghauthor=H.+Oakerveeauthor=P.+Baetiong-Caguioaauthor=F.+Daviesauthor=M.+Ghariboauthor=N.+Rabinauthor=M.+Kurmanauthor=B.+Novakauthor=N.+Shiraishiauthor=D.+Nakashimaauthor=S.+Akinagaauthor=K.+Yong&title=A+phase+I%2FII+study+of+KW-2478%2C+an+Hsp90+inhibitor%2C+in+combination+with+bortezomib+in+patients+with+relapsed%2Frefractory+multiple+myeloma&doi=10.1038%2Fbjc.2017.302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma</span></div><div class="casAuthors">Cavenagh, J.; Oakervee, H.; Baetiong-Caguioa, P.; Davies, F.; Gharibo, M.; Rabin, N.; Kurman, M.; Novak, B.; Shiraishi, N.; Nakashima, D.; Akinaga, S.; Yong, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1295-1302</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: KW-2478 is a novel non-ansamycin Hsp90 inhibitor with modest single-agent activity in relapsed/refractory myeloma but which shows synergistic antimyeloma activity with bortezomib (BTZ) in preclin. studies.  This study detd. the safety, preliminary clin. activity, and pharmacokinetics of KW-2478, an Hsp90 inhibitor, in combination with BTZ in patients with relapsed/refractory multiple myeloma (MM).  Methods: Phase I dose escalation detd. the recommended phase II dose (RP2D) of KW-2478 plus BTZ, which was then used during phase II.  Results: The max. tolerated dose was not reached during phase I and the RP2D was KW-2478 175 mg m-2 plus BTZ 1.3 mg m-2 on days 1, 4, 8, and 11 every 3 wk.  In the efficacy evaluable phase I/II population treated at the RP2D (n=79), the objective response rate was 39.2% (95% confidence interval: 28.4-50.9%), clin. benefit rate 51.9% (40.4-63.3%), median progression-free survival 6.7 (5.9-not reached (NR)) months, and median duration of response 5.5 (4.9-NR) months.  In the phase I/II safety population (n=95), the most frequently obsd. treatment-related grade 3/4 adverse events were diarrhoea, fatigue, and neutropenia (each in 7.4% of patients), and nausea and thrombocytopenia (each in 5.3%).  Conclusions: KW-2478 plus BTZ was well tolerated with no apparent overlapping toxicity in patients with relapsed/refractory MM.  The antimyeloma activity of KW-2478 in combination with BTZ as scheduled in this trial appeared relatively modest; however, the good tolerability of the combination would support further exploration of alternate dosing schedules and combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJQI0ZKrISM7Vg90H21EOLACvtfcHk0liYQyULvYIA5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKmu7vJ&md5=4184f4253bfbc80b37507876d144f93d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.302%26sid%3Dliteratum%253Aachs%26aulast%3DCavenagh%26aufirst%3DJ.%26aulast%3DOakervee%26aufirst%3DH.%26aulast%3DBaetiong-Caguioa%26aufirst%3DP.%26aulast%3DDavies%26aufirst%3DF.%26aulast%3DGharibo%26aufirst%3DM.%26aulast%3DRabin%26aufirst%3DN.%26aulast%3DKurman%26aufirst%3DM.%26aulast%3DNovak%26aufirst%3DB.%26aulast%3DShiraishi%26aufirst%3DN.%26aulast%3DNakashima%26aufirst%3DD.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DYong%26aufirst%3DK.%26atitle%3DA%2520phase%2520I%252FII%2520study%2520of%2520KW-2478%252C%2520an%2520Hsp90%2520inhibitor%252C%2520in%2520combination%2520with%2520bortezomib%2520in%2520patients%2520with%2520relapsed%252Frefractory%2520multiple%2520myeloma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D117%26spage%3D1295%26epage%3D1302%26doi%3D10.1038%2Fbjc.2017.302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peace, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span> <span> </span><span class="NLM_article-title">The developability of heteroaromatic and heteroaliphatic rings – do some have a better pedigree as potential drug molecules than others?</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1062</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1039/c2md20111a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1039%2Fc2md20111a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1062-1069&issue=9&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=S.+Peaceauthor=S.+D.+Pickettauthor=C.+N.+Luscombe&title=The+developability+of+heteroaromatic+and+heteroaliphatic+rings+%E2%80%93+do+some+have+a+better+pedigree+as+potential+drug+molecules+than+others%3F&doi=10.1039%2Fc2md20111a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The developability of heteroaromatic and heteroaliphatic rings - do some have a better pedigree as potential drug molecules than others?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Peace, Simon; Pickett, Stephen D.; Luscombe, Christopher N.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1062-1069</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Aq. soly., protein binding and CYP450 inhibition data for compds. contg. a variety of heteroarom. and heteroaliph. rings were analyzed and compared to det. which ring types fared best and worst in these developability screens.  The results suggest that certain heterorings are generally more developable than others: how this information may be used and some caveats to be borne in mind are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCkxdTaUGig7Vg90H21EOLACvtfcHk0ljckg0nptUOew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE&md5=6aad4bc48b351d9d20683ee9af1a3354</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2Fc2md20111a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20111a%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DPeace%26aufirst%3DS.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26atitle%3DThe%2520developability%2520of%2520heteroaromatic%2520and%2520heteroaliphatic%2520rings%2520%25E2%2580%2593%2520do%2520some%2520have%2520a%2520better%2520pedigree%2520as%2520potential%2520drug%2520molecules%2520than%2520others%253F%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26issue%3D9%26spage%3D1062%26epage%3D1069%26doi%3D10.1039%2Fc2md20111a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Resorcinol-based Grp94-selective inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1013-1018&issue=10&author=A.+Khandelwalauthor=V.+M.+Crowleyauthor=B.+S.+J.+Blagg&title=Resorcinol-based+Grp94-selective+inhibitors&doi=10.1021%2Facsmedchemlett.7b00193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Resorcinol-Based Grp94-Selective Inhibitors</span></div><div class="casAuthors">Khandelwal, Anuj; Crowley, Vincent M.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1013-1018</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucose regulated protein 94 (Grp94) is the endoplasmic reticulum resident of the 90 kDa heat shock protein (Hsp90) family and represents a promising therapeutic target for the treatment of several diseases.  Grp94 is the most unique member of the 90 kDa heat shock protein family due to a five amino acid insertion into its primary sequence, which creates hydrophobic subpockets exclusive to Grp94 that can be utilized for selective inhibition.  The first resorcinol-based Grp94-selective inhibitor I to take advantage of the hydrophobic S2 subpocket has been developed and shown to manifest low nanomolar affinity and ∼10-fold selectivity for Grp94.  Furthermore, these Grp94-selective inhibitors manifest low micromolar GI50 values against multiple myeloma cells, supporting Grp94 as an emerging target for the treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok_wSMzlEsHLVg90H21EOLACvtfcHk0ljckg0nptUOew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs73K&md5=a398cf6e5adaacc4892aed8b2340b901</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00193%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DResorcinol-based%2520Grp94-selective%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D10%26spage%3D1013%26epage%3D1018%26doi%3D10.1021%2Facsmedchemlett.7b00193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catherine Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, M. R.</span></span> <span> </span><span class="NLM_article-title">Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">6273</span>– <span class="NLM_lpage">6278</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.09.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.bmcl.2008.09.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=18929486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6273-6278&issue=23&author=P.-P.+Kungauthor=L.+Funkauthor=J.+Mengauthor=M.+Collinsauthor=J.+Z.+Zhouauthor=M.+Catherine+Johnsonauthor=A.+Ekkerauthor=J.+Wangauthor=P.+Mehtaauthor=M.-J.+Yinauthor=C.+Rodgersauthor=J.+F.+Daviesauthor=E.+Baymanauthor=T.+Smealauthor=K.+A.+Maegleyauthor=M.+R.+Gehring&title=Dihydroxylphenyl+amides+as+inhibitors+of+the+Hsp90+molecular+chaperone&doi=10.1016%2Fj.bmcl.2008.09.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone</span></div><div class="casAuthors">Kung, Pei-Pei; Funk, Lee; Meng, Jerry; Collins, Michael; Zhou, Joe Zhongxiang; Catherine Johnson, M.; Ekker, Anne; Wang, Jeff; Mehta, Pramod; Yin, Min-Jean; Rodgers, Caroline; Davies, Jay F., II; Bayman, Eileen; Smeal, Tod; Maegley, Karen A.; Gehring, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6273-6278</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Information from X-ray crystal structures were used to optimize the potency of a HTS hit in a Hsp90 competitive binding assay.  A class of novel and potent small mol. Hsp90 inhibitors were thereby identified.  Enantio-pure compds. I [n = 1, 2] were potent in PGA-based competitive binding assay and inhibited proliferation of various human cancer cell lines in vitro, with IC50 values averaging 20 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraBHD3PPbhDbVg90H21EOLACvtfcHk0ljckg0nptUOew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOhtrzE&md5=36eb69d7ffb65443bc5328f74806fa0b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.081%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DJ.%2BZ.%26aulast%3DCatherine%2BJohnson%26aufirst%3DM.%26aulast%3DEkker%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DRodgers%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BF.%26aulast%3DBayman%26aufirst%3DE.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DGehring%26aufirst%3DM.%2BR.%26atitle%3DDihydroxylphenyl%2520amides%2520as%2520inhibitors%2520of%2520the%2520Hsp90%2520molecular%2520chaperone%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D23%26spage%3D6273%26epage%3D6278%26doi%3D10.1016%2Fj.bmcl.2008.09.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Digits, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaptason, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neul, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elleraas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, M. R.</span></span> <span> </span><span class="NLM_article-title">Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (Hsp90) molecular chaperone</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1021/jm901209q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901209q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSgtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=499-503&issue=1&author=P.-P.+Kungauthor=B.+Huangauthor=G.+Zhangauthor=J.+Z.+Zhouauthor=J.+Wangauthor=J.+A.+Digitsauthor=J.+Skaptasonauthor=S.+Yamazakiauthor=D.+Neulauthor=M.+Zientekauthor=J.+Elleraasauthor=P.+Mehtaauthor=M.-J.+Yinauthor=M.+J.+Hickeyauthor=K.+S.+Gajiwalaauthor=C.+Rodgersauthor=J.+F.+Daviesauthor=M.+R.+Gehring&title=Dihydroxyphenylisoindoline+amides+as+orally+bioavailable+inhibitors+of+the+heat+shock+protein+90+%28Hsp90%29+molecular+chaperone&doi=10.1021%2Fjm901209q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroxyphenylisoindoline Amides as Orally Bioavailable Inhibitors of the Heat Shock Protein 90 (Hsp90) Molecular Chaperone</span></div><div class="casAuthors">Kung, Pei-Pei; Huang, Buwen; Zhang, Gang; Zhou, Joe Zhongxiang; Wang, Jeff; Digits, Jennifer A.; Skaptason, Judith; Yamazaki, Shinji; Neul, David; Zientek, Michael; Elleraas, Jeff; Mehta, Pramod; Yin, Min-Jean; Hickey, Michael J.; Gajiwala, Ketan S.; Rodgers, Caroline; Davies, Jay F.; Gehring, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">499-503</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of potency and metabolic stability of a novel class of dihyroxyphenylisoindoline amides as Hsp90 inhibitors are presented.  Optimization of a screening hit using structure-based design and modification of log D and chem. structural features led to the identification of a class of orally bioavailable non-quinone-contg. Hsp90 inhibitors.  This class is exemplified by 14 and 15, which possess improved cell potency and pharmacokinetic profiles compared with the original screening hit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEUFJeHqfCcbVg90H21EOLACvtfcHk0ljckg0nptUOew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSgtb3I&md5=ddf40b545bfd06e4bf9f981c7a792eae</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm901209q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901209q%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DP.-P.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DJ.%2BZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDigits%26aufirst%3DJ.%2BA.%26aulast%3DSkaptason%26aufirst%3DJ.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DNeul%26aufirst%3DD.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DElleraas%26aufirst%3DJ.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DHickey%26aufirst%3DM.%2BJ.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DRodgers%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BF.%26aulast%3DGehring%26aufirst%3DM.%2BR.%26atitle%3DDihydroxyphenylisoindoline%2520amides%2520as%2520orally%2520bioavailable%2520inhibitors%2520of%2520the%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520molecular%2520chaperone%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D1%26spage%3D499%26epage%3D503%26doi%3D10.1021%2Fjm901209q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J.</span></span> <span> </span><span class="NLM_article-title">Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5942</span>– <span class="NLM_lpage">5955</span>, <span class="refDoi"> DOI: 10.1021/jm100059d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100059d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVChsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5942-5955&author=C.+W.+Murrayauthor=M.+G.+Carrauthor=O.+Callaghanauthor=G.+Chessariauthor=M.+Congreveauthor=S.+Cowanauthor=J.+E.+Coyleauthor=R.+Downhamauthor=E.+Figueroaauthor=M.+Fredericksonauthor=B.+Grahamauthor=R.+McMenaminauthor=M.+A.+O%E2%80%99Brienauthor=S.+Patelauthor=T.+R.+Phillipsauthor=G.+Williamsauthor=A.+J.+Woodheadauthor=A.+J.+Woolford&title=Fragment-based+drug+discovery+applied+to+Hsp90.+Discovery+of+two+lead+series+with+high+ligand+efficiency&doi=10.1021%2Fjm100059d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency</span></div><div class="casAuthors">Murray, Christopher W.; Carr, Maria G.; Callaghan, Owen; Chessari, Gianni; Congreve, Miles; Cowan, Suzanna; Coyle, Joseph E.; Downham, Robert; Figueroa, Eva; Frederickson, Martyn; Graham, Brent; McMenamin, Rachel; O'Brien, M. Alistair; Patel, Sahil; Phillips, Theresa R.; Williams, Glyn; Woodhead, Andrew J.; Woolford, Alison J.-A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5942-5955</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the chaperone Hsp90 are potentially useful as chemotherapeutic agents in cancer.  This paper describes an application of fragment screening to Hsp90 using a combination of NMR and high throughput x-ray crystallog.  The screening identified an aminopyrimidine with affinity in the high micromolar range and subsequent structure-based design allowed its optimization into a low nanomolar series with good ligand efficiency.  A phenolic chemotype was also identified in fragment screening and was found to bind with affinity close to 1 mM.  This fragment was optimized using structure based design into a resorcinol lead which has subnanomolar affinity for Hsp90, excellent cell potency, and good ligand efficiency.  This fragment to lead campaign improved affinity for Hsp90 by over 1,000,000 fold with the addn. of only 6 heavy atoms.  The companion paper (DOI: 10.1021/jm100060b) describes how the resorcinol lead was optimized into a compd. that is now in clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqISC3cw2labbVg90H21EOLACvtfcHk0lgGuOTrtlZgDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVChsb0%253D&md5=d1ad900aa5a45ba6ba3a5e9ccdcd96b3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm100059d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100059d%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCallaghan%26aufirst%3DO.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCowan%26aufirst%3DS.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%2BR.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DFragment-based%2520drug%2520discovery%2520applied%2520to%2520Hsp90.%2520Discovery%2520of%2520two%2520lead%2520series%2520with%2520high%2520ligand%2520efficiency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5942%26epage%3D5955%26doi%3D10.1021%2Fjm100059d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G. M.</span></span> <span> </span><span class="NLM_article-title">Total synthesis of resorcinol amide Hsp90 inhibitor AT13387</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">11296</span>– <span class="NLM_lpage">11301</span>, <span class="refDoi"> DOI: 10.1021/jo302406w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo302406w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCgsbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=11296-11301&issue=24&author=B.+H.+Patelauthor=A.+G.+M.+Barrett&title=Total+synthesis+of+resorcinol+amide+Hsp90+inhibitor+AT13387&doi=10.1021%2Fjo302406w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of Resorcinol Amide Hsp90 Inhibitor AT13387</span></div><div class="casAuthors">Patel, Bhavesh H.; Barrett, Anthony G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11296-11301</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of C-5-substituted resorcinol amide AT13387 (I), a known Hsp90 inhibitor currently in clin. trials, is reported without the use of phenolic protection in an overall yield of 13.4%.  Biomimetic aromatization and Suzuki-Miyaura cross coupling approach were employed to synthesize the resorcinol and iso-indoline units, resp., which were efficiently coupled using Grignard-mediated amidation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB5oqQ4N5a47Vg90H21EOLACvtfcHk0lgGuOTrtlZgDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCgsbzN&md5=265c4db08cd8d2d0df61888dc542804f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjo302406w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo302406w%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DB.%2BH.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%2BM.%26atitle%3DTotal%2520synthesis%2520of%2520resorcinol%2520amide%2520Hsp90%2520inhibitor%2520AT13387%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2012%26volume%3D77%26issue%3D24%26spage%3D11296%26epage%3D11301%26doi%3D10.1021%2Fjo302406w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2525</span>– <span class="NLM_lpage">2529</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.03.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.bmcl.2014.03.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=24751441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmslahsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2525-2529&issue=11&author=J.+Renauthor=J.+Liauthor=Y.+Wangauthor=W.+Chenauthor=A.+Shenauthor=H.+Liuauthor=D.+Chenauthor=D.+Caoauthor=Y.+Liauthor=N.+Zhangauthor=Y.+Xuauthor=M.+Gengauthor=J.+Heauthor=B.+Xiongauthor=J.+Shen&title=Identification+of+a+new+series+of+potent+diphenol+HSP90+inhibitors+by+fragment+merging+and+structure-based+optimization&doi=10.1016%2Fj.bmcl.2014.03.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization</span></div><div class="casAuthors">Ren, Jing; Li, Jian; Wang, Yueqin; Chen, Wuyan; Shen, Aijun; Liu, Hongchun; Chen, Danqi; Cao, Danyan; Li, Yanlian; Zhang, Naixia; Xu, Yechun; Geng, Meiyu; He, Jianhua; Xiong, Bing; Shen, Jingkang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2525-2529</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Heat shock protein 90 (HSP90) is a mol. chaperone to fold and maintain the proper conformation of many signaling proteins, esp. some oncogenic proteins and mutated unstable proteins.  Inhibition of HSP90 was recognized as an effective approach to simultaneously suppress several aberrant signaling pathways, and therefore it was considered as a novel target for cancer therapy.  Here, by integrating several techniques including the fragment-based drug discovery method, fragment merging, computer aided inhibitor optimization, and structure-based drug design, the authors were able to identify a series of HSP90 inhibitors, e.g. I [R1 = H. HO2CCH2, NH2CH2CH2, MeCONHCH2CH2; r2 = H, Br, O2N, etc.; R3 = H, Br, Me, MeO].  Several compds. can inhibit HSP90 with IC50 about 20-40 nM, which is at least 200-fold more potent than initial fragments in the protein binding assay.  These new HSP90 inhibitors not only explore interactions with an under-studied subpocket, also offer new chemotypes for the development of novel HSP90 inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy4NL6r1yE8rVg90H21EOLACvtfcHk0lj9nUs7ux4z4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmslahsrY%253D&md5=057e15a1982cf723de8c7436accf4fff</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.03.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.03.100%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520a%2520new%2520series%2520of%2520potent%2520diphenol%2520HSP90%2520inhibitors%2520by%2520fragment%2520merging%2520and%2520structure-based%2520optimization%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D11%26spage%3D2525%26epage%3D2529%26doi%3D10.1016%2Fj.bmcl.2014.03.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Addie, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Room-temperature palladium-catalyzed coupling of heteroaryl amines with aryl or heteroaryl bromides</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span> (<span class="NLM_issue">02</span>),  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1055/s-0031-1290069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1055%2Fs-0031-1290069" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=285-289&issue=02&author=T.+A.+Mossauthor=M.+S.+Addieauthor=T.+Nowakauthor=M.+J.+Waring&title=Room-temperature+palladium-catalyzed+coupling+of+heteroaryl+amines+with+aryl+or+heteroaryl+bromides&doi=10.1055%2Fs-0031-1290069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1055%2Fs-0031-1290069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0031-1290069%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DAddie%26aufirst%3DM.%2BS.%26aulast%3DNowak%26aufirst%3DT.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DRoom-temperature%2520palladium-catalyzed%2520coupling%2520of%2520heteroaryl%2520amines%2520with%2520aryl%2520or%2520heteroaryl%2520bromides%26jtitle%3DSynlett%26date%3D2012%26volume%3D2012%26issue%3D02%26spage%3D285%26epage%3D289%26doi%3D10.1055%2Fs-0031-1290069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, J. P.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, S. R.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed couplings of heteroaryl amines with aryl halides using sodium phenolate as the stoichiometric base</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2007</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2331</span>– <span class="NLM_lpage">2336</span>, <span class="refDoi"> DOI: 10.1055/s-2007-985597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1055%2Fs-2007-985597" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2007&publication_year=2007&pages=2331-2336&issue=15&author=J.+P.+Schulteauthor=S.+R.+Tweedie&title=Palladium-catalyzed+couplings+of+heteroaryl+amines+with+aryl+halides+using+sodium+phenolate+as+the+stoichiometric+base&doi=10.1055%2Fs-2007-985597"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1055%2Fs-2007-985597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2007-985597%26sid%3Dliteratum%253Aachs%26aulast%3DSchulte%26aufirst%3DJ.%2BP.%26aulast%3DTweedie%26aufirst%3DS.%2BR.%26atitle%3DPalladium-catalyzed%2520couplings%2520of%2520heteroaryl%2520amines%2520with%2520aryl%2520halides%2520using%2520sodium%2520phenolate%2520as%2520the%2520stoichiometric%2520base%26jtitle%3DSynlett%26date%3D2007%26volume%3D2007%26issue%3D15%26spage%3D2331%26epage%3D2336%26doi%3D10.1055%2Fs-2007-985597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, Y. H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.ejmech.2017.11.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=29202402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=390-401&author=S.+Y.+Parkauthor=Y.+J.+Ohauthor=Y.+Lhoauthor=J.+H.+Jeongauthor=K.-H.+Liuauthor=J.+Songauthor=S.-H.+Kimauthor=E.+Haauthor=Y.+H.+Seo&title=Design%2C+synthesis%2C+and+biological+evaluation+of+a+series+of+resorcinol-based+N-benzyl+benzamide+derivatives+as+potent+Hsp90+inhibitors&doi=10.1016%2Fj.ejmech.2017.11.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors</span></div><div class="casAuthors">Park, Sun You; Oh, Yong Jin; Lho, Yunmee; Jeong, Ju Hui; Liu, Kwang-Hyeon; Song, Jaeyoung; Kim, Soong-Hyun; Ha, Eunyoung; Seo, Young Ho</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">390-401</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design, synthesis, and biol. evaluation of a series of resorcinol-based N-benzyl benzamide derivs. 2,4-(HO)6-5-R1C6H2C(O)R [R = benzylaminyl, N-methyl-N-(4-(propylcarbamoyl)benzyl)aminyl, N-methyl-3,4,5-trimethoxybenzylaminyl, etc.; R1 = Cl, i-Pr] as Hsp90 inhibitors has been reported.  In particular, compd. 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide shows a significant Hsp90α inhibitory activity with IC50 value of 5.3 nM and an excellent growth inhibition with GI50 value of 0.42 μM against non-small cell lung cancer cells, H1975.  Compd. 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide effectively reduces the expression levels of Hsp90 client proteins including Her2, EGFR, Met, Akt, and c-Raf.  Consequently, compd. 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide promotes substantial cleavages of PARP, Caspase 3, and Caspase 8, indicating that 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide induces cancer cell death via apoptotic pathway.  Moreover, cytochrome P 450 assay indicates that compd. 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide has weak inhibitory effect on the activities of five major P 450 isoforms (IC50 > 5 μM for 1A2, 2C9, 2C19, 2D6, and 3A), suggesting that clin. interactions between 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide and the substrate drugs of the five major P 450 isoforms are not expected.  Compd. 2,4-dihydroxy-5-isopropyl-N-methyl-N-(4-(propylcarbamoyl)benzyl)benzamide also inhibits the tumor growth in a mouse xenograft model bearing s.c. H1975 without noticeable abnormal behavior and body wt. changes.  The immunostaining and western immunoblot anal. of EGFR, Met, Akt in xenograft tissue sections of tumor further demonstrate a good agreement with the in vitro results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnyGeDPwxoarVg90H21EOLACvtfcHk0lj9nUs7ux4z4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFejsL%252FK&md5=b9568b778745c305d0dadb727c0d9671</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.054%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BY.%26aulast%3DOh%26aufirst%3DY.%2BJ.%26aulast%3DLho%26aufirst%3DY.%26aulast%3DJeong%26aufirst%3DJ.%2BH.%26aulast%3DLiu%26aufirst%3DK.-H.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DHa%26aufirst%3DE.%26aulast%3DSeo%26aufirst%3DY.%2BH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520resorcinol-based%2520N-benzyl%2520benzamide%2520derivatives%2520as%2520potent%2520Hsp90%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D390%26epage%3D401%26doi%3D10.1016%2Fj.ejmech.2017.11.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">21–22</span>),  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&issue=21%E2%80%9322&author=T.+J.+Ritchieauthor=S.+J.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability%2D%2Dare+too+many+aromatic+rings+a+liability+in+drug+design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0lj9nUs7ux4z4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability--are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26issue%3D21%25E2%2580%259322%26spage%3D1011%26epage%3D1020%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, T. C.</span></span> <span> </span><span class="NLM_article-title">Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1482</span>– <span class="NLM_lpage">1487</span>, <span class="refDoi"> DOI: 10.1128/AAC.41.7.1482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1128%2FAAC.41.7.1482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=9210670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADyaK2sXktlyrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=1482-1487&issue=7&author=T.+C.+White&title=Increased+mRNA+levels+of+ERG16%2C+CDR%2C+and+MDR1+correlate+with+increases+in+azole+resistance+in+Candida+albicans+isolates+from+a+patient+infected+with+human+immunodeficiency+virus&doi=10.1128%2FAAC.41.7.1482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus</span></div><div class="casAuthors">White, Theodore C.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1482-1487</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Resistance to antifungal drugs, specifically azoles such as fluconazole, in the opportunistic yeast Candida albicans has become an increasing problem in human immunodeficiency virus (HIV)-infected individuals.  The mol. mechanisms responsible for this resistance have only recently become apparent and can include alterations in the target enzyme of the azole drugs (lanosterol 14α demethylase [14DM]), or in various efflux pumps from both the ABC transporter and major facilitator gene families.  To det. which of these possible mechanisms was assocd. with the development of drug resistance in a particular case, mRNA levels have been studied in a series of 17 clin. isolates taken from a single HIV-infected patient over 2 yr, during which time the levels of fluconazole resistance of the strain increased over 200-fold.  Using Northern blot anal. of steady-state levels of total RNA from these isolates, we obsd. increased mRNA levels of ERG16 (the 14DM-encoding gene), CDR1 (an ABC transporter), and MDR1 (a major facilitator) in this series.  The timing of the increase in mRNA levels of each of these genes correlated with increases in fluconazole resistance of the isolates.  Increased mRNA levels were not obsd. for three other ABC transporters, two other genes in the ergosterol biosynthetic pathway, or the NADPH-cytochrome P 450 oxidoreductase gene that transfers electrons from NADPH to 14DM.  Increases in mRNA levels of ERG16 and CDR1 correlated with increased cross-resistance to ketoconazole and itraconazole but not to amphotericin B.  A compilation of the genetic alterations identified in this series suggests that resistance develops gradually and is the sum of several different changes, all of which contribute to the final resistant phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcePJcYuq0KrVg90H21EOLACvtfcHk0lj8V87u7YWGCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlyrurw%253D&md5=4496d1afe63335deadeb234dae8b8a20</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.41.7.1482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.41.7.1482%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DT.%2BC.%26atitle%3DIncreased%2520mRNA%2520levels%2520of%2520ERG16%252C%2520CDR%252C%2520and%2520MDR1%2520correlate%2520with%2520increases%2520in%2520azole%2520resistance%2520in%2520Candida%2520albicans%2520isolates%2520from%2520a%2520patient%2520infected%2520with%2520human%2520immunodeficiency%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1997%26volume%3D41%26issue%3D7%26spage%3D1482%26epage%3D1487%26doi%3D10.1128%2FAAC.41.7.1482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Odds, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, N. A.</span></span> <span> </span><span class="NLM_article-title">Candida albicans genome sequence: a platform for genomics in the absence of genetics</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">230</span>, <span class="refDoi"> DOI: 10.1186/gb-2004-5-7-230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1186%2Fgb-2004-5-7-230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=15239821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A280%3ADC%252BD2czlsVChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=230&issue=7&author=F.+C.+Oddsauthor=A.+J.+Brownauthor=N.+A.+Gow&title=Candida+albicans+genome+sequence%3A+a+platform+for+genomics+in+the+absence+of+genetics&doi=10.1186%2Fgb-2004-5-7-230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Candida albicans genome sequence: a platform for genomics in the absence of genetics</span></div><div class="casAuthors">Odds Frank C; Brown Alistair J P; Gow Neil A R</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">230</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Publication of the complete diploid genome sequence of the yeast Candida albicans will accelerate research into the pathogenesis of Candida infections.  Comparative genomic analysis highlights genes that may contribute to C. albicans survival and its fitness as a human commensal and pathogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZ8wMZhrtbR7ZpSb_XWfMrfW6udTcc2eZZmpzAM-k4ubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czlsVChtA%253D%253D&md5=9c6f15ae6ef6abcb772b13b4cbd4d033</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1186%2Fgb-2004-5-7-230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2004-5-7-230%26sid%3Dliteratum%253Aachs%26aulast%3DOdds%26aufirst%3DF.%2BC.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DGow%26aufirst%3DN.%2BA.%26atitle%3DCandida%2520albicans%2520genome%2520sequence%253A%2520a%2520platform%2520for%2520genomics%2520in%2520the%2520absence%2520of%2520genetics%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26issue%3D7%26spage%3D230%26doi%3D10.1186%2Fgb-2004-5-7-230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Granger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durack, D. T.</span></span> <span> </span><span class="NLM_article-title">Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1172/JCI112000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1172%2FJCI112000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=3928681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADyaL2MXltlyhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1985&pages=508-516&issue=2&author=D.+L.+Grangerauthor=J.+R.+Perfectauthor=D.+T.+Durack&title=Virulence+of+Cryptococcus+neoformans.+Regulation+of+capsule+synthesis+by+carbon+dioxide&doi=10.1172%2FJCI112000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Virulence of Cryptococcus neoformans.  Regulation of capsule synthesis by carbon dioxide</span></div><div class="casAuthors">Granger, Donald L.; Perfect, John R.; Durack, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">508-16</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">C. neoformans Is variably encapsulated in vitro, whereas in tissues it develops a large capsule.  It was obsd. that cells of a strain with thin capsules, when growing in a std. fungal culture medium, became heavily encapsulated when incubated in the serum-free cell culture medium, Dulbecco's modified Eagle's medium (DME).  Capsule size was quantitated phys. by measuring cell vol. and chem. by detg. the content of a capsular monosaccharide, glucuronate.  The CO2/HCO3- couple stimulated capsule development, resulting in visible enlargement by 3 h after exposure to high CO2/HCO3-.  The amt. of capsule per cell was directly proportional to the total millimolar CO2/HCO3- concn. between 24 and 2.4 mM at pH 7.35, but at const. PCO2 (40 torr) and varying [HCO3-], the cells were heavily encapsulated down to pH 6.8.  Concn. of CO2/HCO3- in the physiol. range increased elaboration of polysaccharide into the medium and slowed the cell generation time from 2 to 6 h.  Four other 1st-passage clin. isolates were all heavily encapsulated in DME with CO2/HCO3-, but variably encapsulated in DME without CO2/HCO3-.  Exposure of yeast to increased CO2/HCO3- caused a marked redn. in complement-mediated phagocytosis by mouse macrophages.  A stable clone was isolated which contained capsular polysaccharide, but lacked the CO2-inducible phenotype.  This clone was avirulent for steroid-treated rabbits.  Thus, the prevailing CO2 concn. in mammalian tissues may be one stimulus for capsular polysaccharide synthesis.  This could serve as an adaptive mechanism favoring parasite survival in the host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoShgYIceZrabVg90H21EOLACvtfcHk0lj8V87u7YWGCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltlyhuro%253D&md5=6198ec56309728bd9d81a6fbb5e3045b</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1172%2FJCI112000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI112000%26sid%3Dliteratum%253Aachs%26aulast%3DGranger%26aufirst%3DD.%2BL.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DDurack%26aufirst%3DD.%2BT.%26atitle%3DVirulence%2520of%2520Cryptococcus%2520neoformans.%2520Regulation%2520of%2520capsule%2520synthesis%2520by%2520carbon%2520dioxide%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1985%26volume%3D76%26issue%3D2%26spage%3D508%26epage%3D516%26doi%3D10.1172%2FJCI112000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaFayette, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betancourt-Quiroz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunatilaka, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">e1001069</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1001069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1371%2Fjournal.ppat.1001069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=20865172" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=e1001069&issue=8&author=S.+L.+LaFayetteauthor=C.+Collinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=M.+Betancourt-Quirozauthor=A.+A.+Gunatilakaauthor=J.+R.+Perfectauthor=L.+E.+Cowen&title=PKC+signaling+regulates+drug+resistance+of+the+fungal+pathogen+Candida+albicans+via+circuitry+comprised+of+Mkc1%2C+calcineurin%2C+and+Hsp90&doi=10.1371%2Fjournal.ppat.1001069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1001069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1001069%26sid%3Dliteratum%253Aachs%26aulast%3DLaFayette%26aufirst%3DS.%2BL.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DBetancourt-Quiroz%26aufirst%3DM.%26aulast%3DGunatilaka%26aufirst%3DA.%2BA.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DPKC%2520signaling%2520regulates%2520drug%2520resistance%2520of%2520the%2520fungal%2520pathogen%2520Candida%2520albicans%2520via%2520circuitry%2520comprised%2520of%2520Mkc1%252C%2520calcineurin%252C%2520and%2520Hsp90%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26issue%3D8%26spage%3De1001069%26doi%3D10.1371%2Fjournal.ppat.1001069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. W.</span></span> <span> </span><span class="NLM_article-title">Analysis of protein-ligand interactions by fluorescence polarization</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1038/nprot.2011.305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1038%2Fnprot.2011.305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=21372817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADC%252BC3MXislentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=365-387&issue=3&author=A.+M.+Rossiauthor=C.+W.+Taylor&title=Analysis+of+protein-ligand+interactions+by+fluorescence+polarization&doi=10.1038%2Fnprot.2011.305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of protein-ligand interactions by fluorescence polarization</span></div><div class="casAuthors">Rossi, Ana M.; Taylor, Colin W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-387</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Quantification of the assocns. between biomols. is required both to predict and understand the interactions that underpin all biol. activity.  Fluorescence polarization (FP) provides a nondisruptive means of measuring the assocn. of a fluorescent ligand with a larger mol.  We describe an FP assay in which binding of fluorescein-labeled inositol 1,4,5-trisphosphate (IP3) to N-terminal fragments of IP3 receptors can be characterized at different temps. and in competition with other ligands.  The assay allows the std. Gibbs free energy (ΔG°), enthalpy (ΔH°) and entropy (ΔS°) changes of ligand binding to be detd.  The method is applicable to any purified ligand-binding site for which an appropriate fluorescent ligand is available.  FP can be used to measure low-affinity interactions in real time without the use of radioactive materials, it is nondestructive and, with appropriate care, it can resolve ΔH° and ΔS°.  The first part of the protocol, protein prepn., may take several weeks, whereas the FP measurements, once they have been optimized, would normally take 1-6 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPmq_JwlOSg7Vg90H21EOLACvtfcHk0lhUWbO0bbzw3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXislentbg%253D&md5=b78e3bcd884a06cdeb8b090227963d33</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2011.305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2011.305%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%2BW.%26atitle%3DAnalysis%2520of%2520protein-ligand%2520interactions%2520by%2520fluorescence%2520polarization%26jtitle%3DNat.%2520Protoc.%26date%3D2011%26volume%3D6%26issue%3D3%26spage%3D365%26epage%3D387%26doi%3D10.1038%2Fnprot.2011.305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span> <span> </span><span class="NLM_article-title">Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1469</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(94)90520-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=10.1016%2F0006-2952%2894%2990520-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=8185657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;key=1%3ACAS%3A528%3ADyaK2cXkt1Kju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1994&pages=1469-1479&issue=9&author=J.+B.+Houston&title=Utility+of+in+vitro+drug+metabolism+data+in+predicting+in+vivo+metabolic+clearance&doi=10.1016%2F0006-2952%2894%2990520-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance</span></div><div class="casAuthors">Houston, J. Brian</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1469-79</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A review with 54 refs.  The aim of the commentary is to present a strategy to achieve the prediction of in vivo clearance from in vitro data based on the current understanding of metabolite kinetics in vitro and in vivo.  Hepatic microsomes and hepatocyte suspension are the main in vitro system addressed.  The theor. basis of the strategy is outlined and its general applicability evaluated, using a data base of 25 drugs drawn from the literature.  Finally, the prospective value of the approach is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFHqQ8gCJ6lrVg90H21EOLACvtfcHk0lhUWbO0bbzw3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkt1Kju7c%253D&md5=a6d0abdbd2f0b238a6a01ba63ee67739</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2894%2990520-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252894%252990520-7%26sid%3Dliteratum%253Aachs%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26atitle%3DUtility%2520of%2520in%2520vitro%2520drug%2520metabolism%2520data%2520in%2520predicting%2520in%2520vivo%2520metabolic%2520clearance%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1994%26volume%3D47%26issue%3D9%26spage%3D1469%26epage%3D1479%26doi%3D10.1016%2F0006-2952%2894%2990520-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, F. H.</span>; <span class="NLM_string-name">Morgentin, R. R.</span>; <span class="NLM_string-name">Ple, P.</span></span> <span> </span><span class="NLM_article-title">Quinoline derivatives</span>. <span class="NLM_patent">WO2007099323</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=F.+H.+Jung&author=R.+R.+Morgentin&author=P.+Ple&title=Quinoline+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DF.%2BH.%26atitle%3DQuinoline%2520derivatives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikolovska-Coleska, Z.</span>; <span class="NLM_string-name">Abulwerdi, F.</span>; <span class="NLM_string-name">Showalter, H.</span>; <span class="NLM_string-name">Miao, L.</span>; <span class="NLM_string-name">Stuckey, J.</span>; <span class="NLM_string-name">Mady, A.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors of MCL-1 and uses thereof</span>. <span class="NLM_patent">WO2015153959</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+Nikolovska-Coleska&author=F.+Abulwerdi&author=H.+Showalter&author=L.+Miao&author=J.+Stuckey&author=A.+Mady&title=Small+molecule+inhibitors+of+MCL-1+and+uses+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNikolovska-Coleska%26aufirst%3DZ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520MCL-1%2520and%2520uses%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jefson, M. R.</span>; <span class="NLM_string-name">Lowe, J. A.</span>; <span class="NLM_string-name">Dey, F.</span>; <span class="NLM_string-name">Bergmann, A.</span>; <span class="NLM_string-name">Schoop, A.</span>; <span class="NLM_string-name">Fuller, N. O.</span></span> <span> </span><span class="NLM_article-title">Hetero-halo inhibitors of histone deacetylase</span>. <span class="NLM_patent">WO2017007756</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+R.+Jefson&author=J.+A.+Lowe&author=F.+Dey&author=A.+Bergmann&author=A.+Schoop&author=N.+O.+Fuller&title=Hetero-halo+inhibitors+of+histone+deacetylase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJefson%26aufirst%3DM.%2BR.%26atitle%3DHetero-halo%2520inhibitors%2520of%2520histone%2520deacetylase%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJP','PDB','6CJP'); return false;">PDB: 6CJP</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i272"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00826">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_70146"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00826">10.1021/acs.jmedchem.9b00826</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Figures S1 and S2 and Supplementary Tables 1–5 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_001.pdf">jm9b00826_si_001.pdf (737.6 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00826/suppl_file/jm9b00826_si_002.csv">jm9b00826_si_002.csv (10.68 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00826%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-5" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00826" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d4d34ed13c40","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
